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Abstract 
Herpes simplex virus type I (HSV-1), the prototype α-herpesvirus (HV), is a double stranded DNA 
virus that replicates in the nucleus of infected cells. The nuclear pore represents a gateway that must 
be engaged and navigated immediately after cell entry for successful infection by many classes of 
human viruses. For herpesviruses, capsid-tegument assemblies must be targeted to the pore where 
the viral genome exits and transport into the nucleus occurs. We currently have little mechanistic 
knowledge of this fundamental step of infection. 
A swath of evidence indicates that the conserved tegument protein VP1-2 is essential for early 
capsid transport and pore binding, and that it contains a conserved nuclear localisation signal (NLS) 
required for pore docking. In this thesis I undertook a detailed analysis to dissect functional 
determinants within the NLS from herpes simplex virus, to examine putative NLSs in VP1-2 homologues 
from representatives of all sub-families, to characterise protein interactions with VP1-2 and finally to 
construct a GFP expressing entry defective recombinant virus to study the consequences of infection. 
I show that the HSV NLS can function as a mono-or bipartite motif and has a particular 
organisation conserved in the -herpesvirus homologues but distinct from those in the - and -
herpesviruses. The representatives of all 3 classes contain a functional NLS at approximately the same 
position. All bi-partite motifs were able to rescue the HSV VP1-2ΔNLS virus defect albeit to varying 
extent whereas the mono-partite HHV-8 motif did not. I constructed and purified chimeric 
recombinant viruses for the VZV, HCMV and EBV motifs and show distinct differences in their ability to 
replicate in non-complementing cells. In HSV, NLS function in the context of protein nuclear import or 
of viable virus replication, was dependent on lysine 428 and the integrity of the full bi-partite motif. 
Mutations which reduced NLS activity generally caused reduced fitness of recombinant viruses. 
For the analysis of interaction partners of VP1-2 and the NLS, I developed a one-step approach 
to analyse the capsid interactome during entry. Additionally, I constructed mammalian GST-VP1-2.NLS 
fusion proteins and cell lines which inducibly express the N-terminal region of VP1-2 for analysis of NLS 
interacting proteins. Using mass spectrometry (MS) I identified a number of VP1-2-interacting, cellular 
proteins including DTX3L, an important regulator of the DNA damage response. 
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1 Introduction 
1.1 Introduction to herpesviruses 
1.1.1 Discovery and classification of Herpesviruses 
Herpesviruses (HVs) have plagued the human race for the whole of its existence, having evolved 
from ancestral species with their human hosts. Sores likely attributable to herpes simplex virus (HSV) 
infection have been medically described as early as 3500 years ago, even though it was only established 
that herpetic lesions were caused by an infectious agent in 1873. Another 50 years passed before HSV 
was successfully isolated and used for animal studies (Singh & Ruzek 2013). 
HVs are large double stranded DNA (dsDNA) viruses (Baltimore group 1) and include all members 
of the Herpesvirales of which more than 200 have already been described. The phylogenetic tree of 
HVs is expanding rapidly with the improvement of molecular genetic tools. The crudest way to classify 
HVs is on basis of their structure and life cycle includes all HVs, which was used to define the order 
Herpesvirales. They share icosahedral capsid structure and a similar mode of genome packaging. A 
closer look at the capsid and DNA replication (e.g. DNA polymerase) reveals similarities to 
Bacteriophages, which thus are assumed to have a common ancient relative (Trus et al. 2004; Casjens 
& King 1975; Baker et al. 2005; Pellett & Roizman 2013). Protein alignments and sequence comparisons 
add the detail further along the tree to allow for subdivision into three major families, which infect 
mammals and birds (Herpesviridae), amphibians and fish (Alloherpesviridae) and invertebrates 
(Malacoherpesviridae). The available sequence data and model of co-evolution with their host suggest 
that these might have diverged from a common ancestor between 400-1000 million years ago. Thus 
far over 50 genomes have been fully sequenced and over 200 different species of HVs identified 
(Davison 2002; Pellett & Roizman 2013). 
The mammalian, avian and reptilian HVs can be further divided into three sub-families, α-, β- 
and γ-herpesvirinae, which share between 30-43 core function genes collectively facilitating basic 
functions such as capsid morphogenesis, DNA encapsidation, DNA replication, entry and egress (Wang 
et al. 2007; Davison 2002). Many animal species were shown to be infected with at least one HV species 
and HV counterparts between hosts were identified. Thus it is no surprise that the list of HVs is 
predicted to expand through the use of rapidly evolving DNA amplification and sequencing methods 
(Pellett & Roizman 2013). The sub-families are believed to have branched around 200 million years ago 
and most of the currently sequenced HV genomes are classified as belonging to this branch. Besides 
inhabiting similar niches within their hosts, sub-families share some genetic features, that is, chunks in 
the central region of their genomes, which carry core genes, show similar gene arrangement and 
content. The nine human HVs (HHV-1 through 8, with HHV-6 divided into A/B types) span all three sub-
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families and their life cycle shows sub-family specific adaptations. While α-HVs can infect and establish 
latency in neurons, the β- and γ-HVs can form reservoirs in myeloid-derived cells (amongst others) 
(Pellett & Roizman 2013). 
 
1.1.2 Introduction to Herpes Simplex Virus 
HHVs have been associated with trivial ailments such as orolabial lesions, chicken pox and 
mononucleosis, and more severe sequelae such as encephalitis, Guillain Barre Syndrome, keratitis and 
post-transplant disseminated infection but quite often they cause no discernible symptoms at all 
(Roizman et al. 2013). HSV-1 is the prototypical and best described of the human α-HVs and lends itself 
to many morphological and replication studies since it is, at this point in time, easier to grow than most 
of its relatives. HSV-1 is a promiscuous virus infecting many different cell types in vitro but in vivo 
infection usually occurs in epithelial cells leading to characteristic pathology including orolabial lesions 
or keratitis. Generally, disease is recurrent and self-limiting but can, in immunocompromised and 
neonatal individuals, lead to disseminated infection and encephalitis (Pellett & Roizman 2013; Roizman 
et al. 2013). Epidemiological estimates from the USA indicated that HSV-1 infects up to 60% of the 
population (Xu et al. 2002; Xu et al. 2006), which may vary depending on ethnicity and socioeconomic 
status and that it is transmitted through close contact with saliva or exudates and initiates infection 
usually in mucosal sites (Roizman 2011). 
 
1.1.3 Virion structure 
All HVs share common structural features (Figure 1A), each featuring a host cell derived lipid 
envelope which is attached to the viral nucleocapsid via an amorphous protein network termed the 
tegument. The linear dsDNA genome of HHVs ranges in size from 125-236kb and is enclosed under 
high pressure to enable expulsion upon opening of the portal. The capsids of all HVs are icosahedrons 
(T=16) around 100-125nm across which are formed by 150 hexameric and eleven pentameric 
capsomeres which are made up of 955 copies of the 170kDa virion protein (VP) 5 and one portal (12 
copies of portal protein) which is illustrated in Figure 1B. Other constituents of nucleocapsids are the 
320 triplexes, made up of one copy of VP19C and two copies of VP23, which link the capsomeres 
(Newcomb et al. 1993), and the non-essential small capsid protein VP26. Upon assembly of the 
nucleocapsid the tegument layer is sequentially added to it, which enables the recruitment of an 
envelope during the egress phase of assembly (Coller et al. 2007).  
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Figure 1 Structural representation of HV features. 
(A) Electron micrograph showing a negatively stained HV virion comprising a host derived membrane decorated with viral 
glycoproteins. The underlying tegument layer connects the membrane to the icosahedral capsid which encloses the double 
stranded viral DNA genome. (B) Reconstruction of one basic icosahedron that makes up the HV capsid (T=16). It is made 
up of 12 pentons and 150 hexons which are held together by triplexes. (Brown & Newcomb 2011) 
 
1.1.4 The HSV-1 tegument layer 
Tegument constituents are only partially conserved amongst the HVs and composition is 
determined by the virus (i.e. it is mostly cell type independent) but may vary depending on when the 
virus is assembled (early vs. late) (Newcomb & Brown 2009; Loret et al. 2008). Over the years the 
composition of the HSV-1 tegument has been serially refined (see Loret et al. 2008; Kelly et al. 2009) 
including references for a list of tegument components) and, depending on which technique was used, 
up to 24 different protein species have been described within mature virions (Loret et al. 2008; Michael 
et al. 2006; Newcomb et al. 2012; Henaff et al. 2013; Bohannon et al. 2013). Maybe not surprisingly, 
even cellular proteins (Loret et al. 2008) and RNAs (Sciortino et al. 2001) can be found in mature virions. 
Given that >50% of the virion mass is contributed by the tegument layer (Loret et al. 2008) it 
may not be unexpected that these proteins fulfil important, and sometimes essential, functions during 
both virus entry and establishment of the early infection programme (reviewed in Kelly et al. 2009). It 
is not uncommon for tegument protein to function in bi-phasic manner (both pre-early and late) 
although in vitro quite a few can be deleted without any discernible effect on infection or assembly 
(Kelly et al. 2009). Since these proteins are delivered as part of the inoculum most of them likely 
function prior to onset of viral transcription or to facilitate initiation of transcription either directly or 
indirectly. Characteristically, they also fulfil their functions in cells treated with protein synthesis 
inhibitors such as cycloheximide. Their confirmed functional contributions in the very early stage of 
infection include establishment of immediate early transcription (Infected cell protein (ICP) 4, VP16), 
modulation of innate cellular defences (ICP0), degradation of cellular mRNA (by Vhs (virion host shutoff 
protein)), and sequentially, capsid movement along microtubules, delivery to the nuclear pore and 
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uncoating of the genome (VP1-2 and protein product of open reading frame 37 of the unique long HSV-
1 genome segment (pUL37)) (Kelly et al. 2009), and later on inhibition of apoptosis (pUL14 and protein 
product of open reading frame 3 of the unique short genome segment (pUS3)) (Yamauchi et al. 2003; 
Munger & Roizman 2001), modulation of DNA damage repair (ICP0) (Wilkinson & Weller 2006), 
replenishment of cellular nucleotide pools (pUL23) (Chen et al. 1979), cytoskeletal rearrangement 
(pUL21) (Takakuwa et al. 2001), nuclear egress (pUS3) (Purves et al. 1991) and secondary envelopment 
(VP1-2, pUL37, VP16 etc.) (Desai 2000; Klupp et al. 2001; von Einem et al. 2006). 
 
1.1.5 The HV life cycle 
HSV-1 is a promiscuous virus replicating in a variety of cells providing it finds a suitable receptor 
on the cellular surface. For the purpose of this thesis the following paragraphs will highlight the major 
steps in HV entry, transport, nuclear entry, replication and egress during lytic infection. For additional 
information on latency which is beyond the scope of this thesis I refer the reader to some elegant 
reviews by Roizman & Whitley (2013); Nicoll et al. (2012). 
The initial non-essential (but nonetheless quite beneficial) steps in HV infection involves the 
loose binding of enveloped virions to ubiquitous, positively charged cell surface proteoglycans 
(glycosaminoglycans (GAGs)) via its gC glycoprotein (Herold et al. 1991). This brings the virion into 
closer proximity with the cell surface where it can scan, via its gD glycoprotein, for high affinity 
receptors including Nectin-1, HVEM (HV entry mediator) and specifically modified heparan sulphates 
(Figure 2, step 1) (Krummenacher et al. 1998; Nicola et al. 1998; Campadelli-Fiume et al. 2000). This 
interaction is, however, not sufficient for infection but allows the dimer gH/L and gB to initiate fusion 
events (Figure 2, step 2) (Subramanian & Geraghty 2007). While fusion can take place at the 
cytoplasmic membrane as noted in the earliest HSV studies over 40 years ago (Morgan et al. 1968; 
Fuller & Spear 1987), virions can also productively or unproductively be taken up by cells (Nicola et al. 
2005; Epstein et al. 1963; Nicola & Straus 2004). The decision for immediate fusion or endocytosis 
depends on the cell type and thus presence of co-receptors such as specific integrins and viral 
determinants (Hadigal & Shukla 2013). In the absence of gD, for instance, HSV-1 was still seen to enter 
cells via endocytosis but infection never ensued (Nicola & Straus 2004). 
In both cases, the immediate post-fusion events lead to a loss of tegument structures (Figure 2, 
step 3) from the capsid. These are partly retained at the inner surface of the cytosolic membrane as 
seen by immuno-electron microscopy (EM) and eventually lost during transit to the nucleus (Granzow 
et al. 2005; Aggarwal et al. 2012). Both cellular and viral factors have been implicated in mediating this 
partial uncoating or de-tegumentation which facilitates the binding of capsids to the cellular 
microtubule network. These partially uncoated capsids, retaining at least VP1-2 (pUL36), pUL37 and 
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pUS3, migrate in retrograde fashion (Figure 2, step 4) towards the nucleus (Sodeik et al. 1997; Radtke 
et al. 2010; Wolfstein et al. 2006) via the microtubule organising centre (Abaitua et al. 2012). Once 
they reach a juxtanuclear position capsids dock at the nuclear pore in a process likely facilitated by one 
of the inner tegument components. Binding at the nuclear pore initiates a set of poorly defined events 
leading to DNA injection into the nucleus (Figure 2, step 5). 
Through a complex set of events involving tegument proteins, including ICP0, ICP4 and VP16, 
transcription of immediate early (α) genes is facilitated (see Figure 2, step 6) and viral genomic silencing 
is inhibited (Roizman 2011; Post et al. 1981). The α genes include the transcription factor ICP4 and the 
E3 ligase ICP0. These factors also lead to sequential expression of β and later on γ genes, the latter of 
which occurs only once DNA synthesis had been initiated (reviewed in Roizman et al. 2013). At this 
stage the pre-replicative foci forming around the incoming genomes evolve into mature replication 
compartments where the complex DNA replication yields concatemeric DNA intermediates which are 
subsequently packaged (step 7/8) (Liptak et al. 1996; Zhong & Hayward 1997; Schumacher et al. 2012; 
Lo Piano et al. 2011). 
The β and γ genes comprise all viral factors required for appropriate DNA replication and nuclear 
assembly of nucleocapsids at late stages (steps 7-9). The nascent capsids progress from A capsids, 
containing scaffolding proteins but lacking DNA, to B capsids which contain no scaffold any more but 
still lack DNA, to C capsids which contain besides non-nucleosomal DNA the cellular protein spermine 
(Tandon et al. 2015). These types of capsids were named in the order they appear if capsids obtained 
from infected-cell nuclei are purified using a density gradient. Studies in cell free systems and 
baculovirus transduced cells elegantly revealed that capsids can self-assemble in the absence of any of 
the α and β gene products, which are required for their expression. In this model only the small capsid 
protein VP26, which is also not required for virion formation in cell culture, was dispensable (Thomsen 
et al. 1994; Newcomb et al. 1994). Once capsids are fully packaged they embark on the egress pathway. 
While C capsids have been seen to traverse nuclear pores or leave the nucleus through induced 
membrane breakdown, overwhelming evidence lead to the formulation of the generally accepted 
model of primary envelopment at the inner nuclear membrane through the recruitment of several 
kinases by pUL31/34, which in complex can cause vesicle release into the perinuclear space even in 
the absence of infection (steps 9-10) (Mettenleiter et al. 2013; Schulz et al. 2015). These perinuclear 
virions subsequently lose their envelope through fusion at the outer nuclear membrane which is 
facilitated by virion associated pUS3. Unlike pUS3, the complex pUL31/34 is retained at the nuclear 
membrane (Henaff et al. 2013). 
The now cytoplasmic capsids are sequentially tegumented by inner tegument proteins, including 
VP1-2 and pUL37 (Henaff et al. 2013), and later on outer tegument proteins either at trans-Golgi 
Introduction 
 
 
- 21 - 
 
derived vesicles or endosomes via homo- and heterotypic interactions of outer tegument-outer 
tegument and outer tegument-glycoprotein (steps 11-13) (Mettenleiter 2006; Granzow et al. 2001; 
Vittone et al. 2005). The vesicularised mature virions are then transported to the plasma membrane 
where they are released in a process similar to exocytosis (step 14) (Harley et al. 2001; Hollinshead et 
al. 2012; Avitabile et al. 1995). The mature virions can now infect subsequent cells and close the cycle. 
Depending on the cell type and which HV was used to infect a target cell, the cell will produce, besides 
infectious virions, other capsid-less vesicles filled with outer tegument and cellular proteins (light 
particles) (Szilágyi & Cunningham 1991; Dargan et al. 1995).  
 
Figure 2 Simplified cartoon of the HV life cycle. 
Details are explained in the text. Picture taken from (Https://www.fli.bund.de/typo3temp/pics/201d5a0ec0.jpg n.d.). T – 
tegument, M – mitochondrium, MT – microtubules, RER – rough endoplasmatic reticulum, G – Golgi apparatus, 
NP -  nuclear pore, NM – nuclear membrane, N – nucleus, TGN – trans-Golgi network 
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1.2 Properties of VP1-2 
1.2.1 Features and functions of VP1-2 
VP1-2 is the largest HV protein consisting of 3164 residues which are encoded in the UL36 open 
reading frame (ORF) of the HSV-1 genome (McGeoch et al. 1988). Genomic studies on other HVs 
indicate that it is conserved throughout all sub-families (Figure 3) but overall sequence identity is only 
around 30-35% (Izumiya et al. 1999). Structurally the protein can be divided into multiple universally 
conserved areas which are linked by sub-family specific linker regions. The N-terminus features a 
conserved and independently functional ubiquitin-specific protease (USP) domain (Kattenhorn et al. 
2005; Schlieker et al. 2005). Interestingly, while its function is dispensable in cell culture systems, 
deletion of the domain prevents formation of virions suggesting a structural role during assembly. The 
overall sequence conservation is moderate but all homologues feature a conserved cysteine 
characteristic of a cysteine protease. 
The region downstream of the USP is highly variable in both primary sequence and length but 
contains a short stretch of high conservation. Secondary structure algorithms predict this region to be 
disordered which likely is caused by the relative enrichment of proline residues which are known to 
break secondary structures. In HSV, PRV (Pseudorabies virus) and HCMV (human Cytomegalovirus) this 
region was shown to exhibit strong nuclear localisation signal (NLS) activity (Möhl et al. 2009; Abaitua 
& O’Hare 2008). Results obtained by our group (Abaitua et al. 2012) and a group working on HCMV 
(Brock et al. 2013) showed that this NLS was essential to virus replication. Flanking the NLS lie the N-
terminal VP16 (Svobodova et al. 2012) and the C-terminal UL37 binding region (Klupp et al. 2002; 
Mijatov et al. 2007), both of which are also essential to viral replication independently of the NLS. 
Directly adjacent to the UL37 binding region follows a long segment which is relatively well 
conserved across all HVs. Until recently not much was known about its function or structure. In silico 
analysis indicated the presence of several coiled-coil domains but functional significance was lacking. 
It was only recently that structural studies of the middle segment gave an indication as to how VP1-2 
functions as part of the virion (discussed later). That study found that VP1-2 can exist in monomeric or 
dimeric forms forming extended fibres through a series of loop-connected helices between residues 
520-1920 (Scrima et al. 2015). This segment connects to the highly conserved extreme C-terminal 
domain via a poorly conserved linker that seems almost entirely dispensable in cell culture during 
infections with another αHV, PRV (Böttcher et al. 2006). That linker features a UL25 binding domain 
and a PQ repeat. Additionally, in Marek’s disease virus the proline rich section is only present in the 
oncogenic type 1 but not the non-oncogenic type 2 (Izumiya et al. 1999). In contrast the conserved C-
terminus is absolutely required for virus replication and assembly and comprises a second UL25 
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binding domain likely enabling recruitment of VP1-2 to nascent capsids (Lee et al. 2006; Coller et al. 
2007). 
 
Figure 3 Simplified schematic of conserved VP1-2 domain structure of representative HVs of all sub-families. 
The approximate positions of known binding sites of viral proteins in the HSV-1 VP1-2 homologue are demarcated with 
black arrows above. Non-conserved linker regions contain no shading and are demarcated with black arrows below the 
HSV-1 homologue. Shaded areas show regions (or domains) that are conserved across all sub-families. Differences in 
shading indicate relative conservation compared to HSV-1. Four separate conserved regions can be found in each VP1-2 
homologue; the N-terminal USP (ubiquitin specific protease domain, in brown); an essential, highly basic stretch of amino 
acids which possesses NLS activity in at least HSV-1 (red); a relatively well conserved middle segment that likely forms a 
fibril (grey); the very well conserved and essential C-terminus (blue) that facilitates the VP1-2 capsid interaction of at least 
HSV-1. Adapted from (Hennig et al. 2014) with additional information from (Scrima et al. 2015; Fuchs et al. 2004; Lee et al. 
2006; Klupp et al. 2002; Mijatov et al. 2007; Vittone et al. 2005; Pasdeloup et al. 2009; Coller et al. 2007). 
 
1.2.2 Role of VP1-2 during entry 
Evidence from over three decades ago suggested that VP1-2 is transcribed and translated after 
onset of DNA synthesis and that it is incorporated into mature virions isolated from cells either in the 
nucleus or after primary de-envelopment in the cytoplasm. As such it was consistently found as a group 
of up to three high molecular weight bands present in highly purified extracellular virions. From its 
migration properties and band intensity it was estimated to be present in between 110-150 copies and 
due to its resistance to extraction is likely associated with incoming capsids. In fact, it was even possible 
to co-precipitate capsid proteins (e.g. VP5) and, more recently, to see virion-associated VP1-2 in 
immuno-EM studies using a specific antiserum raised against purified VP1-2 (Gibson & Roizman 1972; 
Spear & Roizman 1972; Honess & Roizman 1973; Jones & Roizman 1979; Heine et al. 1974; D S McNabb 
& Courtney 1992; Granzow et al. 2005). The first indication that VP1-2 is essential and might be 
contributing to HSV entry came from experiments using a temperature-sensitive (ts) mutant, tsB7, 
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which was blocked prior to expression of immediate early genes (Figure 2, steps 3-5) but could 
complement the growth of other ts mutants in trans while its phenotype was largely (cis-) dominant. 
Although it was not known which protein(s) was affected by the mutation(s) it was sequentially 
mapped to a region between 0.501-0.503 map units along the HSV-1 genome using a HSV-2 marker 
rescue system. The authors then suspected that the tsB7 lesion likely affected the uncoating process 
(Figure 2, step 5) as viral titres of tsB7 did not rise congruently with a second trans-complemented 
mutant. The uncoating defect was later confirmed elegantly using EM which showed that DNA-filled 
HSV capsids accumulate in a juxtanuclear position and that DNA release was extremely slow at the 
non-permissive temperature (Batterson & Roizman 1983; Knipe et al. 1981; Schaffer et al. 1978). 
Interestingly, full capsids could still be seen at the nuclear envelope (NE) at 6hpi and still productively 
release their cargo upon a short shift to the permissive temperature implying a relative longevity and 
resistance to cellular degradation of mature capsids including any capsid-associated factor required 
for genome uncoating and nuclear pore attachment (i.e. that went through appropriate tegumentation 
and egress). This very much contrasts the observed breakdown of capsids and loss of DNA in gD-null 
mutant viruses that do not recruit their secondary envelope (Figure 2, steps 12/13) and highlights the 
distinct nature of both cytoplasmic capsid species (Campadelli-fiume et al. 1991). 
For a virus particle to reach the nucleus it has to cross the cytosol. Because of the high level of 
viscosity of the cytosol, without appropriate guidance, diffusion of capsids would take quite a long time 
depending on the distance of the nucleus from the cytoplasmic membrane and would be deemed 
unlikely in neurons. Since HSV-1 infection in vitro in non-neuronal cells was detected as early as 45mpi 
(Fenwick & Clark 1982) it can be assumed that migration is assisted by the cytoskeleton. Experiments 
from nearly three decades ago showed that this process was sensitive to microtubule depolymerising 
and stabilising drugs in neurons (Kristensson et al. 1986) although in Vero cells, which feature a 
comparatively short distance between cytoplasmic and nuclear membranes, that inhibition was less 
pronounced and mostly absent with the stabilising agent Taxol (Sodeik et al. 1997). Later results 
expanded these data through detailed microscopic investigations in PRV and HCMV infected cells 
which was equally dependent on microtubules and, more impressively, found capsids localising near 
microtubules (Granzow et al. 2005; Ogawa-Goto et al. 2003). Theoretically, any exposed capsid or 
tegument protein (some examples of microtubule-interacting HSV proteins reviewed in (Döhner et al. 
2005)) can mediate this function and one can draw logical conclusions from several lines of telling 
evidence that narrow down the search for the enigmatic driver of both movement and nuclear pore 
docking during entry. 
(i) VP26, an exposed capsid component, remains attached to capsids during transit and can 
mediate binding to microtubules. Artificially assembled capsids that lack VP26 (VP26-null) bind less 
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well to nuclei (Douglas et al. 2004) but migration did occur without it (Döhner et al. 2006). Earlier it 
was already found that VP26 was non-essential in vitro and in mice although virus recovery was 
reduced (Desai et al. 1998). VP26-null mutants were also able to infect neurons both in vitro (Antinone 
et al. 2006) and, more importantly, in a mouse keratitis model (Desai et al. 1998). Since VP5 and the 
triplexes likely are buried under VP26 and remaining tegument structures the spotlight logically falls 
onto the latter. 
(ii) Incoming capsids only react with specific antisera to VP1-2, pUL37 and pUS3 in immuno-EM 
studies or can be found to retain GFP-VP1-2 or GFP-UL37 during PRV transit in neurons (Granzow et al. 
2005; Luxton et al. 2005) 
(iii) Capsids derived from nuclei, which are devoid of tegument structures, cannot migrate along 
microtubules in vitro. Similarly, capsids extracted with Triton X-100 at physiological salt showed 
negligible migration since they are covered in both outer and inner tegument proteins, which 
theoretically obstructs binding to motor proteins either sterically or through the activity of a tegument 
protein. It was only when virions were extracted in the presence of 0.5-1M KCl, yielding capsids devoid 
of some outer tegument proteins but retaining most of the inner tegument, that these manage to bind 
and mediate capsid migration along microtubules in vitro. This phenomenon was sensitive to the 
cellular microtubule transport inhibitor dynamitin. It has to be noted, however, that in the study by 
Radtke et al. capsids treated with the higher salt concentration lost the ability to precipitate 
microtubule motors (Wolfstein et al. 2006; Radtke et al. 2010). Additionally these capsids looked 
different to those found by immuno-EM in cells in a previous study by Granzow et al. (VP16, VP22 and 
VP13/14 present) but they were able to migrate. One would argue that immunoblotting and MS are 
more sensitive and that immuno-EM relies heavily on the availability of epitopes which may be altered 
by any of the fixation or incubation steps involved in specimen preparation. Nonetheless these results 
essentially preclude capsid protein involvement in microtubule recruitment. Several factors were 
found to bind microtubules in vitro (in isolation) and could contribute to recruitment. The outer 
tegument protein pUL11 (Lyman & Enquist 2009), for example, binds microtubule components and is 
almost completely removed by 1M KCl which also coincides with loss of microtubule recruitment 
(Radtke et al. 2010). However, pUL11 is non-essential to HSV-1 and PRV replication in cell culture 
(Leege, Fuchs, et al. 2009). This leaves the proteins VP1-2, pUL37 and pUS3. 
(iv) The role for pUL37 is more complex and controversial. In PRV, for instance, UL37-null virus 
or an independent mutant in which VP1-2 fails to recruit pUL37 remains viable although virus titres 
drop substantially (Klupp et al. 2001; Fuchs et al. 2004). One study on HSV-1 identified dystonin as 
factor required for secondary envelopment, which was abrogated in UL37-null virus. In contrast to 
PRV, pUL37 is essential in HSV-1 and deletion is difficult without impairing virion formation completely 
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(Pasdeloup et al. 2010). However, this can be elegantly circumvented using a heterokaryon system, in 
which uninfected cells in a monolayer of cells infected at low multiplicity of infection (MOI) are fused 
with infected ones. In this system wild-type and UL37-null HSV-1 were both able to infect uninfected 
nuclei within the boundaries of the same cytoplasmic membrane (Roberts et al. 2009). 
(v) In contrast a VP1-2 deficient virus was not able to spread to other nuclei within the same 
heterokaryon (Roberts et al. 2009). Although there appears to be conflicting evidence on the 
involvement of UL37 during entry this study suggests VP1-2 is the dominant factor for infectivity. 
(vi) A mutant with a similar phenotype, which lacks the extreme C-terminal UL25 binding site in 
VP1-2 was also not able to infect subsequent cells since the VP1-2-capsid association was too loose 
using only one of the UL25 binding domains. Incoming capsids thus lose VP1-2 during de-
tegumentation (Figure 2, steps 2/3) or transit (steps 3-5) precluding successful nuclear docking 
(Schipke et al. 2012). 
(vii) A mutant virus harbouring a deletion of a highly conserved NLS within VP1-2, which did not 
affect virion formation or fusion with the membrane of subsequent cells, was similarly deficient for 
infection. This defect was traced to a defect in either routing capsids from the microtubule organising 
centre (MTOC) to the nucleus or docking at the nuclear pore (Abaitua & O’Hare 2008; Abaitua et al. 
2012; Möhl et al. 2009). A similar defect was later confirmed in HCMV and it was shown that the HSV-
1 motif could partially rescue if the HCMV VP1-2 containing the HSV-1 NLS was expressed in trans 
(Brock et al. 2013). 
(viii) As previously described the tsB7 mutant can bind to the nuclear pore even if entry was 
performed at the non-permissive temperature. This phenotype was exploited in a study by Jovasevic 
et al. in which tsB7 capsids were left to dock at the nuclear pore complex (NPC) at the non-permissive 
temperature. Prior to the shift to the permissive temperature, which would allow genome uncoating 
and immediate early gene expression to ensue, a serine-cysteine protease inhibitor was added to the 
medium which in turn abolished genome release even though the temperature was lowered. The 
authors speculate that cleavage has to occur at the nuclear pore to facilitate a conformational switch 
leading to the release of the HSV-1 genome into the nucleus, since they observed a 55kDa N-terminal 
cleavage product only in conditions that enabled DNA injection (Jovasevic et al. 2008). 
(ix) A poorly conserved area of the αHV VP1-2 C-terminus. Although the VP1-2 C-terminus is 
poorly conserved across the sub-families a large region of 709 residues can be deleted from the PRV 
homologue with minimal effect on replication in cell culture (Böttcher et al. 2006), further work has 
shown that a proline-glutamine repeat embedded within that deletion attenuated infection of neurons 
in a mouse eye infection model (Zaichick et al. 2013). In order to infect neurons, capsids have to move 
along axons in retrograde fashion. Movement along microtubules, however, is not a simple one-way 
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process and capsids were shown to make simultaneous contact with motors of the bi-directional 
machinery (Radtke et al. 2010) but had preference for motion in the ‘right’ direction depending on the 
context. Interestingly, deletion of the PQ rich region (part of the 709 amino acid deletion) caused 
capsids to pause more often, effectively shortening the length of a run (guided motion in one 
direction). Additionally, capsids were seen to move in the ‘wrong’ direction (anterograde) more often 
(Zaichick et al. 2013). (x) Further downstream of the PQ motif lies a region which is also universally 
conserved in all HVs although there are some sequence differences between sub-families.  
The presented evidence essentially narrows down the list of suspects to VP1-2. While not all 
domains of this long protein are required for infectivity (e.g. USP) it still remains the only truly essential 
protein in this process. Very recent structural evidence (Scrima et al. 2015) will likely lead to more 
complete understanding of the effects of the above described mutations and may even give an 
indication how VP1-2 fulfils functions in both assembly, entry and nuclear pore docking. 
 
1.2.3 Role of VP1-2 in replication and assembly 
Along with its previous role in entry VP1-2 is indispensable during assembly of HV virions. It is 
thought to provide the platform for the addition of further tegument structures to nascent capsids by 
directly interacting with essential tegument proteins pUL37 and VP16, which both bind to the N-
terminal half of the protein and likely recruit further proteins (e.g. VP16 was shown to interact with 
multiple tegument proteins), guide capsids to areas of secondary envelopment and prevent auto-
aggregation of capsids in the cytosol (Bucks et al. 2007; Vittone et al. 2005; Mettenleiter 2006; Desai 
2000). Evidence of its essential nature during assembly came from multiple studies using ts mutants, 
ΔUL36 mutant viruses or partial deletions. 
The previously described tsB7 has become a very useful tool for investigation of uncoating. Our 
group has previously shown that map region 0.501-0.503 corresponds to VP1-2 and is associated with 
exactly four substitutions. Of these the Y1453H was sufficient to recapitulate the tsB7 defect (Abaitua 
et al. 2009; Abaitua et al. 2011). But the mutation(s) that were introduced through crude chemical 
mutagens brought with it/them another defect late during replication. When infections were 
performed at the permissive temperature or were shifted to the permissive temperature after nuclear 
docking then DNA uncoating was facilitated. Immediate early and early gene expression appeared to 
occur normally but if the temperature is shifted back to the non-permissive temperature before DNA 
replication started then late gene expression was suppressed. If the temperature was shifted after the 
onset of late protein synthesis then, although levels of VP5 are similar to wild-type virus at late times, 
VP1-2 seemed to aggregate in the cytoplasm which lead to impaired progeny virus production. This 
points to a role for VP1-2 in assembly. The reason for the lack of late gene expression at the non-
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permissive temperature still remains to be elucidated but may not lie within VP1-2 since tsB7 VP1-2 
revertant virus still showed some defect (Abaitua et al. 2011). 
Another point to address would be whether VP1-2 might contribute to nuclear egress which also 
involves the controversial question on where it may be added to nascent capsids. VP1-2 homologues 
in at least PRV and HCMV contain a NLS (Brock et al. 2013; Möhl et al. 2009) and early on it was clear 
that VP1-2 can enter nuclei despite its large size (D. S. McNabb & Courtney 1992). Several studies found 
VP1-2 on nuclear capsids while others showed its absence (Radtke et al. 2010; Henaff et al. 2013). 
The first study in a series of VP1-2 deletion mutants where the C-terminal 2700 residues were 
deleted  indicated that deletion of most of VP1-2 had no effect on HSV DNA encapsidation into nascent 
capsids and little (Desai 2000) to moderate (Luxton et al. 2006) effects of nuclear egress of HSV-1 and 
PRV, respectively, from Vero cell nuclei as judged from fluorescence microscopy and EM. However, 
there were some differences in the mutants used in both studies. The HSV-1 ΔUL36 virus expressed 
the USP domain and the PRV ΔUL36 mutation caused a concomitant reduction of UL37 expression. The 
former might alleviate the ΔUL36 egress defect by contributing USP function while in the latter 
scenario an essential function might be impaired as was seen in a HSV-1 ΔUL37 mutant (Desai et al. 
2001). It has to be noted that Desai et al. mentioned the presence of immature capsids in the cytoplasm 
which contained no DNA but scaffold proteins. However, this might occur artefactually as in these cells 
a vast amount of capsids accumulate in nuclei in contrast to wild-type viruses. Furthermore, these 
capsids never acquired further tegument structures or an envelope and were diffusely localised within 
the cytoplasm (Desai 2000). To answer the question of whether VP1-2 is added in the nucleus could 
also be addressed by indirect evidence from ‘milder’ mutations. Our group has, as described above, 
shown that nuclear localisation of VP1-2 is entirely dependent on the NLS found in its N-terminus 
(Abaitua & O’Hare 2008). In this setting VP1-2 cannot enter the nucleus and, while entry of capsids 
was impaired concomitantly, assembly occurred essentially normally. These results might further 
preclude any additional essential role of VP1-2 in DNA synthesis, packaging and cleavage as hinted by 
ΔVP1-2 mutant since late protein synthesis and DNA encapsidation occurred quite normally (Desai 
2000). Later studies on a true VP1-2-null PRV confirmed the defects in secondary envelopment (Fuchs 
et al. 2004) which is likely amplified in HSV-1. 
The gold standard to confirm where VP1-2 is added to capsids and whether it may thus play a 
role in capsid egress would involve the investigation of nuclear capsids. There are in fact several studies 
giving direct evidence that VP1-2 might not be added to capsids within the nucleus. Most evidence 
came from the study of nuclear capsids which are often used as negative controls for microtubule 
binding assays. Several groups analysed nuclear C capsids, which already contain DNA, for their VP1-2 
and pUL37 status. By EM characteristic tufts extending from pentons are observed in in vitro de-
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tegumented capsids but not C capsids. This was confirmed by immunoblots against VP1-2 in the SDS 
lysates of purified nuclear C capsids derived from infected cells (Newcomb & Brown 2010; Radtke et 
al. 2010; Wolfstein et al. 2006). While this evidence appears conclusive there are studies that 
contradict these findings (Lee et al. 2006; Henaff et al. 2013; Bucks et al. 2007; Leelawong et al. 2012). 
The discrepancy in the data might have resulted from the different systems used to study VP1-2 
recruitment. Some studies use high MOI infections of Hela S3 cells with early lysis while other use low 
MOI multi round infections of BHK-1 cells which might show slightly altered assembly steps and 
localisation patterns of VP1-2. Furthermore at very late time points the cells will have suffered a lot 
from the ongoing cell death, mediator release and general disintegration of the infected cells that 
nuclear transport may have been impaired. Conversely, high MOI infection may also affect nuclear 
transport of VP1-2 or alter the spatiotemporal pattern of assembly and early tegumentation. 
While the role for nuclear VP1-2 is controversial, evidence for later stages appears to 
unanimously implicate VP1-2 in directing capsids to sites of secondary envelopment (Desai 2000; Desai 
et al. 2001; Klupp et al. 2001). Additionally, VP1-2 is both sufficient and essential for the subsequent 
recruitment of other inner and outer tegument structures both directly and indirectly (Bucks et al. 
2011; Mijatov et al. 2007; Klupp et al. 2002). How is it possible for VP1-2 to link capsids to the 
envelope? Evidence suggests that VP1-2 extends outwards from pentons in characteristic ‘tufts’ of 
triton X-100 extracted capsids. These structures appear 30-50nm in length as estimated from EM 
studies (Newcomb & Brown 2010) which would likely be sufficient to span the tegument. This way it 
could serve as an assembly platform for, initially, pUL37 and VP16 which both make contacts with 
subsequent proteins (Vittone et al. 2005). Recently, a study found that the VP1-2 central region 
between residues 520-1920 could form a stalk assembly and may facilitate homo-dimerisation of 
VP1-2 into a superhelix which is sufficiently long to span the tegument layer (Scrima et al. 2015). From 
this evidence combined with EM capsid studies and the fact that deletion of VP1-2 abolishes all 
tegumentation leads to the momentary conclusion that VP1-2 serves as a bridge between capsid and 
envelope as suggested previously. 
 
1.3 The nuclear import machinery 
1.3.1 The nuclear membrane and nuclear pore architecture 
The NE (NE) is a physical barrier that separates the cytoplasmic contents from the genetic 
material. This spatial separation affords cells increased possibilities to regulate their life cycle and 
differentiation state with high complexity which forms the basis of multicellular organisms. This barrier 
is made up of a double membrane and a tight interstitial space, the perinuclear space. The outer 
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nuclear membrane (ONM) is contiguous with the endoplasmatic reticulum (ER) which in theory allows 
proteins from the perinuclear space to access the secretory pathway and vice versa. There are several 
thousand nuclear pores spanning both the inner nuclear membrane (INM) and ONM and both 
envelopes are fused at these pores. These pores allow material transfer between compartments but 
also delineate the boundary between the two membranes which means they comprise distinct 
populations of integral and associated proteins (similar to a tight junction separating basolateral and 
apical sides of a cell). 
To give nuclei their rigidity they maintain their own nuclear cytoskeleton which connects, 
through multiprotein anchoring complexes spanning the NE (Nesprins and SUN proteins), with the 
cytoplasmic cytoskeleton (Figure 4A). This not only holds the nucleus in place but also links mechanical 
signals such as movement with the nuclear environment. On the nuclear side directly underlying the 
INM extends a multi-protein meshwork, the nuclear lamina, which is mainly made up of the 
intermediate filaments A- and B-type lamins. This filamentous layer has been implicated in several 
different functions including spacing of NPCs via interaction with Nup153, genome organisation, 
regulation of gene expression by acting as a repository for transcription factors and DNA replication. 
This may not come as a surprise as extensive connections between the lamina and chromatin form in 
interphase nuclei and its interruption manifests as pathology in certain genetic conditions (genetic 
laminopathies). A-type lamins include two alternatively spliced isoforms, lamin A and C, while there 
are two lamin B genes coding for two major and one minor lamin B protein. B-type lamins are 
farnesylated and methylated at a C-terminal CaaX motif (C- cysteine, a – aliphatic residue, X – any 
residue) which enables the insertion into the INM. A-type lamins on the other hand lose their farnesyl 
appendage through proteolytic cleavage of their C-terminal but still assemble at the nuclear periphery. 
Whether both lamin types interact at the nuclear rim is unknown but evidence suggests they can bind 
to one another in vitro. To maintain tight association of the meshwork with the INM other integral 
membrane proteins, such as lamin-B receptor (LBR), lamin-associated proteins (LAP1 and LAP2) and 
emerin, act as anchor points. Of these LBR, emerin and LAP2 isoforms bind lamin B while LAP1’s and 
emerin bind lamin A/C. Additionally, emerin, LAP2s and MAN1 (Inner nuclear membrane protein 
Man1) comprise a LEM (LAP2, emerin, MAN1) domain that serves as a chromatin anchor by recruiting 
the small DNA binding protein BAF (barrier to autointegration) and LBR separately recruits HP1 
(heterochromatin protein 1) which thus indirectly links the lamina to DNA. This not only serves the 
structural organisation of nuclei but links the position of certain genetic areas to genetic silencing. An 
additional feature of proteins like emerin, LAP2s and MAN1 (and others) is that can also bind 
transcription factors activated by, amongst others, transforming growth factor (TGF)-β and Wnt, 
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mostly inhibiting their activity. Thus the lamina and nuclear structure directly feed back into mitotic 
signalling cascades likely only allowing signalling to occur when the conditions are right. 
The lamina is highly networked which makes it very difficult to extract these proteins directly 
and requires ionising detergents such as sodium dodecyl sulphate (SDS), but during mitosis rapid 
disintegration of the whole NE is observed. The process is kick-started with the simultaneous 
disassembly of all NPCs which coincides with a loss of nuclear transport and the build-up of cytoskeletal 
mechanical stress on the NE. Nuclear influx of kinases or their activating factors causes major 
destabilisation of the lamins which become extensively phosphorylated by kinases including 
cyclin-dependent kinase (CDK) 1 and protein kinase C (PKC) βII. The result of these processes leads to 
rapid mitotic NE breakdown (NEBD) which is a misleading term as the envelope is rather assimilated 
into the ER from where it is later re-assembled. Despite NEBD the expected complete loss of 
compartmentalisation is not observed during mitosis courtesy of several factors remaining associated 
with the segregating chromosomes (e.g. lamins and Ran guanine nucleotide exchange factor 
(RanGEF)). Furthermore, nucleoporin complexes released from the NE, in conjunction with importin-
β, are re-purposed to regulate the ensuing chromosome segregation events by accumulating at the 
spindle poles. This juxtaposes them near the DNA when chromosomes reach the poles and thus 
facilitates appropriate re-assembly of the NE around the genetic material after CDK activity declines 
and lamin phosphorylation events are reversed by phosphatases including protein phosphatase 1 
(information in the above paragraphs had been collectively reviewed in Dechat et al. 2008; Güttinger 
et al. 2009; Foisner 2001; Prokocimer et al. 2006; Wilson & Berk 2010; Brachner & Foisner 2011). 
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Figure 4 Schematic representation of the NE and NPCs of metazoan cells. 
(A) Structure of the NE and associated proteins. (B) NPC showing all known Nucleoproteins and their approximate position 
within the NPC. Colour coding shows areas of the same composition. Images taken from (Güttinger et al. 2009). 
 
The pores in the NE allow exchange of molecules between the nucleus and the cytoplasm, 
however, not all molecules enter the nucleus and trafficking is far faster than would be anticipated by 
simple diffusion. To maintain the integrity of the pore and allow selective gating they are fortified with 
a supramolecular complex made up of over 30 different proteins that weigh in at between 50-125MDa 
(Reichelt et al. 1990; Yang et al. 1998; Cronshaw et al. 2002; Stoffler et al. 1999). All its constituents 
are symmetrically arranged with an eight-fold axis (if viewed from the top) and each pore comprises 
four major bands (Figure 4B) which show two-fold symmetry (if viewed from the side). The two inner 
(magenta, red boxes) and outer (green, blue, brown, orange boxes) two rings, which are anchored by 
integral INM proteins POM121 (Pore membrane protein of 121 kDa) and gp210 (pore membrane 
protein of 210 kDa), are made up of the same complement of nucleoproteins (Nups), that is there is 
also a lot of symmetry between the two sides of the NPC. The inner rings of both sides, consisting of 
Nup205, 188, 93 and 155, anchor further Nups that emanate fibrils into the middle of the pore. These 
fibers contain hydrophobic dipeptide repeats of phenylalanine and glycine (FG repeats) which allow 
docking of transport substrates. Moving outward from the centre of the pore lies the outer ring, which 
comprises besides others the Nup107 complex. This complex is the platform for further FG-Nups which 
project their hydrophobic fibrils approximately 50nm into the cytoplasm. It is these mesh like 
appendages that obstruct free trafficking through the NPC and which allow directional movement by 
virtue of interactions with their FG repeats to the centre of the pore. To contribute to directional 
movement across the centre of the NE the symmetry has to be broken to prevent cargoes moving back 
to the cytoplasmic side. While the Nups themselves do allow cargoes to move in both directions it is 
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the nuclear transport factors anchored either in a gradient across the pore or at strategic positions 
within it. For instance, while the make-up of the outer nuclear ring is similar to the cytoplasmic side, 
the fibrils emanating into the nucleoplasm comprises different FG-Nups (Nup153-Tpr complex and 
others) which form a basket-like assembly. The basket harbours factors that are important for nuclear 
export of proteins, release of imported cargo proteins and for recycling of nuclear transport receptors 
(information in this paragraph was collectively reviewed in Dechat et al. 2008; Güttinger et al. 2009; 
Foisner 2001; Prokocimer et al. 2006; Wilson & Berk 2010; Brachner & Foisner 2011). 
 
1.3.2 NLSs and nuclear import receptors 
To facilitate the directed and fast movement of cargoes across the NPC a set of structurally 
related proteins evolved to cater for cargoes that range across the whole spectrum of protein sizes. 
These nuclear transport receptors are collectively termed karyopherins and include the alpha and beta 
sub-families which enable most transport processes. Karyopherins recognise their cargos through a 
diverse set of NLSs (NLSs) which either specify the classical or non-classical nuclear import pathway. 
Classical NLSs (cNLSs) have two defined aspects; they use the importin-α/β pathway to enter the 
nucleus and can roughly be divided into two classes, the mono- (mpNLS) and bi-partite (bpNLS) NLSs, 
based on the number of positively charged activity-conferring regions which are exemplified by the 
NLSs of the Simian Virus 40 (SV40) protein large T antigen (lTag) (Kalderon et al. 1984) and the cellular 
protein nucleoplasmin (Dingwall et al. 1982). Within the mpNLSs up to five different sub-classes have 
been defined which all comprise at least two out of five basic residues, although stronger signals 
feature at least three basics including an N-terminal lysine. The consensus is not absolute, that is, 
sequences may be extended and large hydrophobic, acidic or polar residues can be accommodated 
(Kosugi, Hasebe, Matsumura, et al. 2009). Despite this variety, most putative NLSs found by in silico 
analysis of the human genome fall into class 1 (Table 1). The much longer bpNLSs were suggested to 
consist of two imperfect mpNLSs which lie around 9-12 residues apart. However, sequences with larger 
linkers have been defined (Vasicova et al. 2013). While small proteins might not require an NLS to get 
to the nucleus their transport is considerably faster if one is present. Transport kinetics vary between 
cargoes and the rate of transport has been suggested to be proportional to relative affinity of the NLS 
to the transport receptor. This view, however, since it was based on experimental data of isolated NLSs 
or NLSs fused to GFP (Kosugi, Hasebe, Matsumura, et al. 2009; Hodel et al. 2006), is a little simplistic 
and transport rate will certainly be affected by the molecular environment (i.e. position of the NLS 
within cargo protein, size and structure of the cargo). 
Despite much research defining the sequence specific import modes the list of atypical NLSs is 
growing. Many of these proteins show no signal sequence that would be recognised by an NLS finder 
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algorithm (described in results section) but still end up in the nucleus. The first to be described was the 
glycine-rich NLS of hnRNP A1(heterogeneous nuclear ribonucleoprotein A1) (Siomi & Dreyfuss 1995) 
which enables binding to importin-β2 (transportin) (Aitchison et al. 1996). Most of these proteins bind 
to importin-β members directly rather than via importin-α and form multiple low affinity (high avidity) 
interactions with the concave surface of these proteins. 
 
Table 1 Overview of the consensus sequences of the six classes of classical NLSs found in eukaryotic, multicellular systems. 
X = any amino acid; subscript shows number of a particular residue. The third column shows the absolute numbers of 
nuclear proteins (as annotated in uniprot) in H. sapiens that contain an NLS of this type. The fourth column shows the 
theoretical number of proteins in the human proteome (total sample size = 43571) containing a sequence matching the 
given consensus (Kosugi, Hasebe, Matsumura, et al. 2009; Chang et al. 2014). 
NLS class Consensus 
No. of confirmed 
proteins 
calculated no. of 
proteins 
Class 1  KR(K/R)R, K(K/R)RK 2473 16038 
Class 2  (P/R)XXKR(D/E)(K/R) 1396 1707 
Class 3  KRX(W/F/Y)XXAF 13 79 
Class 4  (R/P)XXKR(K/R)(D/E) 1528 640 
Class 5  LGKR(K/R)(W/F/Y) 4 25 
Bipartite  KRX10–12K(K/R)(K/R), KRX10–
12K(K/R)X(K/R) 
998 580 
 
In the last two decades it was brought to the field’s attention that the widely accepted NLS 
paradigm needs to be expanded. Nuclear transport as any other process is subject to extensive 
regulatory networks which include epitope masking and post-translational modification such as 
phosphorylation, acetylation and ubiquitination. This also raises the possibility that some NLSs might 
escape discovery as they are only active under certain circumstances. 
The karyopherin-β family is an ancient family spanning all eukaryotic lineages. Significant 
developmental steps can be correlated nicely with the appearance of new sub-groups of β-
karyopherins (O’Reilly et al. 2011). The human β-karyopherin group comprises at least 18 members 
ranging in size from 876-1204 amino acids. These include both import (importin) and export (exportin) 
carrier proteins. While they only share significant sequence homology in the N-terminal RanGTP 
binding domain the rest of the protein remains structurally highly similar (see Figure 5B for importin-
β1 structure) and each of the proteins shows a negatively charged overall character (probably to bind 
basically charged cargoes). Each member contains between 18-24 HEAT repeats which are short 
tandemly arranged modules of approximately 40 residues each consisting of an anti-parallel α-helix 
hairpin connected via a loop. These HEAT repeats are connected via linker regions and stacked with a 
slight clock-wise twist. Structurally they resemble a bent, superhelical rod comprising one concave and 
one convex surface (Marfori et al. 2011; Zachariae & Grubmüller 2008; Conti et al. 2006; O’Reilly et al. 
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2011). This setup allows for extreme structural changes (Kappel et al. 2010) and by virtue of its 
flexibility can accommodate a variety of different cargoes which can be released extremely fast(Lee et 
al. 2005). While RanGTP (N-terminal), importin-α (C-terminal) and directly interacting cargoes (C-
terminal) bind the concave surface of importin-β1, nucleoporins bind the convex surface via 
hydrophobic FxFG motifs. Binding to the convex surface appears to not affect binding of cargo while 
binding of RanGTP alters the overall structure enough to expel cargoes from the concave surface 
(importin-α or directly interacting proteins) in a spring-like manner. Importin-β1, at this time, seems 
to be the only β family member to bind to additional adapters including karyopherin αs, snurportin 
and hRIP isoforms, however, it appears possible that β karyopherins can form heterodimers to 
facilitate transport of specific cargoes as was found for importin-β1 and importin-7 mediated histon-
shuttling (Jäkel et al. 1999). This implies that cells evolved more complex nuclear import pathways 
using more than one receptor at the time and implies that we will discover many more import 
pathways (or combinations of the existing ones) and quite likely find considerable redundancy at least 
in cell culture systems. 
The second group of major transport factors which are thought to contribute to at least 57% of 
all nuclear transport events in yeast (Lange et al. 2007) are karyopherin αs. These shorter transport 
proteins function as adapters between importin-β1 and cargo proteins, while most nuclear transport 
receptors, including importin-β1, interact directly with their cargoes. As this pathway was the first 
described to enable nuclear shuttling, it is termed the classical nuclear import pathway (Goldfarb et al. 
2004). 
The appearance of karyopherin αs not only uncoupled evolution of importin-β1 cargoes from 
importin-β, which cannot change as much being facilitator of transport in many essential pathways, 
but it also increases delivery options and pools of cargoes (Lott & Cingolani 2011). It also allows cells 
to regulate nuclear localisation at a more intricate level and thus integrate diverse signals better 
(Riddick & Macara 2007). Thus far seven α family members have been discovered in humans which 
bind many different, at times overlapping cargoes. The seven members (importin-α1 through α7 or 
karyopherin α1-α8 while there is no α2) can be divided into three groups classed according to sequence 
conservation (α1s, α2s and α3s) (Goldfarb et al. 2004). The different α isoforms are tightly regulated 
and thus fulfil annotated roles during both cellular differentiation and cell proliferation (Koehler et al. 
2002; Pulliam et al. 2009). All eukaryotic cells possess homologues of the α1s while multicellular 
organisms such as humans contain all three classes enabling more complex regulation through tissue 
and time specific expression. In vivo studies in animals that comprise one or few members of each of 
the three classes (Drosophila and C. elegans) yielded valuable functional information. As such, α2s 
were dispensable during development but fruit flies were sterile and C. elegans produced non-viable 
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offspring if the factor was deleted while knock-out of α3 showed additional defects in cell growth on 
a more general level (Goldfarb et al. 2004). 
 
Figure 5 Structural representation of importin proteins. 
Importin-α (A) and importin-β (B) are depicted as ribbon structure showing Armadillo (α) and HEAT (β) repeat 
arrangements. Image taken from (Goldfarb et al. 2004). 
 
Structurally, importin-αs are smaller than the β family members and weigh in at approximately 
50kDa and ranging in size from 499 to 538 residues (UniprotKB database). All feature a short N-terminal 
auto-inhibitory domain (Figure 5B, importin-β binding domain, IBB, bound to importin-β), which also 
facilitates binding to importin-β1, and a C-terminal cargo binding domain made up of ten armadillo 
(ARM) repeats, which consist of three α-helices (Figure 5A). The Armadillo (ARM) repeats structurally 
resemble the HEAT (Huntingtin, elongation factor 3, protein phosphatase 2A, and the yeast kinase 
TOR1) repeats and result in similar regulatory features. For instance, the N-terminal IBB domain when 
released by importin-β1 and the tenth ARM repeat, which is bound by CAS (cellular apoptosis 
susceptibility) and/or Nup50, facilitate efficient cargo release due to conformational changes in 
importin-α (Gilchrist et al. 2002; Matsuura et al. 2003; Goldfarb et al. 2004). Similarly, the ARM repeats 
allow a high degree of flexibility to accommodate cargo proteins and different NLSs (Roman et al. 
2013). Binding of cargoes is facilitated by the two NLS binding sites, the major groove and the minor 
groove, formed by ARM2-4 and ARM7-9, respectively. While mono-partite NLSs can bind to the major 
or minor groove, bi-partite usually make contact with both simultaneously and the distance of both 
grooves sets the optimum spacer length of bi-partite NLSs to between 10-12 residues. 
1.3.3 RanGTP cycle and mechanism of nuclear import 
Nuclear import is a very complex process and it becomes increasingly obvious that the classical 
paradigm of nuclear transport has many exceptions. Over time the ‘diffusion limit’ of the nuclear pore 
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has been based on easily purified substrates (bovine serum albumin (BSA) and ovalbumin) and was 
raised sequentially (Paine et al. 1975; Keminer & Peters 1999; Görlich & Kutay 1999), although proteins 
as large as 110 kDa (Wang & Brattain 2007) have been found to enter nuclei of cells despite the absence 
of any discernible NLS or requirement for ATP (indicating active transport). Diffusion through the pore 
is restricted by unfolded nucleoporins that emanate into the central channel which sets the navigable 
space to approximately 9 nm (Paine et al. 1975; Denning et al. 2003). It has now become widely 
accepted that molecular weight is not the only determining feature since globular proteins might be 
obstructed from entering the nucleus due to exceeding the estimated diameter of the NPC of 9 nm 
and sometimes smaller proteins were found to diffuse slower than larger ones (Görlich & Kutay 1999). 
In the presence of a targeting signal, however, the diffusion barrier is less of a problem and 
theoretically only the full diameter of the NPC can limit import of proteins, although gold particles as 
large as 39 nm were shown to pass the NE in the presence of an NLS (Panté & Kann 2002; Dworetzky 
et al. 1988). Even though diffusion is possible for very small proteins it may be of importance to allow 
fast entry or it may be vital that they are exclusively nuclear (e.g. histone family) and thus targeting 
signals are widely distributed throughout the proteome (see Table 1 for distribution of classical NLSs). 
For active nuclear transport to be sustained a protein requires besides an NLS: 
(i) the ability to dock at the NPC directly or via nuclear transport adapters  
(ii) asymmetrical distribution of some nucleoporins and, most importantly, RanGTP to enable 
directional transport of cargoes 
(iii) energy in the form of ATP/GTP 
(iv) a factor to enable its release from the nuclear transport machinery in the nucleoplasm 
The process of nuclear import, here illustrated using the paradigmatic classical transport 
pathway (for examples of cargoes of the different transporters see Harel & Forbes 2004; Pemberton 
& Paschal 2005; Sorokin et al. 2007), begins in the cytoplasm. Cargo proteins are recognised by 
importin-α isoforms by virtue of their basic NLS. It is generally thought that NLSs form linear epitopes 
binding to the concave surface of importin-α at one of its two binding grooves. In its free form 
importin-α exists in an auto-inhibited form with its N-terminal IBB domain blocking the NLS binding 
sites. Two not mutually exclusive scenarios were suggested to regulate importin-α binding activity. 
Either importin-β binds to the IBB, which increases the affinity to cargo NLSs substantially or NLSs 
displace the IBB which allows binding to importin-β. It would perhaps not be surprising if both 
processes work simultaneously to allow optimum binding of cargoes. While the majority of mpNLSs 
binds the major groove (classes 1 and 2), a smaller proportion binds solely to the minor groove, and 
bpNLSs appear to bind both simultaneously. Formation of the ternary complex (importin-α/β-cargo) 
allows binding to NPC via the convex surface of importin-β. The complex then moves hand over hand 
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along the FxFG repeat ‘gradient’ through the channel as some of these hydrophobic repeat proteins 
are asymmetrically distributed. Inhibition of FxFG protein binding, for example through wheat germ 
agglutinin, which binds these proteins, abolishes directed nuclear transport. This process relies on on-
off rates for FxFG/importin-β interactions and likely on the presence of two separate Nup binding sites 
in importin-β (Harel & Forbes 2004; Bednenko et al. 2003; Kutay et al. 1997). Once the ternary complex 
reaches the nuclear basket, release of the cargo proteins is facilitated by binding of RanGTP which both 
sterically displaces it and causes allosteric changes incompatible with importin-α/cargo binding 
(Cingolani et al. 1999). Importin-β is subsequently recycled back into the cytoplasm in complex with 
RanGTP which prevents it from binding further cargo proteins. In the cytoplasm Ran hydrolyses GTP to 
GDP, stimulated by the activity of the RanGAP1 (Ran GTPase activating protein 1) complex and RanGTP 
binding to Nup358 (Ran binding protein 2 (RanBP2)), causing dissociation of importin-β (Yokoyama et 
al. 1995; Bischoff & Görlich 1997). The nuclear importin-α/cargo complex dissociates independently in 
a process that likely commences through importin-β release of the auto-inhibitory IBB domain and is 
assisted by binding of the CAS/RanGTP complex, the designated recycling transport factor of importin-
α, and Nup50 to the C-terminus. CAS export works similarly to Crm1 export in that it facilitates reverse 
transit by moving along Nups and releases its cargo upon conversion of GTP to GDP, which is stimulated 
by cytoplasmic RanGAP1. 
Pivotal to directional transport across the NPC is the strategic placement of certain regulator 
proteins within the cell (reviewed in (Kalab & Heald 2008)). The determining factor is the asymmetrical 
distribution of both nucleotide-bound forms of Ran (GDP and GTP) which is maintained by exclusively 
cytoplasmically localised RanGAP1 and chromosome bound RanGEF RCC1 (Regulator of chromosome 
condensation 1). When importin-β complexes are dissociated in the nuclear basket by RanGTP this 
complex migrates to the cytoplasmic side where NPC-localised RanBP1 and RanGAP1 stimulate the 
Ran-GTPase activity (Bischoff & Görlich 1997; Mahajan et al. 1997). This facilitates dissociation from 
importin-β but in turn would cause cytoplasmic accumulation of RanGDP. However, in its GDP-bound 
form Ran is recycled back to the nucleus by NTF2 (nuclear transport factor 2). Unlike most importin-β 
mediated transport events, NTF2 dimerises to mediate movement through the pore by sequentially 
binding the relevant Nups (Bayliss et al. 2002). This one-way journey completes through the RCC1 
mediated nucleotide exchange which releases RanGTP from the complex. NTF2 in turn ‘exports itself’ 
upon release of its cargo to close the cycle.  
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1.4 Viral exploitation and modulation of nucleo-cytoplasmic 
transport 
Many viruses besides the HVs, including most DNA virus (except pox viruses) and even some 
RNA viruses (e.g. human immunodeficiency virus (HIV)) must enter the nucleus to complete their 
replicative cycle. However, there are several obstacles to reaching their destination. Firstly, they have 
to traverse the cytoplasmic membrane which, depending on the virus in question, can be via several 
routes; 
(i) Receptor mediated membrane fusion for enveloped viruses as found for, e.g. 
retroviruses(Gallo et al. 2003) and HVs(Browne et al. 2001) 
(ii) Receptor mediated endocytosis (Hasebe et al. 2009; Mercer & Helenius 2009; Grove & 
Marsh 2011), including (macro-)pinocytosis (Nicola et al. 2005; Saeed et al. 2010), 
caveolin-dependent (Hasebe et al. 2009; Anderson et al. 1996) uptake and clarthrin-
mediated endocytosis (Matlin et al. 1981), of both enveloped and non-enveloped viruses, 
e.g. , HVs (in some cell types) and influenza 
(iii) Disruption of the cytoplasmic membrane by non-enveloped viruses (Hogle 2002) 
 
To add to the complexity of virus entry to cells, many viruses were shown to utilise different 
pathways in different cell types. It is conceivable that viruses entering their target cells via multiple 
pathways do this by default and, depending on the physiology of the target cell, reach their destination 
by the one that works best. This would be beneficial to an entering virus since the body is highly 
differentiated ensemble of cells that harbour a very specialised physiology and have at their disposal 
several potential anti-viral mechanisms. Quite often viruses were found to end up in dead-end 
pathways (Gershey & Diacumakos 1978; Diacumakos & Gershey 1977; Thomas et al. 2007; Grove & 
Marsh 2011) leading to their recognition and destruction and depending on the cell type only some 
would lead to infection. For instance, only approximately 1% of SV40 polyomavirus particles, for 
example, were shown to cause an infection (Diacumakos & Gershey 1977; Gershey & Diacumakos 
1978) when virus is added to cells, which can be increased by 1 log unit each by injecting virus into the 
cytosol or nucleus, implying that viral entry is a race which is governed by stochastical events. 
Additionally, observations from HV infection in our lab indicate that the same HSV-1 inoculum yields 
different numbers of plaques depending on the cell type infected. 
Notwithstanding the various different entry mechanisms viruses employ, virus capsids/particles 
have to traverse the densely packed cytosol. This can achieved either by directly/indirectly engaging 
the host cytoskeletal machinery via capsid components or by deploying the endosomal sorting 
components as adapters. Prior to nuclear entry virus particles/capsids usually have to enter the 
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cytosol, except for some described exceptions (Nishimura et al. 1991; Butin-Israeli et al. 2010; Butin-
Israeli et al. 2011), via endosomal lysis or fusion to be able to penetrate the nucleus (Grove & Marsh 
2011). In the last three decades a few routes into the nuclear compartment have been described. 
These include capsid movement through the nuclear pore (Baculovirus), capsid docking at the NPC 
(HSV) which may involve capsid disassembly (Adenovirus), disruption of the NE (parvoviruses), fusion 
with the INM (SV40), transport of previously uncoated ribonucleoproteins (RNPs) through the NPC 
(Influenza and HIV) or NEBD (non-lenti retroviruses). The following paragraphs will summarise these 
pathways using representative examples. 
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Table 2 Overview of how selected viruses use and/or modify the cellular nuclear transport/pore machinery or the NE itself to enter cells. 
 Group Family Virus Viral Component Targets Process Reference 
En
tr
y 
1 
H
er
p
es
vi
ri
d
ae
 
HSV-1 
capsid Importin-β capsid docking at nuclear pore (Ojala et al. 2000) 
capsid Nup358 capsid docking at nuclear pore (Copeland et al. 2009) 
pUL25, capsid Nup214 capsid docking at nuclear pore; DNA release 
(Copeland et al. 2009; 
Pasdeloup et al. 2009) 
pUL25 hCG1 (NUPL-2) 
binds free pUL25; might be involved in capsid 
docking at nuclear pore 
(Pasdeloup et al. 2009) 
pUL25 ?  likely NPC component 
uncoating of DNA at the NPC; soluble pUL25 
inhibited uncoating but not NPC docking 
(Rode et al. 2011) 
P
o
ly
o
m
av
ir
id
ae
 
SV40 
VP1/2/3 
general nuclear transport 
machinery 
capsid delivery to the nucleus; all VPs contain 
classical NLSs which likely use the importin-α/β 
pathway 
(Nakanishi et al. 2002; 
Nakanishi et al. 2007; Clever 
et al. 1991; Yamada & 
Kasamatsu 1993; Nakanishi et 
al. 1996) 
VP1 pentamer 
(unknown mechanism) 
caspase-6, Lamin A/C 
disruption of nuclear lamins by caspase-6 in order 
for capsids to penetrate INM from ER; fluctuations 
in Lamin A/C levels and associated 
phosphorylation at an unidentified residue in 
quiescent cells 
(Butin-Israeli et al. 2010; 
Butin-Israeli et al. 2011) 
A
d
e
n
o
vi
ri
d
ae
 
Ad2/5  Crm1, Hsp70 nuclear targeting of capsids 
(Saphire et al. 2000; Strunze 
et al. 2005) 
Ad2 
hexon 
Nup214, Importin-β and 
importin-7, Histone H1 
nuclear targeting of capsids via adapter protein 
histone H1 
(Trotman et al. 2001) 
hexon Nup214/62/358 
capsids bind Nup214/88/358 to dock at the NPC; 
Nup358 recruits kinesin heavy chain Kif5c to 
promote capsid disintegration; simultaneously 
leads to NPC perturbation 
(Strunze et al. 2011) 
pVII 
Importin-α/β, Importin-7, 
Transportin-1 
nuclear import of Ad genomic DNA post-docking 
(Wodrich et al. 2006; Hindley 
et al. 2007) 
hexon Importin-α/β, Nups nuclear docking of capsids (Saphire et al. 2000) 
Baculo-
viridae 
AcMNPV  Importin-β nuclear delivery of capsids 
(Ohkawa et al. 2010; van Loo 
et al. 2001) 
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 Group Family Virus Viral Component Targets Process Reference 
P
ar
vo
-v
ir
id
ae
 
MVM 
 proteasome nuclear delivery of capsids Ros 2004 
 Caspase-3, lamin B2 NE disruption (ONM) by digestion of lamin B2 
(Cohen & Panté 2005; Cohen 
et al. 2006; Cohen et al. 2011) 
wtAAV2  ? 
? (unknown mechanism but independent from 
trafficking through the NPC) 
(Hansen et al. 2001) 
recAAV2  Importin-β, Importin-7, NPC nuclear delivery of capsids (Nicolson & Samulski 2014) 
H1  
Nup62, Nup153, Nup214, 
Nup358, PKCα, Cdk1/2, 
Caspase-3, Lamins 
binding to NPC via alternative mechanism leads to 
subsequent disruption of the ONM and INM via 
the mitotic kinase-protease axis 
 
(Porwal et al. 2013) 
5 
O
rt
h
o
m
yx
o
vi
ri
d
ae
 
In
fl
u
e
n
za
 A
 
NP Importin-α nuclear import of vRNP 
(Wang et al. 1997; Cros et al. 
2005; Wu et al. 2007; Melen 
et al. 2003; Ozawa et al. 2007) 
NP 
Importin-α1 or 5 + Importin-
β 
nuclear import of vRNP (O’Neill et al. 1995) 
NP Transportin-3 nuclear import of vRNP (RNAi) (König et al. 2010) 
 
CSE1L, KPNB 1, 
NUP214,NUP153, TNPO3 
potentially nuclear import of vRNP (RNAi) (König et al. 2010) 
 
Importin-β, Crm1, Nup98, 
Nup205 
potentially nuclear import of vRNP (RNAi) (Karlas et al. 2010) 
 Importin-5 
likely nuclear import of vRNP as delayed gene 
expression 
(Deng et al. 2006) 
PB1/2, NP, PA + NS1 Importin-α4  (Shapira et al. 2009) 
PB1/2, NP, PA Importin-α7  (Shapira et al. 2009) 
6 
R
et
ro
vi
ri
d
ae
 
HIV-1 
Vpr hCG1, Nup54, Importin-α/β 
NEBD if Vpr overexpressed; greatly improves 
docking of the PIC at the NPC by directly binding to 
nucleoporins; increased affinity of importin-α/β to 
the PIC; Vpr at the NE promotes G2 
arrest/apoptosis 
(Vodicka et al. 1998; Popov et 
al. 1998; de Noronha et al. 
2001; Jacquot et al. 2007; Le 
Rouzic et al. 2002) 
Integrase Nup62 
chromatin associated Nup62 to aid genome 
integration 
(Ao et al. 2012) 
Integrase Importin-7 nuclear transport of pre-integration complex (PIC) 
(Zaitseva et al. 2009; Ao et al. 
2007; Fassati et al. 2003) 
Integrase Nup98 reduction of genome integration (Ebina et al. 2004) 
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 Group Family Virus Viral Component Targets Process Reference 
Integrase Importin-α1 nuclear import of PIC (Gallay et al. 1997) 
Integrase Importin-α3 nuclear import of PIC into T cell nuclei (Ao et al. 2010) 
Integrase, CA Transportin-3 nuclear import of PIC 
(Krishnan et al. 2010; Christ et 
al. 2008) 
CA Nup153, Nup155 nuclear import of PIC (Lee et al. 2010) 
CA Nup358 
targeting of imported PIC and increased efficiency 
of integration in transcriptionally active areas 
(Schaller et al. 2011) 
Matrix  nuclear import of PIC into non-dividing cells 
(Haffar et al. 2000; Bukrinsky 
et al. 1993) 
MLV CA protein 
masking of receptor binding 
site 
inhibits nuclear transport of PIC (Yamashita & Emerman 2004) 
7 
H
ep
ad
n
a-
vi
ri
d
ae
 
HBV core protein importin α/β, Nup153 
capsid entry to the nucleus and capsid arrest at 
Nup153 acts as a maturity checkpoint (coupled 
potentially to phosphorylation state) 
(Kann et al. 1999; Schmitz et 
al. 2010) 
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1.4.1 Adenovirus 
Adenoviruses are large non-enveloped DNA viruses that infect cells through specific interactions 
of the fibre knob domain to the CAR (Coxsackie Adenovirus receptor) or CD46 (cluster of differentiation 
46) viral receptors, which leads to clathrin-dependent endocytosis. This initial attachment is facilitated 
by the fibre knob domain. It is within these pre-early endosomes that structural pH-dependent (Maier 
et al. 2012; Seth et al. 1984; Seth 1994) changes occur liberating pVI (Adenovirus protein 6) from the 
virion leading to lysis of the endosome (Prchla et al. 1995). Cytosolic capsids migrate towards the 
nucleus along microtubules which requires hexon dependent recruitment of dynein motor proteins 
(Smith et al. 2008). The large adenovirus capsid diameter of approximately 90nm cannot enter the 
nucleus through the NPC and a complex series of disassembly events occurs at the NE which leads to 
release of the viral DNA and subsequent transport through the central channel of the pore. 
Initial evidence implies that nuclear pores or at least docking there, are required for disassembly 
of capsids and subsequent import of viral nucleic acid into the nucleus. Intact capsids can easily be 
seen at the NE (Greber et al. 1996). When wheat germ agglutinin or anti-NPC antibody (clone RL1), 
both inhibitors of nucleo-cytoplasmic transport (Akey & Goldfarb 1989; Finlay et al. 1987; Featherstone 
et al. 1988), were injected into cells adenovirus disassembly was blocked and free penton or nuclear 
pVII could not be detected. That implied contact with the NPC is required to allow disassembly (Greber 
et al. 1997; Snow et al. 1987). For actual attachment to the pore hexon and facilitates capsid binding 
to Nup62, 214 and 358, the latter recruiting kinesin heavy chain Kif5c. The close proximity to the 
nuclear environment also allows hexon protein to recruit histone H1, which, in conjunction with 
Kinesin, in turn was found to initiate capsid disassembly (Strunze et al. 2011; Trotman et al. 2001; 
Saphire et al. 2000). Surprisingly, Crm1 (chromosome maintenance 1 or exportin-1), the bona fide 
nuclear export protein, contributed an essential but unknown function to the entry process which 
likely involves release of capsids from microtubules upon reaching the NPC. After uncoating the DNA-
pVII complex recruits nuclear transport factors Importin-α/β to initiate transport of the viral genetic 
material to the nucleoplasm, a process which also requires the protein Hsp70 (heat shock protein 70) 
(Saphire et al. 2000). 
 
1.4.2 HIV 
Retroviruses are positive sense single-stranded RNA (ssRNA) viruses (Baltimore group 6) that 
integrate their genetic material into host cell chromatin. Cryptic remnants can be found all over the 
human genome indicating a long-standing relationship. All retroviruses, usually in form of a pre-
integration complex, require access to the nucleus. While murine leukaemia virus (MLV), a γ-retrovirus, 
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gains access to the nucleus through mitotic NEBD (Roe et al. 1993), HIV, a lentivirus, can also integrate 
into chromatin of quiescent cells (Gartner et al. 1986). 
After receptor binding (CD4 and C-C chemokine receptor 5 (CCR5) or C-X-C chemokine receptor 4 
(CXCR4)) by gp120 at the cytoplasmic membrane fusion and deposition of viral capsid into the 
cytoplasm occurs. Nuclear entry requires partial uncoating and loss of some capsid (CA) protein to take 
place. Recruitment of cellular factors allows migration along microtubules towards the nuclear 
periphery. There is some debate about whether reverse transcription occurs during transit or at the 
nuclear pore. Nonetheless the viral pre-integration complex (PIC) needs to bind to the NPC. In the last 
three decades since its discovery almost every PIC component, including reverse transcription 
products, have been implicated, by virtue of their karyophilic nature and ability to bind NPC 
components, to be important for nuclear import of the HIV genome (reviewed in Matreyek & Engelman 
2013). Both canonical (matrix protein (MA), integrase (IN), viral protein R (Vpr)) and non-canonical 
(Vpr, CA) NLSs were shown to be functional for soluble protein import, recruiting a diverse set of 
nuclear transport factors which include importin-α1 and 3, importin-β1, importin-7 and transportin-3 
(Table 2; also for references). However, subsequent studies also indicated that deletion of karyophilic 
signals in each of the PIC proteins still allowed infection of quiescent cells adding inconvenient 
complexity to the enigmatic and thus far pharmaceutically untouched process of nuclear import of 
PICs. As for many other viruses, these processes are likely redundant and dependent on the 
physiological state of the target cell. It is also conceivable that multiple importins are required for 
distinct steps of PIC nuclear import and integration. As such, one or more factors may be required for 
import per se while others could guide or protect the PIC (Valle-Casuso et al. 2012; Levin et al. 2010; 
Fricke et al. 2013; De Iaco et al. 2013; Ao et al. 2012; Schaller et al. 2011). 
Nucleoporins also play an important role during nuclear delivery of PICs. As such, Vpr, IN and CA 
have all been shown to interact with Nup54, 62, 98, 153, 155, 358 and nucleoporin-like protein 1 
(hCG1) (Table 2; including references). These likely allow importin independent docking at the NPC. In 
fact, the Vpr-hCG1, Vpr-Nup54, IN-Nup98 and CA-Nup153/155 interactions can anchor the PIC to the 
nuclear pore while this likely increases affinity to resident nuclear transport factors such as importin-
α/β. Interestingly, a HIV-1 chimera carrying MLV-CA protein could only infect cycling cells. The block 
here, however, might relate to integration rather than PIC transport (Yamashita & Emerman 2004). 
Recent findings add another layer of complexity since several Nups can bind to chromatin structures 
and modulate diverse processes including transcription and gene silencing (Ruben et al. 2011; Van De 
Vosse et al. 2013; Kehat et al. 2011; Capelson et al. 2010; Kalverda et al. 2010). It appears these could 
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be used, in addition to entry, to target the viral PIC to specific integration sites post-nuclear entry (Ao 
et al. 2012; Schaller et al. 2011). 
 
1.4.3 Influenza 
The Orthomyxoviruses, exemplified by Influenza A virus (IAV), are nuclearly replicating, 
segmented negative sense ssRNA viruses that have to enable each RNP complex to shuttle to the 
nucleus independently. Infecting virions enter non-ciliated cells via terminal sialic acid moieties of 
glycoproteins which are recognised by the Hemagglutinin (HA) virion surface antigen (Knipe & Howley 
2013). This leads to endocytosis and subsequent uncoating (Chen & Zhuang 2008; Eierhoff et al. 2010). 
Alternatively, Influenza may be internalised by macropinocytosis (Rossman et al. 2012). In both cases 
release into the cytosol requires an acidic pH within the virion, which, in the case of influenza A, is 
facilitated by the H+ channel M2 located on the virion envelope (reviewed in (Pinto & Lamb 2006)). In 
late endosomes the low ambient pH induces conformational changes to matrix protein 2 (M2) which 
in turn leads to acidification of the virion interior which causes additional conformational changes to 
release M1 from RNPs (Bui et al. 1996) and to enable HA-mediated fusion ((Bullough et al. 1994) and 
reviewed in (Skehel & Wiley 2000)). 
The liberated RNPs, consisting of genomic RNA wrapped in nucleoprotein (NP) and capped by 
the viral polymerase (PB1/2 and PA), rapidly migrate towards the nucleus through unknown forces, 
although diffusion has been suggested (Martin & Helenius 1991; Chou et al. 2013; Babcock et al. 2004). 
There is a growing list of nuclear transport receptors including importin-α1, 2, 4, 7, importin-β1 and 
potentially importin-5, Transportin-3 and the nuclear export receptor Crm1, that have been implicated 
in facilitating infection with influenza (see Table 2 for references). NP was found to bind the classical 
complement of transport proteins which, as the main component of the RNPs, contributes significantly 
to nuclear import and thus infectivity. Although NP comprises three confirmed NLSs (Bullido et al. 
2000; Neumann et al. 1997; Weber et al. 1998; Wang et al. 1997), but only the most N-terminal of 
which was found to be required for RNP nuclear import (Cros et al. 2005). In their hands peptides 
mimicking the unconventional NLS of NP solely blocked nuclear accumulation of RNPs. 
The advent of screening cells for cellular factors allowed further advances in delineating the 
proteins enabling infection. These screens found interactions of RNP components with importin-α4 
and 7 and indicated that knockdown of importin-β1, Transportin-3 and Crm1 reduced infection in vitro 
(Karlas et al. 2010; König et al. 2010). As influenza is assembled in the nucleus this may not necessarily 
relate to effect on entry but on general replication and/or assembly. Crm1, for instance, shuttles RNPs, 
probably via interaction with NP, to the cytoplasm (Elton et al. 2001). Once the importin-RNP complex 
reaches the NPC, it makes contacts with individual nucleoporins (Babcock et al. 2004) although the 
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exact mechanism is unclear. Knockdown of individual Nups has been shown to reduce infection which 
may relate to entry of virus into cells (König et al. 2010; Karlas et al. 2010) but could equally impede 
replication later on. Data obtained by Babcock et al. shed light on some regulatory aspects of nuclear 
entry implicating M1 in inhibition of nuclear re-entry of newly synthesised RNPs (Babcock et al. 2004).  
 
1.4.4 Baculovirus 
Baculoviruses are large (30-60nm diameter) rod-shaped dsDNA viruses that infect insect and 
mammalian cells. Its glycoprotein Gp64 interacts with an as yet unknown receptor to induce clathrin-
mediated endocytosis (Long et al. 2006; Hefferon et al. 1999). After approximately 30 min cytoplasmic 
nucleocapsids induce directional actin polymerisation by virtue of polarised distribution of VP78/83 to 
migrate towards the nucleus (Xu et al. 2007; Ohkawa et al. 2010). While early evidence suggested that 
Betabaculoviruses inject their DNA via polar attachment of capsids at the NPC (reviewed in (Au et al. 
2013)) it is now widely accepted that Alphabaculovirus capsids may also enter the nucleus through 
another importin-β mediated mechanism (Loo et al. 2001; Au & Panté 2012). Using a rather 
unconventional approach, whole capsids entered the nucleus through the pore which meant that, 
since capsids can measure 30-60 nm in diameter, the NPC is more flexible than anticipated. In the case 
of baculoviruses the required NPC reorganisation was driven by a thus far unknown signal, although it 
was shown that nuclear accumulation of capsids was blocked by wheat germ agglutinin and truncated 
importin-β (Au & Panté 2012; Loo et al. 2001). This at least indicated that direct interactions with the 
NPC and the nuclear transport machinery are required. Further studies will show whether capsids 
directly or indirectly affect the constitution and shape of the NPC. 
 
1.4.5 Viral subversion of nucleocytoplasmic transport 
The NE does not merely function as a barrier to separate nuclear and cytoplasmic proteins but 
in combination with the many nucleo-cytoplasmic transport receptors has also been implicated in a 
growing list of processes including differentiation, inflammation, circadian rhythm, mitosis, gene 
expression and carcinogenesis. All viruses that infect nucleated cells in some way need to modulate 
nucleo-cytoplasmic transport. Besides exploiting the cellular nuclear transport machinery to facilitate 
entry of viral nucleic acid into the nucleus, viruses also regulate the import/export pathway to shuttle 
viral proteins, export mRNA, maintain/modulate cellular protein functions, facilitate assembly and to 
inhibit antiviral responses (see Table 3 including references).  Most of the studies concerning viruses 
have focussed on entry and, albeit less frequently, on exit of viral particles as these represent the 
obvious anti-viral targets.  Since the advent of genomic techniques evidence is mounting that viruses 
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may alter the composition of the NE substantially to change nucleo-cytoplasmic transport on a global 
scale. This may not be surprising as host gene expression is significantly affected and sometimes 
heavily impaired during many viral infections such as with HSV-1. 
HSV-1 infected cells produce a large amount of viral capsids which accumulate in nuclei late 
during infection. At a diameter of over 100nm they are far too large to exit the nucleus through the 
nuclear pore so must have evolved to use an alternative pathway which does not compromise nuclear 
integrity. In fact, through studying α-HVs, such as HSV-1 and PRV, a completely new nuclear exit 
pathway was discovered, which involves budding into the perinuclear space at the INM followed by 
fusion with the ONM (Darlington & Moss 1968; Speese et al. 2012). Two viral proteins, pUL31 and 
pUL34, in conjunction with additional cellular factors and the viral kinase pUS3, facilitate the INM 
budding/ONM fusion process. Intriguingly, in cells transfected with pUL31 and pUL34 (PRV) these form 
a complex at the INM and mediate budding of vesicles into the perinuclear space in the absence of 
infection (Fuchs, Klupp, et al. 2002). This process requires the activity of kinases including PKCα which 
phosphorylate A-type lamins and emerin causing a local disruption of the lamin mesh which underlies 
the NE (Table 3, also for references). It is at such locations where laminar thinning allows capsids to 
bud into the perinuclear space. This pathway may be considered a common theme amongst HVs as an 
analogous process is driven by the pUL50, pUL53 and pUL97 proteins of HCMV (and its mouse 
homologue). In fact, HCMV goes even further and reshapes nuclei to lobe around a central assembly 
compartment that is formed over the MTOC. It is at the concave surface of the NE very close to the 
assembly compartment that capsids exit the nucleus to enter the final steps of assembly. 
Besides the conventional egress pathway, HSV-1 and bovine HV 1, were shown to cause a 
reduction in the number of NPCs and, more strikingly, dilation of the remaining pores which could 
potentially enable capsid egress. Intriguingly, recently it emerged that in the absence of the nuclear 
egress complex (pUL31/34) compensatory (rescuing) mutations facilitate egress of both empty and 
filled capsids from the nucleus. It seems that through the concerted action of several viral proteins the 
cellular MEK kinase cascade is induced culminating in activation of roscovitine sensitive CDKs (cyclin 
dependent kinases). This in turn leads to NEBD by phosphorylation events similar to mitosis (Table 3) 
leading to release of A, B and C capsids. Wild-type HSV-1, probably as a capsid quality control 
mechanism, actively prevents mitosis, although it relies on CDK activity throughout its life cycle (Schang 
et al. 1998; Schang et al. 1999), and so must have evolved ways to stop wide spread breakdown of 
lamins even in the presence of phosphorylation. For instance, HSV-1 infection was found to cause 
inhibition of caspases 3 and 8 and dislocate CDK-5 which contribute to NEBD during apoptosis (Jerome 
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et al. 1999; Jerome et al. 2001; Mostafa et al. 2015) and deletion of pUS3 appeared to enhance NEBD 
(Maric et al. 2014). 
In contrast to HSV-1 other viruses modulate NPC function to alter cellular physiology and likely 
their nuclear assembly and egress. Recently evidence is mounting that HIV-1 infection alters NPC 
function and composition on a global scale (Table 3 including references). The protein level of 
numerous NPC components was reduced which likely affects nucleo-cytoplasmic transport and gears 
trafficking to favour viral production. On an additional albeit more subtle level, Rev protein (HIV) 
directly binds Crm1 to facilitate viral RNA (vRNA) export and Nup62 is redistributed to the cytoplasm, 
which indirectly affects Transportin-1 mediated nuclear import. The latter was also found to be 
incorporated into virions. 
Most RNA viruses are strongly dependent on their ability to antagonise the interferon pathway. 
Ebolavirus can infect humans and the fate of the infected very much depends upon how quickly an 
interferon response can be mounted. To counteract the antiviral signalling the virus encoded VP24 for 
example directly binds to importin alpha-5, 6 and 7 to inhibit STAT1 (signal transducer and activator of 
transcription 1) translocation to the nucleus which is a prerequisite of interferon production (Table 3 
including references). The activity of VP24 thus likely contributes to the severe pathology encountered 
in this viral infection. Through the binding to multiple import factors many cargoes should be affected 
in a similar fashion but to date the only other protein found to be prevented from entering nuclei is 
hnRNP C1/C2. 
The examples given above are only a select set of which there is an extended list in Table 3. The 
list of viral proteins that modulate nucleo-cytoplasmic proteins continues to grow as we investigate 
viral protein functions and will likely yield valuable insights into cellular physiology and open up new 
opportunities to develop anti-virals. 
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Table 3 Overview of how selected viruses subvert the nuclear transport machinery to facilitate efficient replication and virion egress. 
 Group Family Virus 
Viral 
Component 
Targets Process Reference 
Eg
re
ss
/N
EB
D
 
1 
H
er
p
es
vi
ri
d
ae
 
HSV-1 
pUL31/34, 
pUS3, pUL13 
Emerin, lamins and lamin B 
receptor, emerin, Rottlerin 
sensitive kinases, PKC (α, d) 
lamin redistribution through recruitment of 
PKC, Rottlerin sensitive kinase, pUS3 and 
pUL13 by pUL31/34; phosphorylation of 
emerin and lamins; causes INM budding of 
capsids 
(Reynolds et al. 2002; Bjerke & Roller 
2006; Mou et al. 2007; Cano-Monreal 
et al. 2009; Scott & O’Hare 2001; 
Simpson-holley et al. 2004; Klupp et al. 
2007; Leach et al. 2007) 
pUL49, 
pUL46, 
pUL21, 
pUS2, gI, 
pUS9, pUL26 
CDKs, MEK1/2 
Roscovitine sensitive breakdown of nuclear 
integrity during infection to allow exit of 
pUL31/UL34 virus mutant; may reduce 
capsid quality control 
(Klupp et al. 2011; Grimm et al. 2012; 
Schulz et al. 2014) 
pUL31/34, 
pUS3, gB, gH 
ONM 
pUS3 mediated phosphorylation of gB; 
fusion with ONM to release capsid into 
cytoplasm 
(Farnsworth et al. 2007; Wisner et al. 
2009; Wright et al. 2009) 
UL34, gB, gH NE NE breakdown in TorsinA deficient cells (Maric et al. 2014) 
HCMV 
MCMV 
M50, M53, 
pUL97 
p32,PKC, Lamins 
Invagination of inner nuclear membrane; 
redistribution of lamins; increased surface 
area; capsid egress 
(Muranyi et al. 2002; Marschall et al. 
2005; Buser et al. 2007) 
M50/M53 PKC (Ca2+) 
M50/53 complex causes redistribution of 
PKC to INM; phosphorylation and 
subsequent dispersal of at least lamins A and 
C 
(Muranyi et al. 2002) 
pUL97 p32/Lamin B receptor, Lamin A/C 
p32 recruits pUL97 to INM (specifically to 
LBR); pUL97 phosphorylates p32 and lamin B 
to redistribute lamins; capsid egress 
(Marschall et al. 2005) 
HSV-1 
boHV-1 
? NPC 
dilated nuclear pores for capsid egress; 
decreased number of pore with increased 
signal of nucleoporin by 
immunofluorescence 
(Wild et al. 2009; Wild et al. 2005) 
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 Group Family Virus 
Viral 
Component 
Targets Process Reference 
5 
O
rt
h
o
m
yx
o
vi
ri
d
ae
 
In
fl
u
e
n
za
 A
 
NEP, M1 Crm1, RanGTP nuclear export of vRNP through NESs in NEP 
(O’Neill et al. 1998; Neumann et al. 
2000; Watanabe et al. 2001; Elton et al. 
2001; Shimizu et al. 2011; Huang et al. 
2013) 
HA PKCα and ERK pathway nuclear export of vRNP 
(Pleschka et al. 2001; Ludwig et al. 
2004; Marjuki et al. 2006) 
A
lt
er
at
io
n
 o
f 
N
P
C
/N
E 
co
m
p
o
si
ti
o
n
, m
o
d
u
la
ti
o
n
 o
f 
N
u
cl
ea
r 
im
p
o
rt
/e
xp
o
rt
 
1 
H
er
p
es
vi
ri
d
ae
 HSV-1 
ICP27 Nup62 
Through binding Nup62 nucleocytoplasmic 
transport via Importin α/β, Transportins are 
inhibited 
(Malik et al. 2012) 
ICP27 NXF1 viral unspliced mRNA exported (Johnson et al. 2009) 
 Nup153 redistribution to the cytoplasm 
(Hofemeister & O’Hare 2008; Leuzinger 
et al. 2005; Nagel et al. 2008) 
 Nucleoporins, Nup358 
increased O-glycosylation likely at Nups; 
reduction in complexed Nup358 
(Hofemeister & O’Hare 2008) 
EBV BGLF4 Nup62, Nup153 
binds Nups to phosphorylate and inhibit 
Importin-β mediated nuclear import and 
promotes non-NLS mediated import of lytic 
proteins 
(Chang et al. 2015) 
A
d
e
n
o
vi
ri
d
ae
 
Ad2  Nup214/62/358 
capsid binding and disassembly causes NPC 
perturbation through displacement 
(Strunze et al. 2011) 
Ad type C 
E1B55, 
E4Orf6? 
mRNA processing machinery; 
NXF1 
mRNA export inhibition via unknown 
mechanism 
(Yatherajam et al. 2011) 
P
ap
ill
o
m
a-
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d
ae
 
HPV 
L1 Transportin-1 
inhibition of nuclear transport of transportin 
cargoes 
(Pollard et al. 1996; Nelson et al. 2003) 
E5, L1 Importin-5 
inhibition of nuclear transport of importin 
cargoes 
(Krawczyk et al. 2008; Nelson et al. 
2003) 
3 
R
eo
vi
ri
d
ae
 
Type 3 
Reo-virus 
σ1s lamin A, NPC (Nup54 
redistribution of lamin A/C causing nuclear 
herniation, NPC clustered in herniations, 
might cause the observed G2-M cell cycle 
block 
(Hoyt et al. 2004) 
4 
Fl
av
i-
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ri
d
ae
 
HCV NS5A Importin-5 
growth defect in yeast probably through lack 
of nuclear import of ribosomal proteins 
(Chung et al. 2000) 
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 Group Family Virus 
Viral 
Component 
Targets Process Reference 
P
ic
o
rn
av
ir
id
ae
 
Poliovirus  Nup62, Nup98, Nup153 
cleavage of Nups62/98/153 leading to 
inhibition of  importin-α/β and transportin-1 
mediated nucleo-cytoplasmic transport 
(Gustin & Sarnow 2001; Gustin 2003) 
Poliovirus 2A protease 
other proteases?, NE 
components? 
nuclear leakage (Belov et al. 2004) 
Rhinovirus 
14 
 
Nup62, Nup153, Nup214, 
Nup358 
degradation leads to inhibition of nuclear 
import 
(Ghildyal et al. 2009; Gustin & Sarnow 
2002) 
Cardiovirus L Nup62/98/153/358 
general inhibition of nuclear import and 
export through hyperphosphorylation of 
Nups 
(Porter & Palmenberg 2009; Ricour et 
al. 2009; Bardina et al. 2009) 
To
ga
-v
ir
id
ae
 
VEEV H68 Importin-α/β, Crm1 
general inhibition of nucleocytoplasmic 
transport by formation of a ternary complex 
with importins and Crm1 
(Atasheva et al. 2010; Atasheva et al. 
2008) 
5 
O
rt
h
o
-
m
yx
o
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d
ae
 
Influenza A NS1 
CPSF, NXF1, p15, Rae1, E1B-AP5, 
Nup98 
inhibition of mRNA export 
(Alonso-Caplen et al. 1992; Fortes et al. 
1994; Nemeroff et al. 1998; Chen et al. 
1999; Satterly et al. 2007) 
Influenza A  Nup62, NXF1, p15 increased mRNA and vRNA export (Morita et al. 2013) 
Filo-
viridae 
Ebola VP24 Importin-α5/6/7 
inhibition of STAT1 (Interferon signalling) 
and hnRNP C1/C2 nuclear translocation 
(Reid et al. 2006; Reid et al. 2007; 
Mateo et al. 2010; Shabman et al. 
2011) 
Rhabdo-
viridae 
VSV M Nup98, Rae1 
Inhibition of specific import and export 
(mRNA) pathways 
(Her 1997; von Kobbe et al. 2000; 
Enninga et al. 2002) 
6 
R
et
ro
vi
ri
d
ae
 
HIV-1 
Rev Crm1 viral unspliced mRNA exported (Fornerod et al. 1997) 
Rev (as part 
of the vRNA) 
Nup62 
reduction and redistribution 
(NPCcytoplasm) of Nup62 leads to 
inhibition of nuclear import of Transportin-1 
cargoes; Nup62 incorporation into nascent 
virions essential to vRNA export 
(Monette et al. 2011; Monette et al. 
2009) 
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 Group Family Virus 
Viral 
Component 
Targets Process Reference 
 
KTN1, NUP43, NUP58, NUP45, 
Nup50, NUP54, Nup62, GP210, 
POM121 (only at NE not total), 
NUP107, NUP133, NUP155, 
NUP160, NUP37, NUP85, NUP93 
(only at NE not total), Nup358 
reduced levels of anchoring Nups Gp210 and 
POM121 alter NPC composition 
(Monette et al. 2011; Chan et al. 2007; 
Chan et al. 2009) 
 
general composition changes of NPC; 
redistribution of Nups (e.g. Nup153); 
incorporation of some Nups into nascent 
virions 
 
KPNB1, KPNA2, KPNA3, KPNA4, 
KPNA6, IPO5, IPO7, IPO9, TNPO1, 
TNPO2, TNPO3, RANGAP1, RCC1, 
NUTF2, RANBP1, RANBP3, 
RAP1GDS1, SUMO1, RIP (only at 
NE not total) 
Reduction of these proteins that are 
involved in nuclear import 
 
NUP35, NUP98, TPR, NUP153, 
NUP214, NUP93, POM121, RIP, 
XPO1, XPO2, XPO5, XPO7, NXF-1 
(at NE) 
increased expression to facillitate HIV 
replication and likely export of vRNA 
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1.5 Aims of PhD project 
Upon entry of HSV-1 capsids into the cell, they shed most of their tegument layer except for a 
few proteins which remain tightly associated during transport to the nucleus. Capsids of HSV-1 mutant 
tsB7 can be seen docking at the nuclear pore, a function which had been attributed to VP1-2. Further 
evidence showed that deletion of a NLS in the N-terminus of VP1-2 specifically prevented binding to 
nuclei. Although VP1-2 has diverged throughout evolution, some regions have been conserved even in 
the most distant relatives of HSV-1 suggesting that they might fulfil a similar function. This thesis is 
divided into four chapters which investigate the mechanism of HV nuclear docking using HSV-1 as a 
model: 
(i) Investigation of putative NLS function in VP1-2 homologues from all HV sub-families 
(ii) Function of homologous NLSs and HSV-1 NLS mutantsin the context of HSV-1 replication 
(iii) Mechanism of nuclear transport of HSV-1 VP1-2  in the context of soluble proteins and 
incoming capsids 
(iv) Construction of a fluorescently tagged derivative of the VP1-2.ΔNLS virus to track 
incoming capsids and follow infected cells over time 
Chapters one and two investigate the function of the VP1-2 NLS region in HSV-1 and that of a 
select set of homologues from human HVs. Briefly, I wanted to … 
 define the best system to screen putative NLSs 
 narrow down the (NLS) region of interest using VP1-2 protein alignments and NLS 
prediction tools 
 find and characterise motifs from other HV sub-family members in nuclear transport 
assays using a heterologous protein (β-galactosidase) or truncated HSV-1 VP1-2 
 investigate the function of any functional motifs in HSV-1 replication by creating 
chimeric HSV-1 carrying functional NLS motifs from other sub-families 
 characterise the growth characteristics of any chimeric HSV-1 
 characterise the nature of the HSV-1 NLS motif in more detail 
 investigate the implications of mutations on nuclear localisation using a heterologous 
protein and HSV-1 VP1-2 nuclear localisation assay 
 characterise the impact of selected mutations on HSV-1 fitness 
To test the hypothesis whether the N-terminus of VP1-2 of all HV sub-families comprises a 
functional NLS I cloned homologous VP1-2 regions of the representative HVs VZV (Varicella zoster 
virus, α), HCMV (β), EBV (Epstein-Barr virus, γ1) and HHV-8 (γ2) into the N-terminus of a heterologous 
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protein or into HSV-1 VP1-2. Their ability to confer nuclear localisation was tested in transfected cells 
to give a qualitative and quantitative measure of their function. To test the function of the homologous 
putative NLS motifs in replication they were transferred into the HSV-1 VP1-2 protein. This was 
achieved using a recombination-complementation assay based on the defect of the VP1-2.ΔNLS 
mutant. As such, any motifs that allow HSV-1 capsids to dock at the nuclear pore should be able to 
infect cells. Finally, I will correlate the data for nuclear transport for each homologous region with that 
of their ability to rescue HSV-1 virus replication. Recombinant (rescued) virus were isolated where 
possible and the recombinant viruses, which harbour homologous (NLS) regions of VP1-2, 
characterised in several cell lines. 
Chapter three investigates the mechanism of HV capsid nuclear docking using two biochemical 
approaches. I wanted to define the interaction partners of the VP1-2 NLS of HSV-1 and develop a 
system that, in theory, should enable identification of interacting partners of the VP1-2 NLS regions of 
any HV. Briefly, I will try to find VP1-2 interacting proteins with two pulldown approaches using… 
 VP1-21-795 and its ΔNLS mutant 
 HSV-1 wild type and ΔNLS capsids 
The first approach made use of a N-terminal fragment of VP1-2 as bait protein to identify the 
interacting proteins of the NLS. (residues 1-795). A system to select Stable cell lines inducibly 
expressing both the wild-type and the ΔNLS isoforms was developed which subsequently enabled co-
precipitation of VP1-2 binding proteins. Interacting proteins were then analysed by tandem MS. This 
method was aimed to be a comparative analysis. Thus a mutant isoform lacking the NLS was included 
as a control and this should make a direct comparison of the interactome of wild-type and mutant 
isoform possible since nuclear transport factors should only bind to the wild-type protein.  
In an alternative second approach I attempted to optimise an in vitro method to mimic capsid 
entry, de-tegumentation and binding of cellular protein in a more ‘physiologic’ in vitro assay. This 
involved simultaneous de-envelopment using detergent, which would lead to the removal of tegument 
and binding of cellular proteins potentially relevant during entry. The binding proteins will ultimately 
be identified using MS. Comparing the list of proteins precipitated by either wild-type or ΔNLS capsids 
should give an indication of NLS binding partners in the context of capsids similarly to the first approach 
using soluble VP1-2. 
For chapter four I aimed to create a fluorescent derivative of the ΔNLS virus mutant comprising 
a fluorescently labelled tegument protein (VP16). Briefly, I wanted to … 
 isolate GFP-VP16 recombinant VP1-2.ΔNLS viruses 
 characterise viral replication of the recombinant virus 
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 study cellular behaviour using GFP-VP16 recombinant virus 
 find out if the defective VP1-2.ΔNLS virus spreads in rabbit skin cells 
To achieve this, I purified recombinant viruses using a co-transfection approach. At first the 
growth characteristics were validated to confirm that the tags do not interfere with the virus life cycle. 
Subsequently, the GFP-VP16 recombinant virus was used to study the behaviour of infected cells over 
time and to find out why the defective ΔNLS virus appears to retain some rudimentary infectivity in 
rabbit skin cells.. To monitor virus spread in several cell lines, these were infected with complemented 
recombinant virus and images of the same area taken over several days. Additionally, to study cluster 
formation in rabbit cells, images of infected cells were taken every 20 minutes to elucidate how cluster 
formation was brought about. 
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2 Materials and methods 
2.1 Materials 
Table 4 Chemicals used for thesis. Most chemical compounds were obtained from Sigma or VWR unless otherwise stated.  
Reagent Supplier 
2x Taq polymerase master mix Sigma (P4600) 
4′,6-Diamidin-2-phenylindol (DAPI) Sigma (D9564) 
Actinomycin D Sigma (A9415) 
agarose Invitrogen (18300-012) 
ammonium nickel(II) sulfate Sigma (574988) 
bromophenol blue Sigma (B-5525) 
CaCl2 Sigma (C3881) 
cobalt(II) chloride hexahydrate Sigma (C8661) 
Collagen Type I (rat tail) First Link (60-30-807) 
Crystal violet (CV) Sigma (C0775) 
diaminobenzidine (DAB) Sigma (D8001) 
diazabicyclooctane (DABCO) Sigma (D2522) 
Doxorubicin Sigma (D1515) 
Doxycycline Sigma (D3447) 
DRAQ5 Life technologies (62254) 
DTT Sigma (GE17-1318-01) 
Dulbecco's Modified Eagle's Medium (DMEM) Gibco (41966-029) 
Dulbecco's Modified Eagle's Medium/Nutrient F-12 (DMEM F-12) Sigma (D6421) 
EDTA Sigma (E6758) 
EDTA-free protease inhibitor cocktail (tablets) Roche (11873580001) 
Foetal bovine serum (FBS) (Australia) Gibco (10099-133) 
geneticin  Invitrogen (10131) 
glutathione covered sepharose beads Sigma (GE17-0756-01) 
glycerol Fisher (56-81-5) 
goat serum Simga (G6767) 
H2O2 Sigma (216763) 
HEPES Sigma (H4034) 
Leptomycin B Sigma (L2913) 
L-Glutamine Gibco (25030-024) 
LiCOR block for Western blots LiCOR (927-40000) 
Marvel Milk Powder Tesco 
MEM non-essential amino acids (NEAA) Gibco (11140-035) 
MS grade trypsin Sigma (T6567) 
NaCl Sigma (S9888) 
N-bis(2-hydroxyethyl)-2-aminoethane sulfonic acid (BES)  Merck (1152280025) 
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Reagent Supplier 
New-born calf serum (NCS) (New Zealand) Gibco (16010-159) 
paraformaldehyde (PFA) Sigma (P6148-500G) 
Penicillin (100 U/ml) /Streptomycin (100 µg/ml) (Pen/Strep) Gibco (15140-122) 
Phenylmethanesulfonyl fluoride (PMSF) Simga (P7626) 
Phosphate buffered saline (PBS) (x10) Sigma (D1408-500ML) 
Phosphono acetic acid (PAA) Sigma (284270) 
piperazine-N,N′-bis(2-ethanesulfonic acid) (PIPES) Simgma (P1851) 
poly-L-Lysine Sigma (P2636) 
Polyvinyl alcohol (Mowiol 40-88) Sigma (324590) 
Pooled human serum (HS) Seralab (S-112-HS) 
Protein A sepharose Sigma (P9424) 
Protein G sepharose Sigma (P3296) 
Proteinase K Sigma (P2308) 
Q5 polymerase kit NEB (M0491S) 
Restriction enzymes NEB, Fermentas (various types) 
SDS Fluka (05030-1L) 
Silver stain kit Pierce (24600) 
sodium acetate Sigma (S2889) 
SYBR SAFE Invitrogen (S33102) 
Tetracycline approved FBS Gibco (631106) 
Tris-base Sigma (T1503) 
Triton X-100 Biorad (161-0407) 
Trypan Blue (0.4%) Invitrogen (T10282) 
Trypsin-EDTA (0.05%) Gibco (15400-054) 
Tween20 Biorad (170-6531) 
β-mercaptoethanol Sigma (M6250) 
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Table 5 Antibodies used for this thesis.  
 Antigen Clone Supplier Species Concentration 
Pr
im
ar
ie
s 
ICP8 1,10E+03 Abcam (20194) M 1:300 (IF) 
ICP4 10F1 Virusys Corp. (H1A021-1) M 1:500-800 (IF);  1:1600 (WB) 
VP16 LP1 T. Minson M 1:4000 (WB) 
gB R69 Gary Cohen R 1:10000 (WB) 
VP1-2 USP 1E12-E3 EMBL (MONTERONDO, ITALY) M 1:2000 (WB) 
VP26   P. Desai R 1:500 (WB) 
VP5 (ICP5) 3B6 Virusys #HA018 M 1:3200 (WB) 
UL37 C peptide   P. Desai R 1:800-3000 (IF); 1:10000 (WB) 
VP22 AGV30 Regal Group R 1:10000 (WB) 
UL25   V. Preston M 1:1000 (WB) 
V5 epitope tag   
Invitrogen #R960-25 
M 
1:10000 (WB); 1:200 (IP); 
1:1000 (IF) 
GFP (better)   Fitzgerald #20R-1769 R 1:10000 (WB) 
β-galactosidase   Promega #Z3781 M 1:200 (IF) 
γ-tubulin   Sigma #T5192 R 1:2000 (WB) 
ubiquitin FK-2 Enzo #BML-PW8810 M 1:2000 (WB) 
HA epitope tag 16B12 Covance #MMS-101R M 1:1000 (WB, IF) 
anti-DTX3L (BL3622) BL3622 Bethyl #A300-833A R 1:300 (IP) 
anti-DTX3L (BL3624) BL3624 Bethyl #A300-834A R 1:500-1000 (WB) 
53BP1   CST #4937 M 1:100-200 
Se
co
nd
ar
ie
s 
Mouse-Alexa 594   Invitrogen (#A21203) D 1:1000 (IF) 
Mouse-Alexa 488   Invitrogen (#A11029) G 1:1000 (IF) 
Rabbit DyLight594   Thermo Scientific (#35560) G 1:1000 (IF) 
Mouse Dylight 680   Pierce #35518 G 1:10000 (WB) 
Mouse Dylight 800   Pierce #SA5-10176 G 1:10000 (WB) 
Rabbit Dylight 680   Pierce #35568 G 1:10000 (WB) 
Rabbit Dylight 800   Pierce #SA5-10036 G 1:10000 (WB) 
Anti-Mouse-HRP   Biorad G 
1:10000 (WB); 1:2000 
(Immunoperoxidase) 
 
Anti-Rabbit-HRP  Biorad  
1:10000 (WB); 1:2000 
(Immunoperoxidase) 
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2.2 Cell lines 
COS (African Green Monkey fibroblasts) and Vero (African Green Monkey kidney cells) cells were 
maintained in  Dulbecco’s modified eagle medium containing L-glutamine, pyruvate and 4.5 g/l D-
glucose, supplemented with 10% neonatal calf serum and 50 μg/mL penicillin-streptomycin. 
HuH7 (human hepatocellular carcinoma cells), HEK293 (human embryonic kidney cells), RSC 
(rabbit skin cells) and HaCaT cells (immortalized human keratinocyte cell line) were maintained in 
DMEM supplemented with penicillin-streptomycin (50 μg/ml), 1x non-essential amino acid mix and 
10% fetal bovine serum. For all HEK293 cells (including derivatives) flasks were coated with 10 μg/ml 
rat tail collagen type I and coverslips were coated with 200 μg/ml poly-L-lysine to allow for better 
attachment and retention during wash steps. 
RPE-1 (hTERT-immortalized retinal pigment epithelial cell line) were maintained in DMEM 
containing F12 nutrient mixture HAM supplemented with 10% FBS, 1x NEAAs, penicillin-streptomycin 
(50 μg/ml) and 5 mM glutamine. 
RSC-HAUL36 cells are a clonal cell line derived from RSC cells which express chromosomally 
integrated, N-terminally HA-tagged wild type VP1-2. Expression of the protein is maintained by 
supplementation of the media with 1 mg/ml geneticin. 
HS30 cells are a clonal cell line derived from Vero cells which express chromosomally integrated, 
N-terminally HA-tagged wild type VP1-2. Expression of the protein is maintained by supplementation 
of the media with 100 μg/ml geneticin. 
HEK293Tet-on cells (Clontech), a derivative of HEK293 cells constitutively expressing the 
tetracycline reverse transactivator (rtTA) protein, were maintained in HEK293 medium supplemented 
with tetracycline approved FBS and 100 μg/ml geneticin. The NT3 (VP1-2 N-terminal fragment 3) 
derivative cells pTH111 (NT3) and pTH112 (NT3ΔNLS) were additionally grown under puromycin 
selection (3μg/ml). 
Generally cells were split twice weekly at 1:5 to 1:10 ratios. For HEK293 cells (or derivatives 
thereof) flasks were coated with 20 μg/ml rat tail collagen type I in PBS for at least 30 min at 37 °C. If 
HEK293 cells (or derivatives) were plated for immunofluorescence (or any assay involving washing 
steps) coverslips or well were coated with 0.1 mg/ml poly-L-lysine for at least 30 min at 37 °C. Before 
plating cells all flasks or wells were washed once to remove excess collagen or poly-L-lysine. 
2.3 Competent E. coli and transformation 
To prepare competent XL1 blue cells (originally from NEB) a 1:100 diluted overnight culture was 
grown in LB for 2.5 h. Cells were pelleted at 2000 rpm for 10 min (4 °C) and resuspended in 100 mM 
ice cold CaCL₂. Cells were incubated for 45 min on ice, pelleted at 2000 rpm for 10 min at 4 °C and 
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resuspended in cold CaCl₂ supplemented with 16% glycerol. Cells were stored at -80 °C. For some 
applications commercially available low efficiency XL1blue or DH5α or high efficiency DH10 (e.g. for 
larger plasmids) E. coli were used. 
For transformation cells were defrosted on ice, mixed with the ligation mix (1 part ligation mix 
and 9 parts bacteria; see 2.9.1 for ligation protocol) and incubated for 30 min on ice. Cells were heat 
shocked at 42 °C for 45 sec and cooled on ice. Cells were recovered in lysogeny broth (LB) or SOC (super 
optimal broth with catabolite repression) medium under light shaking for 1 h before plating on LB 
plates containing the appropriate selection antibiotic. Transformation with 0.5-1 ng of plasmid in 
100 μl of XL1 blue cells (home-made) gave rise to >100 colonies on LB plates containing appropriate 
antibiotics (>2x105 cfu (colony forming units)/g plasmid). 
2.4 PCR 
For most PCRs Q5 polymerase (NEB) was used. Generally the manufacturer’s recommendations 
were followed and the annealing temperature was determined using the NEB Tm calculator (see NEB 
website). 
To confirm certain types of constructs which could only be obtained with low efficiency and to 
enable screening of a large amounts of colonies, I used a pooled colony PCR approach. Briefly, 
transformed colonies were picked, streaked out on separate LB (+ antibiotic) plates and additionally 
grown in 300 μl LB (+antibiotic) in pools of 5-10 colonies per tube. These colony pools were incubated 
at 37 °C for 2 h and 1 μl was used instead of plasmid per 50 μl PCR reaction. To keep costs to a 
mimimum a 2x Taq polymerase master mix was used (Sigma). Annealing temperatures were estimated 
with the NEB Tm calculator. PCR products were separated on 1% agarose gels and detected using SYBR 
SAFE. 
2.5 Plasmid preparation 
Plasmid stocks were produced with Qiagen Mini- (Qiagen, #27106) or Maxi (#12163) prep kits 
and kept at 4 °C. 100 ng/μl stocks were prepared in double distilled (dd) H₂O which were used for 
transfections.  
2.6 Transfection 
2.6.1 Calcium phosphate protocol 
This method of transfection was essentially performed as outlined in the original report (Chen 
& Okayama 1987) with minor modifications. Briefly, the final volume of the transfection mixture was 
made up in one tenth of the volume of the culture vessel (e.g. 250 μl for 2.5 ml using 6 well plates) and 
the cells were continuously kept at 5% CO2 (rather than the suggested 2-4%). Cells were seeded to 
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reach 50-70% confluency (3x105 RSC cells per well) by the next day (which was the time of 
transfection). For the rescue assay the medium was exchanged 2 h prior to transfection (2.5 ml in 6 
well plates). The transfection mixture was made up freshly each time and left at room temperature for 
20 min prior to addition to the cells. The mix was added drop wise and swirled gently. After 24 h the 
medium was exchanged to fresh 10% medium and left for another 48-72 h for cytopathic effect (CPE) 
to occur. If CPE occurred the cells were scraped into the medium and processed as outlined in the virus 
section. 
To create cell lines that inducibly express NT3 and NT3ΔNLS essentially the same transfection 
principles were applied with additional modifications to the reagents. The actual transduction was 
performed by Anna Stockum (laboratory of Dr Goedele Maertens) due to safety reasons. Briefly, a total 
of 20 μg of plasmid DNA (made up of 8 μg pCG-GagPol (Naldini et al. 1996),, 2 μg pVSV-G (Naldini et 
al. 1996), 10 μg pTH111 or pTH112) were made up with ddH2O to 450 μl. To this 50 μl 2.5 M CaCl2 were 
added and mixed well. This mix was subsequently dropped onto 500 μl 2x Hepes buffered saline (HBS) 
(280 mM NaCl, 50 mM HEPES pH 7.1, 1.5 mM Na2HPO4) and left to equilibrate for 30 min at room 
temperature. The transfection mixture was added drop wise onto the cellular medium and the cells 
incubated with the DNA for 16 h. Cells were washed 2x with warm medium and the medium replaced 
with 5ml per 100mm dish. Virus was harvested at 24 h and 48 h post-infection (medium replaced at 
24 h). The retrovirus was filtered through 0.45 μm cartridges and added directly to recipient 
HEK293TetON cells plated in 100 mm dishes at 1.5x106 cells/dish the day before. 48 h after the last 
transduction selection with 3μg/ml puromycin was started. Within one to two weeks single colonies 
grew out which were picked and expanded. 
2.6.2 GeneJammer protocol 
Cells were seeded in 12 well plates (containing glass coverslips if samples were to be used for 
immunofluorescence studies) at 10⁵ cells/well in 1 ml media. Transfection was undertaken with COS 
or HuH7 cells using the manufacturer’s instructions of the Gene Jammer kit (Agilent; 204131). 3:1 ratio 
of Gene Jammer transfection reagent to DNA was used as standard with a total of 500 ng per 100 μl 
transfection mixture being applied per well. Cells were fixed 24 h post-transfection (unless otherwise 
indicated) with 3.7% paraformaldehyde (PFA)/PBS or Methanol or harvested in 1x SDS sample buffer 
(50 mM Tris-HCl, 2% SDS, 3% glycerol, 5% β-mercaptoethanol, 0.1% bromophenol blue) for Western 
blot. 
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2.7 SDS PAGE, Western blot, Coomassie and silver stain 
procedure 
Cells were washed in ice cold PBS and harvested directly from 6-24 well plates in Laemmli buffer 
(0.05 M Tris base, pH 7.0, 2% SDS, 5% β‐mercaptoethonol, 3% Glycerol and 0.005% Bromophenol Blue). 
If larger plates were used then cells were scraped into 5-10 ml PBS and sedimented before lysis. If the 
sample was very thick due to DNA release they were sonicated briefly (up to 30 sec in a water bath 
sonicator). The samples were heated to 95 °C for 3-5 min and stored at -20 °C or used straight away. 
Dependent on the molecular weight of the proteins of interest they were separated using standard 
running buffer (25 mM Tris base pH 8.3, 192 mM Glycine, 0.1% SDS) at 150 V on 12%, 10%, 8%, 7% 
PAGE gels or 3-8% pre-cast gradient SDS-polyacrylamide gel electrophoresis (PAGE) mini gels 
(>150 kDa) (NuPAGE; # EA03752BOX) using the SureLock system from Invitrogen. For 3-8% pre-cast 
gels a Tris-MOPS buffer was used (Invitrogen, 50 mM MOPS, 50 mM Tris base, 0.1% SDS, 1 mM EDTA, 
pH 7.7). Gels were either stained with coomassie solution for 30 min (0.1% Coomassie Blue, 10% Acetic 
acid, 50% Methanol and 40% H2O) followed by overnight de-staining (10% Acetic acid, 40% Methanol 
and 50% H2O), silver stained (see manufacturer’s instructions for silver stain details; Pierce #24600) or 
wet-blotted at 250 mA for 2 h or 72 mA for 16 h onto nitrocellulose membranes using transfer buffer 
(25 mM Tris base, 192 mM Glycine, 10% Methanol). Membranes were stained with Ponceau S solution, 
blocked with 0.5x LiCOR blocking solution (as 1:1 mix with PBS), probed in the dark with primary and 
secondary antibodies diluted in PBS supplemented with 0.1% Tween20 (PBST) and 5% skimmed milk 
or 1.5% BSA. After each probing step membranes were washed 3x 15 min in PBST and once in PBS. 
Membranes were dried and read with the LiCOR Odyssey imager and stored at room temperature in 
the dark. Image analysis and preparation was done with Image Studio Lite software. Generally images 
were exported as tagged image files (tif). 
2.8 Immunofluorescence microscopy 
Cells were treated as described. For immunofluorescence analysis samples were usually grown 
in 12 well plates containing glass coverslips (+/- poly-L-lysine). Cells were washed once in ice cold PBS 
and fixed in 4% PFA for 20 min (at room temperature) or 100% methanol (at -20 °C) for 5-10 min. Cells 
were washed 3x in PBS. If PFA was used cells were subsequently blocked and permeabilised for 1 h 
with PBS/0.1% Triton X-100 (PBSTx) containing 300 mM glycine and 10% NCS, FBS or Goat Serum. 
Samples were probed with primary and secondary antibodies in a dark, humidified chamber using 
block buffer (no detergent). DAPI (4′,6-Diamidin-2-phenylindol, 0.5-1 μg/ml) or 1, 5-bis{[2-(di-
methylamino)ethyl]amino}-4, 8-dihydroxyanthracene-9, 10-dione (DRAQ5, 0.5-1 μM) were used as 
DNA counterstains as part of the secondary antibody mixture. Coverslips were washed 3x in PBS and 
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ddH₂O, dried (70% Ethanol) and mounted in Mowiol (10% Mowiol 4-88, 25% glycerol, 100 mM Tris-
HCl) containing 2.5% DABCO (1,4-diazobicyclo-[2,2,2]octane). Images were taken with Image Pro Plus 
software on an Axiovert M135 inverted microscope or the LSM 500 Pascal or LSM510 Meta confocal 
laser scanning microscopy setup using 488nm, 543nm and 633nm lasers. 
2.9 Generation of plasmids 
2.9.1 NLS β-galactosidase constructs 
NLS sequences were synthesized as oligo nucleotides (Sigma; see appendix) to generate in-
frame fusion proteins with β-galactosidase (β-gal) as outlined elsewhere (Abaitua & O’Hare 2008; 
Hennig et al. 2014). Briefly, the β-gal vector contains two restriction sites, HindIII and BglII, immediately 
adjacent to the Kozak and translation initiation sites. Two complementary oligos per NLS were 
denatured, annealed and digested as follows: Oligo nucleotides were diluted in ddH₂O to a 
concentration of 10 or 100 μM followed by denaturation at 96 °C for 10-15 min and cooling on ice. 
Annealing mixtures were prepared as 50 μl reactions containing 1x NEBII buffer, ddH2O and 3 μM of 
each oligo nucleotide. To anneal the reactions were heated to 98°C (from ice) and the temperature 
dropped by 1 °C per min until 25 °C was reached. Reactions were digested with 20 U HindIII and BglII 
enzymes for 5 h and purified using a PCR reaction clean-up kit (Qiagen; # 28104). NLSs were ligated at 
14 °C for 4 h with 6:1 excess over vector into 100 ng HindIII/BglII digested β-gal plasmid (6 x [insert in 
bp]/[vector in bp] x 100 ng). Plasmid backbone was digested with 10 U each of HindIII and BglII in 
20-30 μl reactions using NEBII buffer. 1 μl calf intestinal phosphatase (CIP) were added during the last 
hour of the digestion. The backbone was isolated from 1% agarose gels under blue light (SYBR safe) by 
excision and DNA was purified using a QiaEXII kit (Qiagen) according to manufacturer’s instructions. 
This same procedure was used for all other gel purifications. 
R1 constructs were created by chemical synthesis (GeneArt). Each R1 region contained from its 
5’ end in the following order (without DNA spacers): HindIII site, Kozak sequence, ATG codon, HA tag, 
XhoI site, R1 region, NheI site, BglII site. For insertion into the β-gal vector the HindIII/BglII restriction 
strategy was used (see above). The sequences were obtained from NCBI (see comparison of in silico 
NLS prediction algorithms for accession numbers). 
All constructs were sequenced using Beckman and Coulter Sanger sequencing using specific 
primers in the N-terminus of β-gal (see Appendix 1: List of primers with descriptions). 
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2.9.2 Creation of NT6 constructs 
The cloning strategy is outlined elsewhere (Hennig et al. 2014). Briefly, chemically synthesised 
R1/R8 regions flanked by XhoI and NheI sites were inserted into the intermediate vector pTH19 
between these two sites. This vector contained the engineered BamHI-MluI fragment of NT6v2 with 
unique XhoI and NheI sites (silent mutations were introduced leading to no primary amino acid 
sequence changes). BamHI-MluI fragments were subsequently inserted into NT6v2 (between 
BamHI/MluI) and sequenced using Beckman and Coulter sequencing services (see appendix for 
primers). 
2.9.3 Creation of mammalian GST constructs 
An existing GST-NT4 construct, harbouring an EcoRI-EcoRI fragment from the N-terminus of VP1-
2 (around 140 amino acids around the NLS), was used as the basis of my cloning procedure. GST from 
pGEX-6P was cloned into pCAGGS (see Addgene for a map) to allow for mammalian expression and the 
NT4 part was cloned into this by EcoRI-EcoRI ligation (in frame). 
To create NLS bearing GST fusion proteins, the NT4 part was removed and the pCAG-GST 
backbone used for insertion of digested PCR products. The PCR templates were pTH19 derived 
intermediate vectors which contained the chemically synthesised R1s (HSV-1 wild-type, K428A and 
ΔNLS) with flanking HSV-1 sequence (i.e. as part of the BamHI-MluI fragment). These will still be 
referred to as R1 regions in the text. The ΔNLS mutation had to be transferred from NT6.ΔNLS into the 
pTH19 backbone (direct BamHI-MluI insertion). The PCR product was created using the primer pair 
prTH101/102 and contained a 5’ MfeI and a 3’ EcoRI site which were used for the cloning procedure 
(insertion into pCAG-GST). Constructs were sequenced using Beckman and Coulter’s universal GST 
primers. 
2.10  Nuclear import assay (β-galactosidase, GFP and VP1-2 
constructs) 
The procedure was the same as outlined in a previous report (Hennig et al. 2014). Briefly, HuH7, 
HEK293 (with poly-L-lysine) or COS cells were seeded on 13-16mm coverslips at 1.5x105 cells/well 24 h 
prior to transfection. The next day cells were transfected (see 2.4) with 500-1000 ng of a plasmid in 
12 well plates. Cells were fixed 24 h post-transfection with 4% PFA and immunostained (see 2.5) using 
mouse anti-β-gal or anti-V5 antibody and secondary goat anti-mouse 488 labeled antibody. DNA was 
counterstained with DAPI or DRAQ5. Coverslips were mounted in Mowiol contained 2.5% DABCO. 
Images were taken at 10x, 20x, 40x or 63x magnification using fluorescence or confocal microscopes. 
For the nuclear export inhibition assay cells were transfected with NT6 constructs and with the 
additional control constructs GFP, GFP-NLS (CMV.R1) and GFP-NLS-NES (CMV.R1 and Rev NES) for 24 h. 
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Cells were then treated with 10ng/ml leptomycin B for 3h prior to fixation. Controls were treated with 
vehicle only (0.1% DMSO). 
For inducible cell lines (NT3), cells were seeded at 1.5x105 cells/well on poly-L-lysine (Sigma) 
covered 13-16mm coverslips and treated with 1μg doxycycline for a minimum of 19h (up to 36h). 
2.11  Creation of inducible NT3 and NT3ΔNLS cell lines 
The series of vectors created for this part were based on the retroviral backbone (Figure 6) 
created by Dr. Goedele Maertens (Maertens et al. 2010). Initially, the BglII to EcoRI part was excised 
which included the CMV promoter and the multi cloning site (MCS). This was replaced with the PCR 
product of prTH89/90c (BamHI-EcoRI). The PCR product contained the pTRE-tight cassette (pTight 
vector from Clontech) and a designed MCS flanked by 5’ BamHI and 3’ EcoRI sites. The 5’ BglII-BamHI 
ligation lead to loss of either site upstream of the pTight promoter. NT3 (and ΔNLS) were PCR amplified 
using the primer pair prTH93/94 and the purified product was digested with NheI and EcoRI. The 
resulting restriction fragment was inserted between XbaI and EcoRI sites of the new MCS. Vectors were 
tested by transient transfection for inducibility with doxycycline and Western blot. Cell lines were 
created as outlined in 2.5.1. Since the puromycin cassette was preceded by an IRES the selection was 
less efficient since leaky expression was required. Nonetheless, at least one colony of transduced cells 
was obtained for either construct. Cells were tested with Western blot against V5 (tag at the N-
terminus of NT3). 
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Figure 6 Retrovirus vector for creation of pTH111 (NT3) and pTH112 (NT3ΔNLS). (Maertens et al. 2010) 
 
2.12  Immunoprecipitations 
To perform most immunoprecipitations (IPs) a PBS based buffer system was used. PBS (pH 7.4) 
was supplemented with 1% Triton X-100, 1 mM EDTA, protease inhibitor cocktail (1 tablet per 10 ml), 
10 mM DTT and 1 μM Phenylmethanesulfonyl fluoride (PMSF). Any modifications (such as during 
capsid preparations) are mentioned in the text. The method was adapted for the size of the vessels 
used (e.g. 6 well plate for NT6 IP, 100 mm dish for NT3, 550 cm2 dish for GST-R1s) For NT3 IPs cells 
were seeded on poly-L-lysine coated 100 mm dishes at 1.5x105 cells/dish 16-24 h prior to induction. 
Cells were induced with 1μg for a minimum of 19 h but for a maximum of 36 h. Cells were washed 
twice in ice cold PBS and lysed in 1 ml of ice cold lysis buffer for 30 min at 4 °C under gentle agitation 
(all steps from now on at 4 °C or on ice). A small amount of this total sample was diluted with Laemmli 
buffer (Total). Debris were sedimented at 13000 rpm for 10 min. The lysate was pre cleared with 25 μl 
protein A bead equivalent volume for 1 h under agitation, beads sedimented and the Input transferred 
to a new tube. A small sample was diluted with Laemmli buffer (Input). NT3 was bound with anti-V5 
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antibody (1:200) for 2 h under agitation before incubating with 25 μl protein A beads for 1h. Beads 
were sedimented at 6000 rpm for 15 sec and a small sample of the unbound supernatant diluted in 
Laemmli buffer (unbound). Beads were washed 5x with lysis buffer. Proteins were either eluted with 
Laemmli buffer or subjected to on-bead digestion with trypsin. 
2.13  On bead digestion of IPs for mass spectrometric analysis 
NT3 and NT3ΔNLS expressing cells or HEK293 cells were plated in coated 100 mm or 530 cm2 
dishes, respectively. Cells were either induced with 1 μg/ml doxycycline or transfected with 90 μg GST-
R1, GST-R1.K428A or GST-R1.ΔNLS. Cells were lysed and IPs performed as described. GST fusion 
proteins were immobilised with glutathione covered sepharose beads. After the final wash of the IP 
procedure, the buffer was aspirated and the beads resuspended in one volume (use bead equivalent 
volume to calculate) of 50 mM ammonium bicarbonate buffer (pH 8-8.5). Approximately 0.5 μg MS 
grade trypsin was added per 20 μg of substrate. The digestions were incubated for 16 h at 37 °C under 
vigorous shaking to keep beads resuspended. Peptides were analysed by tandam MS in collaboration 
with Dr Remi Serwa (South Kensington Campus). 
2.14  In silico protein analysis 
2.14.1 Protein alignments, NLS, NES and Ubiquitination prediction 
To find regions of conservation protein sequences were retrieved from Uniprot and inserted in 
FASTA format into text files. These were then imported into Clustal Omega and aligned. Sequences 
were then manipulated manually with GeneDoc software and exported as bitmap files. 
To predict putative NLSs in the N-terminus of VP1-2 either just the R1 region or the first 1000 
amino acids were used. The following five online tools were used to make sure putative NLS sequenced 
are not missed: NLSmapper, NLStradamus, Euk-mPLOC 2.0, NucPredict and CELLO (Yu et al. 2006; 
Nguyen Ba et al. 2009; Chou & Shen 2010; Kosugi et al. 2008; Kosugi, Hasebe, Matsumura, et al. 2009; 
Kosugi, Hasebe, Tomita, et al. 2009; Brameier et al. 2007). For this amino acid sequences were 
uploaded in FASTA format and the results collated in a table (see results section). 
Nuclear export signal (NES) and ubiquitination prediction was done in similar fashion using the 
online tools NetNES1.1 (La Cour et al. 2004) and UbPred (Radivojac et al. 2010), respectively. 
2.14.2 Analysis of MS data 
Data was received as a spreadsheet and the lists of proteins were manually filtered using 
Microsoft Office Excel functions. Protein hits were included if they satisfied the following criteria: (i) at 
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least two unique peptide are identified (ii) peptides at least four fold enriched in either sample 
compared to the negative control (IP from the parental HEK293TetON cell line). 
 
[Absolute protein abundance (log2) in sample – Absolute protein abundance in control] >= 2 
 
This way 199 proteins were identified which were subdivided into different categories as 
outlined in the text. Annotations (localisation and main functions) were retrieved from Uniprot (or 
where necessary from GeneCards) using the protein IDs supplied in the MS data. For example, for 
DTX3L (ID: Q8TDB6) ‘DNA repair’ was the retrieved function while ‘ubiquitin-protein transferase 
activity’ was not regarded as a function for the purpose of this analysis. Some proteins were allocated 
multiple functions which is represented in the analysis (i.e. more annotations than proteins). Although 
this introduced subjective bias it was required to simplify the analysis and representation. For graphical 
illustration Prism 5 software was used. 
To obtain enrichment scores the freely accessible DAVID tool was used (Huang, Brad T Sherman, 
et al. 2009; Huang, Brad T. Sherman, et al. 2009). Gene lists were uploaded and Fisher exact scores 
used for the purpose of illustration of significant enrichment. Since many different annotation terms 
are used almost interchangeably but not consistently (e.g. nuclear, nucleoplasm, nucleus, nuclear part, 
etc.), I combined the gene lists for each term that had a Fisher score below 0.00001 (i.e. highly 
enriched). 
2.15  DNA damage assay 
HEK293TetON cells inducibly expressing NT3 or NT3ΔNLS (and parental control) or U2OS cells 
were seeded onto poly-L-lysine coated coverslips to reach 50% density at the time of induction with 
0.1-1 μg/ml doxycycline or transfection with NT3 plasmid DNA. Cells were induced or incubated with 
plasmid DNA for 24 h prior to addition of 100 nM doxorubicin (or 0.1% DMSO) to induce DNA damage. 
Cells were treated for either 4 or 24 h before fixing in 4% PFA (U2OS cells only for 24h) as described 
before. Cells were stained with anti-53BP1 antibody as described in section 2.8 and imaged with an 
inverted fluorescence microscope. For quantification images were taken at 10x magnification with the 
same settings for each condition. Contrast and brightness were enhanced using the Fiji plugin of Image 
J. Individual 53BP1 foci were reduced to single black pixels using the ‘find maxima’ function of Fiji and 
DAPI stained nuclei (as ROIs) were transferred to the resulting binary 53BP1 images. Dots per nucleus 
were counted manually. Since without DNA damaging agents the number of foci was generally lower 
than 10 per nucleus this was taken as a threshold for induced DNA damage.  
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2.16  Protocol for virus culture and infections 
2.16.1 Virus infection 
Cells were seeded in 6, 12, 24 or 48 well plates at 3x10⁵, 1.5x10⁵, 8x10⁴ or 3x10⁴ cells/well one 
day prior to infection, respectively (three times more for HaCaT cells). Media was removed and cells 
incubated with inoculum for 1-2 h on a plate shaker at 37 °C. Inoculum was aspirated and 2% FBS media 
added (unless otherwise indicated). 
2.16.2 Plaque assays 
Cells were seeded at 3x10⁵ per well one day before. Virus titres were determined with 10 fold 
serial dilutions. The standard concentration range was 10-3 to 10-8. Infection was done as described 
above. Media was changed to DMEM/2%FBS supplemented with 2% human serum. Cells were fixed 
with 4% formalin and stained with crystal violet (CV) 3d post-infection and plaques counted at 6.3x 
magnification. 
For plaque size measurements, especially of the smaller recombinant virus plaques, the staining 
protocol was modified from a previous report (Green et al. 1989). Infected cells were fixed as described 
for immunofluorescence. Essentially the staining protocol was the same as used for conventional 
immunofluorescence microscopy but it was performed directly in 6 well plates (rather than on 
coverslips) and samples were not mounted. Primary antibodies of choice were polyclonal rabbit anti-
UL37 (1:3000) or monoclonal mouse anti-ICP4 (1:800) used in combination with horseradish 
peroxidase (HRP) conjugated goat anti-rabbit/mouse secondary antibody (1:2000). After the last wash 
the substrate solution (0.05% diaminobenzidine [DAB], 0.05% cobalt Chloride, 0.05% nickel ammonium 
sulfate and 0.015% hydrogen peroxide in PBS, pH 7.2) was prepared fresh from 20x concentrated 
chemical stocks and 10x concentrated PBS. The sample well were aspirated and 1 ml substrate per well 
was added and incubated until plaques were visible (up to 10 min). Plates were washed in PBS and 
could be dried for storage. Images of individual fields were obtained with Q capture Pro 6.0 software 
using a Leica Wild M420 binocular equipped with a makrozoom wild objective (#376777) an Imaging 
Go-3 camera at 6.3x magnification. Alternatively, tiled images were acquired at 10x magnification 
(Image Pro Plus software, AFA module). Plaque size was measure using Quantity One 4 software using 
the image contour tool. 
2.16.3 Single step growth curve and protein expression analysis 
For single step growth curves, cells were seeded in 12 or 24 well plates to reach 100% confluency 
at the time of infection (next day). Cells were infected at MOI of 5 for 1 h, acid washed (citric acid, 
pH 3.0) for 1 min and incubated with 2% FBS containing medium for the desired time points. Cells and 
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medium were harvested (as total virus produced) by freeze thawing and titrated on both RSC and 
RSCUL36 cells. For protein expression assays, the infected cells were scraped into the medium and 
sedimented at 3000 rpm for 5 min. The cell pellet was washed once in PBS and the cells lysed in 
Laemmli buffer. 
2.16.4 Multi step growth curve 
For multi-step growth curves, cells were seeded in 12 or 24 well plates and infected at 100% 
confluence with a MOI of 0.001 as above. The infection was left to progress in 2% FBS containing 
medium. Monolayers were harvested at 0, 24, 48 and 72 h post-infection (hpi) as above and titrated 
on both RSC and RSCUL36 cells. 
2.16.5 Virus stock production 
Virus stocks for KOS wild type, KOS Bacmid, K.ΔNLS, K.ΔNLS.R, K.ΔNLS.GFP-VP16, strain 17 wild 
type, strain 17.VP16-GFP and strain 17.GFP-VP16 were created in RSC, Vero, RSCUL36 or HS30 cells (all 
ΔNLS versions). Working stocks were made by infecting 2x10⁸ cells at a multiplicity of infection (MOI) 
of 0.001-0.005 (plaque forming units/cell or PFU/cell). Media and cells were harvested 3-4d post-
infection at 100% cytopathic effect, cells sedimented at 3000 rpm at 4°C for 30min and the 
media/supernatant spun at 19000 rpm at 4°C for 90min. The pellet of this media/supernatant was 
resuspended in RSC media (1% FBS) at 4°C overnight and used as extracellular virus stock. The cell 
pellet of was resuspended in 10 ml media (1% FBS) and cell-associated virus released by three freeze-
thaw cycles. Debris were sedimented by spinning at 3000 rpm for 15min at 4°C and the supernatant 
stored as cell associated virus stock. Each stock was titrated on the appropriate cell line (RSC or 
RSCUL36). 
2.16.6 Viral genomic DNA production 
2x10⁸ RSC or RSCUL36cells were infected at MOI of 0.001-0.005 and only the medium was 
harvested at 100% cytopathic effect. The edium was spun at 3000 rpm at 4°C for 30’ to sediment 
cells/debris. The supernatant was spun at 19000 rpm at 4°C for 90min to sediment virus particles and 
the pellet resuspended in buffer (10 mM Tris HCl pH 7.6, 1 mM EDTA, ddH₂O to make 4.75 ml) 
overnight. 
The pellet was resuspended the next day and mixed with SDS (1% final) and proteinase K (50 
μg/ml. The mixture was incubated at 50°C for 4h and the DNA was subsequently phenol-chloroform 
purified (Sambrook and Russell, 2006). Purified DNA was precipitated overnight at -20°C with 500 μl 
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3M Sodium acetate and 12.5 ml 100% ethanol. DNA was sedimented at 3500 rpm at 4°C for 30min. 
The pellet was washed with 18.75 ml 70% ethanol, air dried and resuspended in 200 μl sterile ddH₂O. 
2.16.7 K.VP1-2.ΔNLS virus rescue assay 
For the rescue assay, RSC cells were seeded at 3x10⁵ in 6 well plates one day prior to 
transfection. 1 μg K.VP1-2.ΔNLS DNA and 1 μg of the different NT6 plasmids were transfected using 
the calcium phosphate procedure (Chen & Okayama 1987). Cells were fixed or harvested 3-4d post-
transfection. Fixed plates were stained with crystal violet (0.1% CV, 10% methanol in ddH2O) and 
plaques counted and compared to the positive control (HSV-1 VP1-2 wild type). For yield comparisons, 
instead of CV staining plates, the monolayers were scraped into the medium and everything collected. 
The mixture was lysed by freeze-thawing 3x (switching between dry ice ethanol bath and 37°C). Debris 
were sedimented at 3000rpm for 10’ and the supernatant titrated on RSCUL36 cells. 
To isolate viruses, the lysate was titrated on non-complementing RSC cells. The procedure was 
essentially the same as for VP16-GFP recombinant virus (see below) just that more plaques were 
picked since there was no marker. Since the background of this assay was extremely low, this was 
deemed sufficient to obtain recombinant viruses. Recombinant viruses were confirmed by amplifying 
the region around the BamHI-MluI inserts with PCR (Q5 proof reading polymerase) and sequencing the 
PCR products (Beckman and Coulter). 
2.16.8 Generation of VP16-GFP and GFP-VP26 recombinant 
viruses 
Recombinant viruses were created using the Calcium phosphate transfection protocol of viral 
genomic DNA and plasmid DNA (containing appropriate, homologous flanking regions). RSC or 
RSCUL36 (for ΔNLS) cells were seeded the day before at 5x10⁵ cells/60 mm dish. Media was changed 
2h prior to transfection to 2.5 ml media. A 250 μl transfection mixture contained the following mixed 
in order: 1x BES buffer (50 mM BES [N-bis(2-hydroxyethyl)-2-aminoethane sulfonic acid;, 140 mM NaCl, 
0.75 mM Na₂HPO₄), 1 μg viral DNA, 4 μg plasmid, H₂O (to make 250 μl) and 125 mM CaCl₂. Media was 
changed to DMEM/2% FBS 24 h post-transfection. Cells and media were harvested at 100% cytopathic 
effect, freeze-thawed three times in ethanol/dry ice and titred on complementing or non-
complementing cells (see 2.8.5). For purification of recombinant viruses each titration was overlaid 
with 0.4-0.6% agarose (included in DMEM/2%FBS) and green plaques picked 3 days post-infection (dpi) 
with a blunt ended needle. The titration procedure was repeated until a sufficiently pure stock was 
obtained. 
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Figure 7 Flow chart to create and isolate a recombinant HSV-1 virus. 
(A) Viral genomic DNA (K.ΔNLS or revertant K.ΔNLS.R) was co-transfected with GFP-VP16 encoding plasmid DNA. (B) 
Homologous recombination co-transfected cells. The GFP-VP16 plasmid encodes the appropriate flanking regions. (C) The 
lysate from one co-transfection is used as inoculum to infect a monolayer of complementing cells overlayed with 0.4-0.6% 
agarose containing medium. In sequential steps of plaque picking and re-infection cycles the population can be isolated 
and enriched on the basis of its green colour. 
 
2.16.9 Time lapse microscopy of K.VP1-2.ΔNLS.VP16-GFP infected 
cells 
RSC cells were seeded in 6 well plates and infected the next day (100% confluency) with 
approximately 150 pfu/well as described before (with minor modifications). The medium used was 
DMEM F-12 (15 mM HEPES; see RPE-1 medium) instead of regular DMEM since it does not require CO2 
for buffering. After the infection the cells were transferred to a temperate mini-chamber which sat 
directly on the stage of an inverted fluorescence microscope. Individual fields of infected cells were 
picked which would be imaged over the course of 48 h. Images were acquired every 20 min for 48 h 
(in two parts) using Image Pro Plus software (AFA module). Each image corresponds to one frame of 
each avi movie file. 
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2.16.10 Capsid extraction 
2.16.10.1 Preparation of clean viral stocks  
KOS bacmid strain virions were produced (after optimization) from RPE-1 (high yield of 
intracellular virus at 3 dpi) or HaCaT (slightly higher yield for extracellular virus at 3 dpi) cells (RSC and 
Vero cells were also tested but produced less virus). Briefly, cells were seeded in 800 cm2 roller bottles 
in HEPES buffered medium (DMEM F-12 supplemented with PS, NEAAs, 4mM L-glutamine and 10% 
NCS [RPE-1] or 10% FBS [HaCaT]) due to lack of CO2 ventilation. At 90-100% confluency (around 2-
4x108 cells/bottle) cells were infected at a MOI of 1 and the cells harvested by scraping into the 
medium 24 h later (100% CPE). Cells and debris were sedimented at 300x g and the supernatant 
separated from the cellular pellet. Supernatant associated virus (SN) was collected by high speed 
centrifugation at 19000 rpm for 1 h at 4 °C and subsequent ultracentrifugation of the resuspended 
pellet through a 35% sucrose (in PBS) cushion. The pellet was resuspended in 200-500 l PBS or water. 
Cellular virus was liberated from cells on ice by incubation with TNE (Tris pH 8, 500 mM NaCl, 1 mM 
EDTA) for 30 min under periodical agitation. The resulting procedure was repeated once. The cellular 
debris were sedimented at 3000 rpm for 10 min and supernatants pooled and further sedimented 
through 35% sucrose (= TNE stock). For test purposes the left-over cell debris were freeze thawed 3x 
and sedimented through 35% sucrose. Virus was titrated on RSC cells. 
2.16.10.2 Capsid extraction 
Purified virions were extracted using different buffer systems (see 5.2.2) but analogous to the 
following method: 50 l virions in PBS (for some applications virions were produced in water for buffer 
compatibility) were mixed with 150 l of PBS (or other) and 200 l of 2x concentrated extraction buffer 
(here PBS containing 1% TX-100, 2 mM EDTA, 2x protease inhibitors, 2 μM PMSF). For some 
applications, 200l of HEK293 cell extract of 2-4x106 cells was added as 2x extraction buffer. For this 
107 HEK293 were washed in PBS, scraped and extracted using 500 l PBS (or piperazine-N,N′-bis(2-
ethanesulfonic acid) (PIPES)) buffer containing 1% TX-100, 2x protease inhibitors and 2 μM PMSF for 
30 min. Lysates were cleared for 30 min at high speed (25000 rpm) using a pre-cooled table top 
ultracentrifuge (rotor TLA-45) and low binding Eppendorf tubes (Sigma, # Z666505). The extraction 
reaction was incubated on ice for 15-60 min without significant differences in degradation. Finally, the 
soluble fraction was divided from the capsid containing fraction by sedimentation (with or without a 
35% cushion) for 30 min (or 45 min if through a cushion) at 25000 rpm. Soluble proteins (S fration) 
were aspirated and the pellets (P fraction) washed once in extraction buffer. The final pellets were 
resuspended in 1x Laemmli buffer and analysed using SDS-PAGE and silver staining or Western 
blotting. A small amount of supernatant was kept and diluted with 4x Laemmli buffer (soluble fraction). 
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3 Identifying NLSs of VP1-2 homologues 
3.1 Background 
VP1-2 is an essential tegument component which is conserved across all HVs (Kattenhorn et al. 
2005; Kelly et al. 2009). Although it was shown to be required during assembly (Desai 2000), transport 
and nuclear docking of nucleocapsids (Abaitua et al. 2012; Roberts et al. 2009), parts of the protein appear 
to be dispensable for growth in cell culture without deleterious effects on growth characteristics (Böttcher 
et al. 2008; Bolstad et al. 2011; Böttcher et al. 2006). Several regions were shown to facilitate the essential 
functions of VP1-2. However, which part was required for docking at the nucleus, was, until recently, not 
known (Abaitua et al. 2012). 
For regular proteins to reach nuclear pores, they require NLSs and our laboratory has previously 
shown that a stretch of four basic residues was absolutely required for VP1-2 (HSV-1) nuclear localisation 
(Abaitua & O’Hare 2008) and virus docking at the nuclear pore while being dispensable for nucleocapsid 
assembly (Abaitua et al. 2012). This patch was also sufficient to confer nuclear localisation to a large 
heterologous protein (Abaitua & O’Hare 2008). It appeared reasonable to assume that the NLS in the VP1-
2 N-terminus recruits a nuclear transport factor directly to fulfil its function during entry and thus 
identifying the regions with the same function in other HVs could aid elucidation of how these might traffic 
to the NPC. Identification of NLS types in other HVs could lead to elucidation of their mode of nuclear 
docking which, theoretically, could lead to the identification of drugable entry pathways that may be used 
to lower the health risks posed by HVs in immunocompromised patients such as transplant recipients or 
AIDS patients. My hypothesis was that VP1-2 homologues from all HV sub-families contain a NLS at an 
analogous position, that is, the first basic patch adjacent to the N-terminal USP domain. To empirically 
determine if there could be functional NLSs in the primary sequence other VP1-2s a two-step analysis of 
VP1-2 sequences was performed. Initially, the representative protein sequences of the VP1-2 homologoes 
of all HV sub-families were aligned based on the conservation in the USP domain and the body of VP1-2. 
Since the HSV-1 NLS was found in the N-terminus this narrows down the initial search to a similar region 
of the homologues. Subsequently, to identify putative NLSs in the aligned sequences several NLS 
prediction algorithms should enable me to decide which specific areas to test in nuclear transport assays. 
 
3.1.1 Sequence alignment of the VP1-2 NLS regions from all HV sub-
families 
The first step to identifying putative NLS regions was to align areas within the primary sequence of 
VP1-2 homologues that show similarity. Due to the high degree of conservation between VP1-2 proteins, 
I assumed that each linker between USP and middle segment, despite poor overall homology, contains 
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similar activity. Both the USP and middle segment are relatively easy to spot using available protein 
alignment tools. The residues linking these two domains are only poorly conserved overall. The most N-
terminal basic regions of this linker were aligned (Figure 8). The alignment highlights a common basic 
character (red background, white letters) and subgroup-specific conservation (see Figure 8, A through D). 
In all linker segments additional enrichment of prolines (grey shading) can be identified. This indicates 
that this region may not form intricate secondary structure due to the negative effect of prolines on both 
helices and beta sheets (Chou & Fasman 1974). Additionally, all equivalent regions feature an abundance 
of phosphorylatable residues (serines, threonines) and acidic residues, which could form so called PEST 
sequences. Such regions intrinsically destabilise secondary structure (Dunker et al. 2001) and thus would 
aid the presentation of any NLS in that region as linear epitopes. Four distinct, mostly sub-family specific 
patterns can be grossly distinguished. 
(i) Within the -HVs (Figure 8A) two basic regions, designated R4 and R5, are divided by a long, well 
conserved spacer enriched in potential phosphorylation sites (serines and threonines; yellow 
background). Despite the significant conservation at the N-terminus of the spacer the spacing of the two 
basic patches varies from 8-30 residues with most exceeding 16 amino acids. That is, at least four, and in 
the case of VZV up to 18, residues longer than described by the consensus of a classical bi-partite NLS 
(Marfori et al. 2011; Dingwall & Laskey 1991). On the one hand R4 is, with few exceptions, almost perfectly 
conserved featuring at least four consecutive basic residues mostly starting with a lysine (Figure 8A, K428, 
HSV-1 numbering). On the other hand R5, retaining general basic character, diverged but retains an overall 
positively charged character. All R5s that were evaluated, except for that of equine Herpesvirus-1 (EHV-
1), comprise 5-9 basic residues (of around 20 residues in total) with a preference for lysines in HSV-1/2 
and VZV. All sequences show an abundance of prolines (grey shading), multiple serines, threonines and 
glutamates (PEST sequences) which point to general disorder of this region. 
(ii) The -subfamily region (Figure 8B) comprises two well conserved basic motifs consisting, with 
few exceptions (murid herpesvirus 1 and 2 (MuHV-1 and 2)), of two runs of three to four consecutive basic 
residues divided by a short, variable spacer (8-12 residues). These motifs generally fit the consensus of 
both mpNLSs and bpNLSs (Table 1 in 1.3.2, Figure 13D). PEST residue clusters can generally be found 
flanking and within the basic patches. 
(iii) While the two basic patches are still conserved, the spacer appears further reduced (around 8 
residues in all three members examined) in the γ1 subfamily (Figure 8C). Conservation of R4’ is high 
between representative viruses. This area may represent a mpNLS or a bpNLS with a short 8 residue 
spacer. In addition, the basic residues are again surrounded by PEST residues indicating general disorder 
as mentioned for the other regions. Interestingly, the patch of serines and threonines is, due to the 
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presence of the directly adjacent acidic residues, potentially subject to phosphorylation (Meggio & Pinna 
2003). 
(iv) In the γ2 HVs (Figure 8D) no discernible homology can be found in the most N-terminal region 
after the USP that exhibits basic characteristics. Despite the lack of conservation class 1 and 2 mpNLS 
motifs (compare Table 1 and Figure 8D) can be identified in the sequences of bovine Herpesvirus 4 (BoHV-
4) and Herpesvirus Saimiri (HVS), respectively, while the other two sequences cannot be allocated to the 
described classes and might thus represent an atypical basic NLS. As with the other groups PEST residues 
are overrepresented in this region.  
 
 
Figure 8 Alignment of putative NLS regions of the VP1-2 N-terminus of representatives of the different HV sub-families. 
(A) Position and alignment of the VP1-2 NLS regions of α-HVs (R1 and its sub-regions R2, R4 and R5). The complete highly basic 
patch was designated R1 in each of the members which corresponds to the first basic region in the linker between the USP 
and the middle segment. The α-HV R1 region was further subdivided into two basic motifs, R4 and R5. Lysine at position 428 
(HSV-1 numbering), the first basic residue of R4, is indicated. (B-D) Alignment of the VP1-2 R1 regions of β- (B), γ1- (C) and γ2-
HVs (D). The R1 regions were aligned with the R1 region in the α-HV (see black line in A). The R4 equivalent region in these 
sub-families was designated R4’ and shows the amino acid sequences I chose as the equivalent region to HSV1.R4. Background 
colours indicate amino acid groups with similar properties: red (lysine, arginine), yellow (serine, threonine, tyrosine), blue 
(aspartate, glutamate), green (leucine, valine, isoleucine, methionine, phenylalanine), grey (proline), without background 
(glycine, histidine, alanine, glutamine, asparagine, cysteine). Amino acids in single letter code. Adapted from (Hennig et al. 
2014). 
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In conclusion the basic regions were easy to spot in the primary amino acid sequence and aligned 
reasonably well amongst members of the same sub-family. The described patterns also appeared to be 
conserved in (parts of) HV sub-families. To derive meaning from the observed differences in organisation 
it would be intriguing to hypothesise that they evolved as an adaptation to the particular type of host cell 
these virus groups infect since even HVs infecting different species show similarities. 
 
3.1.2 In silico NLS prediction in the N-terminus of VP1-2 orthologues 
To shuttle a nuclear protein into the nucleus cells have assembled an arsenal of nuclear transport 
receptors which recognise many different signal sequences. As importins not only interact with an NLS 
but quite often with extensive regions around the NLS of unrelated cargo proteins, multiple, similar 
transport receptors have evolved to recognise similar NLSs displayed by completely different proteins. 
Thus finding NLSs can prove a daunting task. To find NLSs in VP1-2 homologues would have probably 
required me to empirically screen the whole linker sequence between the USP and the body of VP1-2 (and 
potentially more). To aid my analysis and guide my choice of regions of interest I deployed five different 
nuclear localisation prediction algorithms to screen for putative signals. These tools can be divided into 
two groups, which wither consider only the primary sequence (NLSmapper, NLStradamus) or also 
implement other sequence data including structure and protein composition (Euk mPLoc 2.0, CELLO, 
NucPredict). For this analysis (summarised in Table 7) I initially analysed the first 1000 residues of VP1-2 
homologues. CELLO and NucPredict use a scoring system for the whole polypeptide with higher scores 
indicating higher confidence that a given sequence localises to the nucleus. Euk-mPloc works similarly but 
without scoring the input sequences. In contrast, NLSmapper and NLStradamus give an indication whether 
and where an NLS is present in the input sequence. Not all algorithms indicate which sequence would act 
as an NLS and some integrate ‘other sequence information’. To account for the different weighting of 
‘other sequence information’ I also screened the aligned R1 region (Figure 8), since, judging by the 
structural conservation of VP1-2, any putative NLS sequence might be found in the first basic patch after 
the USP. Using the short R1 should allow some of the algorithms to disregard other sequence information 
which might alter the verdict (e.g. other dominant or cryptic signals such as for secretion). In order to put 
the findings of in silico nuclear prediction into perspective, these were compared to the truly nuclear SV40 
lTag and cytoplasmic β-actin or the HSV-1 VP1-2ΔNLS as positive and negative controls, respectively (Table 
6 and Table 7). ‘Positive’ signals (or nuclear localisation) were judged compared to the SV40 signal score 
(see Table 6 and Table 7, >70% of the score was regarded as positive = green, <40% was regarded as 
negative = red) 
Although the algorithms use different analysis methods I identified a NLS in HSV-1 with three 
(NLSmapper, NLStradamus, Euk mPLoc 2.0) of the five prediction tools if the whole N-terminus was 
Identifying NLSs of VP1-2 homologues 
 
 
- 81 - 
 
considered. This could be improved to four out of five algorithms using only R1 (CELLO). The prediction of 
NLSmapper and NLStradamus even picked up the previously confirmed HSV-1 NLS but additionally 
indicated that R1 might actually comprise a bpNLS. The other α-HVs (VZV, PRV, BHV-1) scored positive up 
to two times. The VZV VP1-2 equivalent region scored low in CELLO and NucPredict or was not predicted 
to contain any putative NLS sequence in R1. The predicted NLS in the VZV VP1-2 homologue was suggested 
to lie further downstream, outside the linker region. Taking into account VP1-2 structural conservation 
and recent evidence that the central region of VP1-2, where the NLS was predicted, forms a ordered 
structure (Scrima et al. 2015), it would be of no relevance for my studies. Interestingly, the BHV-1 
homologue was predicted NLSmapper to comprise an NLS even though the linker region lacks the first 
lysine (similar to VZV). A possible explanation why the putative VZV NLS was not picked up could lie in the 
unusually long spacer between the two basic patches within the VZV.R1 (30 residues compared to 8 for 
BHV-1) and the presence of a KR motif four residues upstream of the BHV-1 R4. probably because of the 
long linker and lack of a lysine in the first basic patch (Figure 8). The PRV sequence at least twice scored 
lowest (NucPredict with 0.35 and CELLO with 1.054), although it was previously confirmed to contain two 
functional NLSs (Mohl et al. 2009) and adheres to the consensus of a mpNLS better than the corresponding 
region of VZV (Figure 8, see KRRR motif). 
The sequences of the other HV sub-families were more heavily linked with nuclear localisation. As 
such HCMV was predicted to localise to the nucleus with all algorithms except for NLSmapper. In fact, the 
confirmed bpNLS (Brock et al. 2013) was correctly picked up by NLStradamus. The sequences of the EBV, 
HHV-8 and HVS homologues were also consistently predicted to contain a NLS (first 1000 residues). 
Interestingly, HHV-8.R8, which did not look like a NLS at first glance due to presence of so few basic 
residues, was also spotted with NLSmapper and NLStradamus. 
The difference between the results of the long and short regions highlights the varying weighting 
each algorithm gave to whole sequence. NucPredict, CELLO and Euk-mPloc 2.0 look more at overall 
protein composition and may thus be more useful to analyse uncharacterised proteins. NLSmapper and 
NLStradamus appeared to search for NLSs in the primary amino acid sequence, which would probably 
make them useful if one knows the protein structure and thus where importin-accessible regions lie. 
However, these algorithms have their limitations. For once the analysis of the VP1-2ΔNLS sequence only 
had a minor effect on the verdict using four out of five tools (only NLSmapper predicted lack of a NLS). 
Moreover, it would be very difficult to spot unconventional NLSs with these algorithms and to consider 
changes to cellular physiology that happen during events such as viral infection. 
In conclusion I was able to narrow down the search for NLSs to mostly R1 (Figure 8) although not 
all sequences were consistently identified (e.g. VZV). After this exercise I was confident that I was looking 
at the correct region (R1) to test for NLS function. The data obtained by this in silico analysis, however, 
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cannot substitute for empirical (manual) analysis of the primary sequence and required experimental 
verification. 
Table 6 NLS prediction of two proteins that contain a confirmed classical mpNLS (SV40) or a confirmed bpNLS (nucleoplasmin). 
Accession Virus NucPredict CELLO 
Euk-mPLoc 
2.0 
NLSmapper NLS 
tradamus NLS score 
P03070 SV40 T-ag 0.88 2.601 Nuclear Mono 16 127-130 
P60709 β-actin 0.09 0.18 Cytoplasmic None found None found 
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Table 7 Overview of NLS predictions in the N-terminus of VP1-2 homologues using five different, freely available NLS prediction algorithms. 
Protein sequences were entered in FASTA format into the online tool which predicts localisation either associated with a likelihood score (CELLO, NucPredict; the higher the score the more 
likely the protein may be found in the nucleus), or showing the region containing the putative NLS (NLStradamus, NLSmapper) or giving an overall verdict (Euk-mPLOC 2.0, CELLO). As control 
the cytoplasmic VP1-2ΔNLS mutant (Abaitua & O’Hare 2008) was included in this analysis. Red font = <40% of SV40 lTag score in NucPredict and CELLO only (NucPredict = 0.88; CELLO = 
2.601), green font >70% of SV40 lTag score, orange font between 40-70% of SV40 lTag score. For Euk-mPloc 2.0, NLSmapper and NLStradamus green font indicates a positive result (nuclear 
or NLS), red font indicates a negative result (e.g. extracellular). Algorithms based on Yu et al. (2006); Nguyen Ba et al. (2009); Chou & Shen (2010); Kosugi et al. (2008); Kosugi, Hasebe, 
Matsumura, et al. (2009); Kosugi, Hasebe, Tomita, et al. (2009); Brameier et al. (2007). 
Accession Virus 
NucPredict CELLO Euk-mPLoc 2.0 
NLSmapper 
NLS tradamus 
aa 1-1000 
aa 1-1000 R1 (or R8) 
aa 
1-1000 
R1 (or R8) 
aa 
1-1000 
R1 (or R8) aa 1-1000 R1 (or R8) NLS Score NLS Score 
ABI63498.1 
HSV-1 0,51 0,46 1,428 2,951 Nuclear, cytoplasm extracellular mono, bi 8, 7.9 mono, bi 8, 7.9 425-467 
HSV-1 
NLS 
0,38 0,26 1,32 2,089 Nuclear, cytoplasm extracellular none found 442-461 
A6XEB1 VZV 0,5 0,34 0,841 2,024 Nuclear extracellular 
mono (not 
R1) 
9 none found none found 
Q5PPB8 PRV 0,35 N/D 1,054 N/D Extracellular N/D mono, bi 9, 5.5 N/D N/D 278-297 
Q65553 BHV-1 0,43 N/D 1,39 N/D Extracellular N/D bi 5,6 N/D N/D N/D 
P16785 HCMV 0,77 0,63 2,216 2.701 Nuclear extracellular, nuclear none found 281-304 
K9UT36 EBV 0,84 0,68 3,485 2.866 Extracellular, nuclear nuclear mono, bi 5, 5.2 mono 5 411-432 
Q2HR64 HHV-8 0,8 
0.38 (R1) 
2,723 
2.45 (R1) 
Nuclear 
nuclear (R1) 
mono 8 
none found 
304-322 
0.57 (R8) 2.336 (R8) nuclear (R8) mono (R8) 8 (R8) 
Q01056 HVS 0,72 
0.16 (R1) 
3,516 
2.26 (R1) 
Nuclear 
nuclear (R1) 
bi 8,2 
none found 
258-308 
0.32 (R8) 1.896 (R8) nuclear (R8) bi (R8) 8.2 (R8) 
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3.1.3 Analysis of NLS functionality 
To test whether the predicted NLSs are functional motifs, several approaches could be 
employed. (i) Nuclear localisation could be analysed using VP1-2 homologues from representative HV 
sub-family members. This would be considered the most physiological approach. (ii) Putative NLSs 
could be screened using a heterologous protein, such as GFP or similar. This would allow looking at 
isolated regions which could be useful since it would effectively remove NLS presentation issues. (iii) 
NLS regions from analogous positions of representatives from other HV sub-families could be cloned 
into the HSV-1 VP1-2 protein since domain structure appears to be conserved across all VP1-2 
homologues (see Figure 3). This would allow screening regions of interest in the context of a conserved 
protein at an analogous position. 
(i) Since cloning the full length VP1-2 homologues from the other sub-families could be 
problematic the first approach could take a long time to complete. This would have to be followed up 
by more detailed analysis using mutations to identify the actual NLS. 
(ii) Our group had already successfully used the β-gal system to identify the HSV-1 NLS (Abaitua 
& O’Hare 2008). Thus it seemed reasonable to continue with this system and clone any predicted 
putative NLS sequence into the N-terminus of it. However other heterologous proteins, including GFP, 
that could also be suitable for screening putative NLSs, should be considered. These systems are useful 
since they isolate the test region at the protein terminus it is fused to, although this may lead to false 
positive results. Any positive signal still has to be confirmed with another technique (see iii). 
(iii) There are multiple reasons why it could be feasible to study the homologous R1s in the 
context of HSV-1.VP1-2. (a) Our lab has already cloned and worked with HSV-1 VP1-2 and the HSV-1 
BACMID system. (b) The localisation of VP1-2 has already been well characterised (Abaitua & O’Hare 
2008; D S McNabb & Courtney 1992; Möhl et al. 2009). (c) NLSs usually present as linear epitopes, 
which is the reason why NLSs tend to be transferrable (if this is their sole function) and only require a 
cellular transport factors to be present (e.g. importin α subtypes). (d) The linker region connecting the 
USP and middle segment is not well conserved (while the USP and middle segment are) and most 
importantly not predicted to contain secondary structure that could be disrupted by inserting a foreign 
sequence. (e) The VP1-2 homologues show high levels of conservation across independent areas, and 
especially within the putative NLS regions. The areas surrounding the putative NLS all contain multiple 
helix/sheet breaking residues indicating a similarly disordered character as the HSV-1 part. Assuming 
that nuclear docking was the only function of the 70 residue patch around the NLS, this part of the 
linker between USP and middle segment can be swapped directly (Figure 14A) to allow functional 
analysis. Domain or even complete protein transfer between related viruses has been done before and 
can be a useful tool to study protein function (Kuhn et al. 2008). (f) Finally, for the HSV-1 protein our 
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group has already shown that deletion of part of the NLS allows for normal virion formation (including 
recruitment of other tegument proteins) and replication precluding a structural function of this motif 
in VP1-2 and in the context of viral capsids. 
Thus I used two complementing approaches mentioned in (ii) and (iii). Initially, to screen for any 
motives that contain NLS function, a non-quantitative screen utilising the large bacterial protein β-
galactosidase (β-gal) was deployed. For this, regions of interest were cloned in frame into the N-
terminus of β-gal. This approach was designed to find any putative NLS motifs regardless of their 
strength or whether they could function in physiological context, since they will be presented as linear 
epitopes. All fusion constructs were screened for their ability to localise β-gal to the nucleus. The 
second approach was designed to assess NLS function in a more physiological setting and to study NLS 
function/efficiency qualitatively and quantitatively. For this, the extended NLS regions (R1) from 
representative VP1-2 homologues from all HV sub-families were inserted into HSV-1 VP1-21-1875 (NT6) 
which would mimic a more physiological context of the VP1-2 NLS. 
 
3.2 Results 
3.2.1 Development of the -galactosidase nuclear translocation 
assay 
In order to evaluate the NLS activity of a variety of regions of interest it was important to test 
their capacity to translocate a cytoplasmic protein to the nucleus. There were three options for 
screening NLS activity in VP1-2 homologues. For an initial screen I chose to pursue a heterologous 
protein translocation assay to find functional NLS motifs. Initially, I wanted to see which was the best 
screening protein for my studies (i.e. not nuclear without NLS and nuclear with NLS and easy to detect). 
For this I chose to investigate, GFP and -gal fused to known HSV-1 NLSs (Abaitua & O’Hare 2008). 
Although these screening vectors do not show the same structural constraints as VP1-2, where the 
putative NLS presumably lies between two folded domains (USP and middle segment, Figure 3), they 
are fully folded proteins which are not disrupted by adding short or even long sequence tags. In fact, 
any sequence added is likely solvent exposed and thus freely accessible to the nuclear transport 
machinery which I assumed would be the case in the VP1-2 linker. This approach was not designed to 
score functional efficiency of test NLSs but to find any sequence able to confer nuclear localisation to 
a heterologous protein, and it will be complemented by a second study of NLS activity within HSV-1 
VP1-2. 
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Figure 9 Development of the nuclear translocation assay; comparing GFP and β-gal NLS fusions. 
(A) Overview of the sets of constructs planned for this thesis.  For β-gal and GFP the NLSs were fused in frame into its N-
terminal. (B, C) Representative images of fixed HuH7 cells show steady state localisation of (B) GFP (I), GFP-R4 (II) and GFP-
R2 (III) or (C) -gal (IV) and β-gal fusions with SV40 lTag NLS (V), R4 (VI) and R2 (VII). Cells were fixed 24h post-transfection 
(B, C) and stained with anti β-gal antibody (C). Nuclei were counterstained with DAPI. R4 and R2 are HSV-1 specific 
sequences (see Figure 8). Cells were imaged at 63x magnification. 
 
For the purpose of this particular analysis, NLS regions R2 and R4 were fused in frame to GFP 
and β-gal (see Figure 9). GFP itself (panel I) showed both nuclear and cytoplasmic signal but was 
enriched in the nucleus even in the absence of any exogenous NLS. Upon fusion of R4, the smaller of 
the NLS regions, to GFP, the fusion protein appeared to enrich in the nucleus not much beyond what 
was seen for GFP alone as judged by remaining cytoplasmic signal (Figure 9B, panel II). When the longer 
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R2 region containing the second basic patch (i.e. R2 = R4 + R5) was fused to GFP, the fusion protein 
now almost exclusively localised to the nucleus (Figure 9B, panel III) implying there are additional 
signals that either enhance nuclear translocation or that retain the protein in the nucleus. Upon closer 
inspection, R2-GFP appeared to accumulate in nucleoli as the regions of strong green signal overlapped 
with areas of low DNA density. The lack of DAPI signal indicates a lack of DNA in that region which is a 
characteristic feature of protein dense nucleoli. In silico analysis (Nucleolar localisation sequence 
detector, University of Dundee) of R1 predicted a nucleolar localisation signal in the C-terminus of the 
NLS (i.e. R5) which could be causing this sub-nuclear compartmentalisation (Scott et al. 2010). 
β-gal exhibited a mainly cytoplasmic diffuse pattern of localisation (Figure 9C, panel IV) with very 
little staining observed in the nucleus. However, the strength of the nuclear signal varied from 
experiment to experiment but was generally much weaker than in the cytoplasm. If the strong 
experimentally verified NLS of the SV40 lTag was fused N-terminally to β-gal the fusion protein 
localised exclusively to the nucleus (Figure 9C, panel V), validating the assay format. Fusing R4 to β-gal 
(Figure 9C, panel VI) showed a similar effect on localisation as the SV40 NLS, which was not enhanced 
by extending the NLS to include the second basic patch (Figure 9C, panel VII). Intriguingly, R2.β-gal did 
not recapitulate the nucleolar accumulation found with GFP-R2Actually, R4.β-gal appeared to be 
excluded from distinct weakly DAPI-stained sub-nuclear compartments. 
GFP is a small fluorescent protein making it useful for live cell imaging. However, its relatively 
small size of 27kDa allows it to enter the nucleus without the need of an NLS (Figure 9B, panel I). On 
the other hand the bacterial protein β-gal is large (130kDa) enough to be excluded from nuclei (Figure 
9C, panel IV) and does not contain any putative NLS or NESs making it a good candidate cargo. The 
latter fact makes it ideal to find even weak NLSs as once nuclear, it remains there unless nuclear 
integrity is disrupted. The fact that R4 NLS activity might have been missed using GFP as a heterologous 
transport cargo lead me to focus on β-gal as a screening tool to find NLSs, since there would be a higher 
chance to identify even weak signals. 
 
3.2.2 Analysis of NLS function of the VP1-2 R4 regions using the 
-gal system1 
After establishing the screening system I could now think about which regions to test first. Due 
to the striking conservation in the -HVs and the relatively strong conservation of basic residues in the 
other sub-families, I initially analysed a homologous region (R4 for α-HVs and R4’ for the other HV sub-
families as shown in Figure 8) around the core basic residues in representative human viruses from all 
                                                          
1 Figures of this sub-chapter were adapted from (Hennig et al. 2014) 
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three sub-families: VZV (), HCMV () EBV (1) and HHV-8 (2). These regions were chosen due to their 
position within VP1-2 (first basic patch after the USP domain) and cloned in-frame into the N-terminus 
of the -gal ORF. For analysis of localisation constructs were transfected into HuH7 cells and their 
localisation examined at steady state after 24 h of expression by indirect immunofluorescence to β-gal 
(see Figure 10). 
 
 
Figure 10 Localisation of β-gal fusion proteins comprising R4 homologous regions from different HV homologues. 
HuH7 cells were fixed 24h post-transfection. Localisation of fusion protein was detected using anti β-gal antibody and 
nuclei were counterstained with DAPI. Representative images are shown. Each panel consists of two images, top and 
bottom, showing the FITC and the DAPI channel, respectively.  
 
The control constructs (Figure 10, panels I-III) exhibited exclusively nuclear localisation for NLS 
sequences of SV40 lTag and R4 (panels II and III, respectively) and mostly cytoplasmic accumulation for 
β-gal alone (panel I). Unexpectedly, the highly conserved VZV.R4 fusion shows mainly cytoplasmic 
distribution (Figure 10, panel IV) similar to that of the negative β-gal control (panel I). This might 
indicate that either the VZV homologue does not contain a functional NLS or that the NLS may lay 
downstream or encompasses a larger region. This result also raised the question whether this would 
be similar for the other representatives of the - and -HVs. Expectedly, the HCMV.R4’ and EBV.R4’ 
regions containing both short basic patches showed strong activity exhibiting almost exclusively 
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nuclear localisation which parallels the activity of the HSV-1 peptide (Figure 10, panel V and VI, 
respectively). To cover all the different types of linker regions present in the HV sub-families, it was 
necessary to include a 2 representative, namely HHV-8, since the sequence barely resembles that of 
any other sub-family (Figure 8D). HHV-8.R4’ lacks N-terminal lysines but contains several arginines 
clusters of no more than two consecutive residues, thus, perhaps as anticipated, it did not enable 
nuclear translocation of -gal beyond control levels (Figure 10, panel VII). As for VZV, the NLS activity 
might be absent from this region or still be found further downstream or be part of a multi-partite 
signal. 
 
3.2.3 Analysis of NLS function of the extended VP1-2 R1 regions 
using the β-gal system 
To expand upon the study of R4s and to clarify the lack of NLS activity in VZV and HHV-8 the test 
region was expanded to include all basic residues within an approximately 70 residue stretch around 
R4 (designated R1, Figure 8). For this, HA-tagged R1s were cloned in-frame into the N-terminus of β-
gal and localisation was analysed by indirect immunofluorescence to the HA tag. 
Consistent with the results from R4, HSV-1.R1 showed strong nuclear accumulation (Figure 11, 
panel III) whereas HA-β-gal accumulated in the cytoplasm (Figure 11, panel I). I noted marginally 
increased nuclear signal with this control compared to β-gal lacking the HA-tag but the dynamic range 
between negative and positive control (HA-β-gal vs HA-NLS-β-gal) was still large enough to be easily 
analysed. A further control using a cellular NLS (Myopodin; MyoNLS) inserted within HSV-1.R1 in place 
of the first basic patch in R4 (Figure 11, panel II) also showed nuclear staining. Since β-gal cannot exit 
the nucleus once it entered, it was thus difficult to judge if the strong MyoNLS could improve upon R4 
activity, underscoring the limits of this nuclear transport assay system.  
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Figure 11 Localisation of β-gal fusion proteins featuring R1s from HV VP1-2 homologues. 
HuH7 cells were fixed 24h post-transfection and the N-terminal HA-tag was used to detect the fusion protein. As an 
additional control the Myopodin NLS was cloned into R1 in place of the first basic patch of R1 (Myo.R1). Nuclei were 
counterstained with DAPI.  
 
Intriguingly, the expanded region of VZV showed strong nuclear staining (Figure 11, panel IV), 
which indicates the NLS might be bi-partite. Consistent with the result from the analysis of R4s, the 
CMV and EBV fusions confirmed that the R1 region of these representative HVs contains a NLS (Figure 
11, panel V and VI, respectively). In contrast to this, extending the HHV-8 test region downstream of 
R4 to include additional basic residues did not lead to detectable nuclear localisation function in this 
assay (Figure 11, panel VII). Thus the first large basic patch downstream of the USP in HHV-8 VP1-2 
does not contain a NLS. This function may not be present in this region but this requires further 
experimental validation. 
These results lead to the conclusion that all respective VP1-2 regions contain a NLS if these 
comprise a run of at least three basic residues with an N-terminal lysine or two patches with one 
consecutive run of at least three basics and additional lysines further downstream (compare Figure 8). 
The area in HHV-8 showed an overall basic character but did not satisfy these criteria and thus probably 
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not surprisingly did not confer nuclear localisation to β-gal.Further analysis of NLS function in HHV-8 
VP1-2 using the β-gal system 
Since all VP1-2 homologues except HHV-8 were found to contain a NLS in R1 I wanted to check 
whether this function was present elsewhere in the linker region. Thus I extended the analysis to to a 
region further downstream of R4 (Figure 12B). The linker region indeed contained areas comprising 
further arginines or lysines (Figure 12A, red vertical lines) and two, R5 and R9, were chosen for analysis. 
In fact R5 was predicted by NLStradamus and R9 conforms loosely to the consensus of a class 3/4 
mpNLS (KRKF). Although HHV-8 showed low conservation, the region designated R8 aligned 
comparatively well amongst γ2 members if the heavily acidic patch was used as a point of reference 
(Figure 12C). At least one other γ2-HV (Figure 12C, BoHV-4) actually comprised a stretch of four basics 
with an N-terminal lysine resembling the class 1 NLS consensus. Surprisingly, HHV-8.R8 also bore some 
limited resemblance to the γ1-HV.R1 (Figure 12D) when the region was aligned based on the homology 
of the short HHV-8 basic and acidic patches. 
The negative controls β-gal (Figure 12E, panel I) and HHV-8.R4-β-gal (panel II) again showed no 
nuclear localisation. Since HHV-8.R1 was already known to not confer nuclear localisation to β-gal 
(panel IV) it was maybe not surprising that HHV8.R5 was also functionally inert in this assay (panel III) 
although it includes two more basic residues that were not included in R1 (see Figure 12A). 
Unexpectedly, and despite the presence of only five basic residues and generally highly acidic character 
of HHV-8.R8, this sequence conferred nuclear localisation to β-gal (Figure 12E, panel V). The actual 
NLS, however, precedes the acidic patch and resides in the four basic residues of R9 (Figure 12E, panel 
VI) implying that this motif is a mpNLS These data taken together with the results on the other HV 
motifs I conclude that likely all HVs contain a NLS in the linker region between USP and middle domain 
which could function similarly during entry of HV capsids. 
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Figure 12 Analysis of a basic region in HHV-8 VP1-2 downstream of R1. 
(A) Schematic overview of the location of basic residues in the non-conserved linker region of HHV-8 VP1-2. The linker is 
expanded below and the red vertical lines indicate the relative position of basic residues within the linker region. Sub-
regions are indicated by black lines. (B) Alignment of γ2 HV VP1-2 region around R1 to compare to the improved alignment 
in C. R4’ and R5 = black line, R1=red dotted line. (C) Alignment of an acidic region found in the γ2 representatives shows 
upstream conservation of a short basic patch which conforms loosely to the NLS consensus. (D) Alignment of HHV-8 R8 
with R1s of γ1-HVs, which show some conservation around the central KRKK motif including a downstream polar-acidic 
patch. R9 = black line, R8 = red dotted line. (A-D) Amino acids in single letter code with same colour coding as in Figure 8. 
(E) Representative images showing the localisation of N-terminal β-gal fusions of the in (A) depicted regions detected with 
anti-HA antibody in HuH7 cells. 
 
3.2.4 Analysis of determinants of NLS function of HSV-1 VP1-2 
using the β-gal system 
The striking difference in activity between the HSV-1.R4 and VZV.R4 was a reason to look more 
closely at the determinants that govern NLS function of this region. Although these two α-HVs 
contained a NLS in R1 it came as a surprise that VZV.R4, despite showing a very high degree of 
conservation, was an exception. Thus, I first examined the sequence around R4 in more detail. 
Although they look very similar (Figure 8), there are three main differences: (i) There is a run of five 
basic residues in at least two VZV strains compared to the four basics found in most α- and β-HVs. (ii) 
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VZV.R4 lacks a lysine at the first position of the basic run in R4 compared to the HSV-1 sequence (Figure 
8A, equivalent of HSV-1 K428). This also deviates from the consensus of mp or bpNLSs (see Figure 13D 
and Table 1). (iii) The gap between the first and second basic patch counts 30 residues compared to 16 
for HSV-1 which may affect the utility of a bpNLS but should not affect mono-partite signals. To 
examine these peculiarities further I introduced mutations into the previously tested regions (R1 and 
R4) of both HSV-1 and VZV and checked whether this affected the localisation of the respective β-gal 
fusion proteins. 
Representative images of the controls for this assay are depicted in Figure 13A which show 
nuclear localisation for HSV-1.R4 and HSV-1.R1 (Figure 13, panels II and III, respectively) while VZV.R4 
and β-gal alone remained cytoplasmic (panel IV and I, respectively). The R>P substitution of the first 
arginine from VZV.R4 confirmed that the run of five basic residues was not the culprit for lack of 
function of this region (Figure 13B, panel VI). Vice versa, the P427R substitution in HSV-1 had no effect 
on function of the HSV-1.R4 sequence (Figure 13B, panel V). This also indicates that the reasonably 
well conserved proline plays no direct role in recruitment of nuclear transport factors in this assay.  
The consensus of mpNLSs (Figure 13D, top two lines) specifies a lysine at the most N-terminal 
position of the basic patch. To see whether the lack of a lysine did indeed play a role in NLS function, 
a second mutation was introduced into both R4s. The K428R substitution in HSV-1 completely 
abolished nuclear localisation consistent with the consensus requirements of a mpNLS (Figure 13B, 
panel VII). Vice versa, introducing a lysine at the analogous position (the second arginine) in VZV.R4 
(Figure 13B, panel VIII) conferred nuclear localisation to -gal. This is not further enhanced by the 
double mutation, RR>PK, in VZV.R4 (Figure 13B, panel IX). These results indicate that the VZV structure 
likely does not encompass a mpNLS in R4 due to the lack of a lysine at position 432 (VZV numbering). 
The above mutations looked at R4 in isolation but since the second basic patch was conserved 
in its position (i.e. downstream of R4) it was reasonable to assume it would aid R4 function since both 
basic patches contribute to transport factor binding. Thus the same mutations were introduced into 
R1-β-gal fusions. Interestingly, the K428R mutation in HSV-1.R1 (Figure 13C, panel XI) did not 
recapitulate the deleterious phenotype of the same change in the context of HSV-1.R4 (Figure 13B, 
panel VII, HSV-1.R1.K428R showed NLS activity but R4.K428R did not). This corroborated the finding 
that the VZV.R1 harbours NLS activity as part of R1 but not R4 (Figure 13A/C, panels IV and X) since it 
also lacks a leader lysine. To further test whether the first basic residue would at all be required for 
NLS activity as part of R1 a non-conservative mutation, K428A, was introduced into HSV-1.R1, which 
should sufficiently destabilise importin-NLS interaction. Expectedly, this change abolished nuclear 
localisation completely (Figure 13C, panel XII) confirming that R4 has a dominant role in conferring NLS 
activity. Conversely, this serves as an additional control showing that R5 alone is not a functional NLS 
Identifying NLSs of VP1-2 homologues 
 
 
- 94 - 
 
(Figure 13C, panel XIII) but R4 is (Figure 13C, panel XIV). Taken together, this indicates that the second 
basic patch of HSV-1.R1 contributes to NLS function in HSV-1, although R4 may function as a mpNLS in 
isolation. Expanding upon previous findings I hypothesise that this region likely functions as a bi-partite 
motif during viral replication as well.  
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Figure 13 Effect of point mutations in the VP1-2 NLS of HSV-1 and VZV on localisation of -gal fusion proteins. 
Mutations were introduced into the HSV-1 NLS region and the analogous residues of the VZV NLS. (A) Localisation of control 
fusion constructs described before. (B, C) Mutational study of the R4 region (B) and of the R1 region (C) of HSV-1 and VZV. 
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Mutated NLSs were cloned in frame into the -gal ORF (also contained N-terminal HA-tag). Localisation was detected in 
HuH7 cells using anti-HA antibody 24h after transfection. Representative images are shown for each construct (incl. DAPI). 
(D) The consensus of classical a mpNLS and bpNLS that would conventionally employ importin- and  mediated nuclear 
import pathway (see Table 1). This is compared to the mpNLS of HSV-1 (in R4) and the potential bpNLS variants that could 
enable nuclear transport in HSV-1 and VZV. Residues designated P1, P2, etc. show positions in a mpNLS or the second basic 
patch of a bpNLS. Positions designated P1’ and P2’ show the first (upstream) part of a bpNLS. X = any amino acid with 
numbers in subscript indicating number of residues. Red letters are important consensus residues. Green residues match 
the consensus and blue residues show deviation from the consensus. 
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3.2.5 Studying NLS function in the context of HSV 1 VP1-2 
To complement and confirm the β-gal data I designed a strategy to insert all R1s into HSV-1 
VP1-2 (Figure 14A) which enabled me to easily screen multiple sequences. For this, the VP1-2 DNA 
sequence was modified by inserting two restriction sites near the NLS without changing the protein 
sequence. These sites were subsequently used to insert any foreign sequence (such as the R1s from 
VP1-2 homologues). 
To create an easy to interpret nuclear transport assay system a few things required my 
consideration. Firstly, the positive control should preferably localise exclusively to the nucleus and, 
secondly, this localisation should optimally depend on the presence of a NLS only. However, the 
localisation pattern of full length VP1-2 is heterogeneous showing cytoplasmic and nuclear localisation 
likely caused by the presence of multiple domains with separate but presumably, at least in the context 
of transfection, competing functions (D S McNabb & Courtney 1992; Abaitua & O’Hare 2008; Möhl et 
al. 2009; Brock et al. 2013; Schipke et al. 2012). Thus in order to create a robust and easy to analyse 
system to study the nuclear localisation function of the homologous R1s in the context of HSV-1 it was 
necessary to truncate VP1-2. The truncated VP1-21-1875 protein, designated NT6 (N-terminal product 
6), which had the C-terminal 40% removed, is too large to enter the nucleus by simple diffusion and 
showed strong nuclear localisation in the majority of cells (Figure 15, panel I and B). This was entirely 
dependent on the presence of the NLS in R1 (Figure 15, panel II and B) and not due to passive diffusion 
(too large) or presence of a second motif with similar activity, since deletion of the first basic patch 
almost completely abolished nuclear localisation. Using this system it was possible to test for NLS 
function of R1s in a more physiological context. 
 
3.2.6 Expression of chimeric VP1-21-1875 
Due to the size of full-length VP1-2 it also is not expressed too well in transient transfections. C-
terminal truncation should improve expression and stability of the protein (VP1-21-1875) I wanted to 
check whether NT6 can be recovered from cells intact, since it was suggested that VP1-2 could be 
cleaved during its life span (Kattenhorn et al. 2005; Jovasevic et al. 2008; Fuchs et al. 2004). Shorter, 
cleaved forms of NT6 could potentially migrate into the nucleus freely, which could obscure the data. 
All of the test NT6s expressed sufficient amounts of the protein in transfected cells as detected by 
Western Blot analysis (Figure 14). Breakdown products of NT6 could sometimes be found (compare 
lanes 2 and 11 in Figure 14B) but detection of full length product varied only marginally between the 
different constructs in the same experiment. The occasionally observed breakdown could relate to 
sample handling  and may be minimised by omitting the sonication step to fragment cellular DNA (e.g. 
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treat lysate with DNase prior to adding SDS buffer, dilute sample or shear DNA). Since NT6 was tagged 
at the N-terminus, the observed breakdown products between 40-58 kDa (Figure 14B, left) could 
obscure the localisation pattern since small proteins (usually <40kDa) can enter the nucleus through 
diffusion. This should be taken into account for the later described localisation analysis.  
 
Figure 14 (A) Cloning strategy to create chimeric NT6 derivatives and their expression in HuH7 cells. 
Unique BamHI and MluI sites in the 1875 residue NT6 portion of VP1-2 were used to insert the homologous test regions 
(R1s, in red) of representatives of HV sub-families via an intermediate vector containing a chemically engineered BamHI-
MluI fragment containing two additional unique restriction sites, XhoI and NheI (red arrows), which were used for further 
cloning. All chemically synthesised R1s (and HSV-1 mutants) were inserted via XhoI and NheI restriction sites into the 
BamHI-MluI carrying vector and subsequently transferred to NT6 via ligation between BamHI and MluI. Colour coding 
indicates sequence homology between different regions compared to HSV-1. (B) Western blots showing expression of NT6 
in HuH7 cells transfected for 24h. NT6 protein in cell-equivalent fractions was detected using anti-V5 antibody. 
 
3.2.7 Analysis of localisation of mutant NT6 
After confirming expression of the chimeric and mutant NT6s in transfected cells the next step 
was to qualitatively and quantitatively analyse protein localisation. For qualitative analysis HuH7 cells 
were utilised and representative images of localisation patterns are shown in Figure 15B.To minimise 
localisation artefacts NT6 cellular distribution was examined in three different cell lines and more than 
100 cells were scored. To simplify analysis the observed localisation phenotypes were allocated to 
three categories (Figure 15A, HuH7 cells depicted); nuclear only + nuclear > cytoplasmic (cat I, Figure 
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15A, panels I and II), evenly distributed signal (Figure 15A, cat II, panel III) and cytoplasmic > nuclear 
(Figure 15A, cat III, panel IV). 
As previously mentioned, the controls of the nuclear transport assay exhibited a large dynamic 
range. NT6 showed strong nuclear localisation with the majority of cells showing only nuclear staining 
(panel I, Figure 15B/C). This was entirely dependent on the presence of the NLS in R1 (Figure 15B/C, 
panel II). 
With these robust benchmarks nuclear localisation of NT6 derivatives could be tested by indirect 
immunofluorescence in transfected cells (Figure 15B, panels III-XI). More than 75% of HuH7 cells 
transfected with NT6 harbouring the VZV.R1 sequence show increased nuclear localisation compared 
to NT6ΔNLS (Figure 15A, panel II and III; B). However, VZV.R1, which shows the highest level of 
conservation compared to HSV-1 (Figure 8), caused a 50% reduction of cells that show only nuclear or 
mostly nuclear staining (B)). In fact, almost no cells were found to contain only nuclear staining. This 
conclusion was corroborated by results obtained using the NT6.K428R mutant (Figure 15B, panel IX; B) 
which recapitulates the drop in nuclear localisation found for NT6.VZV.R1 (B). Furthermore, the 
introduction of the K428A mutation (Figure 15B, panel X) almost completely abolished nuclear 
translocation as was previously found for the β-gal fusion protein. The role of the second basic patch 
was initially hinted by the failure of VZV.R4 to translocate β-gal to the nucleus so I was interested in its 
role in the context of VP1-2. In agreement with previous results deletion of R5 still allowed nuclear 
translocation of NT6 (Figure 15B, panel VIII) although NLS efficiency dropped to a level comparable to 
the VZV sequence (B). To see whether NLS activity could be compromised by insertion of a different 
NLS in place of the basic patch in R4 a cellular mpNLS (from Myopodin) was inserted. This construct 
localised to the nucleus with similar efficiency as wild-type NT6 (Figure 15B, panel XI, B), indicating that 
the combination of a different, strong NLS and R5 did not interfere with function of R1 although R5 
was required for full function previously. 
Taken together these data imply that R4 has the dominant role in facilitating nuclear transport 
of VP1-2 and R5 only contributes to this since deletion of R5 had only a modest effect on whereas 
K428A abolished nuclear transport. In addition the lysine (K428) plays a crucial role for full NLS function 
in the context of NT6 and probably VP1-2. This leads to the conclusion that the NLS in HSV-1 can 
function as a weak mpNLS and a stronger bpNLS and that for full activity integrity of HSV-1.R1 is 
required. 
Notwithstanding the dramatic changes in sequence and organisation of R1s in the β and γ1 sub-
families, nevertheless the CMV.R1 (Figure 15B, panel IV) and EBV.R1 (Figure 15B, panel V) regions 
showed strong NLS activity which looked at times more efficient at translocating NT6 to the nuclear 
compartment than their wild-type counterpart. The γ2-HV regions from HHV-8 recapitulated what had 
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already been found for the β-gal fusions. HHV-8.R1 showed no NLS activity above that of NT6ΔNLS in 
HuH7 cells (Figure 15B/C, panel VI). In contrast, HHV-8.R8 showed activity comparable to the wild-type 
sequence (Figure 15B, panel VII). This shows that NLS activity is transferrable between the different 
VP1-2 homologues and that the structure of NT6 probably was not affected by insertion of 70 foreign 
residues. 
Next I examined the effect of mutations within the HSV-1.R1 region. These generally affected 
nuclear transport of NT6. Expectedly, the K428A substitution (Figure 15B/C, panel X) essentially 
abolished nuclear translocation, which was in agreement with the previous β-gal study. If the 
conservative substitution K428R was introduced into NT6, the NLS remained functional (Figure 15B/C, 
panel IX) although at modestly reduced level. In theory, the stronger a NLS binds to its importin 
receptor the more efficiently it traverses the NPC (Hodel et al. 2006) implying that the K428R mutation 
destabilised the importin-NLS interaction. The most prominent reduction in utility of the K428R NLS 
was observed in HEK293 cells. Interestingly, the K428R mutant NLS still functioned more efficiently 
than VZV.R1 (Figure 15C) implying that other features, probably residing in the spacer, R5 and/or the 
surrounding area contribute to function (which are HSV-1 specific and only work fully in conjunction 
with the HSV-1 NT6). Deletion of R5 modestly affected NT6 localisation in HuH7 cells (Figure 15B/C, 
panel VIII) whereas it had a more pronounced effect on NT6 localisation in HEK293, although NT6ΔR5 
still showed some nuclear localisation above the level of NT6ΔNLS (Figure 15C). These data were in 
agreement with previously obtained results for β-gal fusion protein in thatR4 is the dominant feature 
for nuclear localisation in NT6 and probably VP1-2, while R5 only contributes accessory functions. 
To lower the chance of localisation artefacts due to the choice of cells, two further easily 
transfectable cell lines were chosen (COS-1 and HEK293) to score localisation of some constructs with 
lowered nuclear translocation efficiency as described before. In quantitative terms the results were 
largely consistent with the data obtained for localisation in HuH7 cells although it appeared that in 
HEK293 cells nuclear transport was more tightly regulated (Figure 15C, right graph). This could have 
been caused by differences in availability of nuclear transport factors in the different cell types. 
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Figure 15 Localisation of NT6 proteins (described in Figure 14) in HuH7 cells. 
(A-C) The localisation of transiently expressed chimeric or HSV-1 mutant NT6 was detected using anti-V5 antibody. Four 
major localisation patterns (A) were observed which were categorised into three categories; category I includes all nuclear 
only and nuclear > cytoplasmic events, category II includes cells showing even distribution of signal (nuclear = cytoplasmic), 
category III includes all cells showing nuclear < cytoplasmic staining for NT6. The white arrowhead indicates the cell of 
interest. Representative images of the main phenotypes observed in HuH7 for the different constructs are shown in B. The 
localisation pattern was scored manually (for categories see A) in more than 100 HuH7 or HEK293 cells for NT6 mutants 
which showed intermediate localisation phenotypes (C). 
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3.3 Discussion 
Work presented in this chapter has led to the discovery of a NLS in approximately the same 
position in VP1-2 homologues of representatives from all HV sub-families, although the organisation 
of the region varied considerably between sub-families. NLS activity was confirmed in a heterologous 
system and in the context of HSV-1 VP1-2 in a variety of cell lines. Furthermore, I was able to show 
that the R1 region of HSV-1 and VZV, and probably all other α-HVs, comprises a bpNLS, which depends 
on the presence of a lysine at position 428 (or 432 in VZV). 
 
3.3.1 The choice of cargo protein can alter the outcome of the 
assay 
To confidently identify functional NLSs in VP1-2 a good screening system had to be chosen. The 
standard way to confirm NLS activity in a particular sequence is to monitor the localisation of fusion 
proteins of the test sequence and an easily tractable cargo. One common choice is GFP. Although this 
system lends itself to live cell imaging there are some notable pitfalls. Its relatively small size of 27kDa 
allows GFP to enter the nucleus without the need of a NLS (Figure 9B, panel I). Another choice was the 
bacterial protein β-gal, which is large (130kDa) enough to be excluded from nuclei (Figure 9C, panel IV) 
and does not contain any putative NLS or NESs making it a good candidate cargo. The latter point would 
make it an ideal cargo to find even weak NLSs as, once nuclear, it should theoretically remain there 
unless nuclear integrity is disrupted. Initial comparisons of HSV-1 NLS regions fused to both GFP and 
β-gal showed some disparities in trafficking in the GFP/β-gal fusion proteins with R4 and R2. Firstly, R2 
was able to pull only GFP into sub-nuclear compartments which might be nucleoli (Figure 9, panel III). 
Secondly, the nuclear transport activity of R4 would likely not have been noticed using the GFP system 
(Figure 9, compare panels I and II). What are the reasons for the differences observed for R4 or R2 
targeting activity? One of the following two theories might explain the GFP/β-gal sub-nuclear 
compartmentalisation observed in the context of the R2 fusions. (i) GFP contains additional 
determinants that allow it to stick to components of or enter nucleoli which β-gal does not. (ii) If one 
assumes that R2 contains additional features which target the protein to the nucleolus, then β-gal 
could simply be too large a protein to access this protein dense structure. 
The discrepancy around NLS activity of R4 might touch upon similar problems. GFP is small 
enough to enter the nucleus but it may by definition then also freely re-enter the cytoplasm. BpNLSs 
are formed by two basic sequences and thus R4, containing only one of the basic patches, might simply 
be less efficient at nucleocytoplasmic shuttling than R2 due to weaker binding to importin-α. This in 
turn would be exacerbated by the tendency of GFP to exit the nucleus again. In comparison, β-gal could 
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not exit the nucleus and thus might accumulate in the nucleus ‘more effectively’ as part of a R4 fusion 
protein. Thus the β-gal system might allow for more accurate identification of even weaker test NLSs 
and was the preferred choice for the purpose of the work presented herein. 
In addition to the β-gal system, NT6 was employed to more faithfully mimic the spatial and 
structural constraints of VP1-2. Effectively, NT6 was the more stringent system to assess NLS function 
since the structure mimics the native NLS position of the homologues more closely than β-gal. 
 
3.3.2 All VP1-2 homologues contain a NLS 
Using the sequence alignments and NLS prediction software as a guide I was able to show in two 
systems that the VP1-2 homologues from human representatives from all HV sub-families feature a 
functional NLS in the N-terminal linker immediately downstream of the USP. The functional 
determinants can be narrowed down to the first positively charged region comprising two basic 
patches (see R1 and R4’ in the alignment in Figure 8 and results in Figure 10 and Figure 11) for α, β and 
γ1 sub-family members. HHV-8, and at least two other γ2 members (Figure 12), appeared to be the 
exception to the rule. The HHV-8 NLS lies somewhat downstream of the first basic region and exhibited 
different organisation. Although some minor conservation of the basic residues remained after some 
manual manipulation of the alignments only one basic patch was present which might represent an 
adaptation to the viral life style. As part of this thesis I presented two systems which I used to study 
nuclear import of VP1-2 homologues; the first using β-gal and the second using HSV-1 VP1-2 (NT6). 
With the β-gal system it was virtually impossible to test relative strength of test NLSs since it cannot 
exit the nucleus, it is not live tractable and cannot be bleached precluding their use in assays of 
fluorescence recovery. Using NT6, however, I was able to make some limited conclusions regarding 
NLS strength and utility. The data presented here indicate that all NLSs with a leader lysine similarly 
efficiently translocated a large cargo protein (NT6) to the nucleus. Also signals with two basic patches 
and a leader lysine were tolerant of mutations of key residues. As such the K428R substitution and the 
VZV.R1, which did not perfectly match the full bpNLS consensus, were still active (Figure 15). Since NLS 
activity correlates with importin-NLS binding strength (Hodel et al. 2006) it could be possible that the 
arginine at the first position (e.g. VZV.R1) cannot make a similarly strong connection to one of the 
importin-α binding grooves which could explain why in R4 the K428R abolished nuclear transport. 
Other exceptions from the consensus have been reported. For example, the bpNLS of CBP80 comprises 
three arginines in the first patch and still make functional contacts with the minor NLS binding groove 
of importin-α (Dias et al. 2009). This negative effect was likely exacerbated by the K428A mutation 
which lost complete activity and thus presumably indicates loss of interaction with the relevant import 
factor. Similarly, when R5 was removed from NT6, nuclear import efficiency dropped likely indicating 
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weaker binding to importin. This could also explain why in PRV both basic patches were required for 
full activity of the NLS (Möhl et al. 2009). Taken together, the NLS-importin interaction probably 
requires both patches, although R4, but not R5, might be able to weakly interact with the nuclear 
transport machinery in isolation. 
To test this proposition a combination of biochemical approaches may be useful. Wild type and 
mutant peptides can be coupled to a solid support (e.g. beads) via a tag and this can be used in vitro 
as a bait to bind a particular importin. The complex could be subjected to increasingly stringent washes 
which should give an indication how strong their interaction is. Using the Biacore system, affinity of 
different NLS peptides to a particular importin can then be measured. 
 
3.3.3 What is the nature of the NLS? 
I initially worked on the assumption that HSV-1 comprised a mpNLS. Due to the striking 
conservation in R4 I anticipated that all other α-HVs would feature similar NLS properties. Thus far six 
classes of classical NLSs (Table 1 in 1.3.2) have been identified (Kosugi, Hasebe, Matsumura, et al. 2009; 
Dingwall & Laskey 1991). The α-HV R4s and the first basic patch of most β-HV and γ1-HV R4’ regions 
would, according to this classification, be defined as class 1 mpNLS with a leader lysine followed by 
three basic residues, at least one of which has to be an arginine. At least for HSV-1 and PRV R4 NLS 
function was experimentally confirmed (Abaitua & O’Hare 2008; Möhl et al. 2009). There are notable 
exceptions to this class 1 rule; at least two strains of VZV comprise five consecutive arginines; bovine 
Herpesvirus 1 (BHV-1) features only four arginines, preceded by KR motif some four residues upstream; 
MuHV2 only contains three consecutive basic residues with the first being an arginine and an additional 
lysine two residues upstream. Unexpectedly, the analysis of NLS function of both the VZV and HSV-1 
homologues gave rise to some puzzling results, which did not fit this initial hypothesis. Firstly, VZV.R4 
lacked nuclear transport activity which was recovered by extending the test region to R1. Secondly, 
the R432K (VZV numbering) substitution resulted in a gain-of-function of VZV.R4 in the nuclear 
transport assay. Thirdly, the K428R substitution in HSV-1 abolished nuclear transport of β-gal only in 
the context of R4 but not R1. And fourthly, in NT6, the K428R mutation showed similar efficiency as 
VZV, and, finally the K428A mutation completely abolished nuclear transport of NT6. This prompted 
me to revisit the sequence analysis and to consider the possibility that the α-HVs might feature a 
bpNLS.  
A closer look at the R1s of the β and γ1 sub-family revealed features reminiscent of a classical 
bpNLS with spacers between 8-14 residues. The presence of a bpNLS was recently confirmed for at 
least HCMV (Brock et al. 2013), although it has to be noted that both basic patches in HCMV clearly 
adhere to the mpNLS consensus. While the HCMV report (Brock et al. 2013) formally excluded the 
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presence of a mpNLS, such activity might have gone unnoticed since the authors used GFP-NLS fusion 
proteins, which accumulated in the nucleus even in the absence of an NLS similarly to the results 
presented in Figure 9B (panel I). The α-HV spacer length coincided with the length of sequence that 
would be necessary to bridge the distance between the two NLS binding grooves of importin-α (Kosugi, 
Hasebe, Matsumura, et al. 2009). In contrast to this, the bpNLS in the α-HVs showed considerable 
deviation from the consensus (Figure 13D) although it would be impossible, without further 
experimental information, to say which part of R5 was contributing to NLS function. Strikingly, at least 
15 different sequences of different HSV-1 strains/isolates showed perfect conservation of R5 (see 10: 
Appendix 2) indicating that potentially all of R5 would be required. Theoretically though, the NLS 
spacer could be as short as 16 residues in HSV-1 although it likely counts at least 25 residues if one 
considers which basic residues are conserved between the very similar HSV-1 and HSV-2 homologues 
(Figure 8A). The most extreme version of NLS spacer found in the α-HVs would feature 40 residues for 
VZV (see Figure 8 and Figure 13D). However, for each of the bpNLS combinations at least one residue 
did not match the consensus and even dramatic changes of charge were observed (Figure 13D, blue 
letters, e.g. R>T or K>S). This may not be a problem per se, since extremely long spacers with 
considerable sequence flexibility have been characterised previously (Mclane et al. 2008; Moore et al. 
1998; Lange et al. 2010). The reports suggest that spacer residues would form a NLS scaffold and some 
of the amino acids would make contact with importin-α outside the NLS binding grooves. This would 
make some spacer residues equally important NLS constituents, although it was shown that spacers 
are more accommodating to mutations than the key basic residues (Lange et al. 2010; Kosugi, Hasebe, 
Matsumura, et al. 2009). Despite the considerable diversity of the α-HV spacer the R4-proximal 
sequence is highly conserved. This might indicate that this region contributes important functions to 
this region which may relate to interactions with importin-α sub-types. 
The α-HV spacer comprises features also highlighted by Kosugi et al. (2009). Of note would be 
an enrichment of prolines (Figure 8, grey background) at either end of the spacer and acidic residues 
(Figure 8, blue background with white letters) in the central region (part of the PEST sequence). Both 
can be seen in VZV and to a lesser extent in the other α-HVs. PEST residues would presumably 
contribute to disorder and thus allow presentation of the NLS. The peptide screen presented by Kosugi 
et al. (2009) did not account for potential phosphorylation events. Since acidic residues can mimic the 
phosphorylated state of serine or threonine the acidics identified in the central region of bpNLS spacers 
could also represent phosphomimetics. The R1 spacer of all HVs comprises many potentially 
phosphorylatable residues (Figure 8, yellow background) which, upon phosphorylation, could 
resemble the properties of acidic residues and augment NLS activity. Phosphorylation has previously 
been shown to allow regulation of NLS activity. For example, the strong mpNLS of SV40 lTag was 
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confirmed to be activated by casein kinase (CK) 2 and CDK phosphorylation (Hübner et al. 1997; Rihs 
et al. 1991; Xiao et al. 1997). A putative CK2 site, namely SSVEDL (or slightly different), is conserved in 
the α-HV spacer and between 7-12 additional putative phosphorylation sites for various kinases 
(including Ataxia telangiectasia mutated (ATM), CK2 and Aurora) are predicted in HSV-1.R1 using 
several algorithms (Wong et al. 2007; Xue et al. 2011; Xue et al. 2008; Blom et al. 1999). One could 
envisage that the presence of multiple phosphorylation sites could be a means to augment or to allow 
regulation of NLS activity depending on the cell type and/or the phase of infection (e.g. entry versus 
assembly/egress).  
To gain a more detailed understanding of the functional determinants of the HV NLS it would be 
important to include more VP1-2 sequences into the in silico analysis. Differences between very closely 
related virus species or even strains of the same virus (although no differences were found between 
15 HSV-1 strains as shown in appendix 2) might give an indication of which parts are actually 
contributing to function. Any notable conservation or sequence deviations can be investigated with 
the herein established methods. Conserved residues could be studied by alanine scanning, where one 
or more residues are substituted with alanine. This would be useful to assess which features of R1 
contribute to function in nuclear transport assays and which mutations prevent complementation of 
a VP1 2 null virus. Other mutational studies (phosphomimetics, S/T>E substitutions) could yield 
information on regulation of this region and whether this affects the ability of HSV-1 to infect target 
cells. 
 
3.3.4 An improved system for screening NLSs 
There are many options to screen NLSs but which one is the most suitable? Besides identification 
of NLSs it might also be required to judge their strength. At the very least a nuclear localisation assay 
should consider some basic aspects. 
(i) The NLS needs to be exposed so fully folded cargos where the tagged end is not buried 
in the structure 
(ii) Mimicking the position of the NLS in the native protein is desirable (i.e. between two 
domains or at the termini) 
(iii) The cargo should be mostly, if not exclusively, cytoplasmic in the absence of a NLS 
(iv) The cargo should be reasonably inert, that is, not form cytoplasmic or nuclear 
complexes that could anchor the protein in either compartment 
(v) The cargo should be easily tractable (e.g. fluorescent or via good antibody) 
Although my study revealed NLSs in all VP1-2 homologues the data could be more 
comprehensive in respect to efficiency. Some minor modifications could even allow live screening of 
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nuclear transport inhibitors. In retrospect GFP would have been a useful due to its life tractability. In 
order for GFP to become a better option for this kind of assay, its size could be increased beyond the 
assumed limit of free entry/exit from the nuclear compartment (>40-60kDa). This could be done by 
fusing several GFPs in tandem, or fusing GFP to NT6. GFP-NT6 would be the most ‘physiological’ system 
since the test NLS would be presented either in context of VP1-2 structure. Alternatively, the test NLS 
could be inserted between GFP and β-gal to mimic the position between two folded domains (USP and 
body of VP1-2). Such a GFP based system would allow me to better analyse the strength and efficiency 
of the different NLSs by enabling another technique, FRAP (fluorescence recovery after 
photobleaching). For this, nuclear fluorescence (GFP fusion) is microscopically bleached and the time 
of recovery (that is, import of new protein) measured. 
Ultimately, a HV study should not only aim to understand replication but also to improve current 
anti-viral treatments since resistance to current antivirals is an increasing problem in 
immunocompromised patients. Knowing how all HV capsid dock at the nuclear pore should enable the 
development of chemical agents that specifically inhibit nuclear transport of HV capsids by blocking 
(binding) the exposed NLS in VP1-2 or the importin-VP1-2 complex. Using chimeric NT6 as a model, 
and with a few minor modifications to the construct, this could be done in culture for any HV. Ideally 
an inhibitor of nuclear transport should only be added briefly to avoid cellular toxicity. When NT6 is 
expressed in cells and the inhibitor were added after 24 h of expression, most of NT6 would already 
be nuclear. Thus it would be best to design a cargo that actively shuttles between the nucleus and the 
cytoplasm. Fusing a CRM1-dependent NES to the C-terminus of NT6 would enable export of NT6 from 
the nucleus (and cytoplasmic accumulation) in the presence of a nuclear transport inhibitor with only 
very short treatment times. Combined with good controls for nuclear transport this could guide the 
development of nuclear transport inhibitors with anti-herpetic activity. 
In addition to screening potential inhibitors of HV infection, in the described system (NT6 
shuttling vector including a NES) it would provide a tool to empirically determine the nuclear transport 
factors that could bind the NLS. Rather than knocking-down importins, dominant negative importin-α 
sub-types could be expressed in cells also expressing NT6. Dominant negative importin-α lacks the 
importin-β binding domain (IBB) which is essential for the nuclear transport process and cargo release 
(Harreman et al. 2003). This would cause cytoplasmic accumulation of NT6 (or a chimera) in the 
presence of a particular dominant negative importin-α. This system also lends itself to pulldown studies 
since the interaction of a cargo to the dominant negative importin-α is stronger than to wild-type 
importin-α (Fanara et al. 2000) and cannot be disrupted since that would require nuclear import, 
importin-β binding and combined activity of the IBB and nucleoporin (Harreman et al. 2003; Gilchrist 
et al. 2002). That means the interaction would be stable during the pulldown procedure rather than 
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transient and the fraction of NT6 bound to dominant negative importin-α would essentially be higher 
than the fraction that is actively transported to the nucleus at any given time.
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4 Analysis of NLS function during HSV-1 replication 
4.1 Studying R1 function during HSV-1 replication 
My hypothesis was that all VP1-2 homologues contain a NLS at the N-terminus, which enables 
incoming capsids to dock at the nuclear pore and thus is a pre-requisite for infection. Since it was 
already established that the HSV-1 R1 region was a functional NLS and absolutely required for 
infectivity (Abaitua & O’Hare 2008) it made sense to initially test the homologues for the presence of 
a functional NLS and then proceed to analysing their function during HSV-1 replication. This way I could 
concentrate on regions comprising NLS function rather than screen several untested candidate regions 
per homologue in parallel. 
When the first basic patch in VP1-2 is deleted (VP1-2ΔNLS virus) the resulting virus virtually does 
not replicate and has to be grown in complementing cells. Complemented ΔNLS virus can enter 
susceptible non-complementing cells from where it subsequently cannot spread further. 
Ultrastructural studies revealed that ΔNLS virion assembly in non-complementing cells is comparable 
to wild type virus. The resulting ΔNLS virions can fuse with uninfected cells and capsids migrate along 
microtubules towards the nucleus. In contrast to wild type capsids, which can be seen at the nuclear 
pore, ΔNLS capsids do not seem to progress past the MTOC, which implies that the sole function of the 
NLS region is capsid docking at the nucleus (Abaitua et al. 2012). Thus it should be possible to test if 
NLS sequences can rescue this defect by supplying the necessary function. The only way to obtain 
infectious ΔNLS stocks is to grow it in VP1-2 complementing cells (e.g. RSCUL36 or HS-30). Rarely, 
revertants contaminate the purified ΔNLS stocks, which arise through recombination with the cellular 
copy of VP1-2. It should be possible to exploit this phenomenon for the purpose of studying the ability 
of test (NLS) sequences to rescue replication of the ΔNLS virus. 
The assay described in Figure 16 was based on the defect of non-infectious VP1-2.ΔNLS virus. 
From purified stocks the viral genomic DNA carrying the VP1-2ΔNLS mutation can be purified by 
removing the viral envelope and digesting the tegument and capsid components with proteinase K. If 
pure ΔNLS viral genomic DNA were transfected into non-complementing cells replication should 
progress normally. Any assembled virions would then carry VP1-2ΔNLS rendering them non-infectious. 
Theoretically, if a vector, containing a test NLS flanked by homologous sequence, were co-transfected 
with the viral genomic DNA, recombination could occur between the homologous regions (Figure 17A). 
In turn, VP1-2 (containing the test NLS), expressed from the recombinant viral DNA, would decorate 
viral capsids, but only if a test region can fulfil the same function as HSV-1.R1 would the virus spread 
through the monolayer of cells and give rise to visible plaques. Most importantly, the NT6 vector used 
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for recombination cannot complement the VP1-2ΔNLS defect in trans since it lacks the essential 
C-terminal domain which is absolutely crucial for capsid binding (and thus VP1-2 function). 
Although in theory this strategy should work, there are a few things to consider. The region I 
exchanged counts over 70 residues, which, although not conserved across the sub-families, might 
contain additional functions. If this approach were to fail, it would be possible to shorten the insert of 
foreign sequence in order to keep as much HSV-1 sequence a possible (i.e. on change basic region or 
part of it). Additionally, the GC content of the inserts can be up to 20% lower (VZV.R1) compared to 
the HSV-1 sequence which might impact recombination or the stability of this DNA region. In that case, 
the insert could be codon optimised to more closely match the HSV-1 sequence. 
Several factors that are difficult to judge could also affect steps after potential recombination. 
For example, the insertion of different R1s could affect folding of full-length VP1-2 or modulate its 
stability which could reduce or abolish viral replication. This may be less likely since NT6 expressed 
similarly well in transfected cells implying stability and/or folding are not an issue. 
 
Figure 16 Schematic representation of the ΔNLS rescue assay. 
(A) The rescue assay was based upon recombination of the non-replicating VP1-2.ΔNLS virus with NT6s containing foreign 
NLSs. This could lead to rescue of the ΔNLS phenotype if the motif allows docking of capsids at the NPC. (B) Viral genomic 
DNA isolated from extracellular virus stocks and NT6 plasmid DNA were co-transfected into non-complementing RSC cells. 
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Viral replication occured from the viral genomic DNA, but only if recombination, which inserts a functional sequence, took 
place, can infectious virus be produced. NT6 protein itself lacks the highly conserved, essential C-terminal domain. This 
means that trans-complementation cannot be the reason for release of infectious virus. If virus is recovered, it will be 
serially purified under 0.4% agarose overlays, sequence confirmed and characterised. 
 
4.2 Function of homologous R1s during HSV-1 replication 
To validate the rescue assay format viral genomic ΔNLS DNA was either transfected alone or in 
combination with NT6 wild-type or NT6.ΔNLS. After three days of infection, only the plate where NT6 
wild-type had been co-transfected with viral genomic ΔNLS DNA showed CPE (Figure 17A, compare 
plates 1-3). When virus preparations from these control plates were titrated, only samples where NT6 
wild-type had been co-transfected contained detectable virus (Figure 18B/C). 
If my hypothesis were true, then the homologous R1s should allow plaque formation. In order 
to test this chimeric NT6 vectors were co-transfected with viral genomic ΔNLS DNA. Only if 
recombination into the viral DNA occurred (see Figure 17A) would cytopathic effect be observed. As 
for the controls (Figure 18A, plates 1-3), viral genomic ΔNLS DNA was transfected in combination with 
the chimeric NT6s (plates 4-7). Cells were then left for three days to allow viral replication to occur. 
After fixation of the co-transfected cells plaques were observed for VZV.R1, CMV.R1 and EBV.R1 
(Figure 17A6). Using exactly the same amount of viral genomic ΔNLS and plasmid DNA for each 
condition allowed a direct comparison of rescue efficiency. Rescue was observed for three out of five 
chimeric NT6s (including the two different NT6s for HHV-8.R1 and R8) and most plaques were obtained 
with NT6.VZV.R1, fewer with EBV.R1 and CMV.R1. In contrast to that, there were no plaques observed 
when the HHV-8 chimeras were co-transfected with viral DNA (Figure 17A, plate 7).  The result of 
plaque formation was confirmed in the virus yield experiment. Cells transfected with the VZV chimera 
yielded approximately 37-fold fewer infectious virions compared to wild type NT6. However, in 
comparison to the other NT6 chimeras VZV gave rise to 6 fold more infectious virus than the EBV 
chimera and 15-fold more than   the CMV chimera (Figure 17C). Despite the drop in titre compared to 
wild type, virus could be purified from these preparations, which was confirmed by sequencing the 
insert. This leads to the conclusion that those regions that comprise a bpNLS were able to rescue the 
HSV-1 ΔNLS mutant while the mpNLS from the HHV-8 chimera was not functional in the context of 
HSV-1 VP1-2.  
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Figure 17 Rescue assay quantification and characterisation of VP1-2 integrity. 
(A) ΔNLS DNA was co-transfected with NT6 plasmids into non-complementing RSC cells and monolayers fixed and stained 
with crystal violet at 3 dpi. DNA alone and in combination with NTΔNLS exhibited no plaque formation, while NT6 wild-
type showed complete cytopathic effect (CPE). Plaque formation was observed for, in descending order of efficiency, 
VZV.R1, EBV.R1 and CMV.R1 in contrast to the HHV-8 sequences. (B and C) Cells from one well of equivalent co-transfection 
experiments were scraped into their respective media, and virions liberated by three to six freeze-thaw cycles (i.e. pooled 
virus). Cleared lysates were titrated on non-complementing RSC or Vero cells. Plaque numbers were quantified. (D and E) 
NT6 plasmids were co-transfected with HA-tagged UL37 expression vector and NT6 immunoprecipitated using anti-V5 
antibody. IP eluates were compared for the presence of HA-UL37 by Western Blot using anti-HA antibody. 
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4.3 Functional determinants of HSV-1 R1 required for replication 
To establish which parts of HSV-1.R1 were important for viral replication, the rescue assay was 
repeated with the mutated HSV-1 NT6s (Figure 17B). Initially, the for localisation more dominant 
region R4 was investigated. Not surprisingly, the K428A mutation, already found to abolish NLS activity 
in R1/4.β-gal and NT6, did not support replication, whereas the conservative K428R substitution gave 
rise to viral titres similar to that of VZV.R1 (Figure 17B). This points to a role of NLS strength during 
replication as by substituting the first lysine with an arginine both nuclear localisation and viral fitness 
appeared impaired. Exchanging the basic residues in R4 for a strong cellular NLS allowed for recovery 
of virus albeit at a 100 fold lower titre than wild-type. This underscores the complexity of capsid nuclear 
transport. The K428R result might imply that the reduction in titre was caused by the reduction in NLS 
activity. This could then be extended to VZV.R1 since the obtained titres were very similar. However, 
while this conclusion might be true for the reasonably well conserved α-HVs it cannot be extended to 
the R1s from the β- and γ1-HVs. Pure strength of the NLS only augmented viral replicationif integrity 
of R1 was maintained since NT6 with the MyoNLS insert was almost exclusively detected in nuclei of 
transfected (Figure 15B) cells but gave rise to lower titres than K428R or VZV.R1 (Figure 17B). Despite 
the loss in recovery, recombinant viruses were purified for both K428R and MyoNLS mutants. 
To establish the role of R5 the assay was repeated with a NT6ΔR5 mutant. Even though R4 was 
intact in this construct it did not complement the replication defect of the ΔNLS virus. This was 
surprising since in comparison to NT6.K428A NT6ΔR5 retained some NLS activity at least in HuH7 and 
COS cells (B/C). Intriguingly, in HEK293 cells NLS activity was similar for both K428A and ΔR5 and only 
marginally above ΔNLS control. This might indicate that using a different cell type might change this 
result although this seems unlikely.These data add to the aforementioned conclusion that NLS strength 
only augmented capsid nuclear entry if the whole R1 region was intact.  
 
4.4 Analysing pUL37 interaction with chimeric VP1-2 
Since the strong NLS sequence HHV-8.R8 was unable to rescue virus growth it was important to 
exclude any deleterious effects the presence of foreign sequence could have on functions of adjacent 
parts of VP1-2 (see Figure 3 in chapter 1.2.1). Possible problems could arise in respect to USP function 
(cleaving ubiquitin from target proteins including VP1-2 itself), VP16 binding, pUL37 binding and 
folding of the middle segment. 
USP function was likely not impaired since NT6 expressed well and to levels comparable to wild 
type NT6 (Figure 17D/E). Any functional impairment of the USP would have destabilised VP1-2 (Bolstad 
et al. 2011). VP16 is at least partially recruited to capsids by VP1-2 but since there is approximately 5-
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fold more VP16 than VP1-2 in virions disruption of this binary interaction likely would not cause 
complete loss of infectivity. In fact, a binding deficient VP16 mutant virus was found to be viable, albeit 
exhibiting a modest defect (Svobodova et al. 2012; Newcomb et al. 2012). Folding of the middle 
segment was probably also not affected since the exchanged region outside the NLS shows little 
conservation till approximately 100 residues downstream of R1. Additionally, unfolded proteins are 
more prone to degradation and aggregation but the levels of all NT6 isoforms were very similar (Figure 
17D/E). The most likely culprit would thus be pUL37, which binds VP1-2 at a site mapped to a region 
encompassing R5 in PRV (Fuchs et al. 2004). The pUL37-VP1-2 interaction is essential to HSV-1 
replication and pUL37 was found to contribute multiple functions including improving microtubule 
transport (Pasdeloup et al. 2012; Krautwald et al. 2009) and facilitating secondary envelopment 
(Jambunathan et al. 2014). 
To test whether R1 exchange could have impaired this interaction, NT6 isoforms and HA-UL37 
were co-transfected into HuH7 cells and NT6 was immunoprecipitated using anti-V5 antibody (Figure 
17D/E). In all cases it was found that HA-UL37 was detected in eluates from protein A coated beads. 
This was entirely dependent on the presence of NT6 (Figure 17D/E, lane 2 and 13) or anti-V5 antibody 
(lanes 5, 10 and 16) but not on the NLS region. There were similar amounts of NT6 and HA-UL37 
precipitated for all constructs tested, including both HHV-8 chimeras (see lanes 20/21). This indicates 
that adjacent functions were likely not affected by the insertion of R1s, although there might be slight 
differences in function of both pUL37 and VP1-2 in RSC cells, where the rescue assay was performed, 
compared to HuH7, in which the pulldown was performed. 
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4.5 Replication characteristics of recombinant viruses 
4.5.1 Analysis of virus production 
To study the role of the different NLS regions during viral replication the rescue assay has limited 
scope. Although the assay yielded valuable information on viability of the different NLSs, it cannot 
really be used to make any conclusions about fitness of a particular recombinant virus. There are just 
too many factors that could have influenced the efficiency of recombination. Nonetheless, the results 
of the rescue assay indicate that recombinant viruses may be recovered from transfected cells. To 
obtain recombinant virus was a simple procedure, which involved serial passage of individual virus 
plaques to reach 100% purity similar to picking a bacterial colony for cloning. Thus to obtain 
recombinant viruses, the rescue assay was repeated with the conditions that previously gave rise to 
plaques. This time the cellular monolayer was scraped into the medium and any cell bound virus 
released by freeze-thawing. This mixture was subsequently used as inoculum to infect non-
complementing cells with a limiting dilution. Through the use of agarose (in the medium) it was 
possible to pick individual plaques and repeat this procedure at least once more. After two passages a 
stock was produced and the region around the NLS sequenced. These viral stocks were then used to 
test how the foreign NLSs compare functionally during HSV-1 viral replication. For this virus yields from 
single and multi-step infections were determined, which give an indication of virus production and 
infectivity. 
 
4.5.2 A cell-type specific defect in replication linked to the VP1-2 
NLS 
Multi-step growth characteristics 
A multi-step growth curve measures how well a particular virus spreads through a monolayer of 
cells over time by evaluating the production of progeny virions. It yields information on a combination 
of virion production and infectivity, since only one in a thousand cells were initially infected. This 
means the virus then has to go through several replication cycles including virion production and re-
infection. This is eventually measured as virus yield after 3 dpi, the time when a wild type virus would 
usually have caused 100% cytopathic effect. 
For the multi-step yield experiments summarised in Figure 18A-D, four different cell lines were 
infected at a MOI of 0.001 and harvested every day for three days. In RPE-1 cells (Figure 18D), a cell 
line that should mimic naturally infected cells of the eye more closely, yield was not affected for any 
of the recombinant viruses at any time point, except for the final yield for the MyoNLS recombinant 
virus. Replication of the MyoNLS recombinant virus in RPE-1 cells was modestly impaired compared to 
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wild-type virus (around 5-10 fold lower titre). These data indicate that the factors required for capsid 
transport by the different NLSs were likely present in these cells. 
In RSC cells recombinant virus yield after 24h was up to 100-fold reduced for EBV.R1, CMV.R1 
and VZV.R1 compared to ΔNLS revertant virus (wild type) and approximately 50 fold lower than that 
of KOS wild-type virus. By 48h the titres of EBV.R1 reached levels around 2-5 fold lower than KOS wild-
type whereas the difference compared to ΔNLS revertant was reduced to around 10-20 fold. VZV.R1 
and CMV.R1 were up to 10 fold and 50 fold lower than KOS wild-type and ΔNLS.Rev, respectively. 
However, after three days in culture titres obtained from all viruses reached similar levels as the whole 
mono layer of cells became infected and started producing virus particles. The reduction in early yield 
was not completely rescued by the complementing cell line RSCUL36 (Figure 18B) and thus might 
indicate that the EBV, CMV and VZV R1s caused an early defect, quite possibly during entry and/or a 
defect during replication generally. 
In Vero cells (Figure 18C), a Monkey kidney cell line commonly used to passage and characterise 
HSV-1 growth parameters, virus yield after three days dropped over three orders of magnitude for 
VZV.R1 (light brown line). CMV.R1 (darker brown line) yielded slightly more virus yet still gave rise to 
significantly lower amount of infectious virus particles (approximately 500 fold reduction). EBV.R1 
(green line) exhibited an intermediate phenotype (15 fold reduced) while the MyoNLS appeared to not 
significantly affect the ability of HSV-1 to replicatate. This defect was already noticeable at 24hpi 
(between 10 and 100 fold reduction) and got sequentially larger, which may be a combination of 
reduced infectivity and slower replication that in the case of a multi-step growth curve cause a knock-
on effect for each subsequent infection (i.e. it takes virions longer to initiate an infection that again 
yields fewer infectious particles which then go on to repeat this cycle).  
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Figure 18 Multi- and single-step yield of recombinant HSV-1 from four different cell lines. 
(A-D) Yield from RSC, RSCUL36, Vero and RPE-1 cells infected for up to three days with low MOI (0.001) was quantified on 
complementing cells after the indicated time points. Cells and supernatant were harvested simultaneously by scraping 
cells and freeze-thawing the mixture 3-6x. (E) Monolayers of the same cell types were infected with MOI of 10 and virus 
particles harvested 24h later (as in A-D). Infectious virus yield was determined on complementing RSCUL36 cells. 
Single-step growth characteristics 
The significant reduction of virus titres observed in the multi-step growth curve revealed a 
defect at some stage of replication but this information was not fully informative. This could have been 
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caused by lower virus production in infected cells, by a defect to establish infection or a defect during 
assembly and egress. To test if lower virus production could have caused both the early reduction in 
multi-step yield observed in RSC cells and the overt defect observed in Vero cells I infected the same 
cell lines with a MOI of 10 (Figure 18E). Since this ensures that almost all cells are infected roughly at 
the same time this allows to check how much virus a cell produces on average during one round of 
infection (here 24h). 
In RPE-1 cells VZV.R1 and CMV.R1 (Figure 18E, light and dark brown bars, respectively) showed 
a very modest reduction in infectious virion production (up to 5 fold) whereas EBV.R1 (green bar) gave 
rise to comparable infectious virus as KOS wild-type. The recombinant virus carrying the MyoNLS insert 
(orange bar) appeared to replicate less well yielding around 20 fold less infectious virus, which may 
have caused the modest reduction in virus titre observed in multi-step growth experiments. These 
results were in agreement with the multi-step growth curve. In RSC cells (Figure 18E) a modest 
reduction of up to 20 fold could be observed for CMV.R1 (dark brown) whereas VZV.R1 (light brown) 
was only 5 fold reduced. EBV.R1 (green) and MyoNLS (orange) exhibited only minor differences 
compared to both wild-type viruses. The modest reduction of progeny virion production for VZV.R1 
and CMV.R1 could explain the initial slow progression in the multi-step infection. Intriguingly, in 
complementing RSCUL36 cells the modestly impaired virus production was not rescued beyond the 
defect in RSC cells. This could indicate that the effect of the chimeric VP1-2 is dominant and would 
require more wild-type VP1-2 to effectively compete with mutant VP1-2 for capsid binding. 
Compared to the other cell lines, Vero cells show quite a large defect in progeny virion 
production for all chimeras although the virus carrying the MyoNLS replicated reasonably well 
(approx.. 10-fold lower yield). A greater than 1000-fold decrement of infectious virions that can be 
recovered after 24 hpi, could indicate a major defect during assembly. However, the lower yield could 
also just reflect a prolonged eclipse phase, that is, extremely slow entry and replication kinetics, which 
would reduce the amount of virus released compared to wild type virus (at most time points). 
 
4.5.3 Analysis of plaque size 
Conventionally, plaque assays are used to determine the titre of a viral stock. However, there is 
additional information that can be extracted from this assay. During a plaque assay a monolayer of 
cells is inoculated. After initial attachment and envelope fusion occurred, anti-HSV neutralising 
antibodies were added to the medium which prevent extracellular spread of infection, that is, virus 
could only spread laterally from cell-to-cell. The size of a plaque, a measure combining virion 
production and infectivity similar to the multi-step growth curve, can then be measured and compared 
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to wild type virus. To see whether the defect in virus production also had an effect on cell to cell spread 
the plaque size of several chimeric viruses was compared.  
For this assay, four cell lines (HaCaT, Vero, RSC and RSCUL36 cells) were infected with a low MOI. 
After three days plaques were detected by immunoperoxidase staining, a technique also used for 
immunoblots and more sensitive than counter-staining cells with crystal violet (commonly used for 
plaque assay). 
In Vero cells reasonably large plaques are formed by wild-type viruses which showed notable 
cytopathic effect. The different chimeric VP1-2s clearly led to a reduction of plaque size but most 
significantly for VP1-2.VZV and CMV (Figure 19B). For these recombinant viruses only up to 10-20 cells 
were infected which could only be detected using immunoperoxidase staining. In contrast to this the 
K428R mutation gave rise to easily visible plaques but nonetheless much smaller than wild type virus. 
This indicated that in Vero cells NLS strength in the context HSV-1.R1 was a determining factor. 
However, the defect of the VZV and CMV chimeras could not be explained by this since the VZV NLS 
harboured an equally potent and CMV.R1 a much stronger NLS than K428R. The VP1-2.EBV and VP1-
2.MyoNLS mutants also presented with small but visible plaques which were bigger than those of VZV, 
for example. It has to be noted that the overall plaque size difference between the different chimeras 
is small compared to the difference in relation to wild-type virus. 
To make this analysis more relevant to HSV-1 infection, plaque size was also compared on HaCaT 
keratinocytes, which should more closely resemble another physiological host cell type (Figure 19A; 
bottom two images and Figure 19B; middle graph). Because these cells produce so much extracellular 
virus it is difficult to quantify exact size of a plaque for wild-type virus. On these cells extracellular virus 
production is large enough to allow virus spread through the medium, forming so called comet tails 
(Figure 19A; red arrows), despite the presence of neutralising serum (here 1-2% human serum). Thus 
plaque size could only be estimated for wild type virus (Figure 19A, see red circles) but cannot be used 
as a real measure. However, it is clearly visible that size is larger than that of the biggest chimeric virus 
(EBV, Figure 19A/B). All chimeras tested showed a defect in cell-to-cell spread reflected in more than 
60% reduction in plaque size (>60% for EBV, >75% for VZV, >85%  for CMV and >90% for MyoNLS), 
suggesting the virus production and/or infectivity could be impaired in HaCaT cells. Unexpectedly, the 
K428R mutation showed only a modest reduction of plaque size of around 30% indicating that NLS 
strength has some limited effect on infectivity and/or virus production in the context of the HSV-1 
motif only.  
As mentioned before comet tails arise even in the presence of neutralising serum. These were 
differentially affected in the different chimeras (see the middle graph in Figure 19B, red plus or minus). 
The results indicate a reduction in extracellular virus release. Most significantly, VP1-2.Myo and VP1-
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2.CMV recombinants did not yield any detectable comet tails while the VP1-2.EBV and less so the VP1-
2.VZV chimeras showed small tails of infected cells (for EBV comet tail examples see Figure 19A). This 
indicates that extracellular virus production and plaque size are certainly linked and the observed 
defect in plaque size and comet tails formation might might have been caused by a general reduction 
in overall production of infectious virions and infectivity (see section 0).  
To check whether the reduction of plaque size was dependent on mutations within VP1-2  I 
wanted to compare plaque size of all chimeras on complementing RSCUL36 cells and non-
complementing RSC cells (Figure 19B; right graph). The VP1-2.EBV chimera formed the largest plaques 
(of all mutants) which were more than 30% smaller (area) compared to wild-type virus on the non-
complementing RSC cells (Figure 19A; top two images). Again wild-type virus forms large merging 
plaques and cytopathic effect was visibly enhanced compared to the EBV chimera (see cleared area 
within red circles). Expectedly, plaque size was rescued for all recombinant viruses (at least double 
except EBV which was 1.6x increased). The highest factor was calculated for the VP1-2.CMV chimera, 
but the baseline in the non-complementing cells was lower than for the other recombinants. Plaque 
size on the complementing RSCUL36 cells improved by a lesser factor for VP1-2.VZV and Myopodin. 
but these were also consistently larger compared to the non-complementing RSC cells. This clearly 
indicates a defect related to VP1-2. 
For the K428R recombinant plaque size on RSC cells was affected more than on other cell lines 
despite yielding similar amounts of infectious virus in single and multi step growth curves compared 
to wild-type. This, in combination with the reduction of plaque size of most chimeras, could indicate a 
specific defect only in cell to cell spread in RSC cells as virus yield was largely not affected. 
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Figure 19 Plaque size comparison of the recombinant HSV-1 mutants on different cell lines. 
(A) Representative fields from 6 well plates showing plaques of NLS.R and of the EBV chimeric virus (the largest plaques 
of all the chimeric viruses). Plaque size for NLS.R was estimated due to their large size (red lines). In HaCaT cells NLS.R 
plaques appeared to form ‘comet tails (red arrow) due to convection currents moving virions that were insufficiently 
neutralised by human serum. (B) Plaque size on Vero (left), HaCaT (middle), and RSC and RSCUL36 (right) cells was 
measured with Quantity One software and the results illustrated using arbitrary surface units (i.e. pixel area). 
 
4.5.4 Analysis of viral protein expression  
The reason why all chimeric viruses were debilitated on Vero cells, showing reduction in 
production of infectious virions in single- and multi-round infections and plaque size, could be caused 
by slower or reduced entry into target cells. This can be tested by Western Blot to measure the time 
till viral protein expression can be detected when all cells in a dish are infected (high MOI infection). 
For this cells have to be infected as explained for the single step growth curve but it becomes vital to 
synchronise entry as much as possible. To achieve synchronisation, the adherence phase was carried 
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out on ice to prevent virus from fusing without impairing attachment. Once the temperature is 
elevated bound virions can fuse and infection progresses as usual. Samples were then taken 
periodically to monitor viral protein expression. 
For the purpose of this analysis I chose to compare the chimera with the smallest average plaque 
size to the wild type virus since it could be assumed that the defect will be strongest and analogous to 
that found in the other chimeric viruses. Vero (large phenotype) and RSC cells (modest phenotype) 
were infected with the VZV chimeric and wild type viruses at high MOI and infected cell lysates, 
harvested at different times, were tested for the presence of representative immediate early (ICP4) 
and late (VP5, pUL37, gB) proteins by Western Blot (Figure 20). Immediate early proteins could be 
detected as early as 3 hpi in RSC with wild type virus while only a weak band was visible for the VZV 
chimera at 5 hpi. The band found in VZV chimera infected RSC cells at 3hpi presumably was residual 
viral ICP4 from the inoculum still present in the cells. When RSC cells are infected with the most 
debilitated NLS virus (i.e. the NLS mutant), the cells produce non-complemented virions but the 
infectivity of equivalent stocks is likely drastically reduced (Abaitua et al. 2012). If the particle to pfu 
ratio were also increased for the VZV chimera then much more input material would enter cells per 
pfu compared to wild-type viruses. Since ICP4 is delivered into cells by the incoming virus the ICP4 
input would be higher per pfu for a debilitated virus. A similar band could be found for pUL37, too 
(Figure 20B). The reason why this probably was input ICP4 (and pUL37) is that the band intensity 
dropped by 5 hpi only to increase again after 7 and 10 hpi. Why only ICP4 and pUL37 (but not VP5 or 
gB) could be found in VZV infected RSC cells is unknown. Both VP5 and gB could be more fragile 
proteins in the context of newly infected RSC cells. Capsids are subject to proteasomal degradation 
(Horan et al. 2013) after entry which would reduce the amount of detectable VP5. The amount of gB 
might also be more limited than that of ICP4 proteins but no evidence of this can be presented. 
Otherwise it still remains possible that the antibodies for ICP4 and pUL37 are just more sensitive and 
thus pick up even minute amounts of protein. To circumvent this problem it might be possible to check 
for gene expression by quantitative real-time PCR rather than actual protein. 
At 5 hpi the wild type virus expressed much more ICP4 than VZV. In fact, the level of ICP4 in VZV 
only reached comparable levels at 24 hpi indicating slower overall infection, which at this point might 
be attributed to slower entry kinetics. A similar phenomenon was observed with the late protein 
pUL37, where residual UL37 appeared to be present at 3hpi in the VZV sample, which declined to 
undetectable levels by 5hpi. While forwild type virus UL37 production was detectable at 5 hpi, in VZV 
similar levels were detected only after 10 hpi (a 5 h delay). VP5 expression which is required for capsid 
formation (it is the major capsid protein) started at least 10 h earlier in revertant virus and only after 
24 hpi for the VZV reached levels approximately 50% of that of wild-type. The late protein gB 
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recapitulated the previous findings of the other proteins. It has to be noted here that in RSC cells the 
absolute levels of all proteins for VZV never reached that of wild-type virus. Although there appeared 
to be an early defect which was probably the cause of the delay in virus production in the multistep 
growth curve and the modest reduction in single round infection, the observed protein levels appeared 
to enable production of infectious progeny virus in RSC cells at least. 
In Vero cells the kinetics were much slower for revertant virus with only weak expression of ICP4 
at 5 hpi and final levels much below that found in the RSC cells. This is found to be the case for all viral 
proteins tested and points to generally slower kinetics of viral infection in Vero cells. This slow-down 
is exacerbated in case of VZV. Here only a faint band for ICP4 was detected at 7hpi which did not 
increase by the same margin as found for revertant virus by 24 hpi. Expression of pUL37 was detectable 
at comparable times in Vero and RSC although levels were much reduced for wild type virus. For the 
VZV chimera the appearance of a pUL37 band was delayed by around 3 h (Figure 20, compare 7 hpi 
RSC and 10 hpi Vero). Analogously, VP5 expression was delayed in Vero cells for both test viruses. By 
24 hpi the levels for the VZV chimerawere barely comparable to the 10 h time point of the revertant 
virus. Also, the levels of gB were generally lower in Vero cells for both viruses but still high enough for 
virion formation since high titre virus stock can readily be obtained in these cells (Figure 18E). In 
comparison to wild type virus gB could barely be detected in the the VZV chimera infected cells  even 
after 24 h of infection. This could have impaired  virion formation in Vero cells and thus contributed to 
the observed phenotype of microplaques and lower stock titre in both multi and single step growth 
curves. 
In conclusion, the reduction in ICP4 levels for the VZV was likely caused by delayed, if not 
impaired, entry of capsids decorated with VP1-2.VZV chimeric proteins. This in turn would lead to a 
significant reduction in viral proteins (including VP5 and gB) at later stages and thus lead to fewer 
virions being released by 24 hpi.  
 
 
Figure 20 Viral protein expression of ΔNLS.R (wild type) and VZV.R1 in Vero and RSC cells. 
(A) Vero cells were infected at high MOI (5) and cells processed for Western Blot analysis at the indicated time points. Cell 
equivalent fractions were separated on SDS-PA gels and four representative proteins were detected by immunoblot. (B) 
As in A but experiment performed in RSC cells. 
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4.6 Discussion 
The data presented in this chapter suggests that NLS function was required but not sufficient for 
rescue of a entry defective VP1-2ΔNLS mutant. Rescue could principally be achieved when both basic 
patches of R1 were intact. Although the efficiency of rescue did not correlate with strength of the NLS 
in the chimeric VP1-2, I was able to show that viral replication is impaired if the HSV-1 NLS is weakened 
but was dependent on integrity of R1. Most importantly, viruses carrying the VZV.R1, HCMV.R1 and 
EBV.R1 could be purified and characterised revealing general debilitation which was most pronounced 
in Vero cells. 
 
4.6.1 A robust assay for evaluation of NLS function in supporting 
virus replication 
The rescue assay was designed to screen for VP1-2 R1 (or other) insertions that can rescue the 
defect during entry of capsids caused by the VP1-2ΔNLS deletion. It relies on recombination of foreign 
sequence from a transfected vector (here NT6) into the viral genome by cellular recombinases. 
Essentially virus can only arise after recombination since NT6 itself, when it is expressed from the 
plasmid, cannot complement virus replication in trans. This made it a very tight and easy to interpret 
screen with few false positive results except for a few circumstances when the rescue vector was sub-
optimally designed. What was the reason to choose this approach over others? At least two other 
theoretically feasible methods exist which could have achieved similar results. 
(i) Bacmid technology to introduce mutations in vitro using conventional cloning 
(ii) Complementing viral replication in trans by supplying full length VP1-2 chimeras 
(i) Bacmid technology allows the insertion of virtually any mutation into the viral genome 
through a combination of PCR and recombination into the viral genome. Although very useful to 
introduce mutations this method involves several cloning and recombination steps that can take 
months to obtain a viral mutant. Passaging a large bacmid in bacteria could introduce further undesired 
mutations which are difficult to control for. However, this technique has the advantage in that any 
mutant (even non-viable ones) can theoretically be made which cannot easily be recovered with my 
rescue approach (Figure 17B, e.g. K428A mutation). 
(ii) The second option would involve using full length VP1-2 expression vectors which can be 
transfected into susceptible cells prior to infection. The protein would then be supplied in trans and, if 
the protein were fully functional, the lysate would then contain infectious virus. Despite a similarly 
easy set up this method has some caveats. 
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Firstly, two types of virus could be obtained in this assay; trans-complemented or recombinant 
viruses, which would in turn complicate the isolation of true recombinant viruses which would face 
stiff competition from the trans-complemented input ΔNLS virus (i.e. background). Secondly, VP1-2 is 
not expressed to high levels from a plasmid and could lead to false negative results. Finally, this method 
is further complicated by the additional cloning required since no convenient restriction sites exist in 
VP1-2.  
 
4.6.2 A NLS in VP1-2 is required but not sufficient for HSV-1 
VP1-2ΔNLS rescue 
As elaborated in section 4.1 my hypothesis was based on the assumption that the only function 
of the R1 region was to facilitate docking of HSV-1 capsids to the NPC by binding nuclear transport 
factors. Thus a foreign test NLS inserted in place of the HSV-1 NLS should allow capsids to dock at the 
NPC. In practise the story turned out to be more complicated. While only test regions with NLS activity 
rescued the ΔNLS defect, NLS function was not sufficient. As such HHV-8.R8, VZV.R1, EBV.R1 and 
HCMV.R1 could substitute NLS function (Figure 15), but rescue of the ΔNLS phenotype was not 
achieved for the HHV-8.R8 sequence (Figure 18A/C). 
This raised the question of why a strong NLS would not rescue replication? Either my 
assumptions were wrong or some additional conditions have to be met besides NLS function. To 
explain this conundrum one has to consider several issues which concern R1-adjacent functions 
including the USP, VP16 and pUL37 binding regions, fibril formation of the central body. 
If USP function were perturbed then it would be expected that very little NT6 could be 
recovered, as this domain was shown to stabilise NT6 by removing ubiquitin chains (Bolstad et al. 
2011). Since all the chimeric proteins were similarly stable (Figure 17E), it seems unlikely that USP 
function had been affected. VP16, which is absolutely required to establish an infection, is a major 
constituent of HSV-1 virions but its recruitment is only partially dependent on VP1-2 (Ko et al. 2010; 
Kelly et al. 2009). Its recruitment to capsids plays a role during secondary envelopment (von Einem et 
al. 2006) which likely was not affected by insertion of a foreign R1 since the HCMV and EBV sequences 
worked. VP16 also likely has no function during capsid docking at the nuclear pore since it is thought 
to dissociate from incoming capsids (Granzow et al. 2005) and I speculate that perturbation of an entry-
related function is unlikely. 
Alternatively the explanation could be a structural matter. In my opinion the failure to rescue 
can most likely be traced back to the structure of the NLS region or the type of nuclear transport factor 
required to capsid docking at the NPS. Firstly, the HHV-8.R8 region contains only one basic patch 
(mpNLS) followed by an acidic region (Figure 12C/D) and might thus pick up a different nuclear 
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transport factor incompatible with capsid binding the NPC. And secondly, in the context of an incoming 
capsid VP1-2 likely adopts a certain conformation; its C-terminus is anchored to the capsid, the central 
body of the protein forming a mono- or multimeric fibre presenting the N-terminus of VP1-2 to the 
cytoplasm, and at least the pUL37 binding region (immediately downstream of R1) being occupied 
during the entry processes. Although I have shown that NT6 still binds pUL37 (Figure 18E) I have not 
checked if the complex would still accumulate in the nucleus. This notwithstanding, the capsid bound 
VP1-2 complex might form a more rigid structure than in the context of isolated soluble VP1-2 and 
thus limit the flexibility of the interaction with a nuclear transport factor and the nuclear pore to such 
an extent that only certain NLS types or conformation are compatible.  
It has been shown that class 1 mpNLSs bind to the major groove (more N-terminal than minor 
groove) and bpNLSs to both grooves of importin-α to facilitate transport (Kosugi, Hasebe, Matsumura, 
et al. 2009; Leung et al. 2003; Conti & Kuriyan 2000). Although being part of a bpNLS, the HSV-1 R4 
region conforms to the class 1 mpNLS consensus, suggesting it may bind to the major groove of 
importin-α when expressed alone and in the context of R1 (thus R5 binds the minor groove). This would 
mean importin-α would be arranged in a way that its N-terminus faces the VP16 and the C-terminus 
the pUL37 binding site. The HHV-8 sequence conforms to the class 4 NLS consensus, which was found 
to bind to the minor groove (Kosugi, Hasebe, Matsumura, et al. 2009). This might require importin-α 
to bind in opposite orientation which might not allow capsid-bound VP1-2 to engage a nuclear 
transport factor or even the NPC in a functionally relevant way. When the Myopodin NLS is inserted in 
place of R4, on the other hand, the virus is still able to replicate, which supports the above hypothesis, 
since it would not alter importin orientation. To fully solve the question of orientation and type of NLS, 
NT6 vectors, which will be used in the rescue assay, should be constructed which harbour: 
(i) only the Myopodin NLS (no R5 and +/- the high homology immediately next to the first basic 
patch in R4) 
(ii) the Myopodin NLS in place of R5 (i.e. R4-MyoNLS combination) 
(iii) a modified R1 with R4 and R5 reversed 
(iv) only a cellular bpNLS (e.g. nucleoplasmin) 
This should indicate whether HSV-1 requires a certain type of NLS (mpNLS v bpNLS) and whether 
the orientation of the NLS plays a significant role during entry. This could be complemented with 
structural studies to see how particular NLS peptides interact with importin-α and whether they bind 
with a preferred orientation. 
Although it could be concluded from these results that NLS function was not sufficient for rescue 
(see HHV-8) and that there was no correlation of rescue and NLS strength (compare recovery of VZV.R1 
to HCMV in Figure 18C) for the chimeric VP1-2s, it was evident that NLS function was required for 
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rescue to occur. It is difficult to say why the weak NLS sequence of VZV.R1 yields the most plaques 
plaques in the rescue assay. 
One explanation could be the recombination itself. Since the inserted DNA sequences are 
approximately of equal length and do not show much conservation across homologous inserts it is 
unlikely that recombination was more efficient using VZV.R1 (the region outside R1 was exactly the 
same for each construct as well). However, the VZV.R1 sequence actually exhibits an average GC 
content around 20% lower than that of the HSV counterpart (while CMV and EBV R1s contain 5.5% and 
3.3% fewer guanines or cytosines than the HSV sequence, respectively). 
A second (and more likely) reason for the discrepancy could be the overall protein conservation 
within R1, which is highest in VZV, and thus may provide better function in the context of HSV-1 VP1-2. 
As such, other cis-acting factors (VP1-2 contains C-terminal domains with essential functions) might 
regulate NLS activity better the more similar it looks to the wild type sequence. It also has to be 
considered that in the system in which nuclear localisation was assayed human or primate cells were 
used. The expressed repertoire of nuclear transport factors might differ in rabbit skin cells or the 
importin homologues might recognise NLSs differently to its human or primate homologue.  
The above conclusions are mostly true for the HSV-1 NLS mutants, although NLS strength 
impacted rescue and viral fitness in some special cases (K428R, compare Figures 16B-D and Figure 
18B). This only holds true if R5 was present. As such I could confirm that deletion of R5 abolished rescue 
although nuclear localisation was not completely absent (Figure 18B). This corroborates data on HCMV 
who showed that the HSV-1 NLS could poorly complement the VP1-2ΔNLS mutant HCMV defect (Brock 
et al. 2013). In their study a VP1-2 construct harbouring the HSV-1 R4 region instead of the HCMV 
bpNLS was used. My data now explain why they were not able to obtain a chimeric virus harbouring 
the HSV-1 motif as part of HCMV VP1-2, since even in HSV-1 the second basic patch was absolutely 
essential to viral replication.  
As part of the HSV-1 mutational study I have shown that R4 alone is not fully functional (see 
Figure 18A and B, ΔR5 rescue).In agreement with the localisation data, R4 was the dominant feature 
for rescue since the K428A mutation completely abolished viral replication. Intriguingly, for these HSV-
1 mutants (likely not for chimeras!) rescue correlated with the presence of category I and II nuclear 
localisation in HEK293 cells (Figure 16D). Here NT6.K428R shows reduced nuclear localisation 
compared to wild type but around 40% category I/II events while for NT6ΔR5 and NT6.K428A not a 
single cell with predominantly nuclear localisation was found. The higher stringency (due to factors 
discussed in the previous chapter) in this case could have revealed that the ΔR5 NLS is more debilitated 
than could be anticipated from the HuH7 data. Quite often some cancerous cell lines show elevated 
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levels of certain nuclear transport factors (van der Watt et al. 2011) and thus a weaker NLS might be 
rescued while this might not be the case in cells with low expression of a particular factor. 
This still leaves the question why R5 is required for HSV-1 replication? This could touch upon 
similar aspects as mentioned with HHV-8.R8. Without R5 the mpNLS in R4 might still bind to importin-α 
at the same site but due to lack of R5 binding the second site on importin-α the NLS-importin complex 
might not adopt a conformation/orientation that is compatible with other adjacent functions (see 
pUL37 and VP16 comment above). 
These data (Figure 18B, lack of rescue with ΔR5) contrast what was found for another α-HVs, 
PRV (Fuchs et al. 2004). They argue that a 238 amino acid deletion within the VP1-2, which includes 
most of the PRV.R1 region downstream of the basic residues in R4 (sequence deleted after PKRRRP 
motif), still allows some replication to 50 fold lower titres. This defect was attributed to lack of UL37 
binding capacity. However, I was able to co-precipitate pUL37 with NT6.ΔR5 (and all of the chimeras 
tested) which indicates that R5 does not contribute to pUL37 binding. In fact, their phenotype might 
actually relate to loss of R5 rather than pUL37 binding since, in contrast to HSV-1, in PRV the pUL37 
protein is not essential to replication in cell culture (Klupp et al. 2001). Moreover, a later study has 
shown that the residues critical for the interaction of VP1-2 and pUL37 can be found more than 150 
residues downstream of R5 in HSV-1, in a region which shows significant homology between all α-HV 
VP1-2s (Mijatov et al. 2007). It has to be noted that at least one more downstream deletion beyond 
the defined pUL37 binding region in the PRV homologue occurred in that study by Fuchs et al. (2004) 
which could have compensated for the loss of R5 in some unexplained way and explain why the virus 
still replicated.  
 
4.6.3 Insertion of a foreign NLS affects viral fitness 
The data presented above show that through rescue of the defective ΔNLS virus I was able to 
isolate and purify recombinant viruses for the chimeras VP1-2.VZV, CMV, EBV and MyoNLS, and 
another HSV-1 NLS mutant, K428R. All showed varying levels of debilitation on multiple cell lines 
measured with different techniques which likely indicate a defect during the establishment of infection 
(likely entry). This effect did not correlate with NLS strength if the whole R1 was exchanged but reduced 
NLS activity associated with the K428R mutation certainly affected HSV-1 replication. Although there 
were defects observed in most cell lines tested, the following paragraphs will discuss this defect using 
Vero cells as a model. 
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4.6.3.1 Specific defect in Vero cells 
Vero cells turned out to be the worst cell line for propagating these recombinant viruses. This 
was unexpected since these cells are conventionally used to propagate a variety of viruses since it lacks 
the type I interferon system. If one considers the defect of the chimeras which is likely due to delayed 
entry kinetics, this is particularly puzzling. The initial stages of viral infection can be seen as a race to 
establish the viral programme before the cell can mount an anti-viral response. Due to the lack of the 
interferon type I system it would be reasonable to assume that slowed kinetics were less of an issue. 
However, even in the absence of neutralising antibody the VZV chimera barely spread through the 
monolayer for the multi-step growth analysis indicating a major problem associated with the inserted 
sequence. 
The most significant reduction in viral fitness was observed in Vero cells with the VZV chimeric 
recombinant virus. Detectable levels of ICP4 were delayed by as much as 5 h which is very significant 
for a virus with a relatively short replication cycle. Such a delay in immediate early gene expression 
could be caused by slower entry. Since the ΔNLS capsids congregate around the MTOC during early 
infection (Abaitua et al. 2012) the VZV motif likely fulfils a function allowing docking at the NPC. This 
would indicate that the process of picking up a nuclear transport factor near or at the NPC is less 
efficient, in this case not solely because the NLS is weaker but also because of other changes to this 
region. Alternatively but not mutually exclusively, the required nuclear transport factor is limited in 
Vero cells and thus prevents mutant capsids from docking at the pore in the same time as wild type 
virus. This could explain why the K428R recombinant virus was also strongly debilitated in Vero cells 
(Figure 20B). 
To test whether presence (or absence) of the required importins could be the limiting factor, 
expression of these could be tested by Western Blot. Since specific antibodies to each importin have 
not been completely developed it might be easier to check for expression by quantitative real-time 
PCR. If this hypothesis were to be true it would also be possible to exogenously express each importin 
and analyse their capacity to rescue the entry defect, or vice versa knock-down individual importins 
with siRNA and check if the wild type becomes impaired in a similar or the chimeras lose infectivity 
completely (if expression of the limiting importin is even further reduced). 
Besides docking at the nucleus cleavage was suggested to occur while capsids are docked at the 
NPC. When cells were infected with tsB7 at the non-permissive temperature these capsids can dock at 
the nucleus but fail to eject their DNA through the NPC when the temperature is switched to the 
permissive temperature in the presence of a protease inhibitor (Jovasevic et al. 2008). The defect was 
later traced to a single residue in VP1-2 (Abaitua et al. 2011). A VP1-2 cleavage site is anticipated in a 
region near R1 (Kattenhorn et al. 2005) but was never confirmed. When you compare the VZV to the 
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K428R recombinant, both show smaller plaques, but that of K428R were still >5-fold larger. It could be 
that the insertion of a foreign R1 could, in addition to affecting binding to nuclear transport factors, 
impair such a cleavage event making DNA release a very slow process which might be exacerbated in 
Vero cells more than in other cells. The K428R mutant would in that respect not be affected since it is 
otherwise wild type sequence. 
If cleavage were to be an issue this could be tested using a nuclear entry assay. When cells are 
infected with ultra-high MOI it is possible to see capsids docked at the NPC with EM. This would yield 
information on how many capsids are docked at the nucleus at any given time and should also show 
whether the capsids are empty or DNA-filled. One would assume if the above assumptions are true, 
that fewer capsids reach the nucleus compared to wild type (at any given time) up to a point of 
saturation and that more mutant capsids would contain DNA. 
Besides the entry phenotype, virion production also appeared much reduced in Vero cells for all 
chimeras. This suggests that there might be another defect later on during infection although it could 
be possible that the viral life was just so much slower that the peak of virion assembly was not reached 
by 24 hpi. Thus to further assess the defect of the chimeras it would be worth looking at the kinetics 
appearance of replication compartments and capsids. The Western blot results indicate reduced VP5 
content and generally an extended viral life cycle. Thus it appears likely that capsid assembly and 
maybe also DNA replication will be delayed or much reduced which can be investigated by EM of 
infected cells (to check for nuclear capsids) or checking how many genomes enter nuclei and progress 
to become pre-replication compartments. Our group has also optimised a way to analyse the kinetics 
of viral genome uncoating and DNA replication using ‘Click’ chemistry (unpublished data) which will be 
a useful tool to delineate the defect of the chimeric viruses in more detail. If entry kinetics were slower, 
then fewer genomes should enter the nucleus at any given time point compared to wild-type virus. 
This would also delay the appearance of a large (peak) replication compartment. 
Where the role lies for the VP1-2 NLS remains to be discovered but it is difficult to reconcile my 
data and that presented in the literature with a nuclear assembly function. Although it localises to the 
nucleus and was found on nuclear capsids (D. S. McNabb & Courtney 1992; Abaitua & O’Hare 2008; 
Henaff et al. 2013) several studies show that it might not be required for nuclear egress (Desai 2000; 
Möhl et al. 2009). Assembly was not affected using the ΔNLS mutant although nuclear localisation of 
VP1-2 was abolished (Abaitua et al. 2012). Thus it would be a good idea to check localisation of chimeric 
VP1-2 though, since altering the NLS could alter its regulation and thus theoretically affect viral 
assembly. Phenotypes could here be evaluated against the literature by EM which has been done for 
a variety of VP1-2 mutants already. Of particular interest would be the total number of capsids 
produced and the appearance of cytoplasmic and perinuclear capsids. Combined with the 
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aforementioned studies on entry/replication kinetics and ultrastructural investigations of nuclear 
docking and DNA release this should yield an explanation of why the chimeric viruses might be 
impaired. 
 
4.6.4 Future directions 
The main aim of our group is to solve how VP1-2 facilitates nuclear uncoating and which role the 
NLS has in that context. In our group the goal was to make HSV-1 research more physiological. Hence 
cell types that represent more natural host cells were introduced to study the defects of the chimeric 
viruses. The next steps would be to fully characterise the defect of these viruses and potentially expand 
the analysis of functional determinants of the HSV-1 R1 region. Of particular interest would be the 
study of neuronal infection. The HV R1 regions show sub-family specific features and it is intriguing to 
speculate that some of these arose as an adaptation to the cells they infect. Since most cells tested 
(except Vero) were still susceptible to the chimeric viruses it would be interesting to expand this study 
to include neurons. Can the chimeras successfully migrate along the long axons since importin might 
be required for this process, and if so, can they unload their DNA cargo into the nucleus? Would these 
chimeras be able to establish latency in an animal model? 
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5 Biochemical analysis of VP1-2 binding partners 
5.1 Using the VP1-2 N-terminus to identify relevant nuclear 
transport factors 
Over the last two decades knowledge on how HV capsids unload their cargo into the nucleus has 
gradually lead to the conclusion that VP1-2 is the major driver of early events including transport and 
docking at the nuclear pore (see section 1.2 including references). However, the mechanism how 
capsids dock at the nucleus is only incompletely understood. The accumulation of VP1-2ΔNLS capsids 
around the MTOC (Abaitua et al. 2012) and rescue assay results imply that one piece of that puzzle 
could be the recruitment of a nuclear transport factor and that this could well be a conserved function 
of R1 in all HVs. It would be vital to identify VP1-2 recruited nuclear transport factors to establish a 
more complete model of nuclear docking of HV capsids. 
In this chapter I set out to pursue two parallel systems to identify importins recruited by VP1-2 
in its soluble and capsid-bound form. The first approach makes use of a N-terminal fragment of VP1-2 
(VP1-21-795, NT3, Figure 21B). When exogenously expressed in cells this protein would serve as a bait 
with which VP1-2 interacting proteins can be co-precipitated and subsequently identified by sensitive 
MS (see Figure 21A for a flowchart of the proposed work). In combination with a NT3 mutant that lacks 
the NLS (NT3ΔNLS) nuclear transport factors might be identified by comparing the lists of binding 
proteins from the separate pulldowns (of NT3 and NT3ΔNLS) since, theoretically, only NT3 should be 
able to co-precipitate nuclear transport factors.  
This system may also be useful to answer unrelated questions which could still be affected by 
the presence of the NLS. During HSV-1 infection VP1-2 was suggested to be cleaved into a product that 
ends somewhere in the vicinity of R1 (Kattenhorn et al. 2005), that is, either before or after the NLS. 
The product could thus act either as a nuclear or cytoplasmic protein. NT3 and NT3ΔNLS could mimic 
these products and the profile of binding partners could yield information on what this cleavage 
product could do during HSV-1 infection. Herein, I present data on the developed pulldown system 
and the follow-up of one identified interacting protein. 
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Figure 21 Overview of the strategy to identify binding partners of the N-terminus of VP1-2 and the NLS domain. 
(A) Flowchart highlighting the steps which were performed to obtain potential binding partners for VP1-2. (B) Constructs 
used as a basis for the interaction studies. NT3 represents a 795 residue N-terminal fragment of HSV-1 VP1-2 and its nuclear 
localisation is entirely dependent upon the presence of the NLS. As a control for the proposed MS analysis, a second 
construct lacking the NLS was also constructed. (C) Retroviruses that enable doxycycline inducible expression of NT3 or 
NT3ΔNLS were created and used to transduce HEK293 TetON cells which express the rtTA reverse transactivator. The pTight 
doxycycline regulatable promoter cassette was cloned from pTight (Clontech) with a multi-cloning site (MCS) and inserted 
into pQ-Flag (Dr. G. Maertens). NT3 or NT3ΔNLS were inserted into the MCS resulting in a retrovirus system that contains 
a bi-cistronic expression cassette for doxycycline inducible expression of NT3 and puromycin phosphotransferase 
(selectable marker). Alternatively, the IRES was exchanged for a SV40 promoter to result in the same construct coding for 
two mRNAs (NT3 and puromycin resistance). pCMV – CMV immediate early promoter, LTR – long terminal repeat, IRES – 
internal ribosomal entry site, PuroR – puromycin phosphotransferase. 
 
To complement the study of soluble VP1-2 and to validate any identified protein it would be 
necessary to test whether these would also bind VP1-2 in its capsid-bound form. For this I present data 
on the optimisation of an in vitro system to identify capsid bound proteins in the context of wild-type 
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VP1-2. The aim of this part was to compare the cellular binding proteins of capsids covered in wild-
type and VP1-2ΔNLS by proteomic analysis and Silac. The assay uses capsids that have been treated 
with detergent to remove the envelope and several conditions (different [salt], reducing environment, 
cellular proteins) to remove as much of the capsid-associated tegument as to allow binding of relevant 
cellular proteins. Ultimately, comparing the profile of identified binding proteins precipitated by wild-
type and VP1-2ΔNLS mutant capsids should enable the identification of nuclear transport factors that 
would be recruited during the early entry steps. 
 
5.2 Results 
5.2.1 Protein interaction study using the VP1-2 N-terminus 
5.2.1.1 Creating stable cell lines expressing VP1-2.NT3  
Although NT3 expressed very well in transient expression assays and, more importantly, to 
higher levels than NT6 I wanted to minimise assay variation due to transfection efficiency and create 
a cell line with consistently high expression of my bait protein. Since it is possible that the 
deubiquitinating activity of the USP domain could interfere with cellular function in the long term (i.e. 
over multiple passages) I opted for a doxycycline inducible system. In this way only when doxycycline 
was added to the medium would the protein be expressed to high levels. Effectively, in this system 
exactly the same cell line can be used as positive and negative control (+/- doxycycline).  
To establish two cell lines expressing NT3 or NT3ΔNLS a retrovirus system  was used to transduce 
a doxycycline regulatable NT3 or NT3ΔNLS open reading frame into HEK293 TetON cells, which express 
rtTA (protein that activates transcription in response to doxycycline). For this a retrovirus system 
(kindly provided by Dr G. Maertens) was modified by exchanging the CMV promoter with a pTight 
promoter comprising seven repeats of the doxycycline transactivator binding site coupled to a minimal 
CMV promoter (Figure 21C). This, in combination with the reverse transactivator (rtTA), renders the 
downstream ORF inducible by doxycycline. As part of the cloning process a multi-cloning site was 
introduced downstream of the pTight promoter to enable insertion of NT3 and potentially other open 
reading frames. To allow selection this vector contains a puromycin resistance cassette, which was 
expressed from the same transcript as NT3 through the activity of an IRES. Through puromycin 
selection it was possible to recover cellular clones, expressing bait proteins to high levels upon 
induction with doxycycline (Figure 22). 
To confirm inducible expression of NT3 and NT3ΔNLS, cellular clones for each protein were 
induced for 19 h or 36 h with different concentrations of doxycycline ranging from 0.001 μg/ml to 
1 μg/ml (Figure 22A/B). Without the antibiotic the selected clones did not express detectable 
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NT3/NT3ΔNLS which shows that expression is tightly regulated (Figure 22A/B, lanes 1 and 6 in both 
blots).  
For both NT3 and NT3NLS expression was detected at concentrations as low as 0.01 μg/ml and 
increased to near maximal levels at >0.1 μg/ml at 19 h post-induction (Figure 22A/B, see lanes 4 and 
9). There was a considerable amount of shorter protein products that were reproducibly detected with 
anti-V5 antibody, which detects the N-terminal tag of NT3 (Figure 21B). The observation might indicate 
cleavage and might be explained by overload of the cell with the protein resulting in detectable N-
terminal cleavage products. At high concentration of doxycycline (> 0.1 μg/ml) and more prominently 
after longer induction, a ladder appears at molecular weights larger than NT3. This could indicate 
potential ubiquitination which was not removed by the cis-acting USP domain and was only detectable 
when the protein was vastly overexpressed. This pattern did not change significantly from NT3 to 
NT3ΔNLS although cellular localisation was altered to a large extent (Figure 22C). 
To test whether NT3 could practically use the nuclear transport machinery in HEK293 TetON 
cells, clones for both constructs were induced and analysed by indirect immunofluorescence. It was 
striking that virtually all cells expressed the bait protein while control cells not treated with the 
antibiotic did not show any signal in the FITC channel if imaged with the same microscopy settings for 
gain and exposure (Figure 22C). NT3 showed moderate to strong nuclear accumulation in the majority 
of cells (Figure 22C) which was virtually abolished with the deletion of the NLS. It has to be noted that 
NT3 still accumulated in the cytoplasm of cells which likely could be due to overloading the cell with 
nuclear transport cargo. Nonetheless these data imply that the selected clones express proteins that 
could be used to potentially identify nuclear transport factors.  
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Figure 22 Characterisation of transduced HEK293 TetON cell clones. 
(A and B) Selected clones from NT3 wild-type (A) and ΔNLS (B) were grown in collagen-coated 6-well plates and induced 
the next day for either 19h (lanes 1-5) or 36h (lanes 6-10) using increasing concentrations of doxycycline (0, 0.001 μg/ml, 
0.01 μg/ml, 0.1 μg/ml or 1 μg/ml). Proteins were extracted by scraping cells into Laemmli buffer and NT3 was detected by 
Western blot using anti-V5 antibody. γ-tubulin was used as a loading control. (C) Immunofluorescence studies of one 
selected cell clone for each construct is shown. NT3 or NT3ΔNLS were induced with 1 μg/ml doxycycline for 19 h and their 
presence was detected using anti-V5 antibody. Nuclei were counterstained with DRAQ5. NT3ΔNLS exhibited exclusively 
cytoplasmic localisation whereas NT3 was also detectable in the nucleus and cytoplasm. 
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5.2.1.2 Identification of VP1-2 interacting proteins: Part I 
To find interaction partners two cellular clones inducibly expressing NT3 were initially compared 
to the NT3ΔNLS clone using immunoprecipitation. Western blot analysis showed that all NT3 and 
NT3ΔNLS clones expressed a protein of the same size although NT3 clone 15 and NT3NLS appeared 
to express slightly better than NT3 clone 4 at the conditions tested (Figure 23A, compare lane 2-4). The 
control parental HEK293 TetON cell line showed no detectable band at the expected size (Figure 23A, 
lane 1). Moreover, NT3 species (lanes 11-14) were precipitated only in NT3 and NT3ΔNLS clones but 
not in the parental control. Conversely, the cytoplasmic protein γ-tubulin was not enriched in any IP 
sample. It has to be noted that significant amounts of NT3 were still present in the unbound, soluble 
fraction after the precipitation step (Figure 23A, lanes 8-10) indicating poor recovery which needs to 
be improved to gain sensitivity. Protein profiles of the same samples analysed on a silver stained SDS-
PA gel (Figure 23B) showed strong bands at the expected size of NT3 which were not present in the 
parental control. There were some significant contaminating, non-specific bands in the parental 
control IP (examples marked with green arrows). These could not be removed by pre-clearing of the 
cellular lysates with protein-A bearing beads which were used to immobilise the anti-V5 antibody. 
Since these bands re-appeared in repeat experiments it is likely that they get co-precipitated non-
specifically by anti-V5 antibody. 
The banding pattern of the NT3 sample was reproducible with two NT3 clones and over multiple 
experiments for the same NT3ΔNLS clone. The strong bands above (60 kDa) and below (40 kDa) the 
immunoglobulin (Ig) heavy chain likely match the N-terminal breakdown products also seen in the 
Western blot (Figure 22) and would thus be of no significance. Other bands that were present both in 
NT3 and NT3NLS but not in the control sample could be interacting proteins of any region of NT3; the 
N-terminal USP, the region after the USP (including the NLS) or the C-terminal part. To discover 
transport factors, lanes 2 or 3 (NT3) have to be compared to lane 4 (NT3ΔNLS) (Figure 23B). Several 
bands were reduced in staining or failed to show up completely in the NT3ΔNLS sample compared to 
wild-type NT3 sample (Figure 23B, lane 4, red arrow heads). Two bands between 70-80 kDa (black 
arrowheads), which were absent from NT3ΔNLS, were excised, tryptically digested and analysed by 
tandem MS. In those bands six proteins of approximately the correct size were at least four-fold 
enriched in the NT3 compared to the NT3ΔNLS sample (see Figure 23C). The proteins identified are 
involved in nuclear functions including transcription (DDX3X, DDX17, PABP1) and repair of damaged 
DNA (DTX3L) and have not previously been identified as VP1-2 interacting proteins. Their enrichment 
in the NT3 sample might not directly reflect the deletion of the NLS but rather the change in localisation 
of NT3 compared to NT3ΔNLS. This band excision analysis represented an initial validation that 
proteins enriched in the NT3 compared to the NT3ΔNLS sample could be identified by MS. This result 
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indicated that it might be a feasible strategy and thus I proceeded to the next stage which involved an 
unbiased MS screen of all proteins precipitated by NT3 or NT3ΔNLS.  
 
Figure 23 Small scale immunoprecipitation of NT3 and NT3ΔNLS to identify VP1-2 interacting proteins. 
(A) Western blot showing the presence of NT3 and NT3ΔNLS in cellular lysates and the IP fraction (detected with anti-V5 
antibody). (B) Silver stained SDS-PA gel of the same IP samples after elution from protein A beads using Laemmli buffer. 
Green arrowheads show examples of non-specifically precipitated proteins. Red arrowheads show areas where bands 
were less intense or absent in the NT3ΔNLS sample compared to NT3. Black arrowheads show bands that were excised for 
tryptic digestion and subsequent mass spectrometric analysis. (C) Selected proteins identified in the excised bands by MS. 
Only proteins that were enriched at least four-fold in NT3 versus NT3ΔNLS and that were of approximately the correct size 
were included in the list. Values for NT3 (column 2) and NT3ΔNLS (column 3) show absolute abundance with a difference 
of 1 unit between NT3 and NT3ΔNLS indicating two-fold enrichment. 
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5.2.1.3 Identification of VP1-2 interacting proteins: Part II 
To get an overview of which proteins the various bands in the NT3 or NT3ΔNLS samples 
represented (see Figure 23B) the IP was repeated on a larger scale and all co-precipitated proteins 
were directly subjected to tryptic digestion and the resulting peptide mixtures compared by mass 
spectrometric analysis. Western blot analysis showed enrichment of NT3 in the IP fraction which was 
subjected to tryptic digestion (Figure 24A, lanes 8 and 9, similar background bands as before, full blot 
not shown). Again no γ-tubulin was found in the IP fraction and a reasonably high amount of NT3 
remained in the soluble fraction after the precipitation step (lanes 6 and 7). The MS results revealed 
highly similar levels of precipitated NT3 and NT3ΔNLS (NT3/NT3ΔNLS ratio 0.999) in either sample, 
with a total of 43 and 35 peptides identified for NT3 and NT3NLS, respectively. This was corroborated 
by comparable band intensity in the IP fraction (see Figure 24A, lanes 8-9). Overall, NT3 (and NT3ΔNLS) 
showed more than 8000-fold enrichment in the expressing cell clones compared to the parental 
control, which was deemed acceptable to proceed with the analysis of MS results. 
 
 
Figure 24 NT3 and NT3ΔNLS IPs and summary of co-precipitated proteins identified by MS. 
(A) Western blot showing presence of NT3 and NT3ΔNLS in samples destined for MS. There was some degradation detected 
in Total and Input samples but mostly full length NT3 was precipitated with anti-V5 antibody. γ-tubulin was used as loading 
control. (B) Schematic overview of proteins that were >4 fold enriched in the NT3/NT3ΔNLS samples compared to the 
parental control. Of the 199 proteins that were found, 162 and 93 were enriched in NT3 (red, category I) and NT3ΔNLS 
(green, category II), respectively. 56 proteins were found in both samples (brown). The 199 proteins were further sub-
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divided. Category III includes 99 proteins that were >4 fold enriched in NT3 compared to NT3ΔNLS. Category IV comprises 
32 proteins that were enriched in NT3ΔNLS compared to NT3. Category V includes 54 proteins that were found enriched in 
both NT3 and NT3ΔNLS compared to control (and less than 4 fold different between NT3 and NT3ΔNLS). 2 proteins from 
the overlap were assigned to category III due to >4 fold enrichment in NT3>NT3ΔNLS. 9 proteins from Cat. I and 5 from Cat. 
II were excluded as the co-precipitated protein was only enriched in one sample compared to control but the difference 
between the bait samples was less than four fold. 
 
The MS results were filtered to remove any proteins that could typically contaminate MS (e.g. 
trypsin from the digestion, albumin, etc.) and to remove proteins that were poorly enriched in both 
bait protein samples (i.e. less than four-fold enrichment compared to parental control). A list of 199 
proteins remained (Figure 24B). Of these, 162  and 93 proteins were found to bind NT3 or NT3NLS, 
respectively, with 56 proteins represented in both samples. Of the 162 proteins that bound NT3 better 
than the beads (parental control) 99 were additionally at least four-fold more abundant compared to 
the NT3ΔNLS sample (Figure 24B, NT3 > NT3ΔNLS, category III). Of the 93 proteins identified in the 
NT3ΔNLS sample (compared to control) 32 proteins were additionally at least four fold enriched 
compared to the NT3 sample (Figure 24B, NT3ΔNLS > NT3, category IV). 54 of the remaining proteins 
were at least four fold enriched in both NT3 and NT3NLS samples compared to the parental control 
(Figure 24B, category V), but showed a less than four-fold difference between NT3 and NT3ΔNLS 
samples.  
 
5.2.1.4 Localisation and functions of proteins that were enriched 
compared to the parental control (categories I and II) 
It could be expected that proteins that bind a nuclear bait would naturally also localise to this 
compartment and vice versa for proteins binding a cytoplasmic bait. This data could then be taken as 
an internal validation of the pulldown and aid the categorisation of identified proteins. For this 
experimentally confirmed localisation data was gathered manually from UniprotKB (and GeneCards if 
UniprotKB did not contain any annotation). While some of the 199 proteins pass through multiple 
compartments, at least 67% of the 162 proteins enriched in NT3 over control (Figure 25A, category I) 
localise to the nucleus at some stage compared to only 56% of the 93 proteins that bound NT3ΔNLS 
better than control (Figure 25B, category II). This manual analysis compared well with the data 
obtained with the automated annotation tool DAVID (Huang et al. 2007), where at least 60% of the 
162 proteins enriched in the NT3 sample versus control (category I, Fisher score <5x10-26) were 
categorised as nuclear proteins compared to 52% of the 93 proteins enriched in the NT3ΔNLS sample 
versus control (Fisher score <1.5x10-8). The low Fisher scores indicate statistically significant 
enrichment of  nuclear proteins (more than expected by chance in a sample set) in both sample sets, 
although the enrichment in the NT3 sample (category I) was expectedly much higher. Interestingly, 32 
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NT3 binding proteins (category I) were also found in nucleoli in some experimental settings, which 
suggests that NT3 might localise to this compartment. In agreement with this theory R5 is predicted to 
contain a nucleolar localisation signal and could explain sub-nuclear compartmentalisation of GFP-R2 
(see Figure 9B, panel III). 
 
Figure 25 Simplified overview of annotated localisation and functions of NT3 binding proteins 
Localisation of proteins that were enriched at least four-fold in the NT3 sample (A and C, category I) or NT3ΔNLS sample 
(B and D, category II) versus the parental control are shown. Annotations were collated mainly from UniProtDB but also 
GeneCards if no annotation was found. Some proteins localise to multiple compartments or have multiple annotated 
functions. Cytoplasmic includes other compartments (ER, Golgi, mitochondriae, etc.). The top five functions are also shown 
as percentage of all proteins from that category. 
 
It could be expected that importins would be found in both category I and III (Figure 24B) since 
NT3 contains the NLS. However, no nuclear transport factors were identified in the NT3 sample. This 
implies that this type of assay might not be the right one or that it requires modification. Nonetheless 
this assay could yield valuable information on functions of another part of NT3; the USP, which gets 
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liberated by a proteolytic event during infection (Kattenhorn et al. 2005). The putative cleavage site in 
VP1-2 is still unknown but lies somewhere around R1 both NT3 and NT3ΔNLS. Additionally, VP1-2 can 
be found both in the nucleus and in the cytoplasm in its full length form (D S McNabb & Courtney 1992; 
Abaitua & O’Hare 2008). This could effectively mean that a free USP domain can affect targets either 
in the nucleus (if the cleavage site is after R1) or the cytoplasm (if the cleavage event occurs before the 
NLS). The USP can act on VP1-2 to modify its own stability (Bolstad et al. 2011) and another report exist 
of the VP1-2 de-ubiquitinating activity modulating the immune response to HSV-1 infection (Wang et 
al. 2013). Thus the NT3 and NT3NLS system could potentially lead to the identification of VP1-2 
interacting proteins and a more complete understanding of how VP1-2 fulfils some of its functions. In 
fact in another study (Calistri et al. 2014) an interaction of VP1-2 and a component of the ESCRT 
pathway was found using a NT3-like fragment. With these precedents I believe that following up some 
of the identified proteins could give rise to new ideas in how HSV-1, via VP1-2 or the USP, modulates 
cellular behaviour. 
Of particular interest is the group of proteins that were enriched in both samples compared to 
the control (Figure 24B, category V) since they bound both bait proteins (similar to a biological 
replicate). To gain an insight into what the sample proteins could be doing during an infection, 
annotated molecular functions were manually gathered from UniprotKB (and GeneCards if no 
annotation was found in Uniprot) for proteins that bound NT3 and/or NT3ΔNLS (Figure 25C/D). These 
were divided into 13 functional groups. A great majority of the 199 proteins have roles handling RNA 
with approximately 27% of all proteins presumably involved in transcription or mRNA metabolism. An 
additional 11% function in other RNA metabolism, such as RNA binding which could be involved in 
immune recognition, tRNA and miRNA metabolism. Besides this, 10% of proteins were shown to be 
involved in translation and ribosome function and, in fact, many of the identified proteins play 
prominent roles at every level in the chain of protein expression which could be modulated to keep up 
protein production and gear this process towards expression of HSV-1 proteins.  
The second largest functional grouping relates to cell cycle and DNA replication. 13% of proteins 
that were enriched compared to control (of all 199 proteins) were shown to be implicated in these 
functions which may contribute to modulation of the replicative machinery to allow replication of viral 
genetic material. A small proportion (6%) of proteins are associated with transport functions which 
could be interesting since during an infection HSV-1 capsids have to navigate the cytoplasm to reach 
the nucleus or the place of virion assembly. Unexpectedly, the only identified nuclear transport factor 
(importin-8) was found in the NT3NLS data sets. This implies that, despite deletion of the whole basic 
patch in R4, importins may still bind to NT3 without fulfilling their transport function. 
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A closer look at the raw data, however, reveals that additional nuclear import receptors were 
identified. On the one hand, importin-9 which also bound to NT3ΔNLS. On the other hand Importins 
β1, and importins 4, 5 and 7, and importins alpha 1, 3, 4, 5 and 7 were also precipitated in the parental 
HEK293 TetON control. In fact, most nuclear transport factors, except for importin-9, were found to 
bind best to the beads in the parental control sample, which did not contain any bait protein. This 
implies that in spite of pre-clearing over protein A beads these proteins still bound to beads coated 
with anti-V5 antibody which presents a substantial problem if the aim was to identify these factors. 
To get at functions of potential targets of the USP domain in the context of NT3 (or NLS) the 
functions of all identified proteins in categories I and II were analysed. In categories I and II, which 
represent NT3 and NT3NLS binding proteins (Figure 25C/D), respectively, the former showed 
comparative enrichment for proteins involved in cell cycle (15% in the NT3 vs 9% in the NT3ΔNLS 
sample), transcription (16% vs 8%) and DNA repair and genome structure (8% vs 5%), all proteins that 
likely function in the nucleus. Conversely, proteins that preferentially bound NT3NLS are involved in 
metabolism (9% in the NT3ΔNLS vs 3% in the NT3 sample), transport (12% vs 8%) and protein folding 
(chaperones; 11% vs 4%), which likely function in the extra-nuclear compartments A select set of 
proteins divided into categories III to V are listed in Table 8 (proteins enriched in the NT3 compared to 
the NT3ΔNLS sample), Table 9 (proteins enriched in the NT3ΔNLS compared to the NT3 sample) and 
Table 10 (enriched in both samples compared to the control sample). 
A particularly interesting duo of binding proteins were DTX3L and its interaction partner PARP9. 
Interestingly, these two proteins are thought to form a complex which is implicated in the DNA damage 
response (Yan et al. 2009; Yan et al. 2013). Both were enriched in the NT3 and NT3ΔNLS samples 
compared to control (Table 8 and Table 10). DTX3L was also identified in the gel slices excised from 
the initial silver stained SDSPA-gel (Figure 23C). In absolute terms the levels of DTX3L and PARP9 
precipitated by NT3 were almost identical as judged from the peptide intensity score (compare Table 
8 and Table 10) but NT3ΔNLS appeared to bind PARP9 slightly better than DTX3L. These data suggest 
that NT3 potentially co-precipitated these proteins as a complex. The increased level of PARP9 
compared to DTX3L in the NT3ΔNLS indicates that DTX3L might not be precipitated through a direct 
interaction with NT3 but rather via PARP9, although this cannot be said with full confidence (more 
experiments required). 
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Table 8 Selected Proteins that bound NT3 >four-fold better than NT3ΔNLS and parental control (Category III). 
Absolute intensity given as log2.with a change of 1 unit equalling a doubling in abundance. Experimental details are given in Figure 24. The full list of enriched proteins can be found in 12: Appendix 4. 
# 
intensity 
PEP 
score 
MS/MS 
Count 
unique peptides 
MW Name Gene Function(s) important for HSV-1? References 
NT3 
NT3 
ΔNLS 
parental NT3 NT3NLS control 
1 30,075 27,4888 0 6E-174 34 18 15 0 84 
E3 ubiquitin-protein ligase 
DTX3L 
DTX3L Ubiquitination 
upregulated 4.8x in retinal endothelial cells; 
recruitment 53BP1 to DNA damage sites; stimulates 
NHEJ which is detrimental to HSV-1 infection 
(Miyazaki 
et al. 2011; 
Yan et al. 
2009; Yan 
et al. 2013) 
2 28,348 24,2055 23,0033 
6,29E-
86 
14 15 4 3 161 
Mediator of RNA polymerase 
II transcription subunit 14 
MED14 transcription 
required for HSV, HCMV and slightly less for VZV 
infection (siRNA) 
(Griffiths et 
al. 2013) 
3 23,143 0 0 3,2E-09 4 2 2 2 219 Endoribonuclease Dicer DICER1 
miRNA 
metabolism 
No reference found  
4 24,645 0 0 
2,92E-
09 
3 3 0 0 69 
E3 ubiquitin-protein ligase 
RLIM 
RLIM Ubiquitination 
modulation of LIM-HD function; involved in neuronal 
development; LIM knockdown blocks HSV-1 
infection; LIM-HD factor synergises with NFkB 
(Griffiths et 
al. 2013; 
Patel et al. 
1998; 
Rascle et al. 
2009) 
6 26,483 24,3834 0 4,6E-14 3 3 2 1 25 Casein kinase II subunit beta CSNK2B 
protein kinase, 
multiple pathways 
at least six HSV-1 proteins phosphorylated by CK2; 
EBNA-2 and ZEBRA of EBV 
(Meggio & 
Pinna 
2003) 
7 25,459 0 0 
4,61E-
12 
3 3 1 1 50 
DNA polymerase delta 
subunit 2 
POLD2 cell cycle 
ubiquitinated due to DNA damage; DDR upregulated 
in HSV-1 infected cells 
(Lee et al. 
2014) 
8 25,73 0 0 
5,54E-
13 
3 3 1 1 101 
General transcription factor 
3C polypeptide 2 
GTF3C2 transcription required for HSV infection (siRNA) 
(Griffiths et 
al. 2013) 
9 31,293 0 0 
2,06E-
06 
2 2 1 1 201 
E3 ubiquitin-protein ligase 
listerin 
LTN1 Ubiquitination 
potentially associated with HSV-1 susceptibility in 
mice 
(Thompson 
et al. 2014) 
10 22,807 0 0 
9,19E-
04 
2 2 1 0 40 Modulator of apoptosis 1 MOAP1 apoptosis 
inhibits HSV-1 infection (siRNA); facilitates TNF 
mediated apoptosis; K63 ubiquitination at K278 
appears to promote cell death 
(Griffiths et 
al. 2013) 
11 25,013 0 0 
3,92E-
13 
2 2 0 0 27 
Cyclin-dependent kinase 2 
Cyclin-dependent kinase 3 
CDK2 
CDK3 
protein kinase, cell 
cycle 
CDK2 activated during HSV-1 infection, Cdk inhbition 
blocks HSV-1 infection 
(Schang et 
al. 1999; 
Schang et 
al. 1998) 
12 26,633 0 0 
5,10E-
11 
2 2 1 1 14 
Cyclin-dependent kinase 
inhibitor 2A, isoform 4 
CDKN2A cell cycle appears to inhibit HSV-1 replication (siRNA) 
(Griffiths et 
al. 2013) 
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# 
intensity 
PEP 
score 
MS/MS 
Count 
unique peptides 
MW Name Gene Function(s) important for HSV-1? References 
NT3 
NT3 
ΔNLS 
parental NT3 NT3NLS control 
13 23,477 0 0 
3,10E-
04 
2 2 0 0 61 
Cell division cycle 7-related 
protein kinase 
CDC7 
protein kinase, cell 
cycle 
promotes cell  survival in presence of DNA damage, 
promotes DNA replication 
(Suzuki et 
al. 2012) 
14 24,374 0 0 
2,69E-
15 
2 2 1 1 179 
Ras GTPase-activating-like 
protein IQGAP3 
IQGAP3 
small GTPase, cell 
cycle, signalling 
  
15 26,169 0 0 
8,64E-
04 
2 2 0 1 104 
Exocyst complex component 
2 
EXOC2 exocytosis 
in vesicles with activated STING to effect innate 
response to DNA (IFN-β); STING is anti-HSV-1 
effector 
(Ishikawa 
et al. 2009) 
16 23,827 0 0 8,4E-06 2 2 0 0 75 Symplekin SYMPK 
mRNA 
metabolism 
required for HSV infection (siRNA); also important for 
West Nile Virus infection 
(Griffiths et 
al. 2013) 
17 24,032 0 0 
2,86E-
10 
1 2 1 1 63 Protein AATF AATF 
apoptosis, protein 
kinase 
binds Tsg101; ubiquitinated/degraded during 
apoptosis 
(Burgdorf 
et al. 2004; 
De Nicola 
et al. 2014) 
18 23,544 0 0 1,7E-06 1 2 1 0 11 
Cyclin-dependent kinase 
inhibitor 2A isoforms 1/2/3 
Cdk4 inhibitor B 
CDKN2A 
CDKN2B 
cell cycle inhibits HSV-1 infection (siRNA) 
(Griffiths et 
al. 2013) 
19 23,439 0 0 
3,46E-
05 
1 2 1 1 616 Dystonin DST cytoskeletal 
plus-end directed capsid transport, dystonin = NLS 
phenotype 
(McElwee 
et al. 2013; 
Pasdeloup 
et al. 2012) 
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Table 9 Selected proteins that bound NT3ΔNLS >4-fold more than both NT3 and control (Category IV). 
Absolute intensity given as log2.with a change of 1 unit equalling a doubling in abundance. Experimental details are given in Figure 24. The full list of enriched proteins can be found in Appendix 5: Category IV 
(proteins at least four fold enriched) 
# 
intensity PEP 
score 
MS/MS 
Count 
unique peptides 
MW Name Gene Function(s) important for HSV-1? References 
NT3 NT3 ΔNLS parental NT3 NT3NLS Parental 
1 0 26,6598 0 
9,31E-
14 
7 1 4 0 11 Protein S100-A7 S100A7 immunity 
binds UL20 (Y2H) which is required for membrane 
fusion during assembly, upregu-lated during 
inflammation/wound healing 
(Griffiths et 
al. 2013) 
2 0 24,275 0 
2,69E-
06 
3 0 3 1 42 
Prostaglandin E synthase 2 
Prostaglandin E synthase 2 
truncated form 
PTGES2 
metabolism, 
immunity 
COX-2 upregulated in neurons upon reactivation, 
COX-2 inhibition reduced reactivation in vitro 
(Kurane et 
al. 1984; Liu 
et al. 2014) 
4 0 24,2396 0 
1,12E-
05 
2 1 3 2 120 Importin-8 IPO8 
nuclear transport 
factor 
  
5 0 23,1143 0 
6,57E-
05 
2 1 2 1 46 
Nuclear pore glycoprotein 
p62 
NUP62 
nuclear pore 
protein 
  
6 0 23,6455 0 0,00102 2 1 2 1 134 Tight junction protein ZO-2 TJP2 cell adhesion 
tight junctions protect HSV-1 from neutralising 
antibodies (cell-cell spread) in HaCaT cells 
(Abaitua et 
al. 2013) 
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Table 10 Proteins that were >4-fold enriched in both NT3 and NT3ΔNLS samples compared to parental (Category V). 
This table includes proteins that are less than four fold different between NT3 and NT3ΔNLS. Absolute intensity given as log2.with a change of 1 unit equalling a doubling in abundance. Experimental details 
are given in Figure 24. The full list of enriched proteins can be found in Appendix 6: Category V (proteins at least four fold enriched) 
# 
intensity 
PEP 
score 
MS/MS 
Count 
unique peptides 
MW Name Gene Function(s) important for HSV-1? References 
NT3 
NT3 
ΔNLS 
paren 
tal 
NT3 NT3NLS parental 
1 32,719 30,7855 26,4064 0 106 38 28 10 119 
Large proline-rich protein 
BAG6 
BAG6 Chaperone 
UBL4A-GERT4-BAG6 complex mediates BRCA1 
recruitment and apoptosis in response to DNA 
damage 
(Krenciute 
et al. 2013; 
Thierry-
Mieg & 
Thierry-
Mieg 2006) 
2 30,833 30,1861 23,2049 4E-209 46 21 17 3 92 
Vacuolar protein sorting-
associated protein 35 
VPS35 transport 
retrograde endosomal transport;  Tip-VPS35 
interaction during HVS infection downregulates 
CD4 
(Kim et al. 
2010; 
Kingston et 
al. 2011) 
3 30,157 30,5403 27,4961 9E-189 44 18 15 12 35 
E3 ubiquitin-protein ligase 
CHIP 
STUB1 
Ubiquitination, 
DNA repair 
  
4 30,198 28,3735 0 3E-169 43 23 17 1 96 
Poly [ADP-ribose] polymerase 
9 
PARP9 
DNA repair, 
immunity 
4.2x upregulated during HSV-1 infection of corneal 
endothelial cells; binds DTX3L 
(Miyazaki et 
al. 2011; 
Takeyama 
et al. 2003) 
5 28,451 27,5324 24,5152 2,4E-36 17 8 7 3 18 Ubiquitin-like protein 4A UBL4A transport required for HSV infection (siRNA) 
(Griffiths et 
al. 2013) 
6 28,02 27,7688 0 3,3E-50 17 10 6 0 39 
Vacuolar protein sorting-
associated protein 26B 
VPS26B transport in complex with VPS35 (see above) 
(Kim et al. 
2010) 
7 28,473 27,2566 25,8036 1E-55 15 8 7 5 39 ATPase ASNA1 ASNA1 transport binds UBL4A 
(Thierry-
Mieg & 
Thierry-
Mieg 2006) 
8 27,337 26,1278 0 5,4E-44 15 6 5 1 37 
Golgi to ER traffic protein 4 
homolog 
GET4 transport binds UBL4A, see BAG6 
(Krenciute 
et al. 2013; 
Thierry-
Mieg & 
Thierry-
Mieg 2006) 
9 27,096 25,3863 24,2501 6E-40 13 7 4 2 28 Myeloid leukemia factor 2 MLF2 not annotated inhibits HSV infection in Hela cells 
(Griffiths et 
al. 2013) 
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# 
intensity 
PEP 
score 
MS/MS 
Count 
unique peptides 
MW Name Gene Function(s) important for HSV-1? References 
NT3 
NT3 
ΔNLS 
paren 
tal 
NT3 NT3NLS parental 
10 22,795 23,1311 0 9,1E-05 5 2 2 2 90 
U4/U6.U5 tri-snRNP-
associated protein 1 
SART1 
mRNA 
aumetabolism 
required for HSV infection (siRNA) 
(Griffiths et 
al. 2013) 
11 25,021 23,4432 22,9097 
3,28E-
17 
5 4 2 2 88 
BRCA1-associated ATM 
activator 1 
BRAT1 DNA repair Kinase of ATM in DNA repair 
(Aglipay et 
al. 2006) 
12 24,405 23,9568 0 1,1E-05 4 3 3 2 74 
Nucleolar and coiled-body 
phosphoprotein 1 
NOLC1 cell cycle required for HSV infection (siRNA) 
(Griffiths et 
al. 2013) 
13 24,057 23,1927 0 1,4E-11 3 3 2 1 105 
Ubiquitin carboxyl-terminal 
hydrolase Ubiquitin carboxyl-
terminal hydrolase 11 
USP11 Ubiquitination 
modulates NFkB activation by targeting IkB; 
facilitates survival in repsonse to DNA damage 
(Yamaguchi 
et al. 2007; 
Schoenfeld 
et al. 2004) 
14 24,155 25,1036 0 1,3E-10 3 2 2 1 16 
DNA-directed RNA polymerase 
II subunit RPB4 
POLR2D 
mRNA 
metabolism, 
translation 
required for HSV infection (siRNA); ubiquitinated 
during DNA damage 
(Griffiths et 
al. 2013) 
15 23,974 23,9065 0 0,00068 3 2 2 1 49 
Vacuolar protein sorting-
associated protein 4A /B 
VPS4A/B 
FIGNL1 
cell cycle, 
transport 
required for HSV-1 envelopment 
(Crump et 
al. 2007) 
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5.2.1.5 NT3 interacts with DTX3L in HEK293 cells 
To follow up on the candidate VP1-2 binding protein DTX3L, which was identified by MS in the 
excised band from the NT3 sample, and in both samples from the large scale IP (Figure 23C, Table 8) 
the previously successful IP approach was repeated to precipitate NT3 (see Figure 26A-C). Briefly, 
HEK293TetON cells expressing either NT3 or NT3ΔNLS were induced with doxycycline before the cells 
were lysed. From separate sets of lysates either NT3, NT3ΔNLS (using anti-V5 antibody) or DTX3L (using 
a DTX3L specific antibody) were precipitated and the resulting precipitates analysed for the presence 
of DTX3L or NT3/NT3ΔNLS (Figure 26). 
Again, NT3 and NT3ΔNLS were precipitated in good amounts but much of the bait protein from 
the input fraction was not precipitated which was consistent with previous results (Figure 26, lanes 
11/12). Both versions of NT3 were precipitated at reasonable and similar levels (lanes 5/6) and when 
the same blot was probed with a polyclonal antibody to DTX3L, the protein appeared to be present in 
both NT3 samples, although it seemed that NT3ΔNLS bound it less well (lanes 2/3). This was in 
agreement with the MS results indicating at least four fold less DTX3L co-precipitated with NT3ΔNLS 
compared to NT3 (Table 8). There was no DTX3L precipitated in the parental control (lane 1) despite 
the levels in the input fraction of this sample being comparable to the NT3 and NT3ΔNLS samples 
(compare lanes 7-12 for input and unbound). This also corroborated the lack of detection of DTX3L in 
the MS control sample. Intriguingly, the level of DTX3L appeared slightly increased in the cells that 
express NT3 (Figure 26, lanes 8, 11, 20 and 23) compared to both the control (lanes 7, 10, 19 and 22) 
and NT3ΔNLS (lanes 9, 12, 21 and 24) expressing cells. This effect on DTX3L levels appeared 
reproducibly in two biological replicates (i.e. the anti-V5 and anti-DTX3L IPs were performed with 
independent cellular lysates). 
The reverse IP (anti-DTX3L; Figure 26D/E) using a polyclonal antibody to DTX3L appeared to co-
precipitate both NT3 and NT3ΔNLS (lanes 17/18), although the anti-DTX3L antiserum only poorly 
precipitated the antigen and additionally gave rise to multiple bands (Figure 26D). This, in combination 
with some technical difficulties gave rise to ambiguous results for the reverse IP since a co-migrating 
band corresponding to NT3 in the negative parental control sample, which theoretically did not contain 
NT3, was detected (Figure 26E, lane 16, red asterisk). 
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Figure 26 Western blot images showing the results from reciprocal co-immunoprecipitations of NT3 (A-C) and DTX3L (D-F). 
Either NT3 or DTX3L were precipitated from 2x107 dox-induced HEK293 cell clones (and parental control containing neither 
NT3 nor NT3ΔNLS). IP eluates (IP against V5 or DTX3L) were blotted and membranes probed for presence of NT3 (in B the 
V5 epitope and in E an anti-USP antibody were used) or DTX3L were detected on the same blot (Licor two colour imaging 
system). Input and unbound (soluble left after precipitation) fractions correspond to 1/200th of the total while one quarter 
of the IP fraction was loaded. Red asterisk demarcates a band detected with anti-USP antibody in the parental control. 
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5.2.1.6 NT3 abolishes clustering of 53BP1 in response to the DNA 
damaging agent doxorubicin 
One of the roles of DTX3L (and PARP9) is to aid recruitment of factors, such as 53BP1 (p53 
binding protein), via ubiquitination (Yan et al. 2013), to sites of dsDNA breaks (Huen & Chen 2008). 
53BP1 is thought to favour non-homologous end joining (NHEJ), which is a detrimental process during 
HSV-1 infection (Taylor & Knipe 2004) and may be forming part of an interferon induced immune 
response against HSV-1 (Juszczynski et al. 2006; Lilley et al. 2011). To see if HSV-1 VP1-2 could 
modulate DNA repair mechanisms, 53BP1 localisation in the NT3 expressing cells in response to DNA 
damaging agents like doxorubicin could be analysed (e.g. 53BP-1 foci formation). 
For this the previously described clone expressing doxycycline inducible NT3, was grown with or 
without doxycycline for 24 h (to induce expression of NT3) prior to inducing DNA damage through 
treatment with 100nM doxorubicin for 22 h (Figure 27A). In parental cells 53BP1 foci could be seen in 
untreated cells (panel C1). This was not affected by treatment with doxycycline (Figure 27A, compare 
panels A1 no doxycycline, B1 with doxycycline). By 22 h of doxorubicin treatment virtually all non-
induced cells showed 53BP1 foci (Figure 27A, panels A1, B1) indicative of an active DDR. Some cells in 
panels C1 showed few or no foci. Some DNA damage inherently occurs during DNA replication thus 
few, sometimes quite large foci (red arrowheads) could be seen even in untreated cells. Since 
doxorubicin induced damage is maximised during actual DNA replication (Gewirtz 1999) this indicates 
that cells without foci (green arrowheads) probably were not actively synthesising DNA. In non-induced 
NT3 expressing cells (Figure 27A, panels A2) similar 53BP1 foci were observed as for parental cells 
(Figure 27A, panels A1, B1). Strikingly, these 53BP1 foci were virtually absent in the presence of NT3 
after 22 h of DNA damage (B2). Foci disruption led to diffuse nuclear staining of 53BP1 (Figure 27A, 
panels B2, yellow arrowheads). Unsurprisingly, NT3 also affected the basal DDR as judged by absence 
of 53BP1 foci (Figure 27A, panel C3).  
To confirm the above result, the assay was repeated in U2OS transfected with NT3. DNA damage 
was induced with 100 nM doxorubicin 24 h post-transfection and after 22 h of incubation 53BP1 foci 
were quantified. Cells with more than 10 nuclear 53BP1 foci were regarded as positive for DNA damage 
since cells not treated with doxorubicin generally showed fewer than 10 foci per nucleus while at least 
80 % of cells exposed to doxorubicin showed in excess of 10 foci (Figure 27B, bars 1 and 2). NT3 reduced 
the number of cells positive for DNA damage foci to around 25 % (Figure 27B, bar 4) while an unrelated 
exogenously expressed nuclear protein, CREB-H, did not affect foci formation (Figure 27B, bar 3). 
Unsurprisingly, cells expressing more NT3 showed fewer 53BP1 foci reducing the number of positive 
cells to baseline (Figure 27B, bar 6). This reduction in 53BP1 recruitment was dependent on USP 
activity, since a USP-inactive mutant (Figure 27B, bar 5 and 7, NT3C65A) did not reduce the number of 
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cells showing more than 10 foci per nucleus. Taken together, these data suggest a role for the VP1-2 
USP domain in modulating the DDR, probably facilitated via its interaction with DTX3L. 
 
Figure 27 53BP1 foci formation in NT3 expressing cells after doxorubicin treatment. 
(A) Previously described NT3 expressing HEK cells were induced with doxycycline for 24 h and subsequently treated with 
DNA damaging reagents (doxorubicin 100nM) for 22 h. The cellular response was measured by staining for 53BP1 
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(MAB3802) which is thought to form foci in the nucleus. The red arrowhead demarcates a representative untreated nucleus 
with normal, replication-induced 53BP1-containing DNA damage foci; the green arrowhead shows a representative 
nucleus without 53BP1 foci (i.e. cells that have not synthesised DNA during doxorubicin treatment); the yellow arrowhead 
shows a representative nucleus with diffuse 53BP1 localisation lacking obvious foci. (B) U2OS cells transiently expressing 
NT3, its USP-inactive mutant NT3.C65A or the unrelated transcription factor CREB-H were exposed to doxorubicin (100 nM) 
for 22 h and 53BP1 foci formation was quantified. Cells with > 10 foci per nucleus were regarded as positive of DNA damage 
since less than 5 % of cells showed > 10 foci per nucleus in the absence of DNA damaging agents. Cells positive for DNA 
damage generally showed between 10 and 60 foci with a mean of approximately 30. High expression of NT3 was 
discriminated by applying a threshold using the Fiji software. More details on quantification can be found in the materials 
section. 
.
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5.2.2 Development of a system to identify cellular binding partners 
of incoming viral capsids 
To complement the investigation of interaction partners of soluble VP1-2 and the NLS, I 
attempted to develop a system to delineate the interactome of incoming capsids. For the purposes of 
this analysis it was important to mimic the features of capsids on the way to the NPC, that is, during 
the first 5-30 min after infection. During that time virions would have lost their envelope either through 
fusion at the plasma membrane or endosomes. Subsequently, capsids are sequentially stripped off 
most of the tegument structures except for, theoretically, VP1-2, pUL37 and pUS3 (see 1.1.5). To obtain 
capsids fulfilling these requirements three different methods could principally be employed. 
 
5.2.2.1 Possible approaches to identify capsid-binding nuclear 
transport factors 
(i) nuclear capsid preparation 
The first approach would obtain newly assembled capsids from nuclear preparations as these 
could easily yield high amounts of material. These could be used as an affinity matrix for potential 
binding partners. However, these capsids may not look like the ones during entry (see 1.2.3). 
Conflicting evidence exists as to whether VP1-2 is recruited to assembling capsids in the nuclear 
compartment or whether it is added at a later stage which is discussed in the introduction. Depending 
on the cellular system used one might not obtain usable (i.e. comprising VP1-2) nuclear C capsids for 
this assay. Other essential tegument members that could play a part during entry, such as pUL37, are 
dependent on VP1-2 and their addition likely coincides or follows VP1-2 recruitment. Recruitment of 
nuclear transport factors is assumed to require VP1-2 but whether other tegument proteins are 
involved in this process is unknown. However, to avoid revisiting the longstanding issue of VP1-2 
recruitment and since it would be difficult say what incoming capsids should look like I decided against 
using this approach. 
(ii) Isolating capsids on the ‘way in’  
To isolate capsids on their way to the nucleus should be the most relevant approach as virions 
will go through the physiological process of uncoating, de-tegumentation and binding of transport 
proteins. SV40, another DNA virus, that requires access to the nuclear compartment, only 1% of an 
inoculum was found to be infectious and much of it never reaches the nucleus (Flint 2009). I would 
define this 1% of the total capsids as the ‘good material’. Assuming a similarly poor scenario for HSV-1 
(Frenkel et al. 1975) it is conceivable that, to obtain analysable material, cells probably need to be 
infected at very high MOI (50-100) followed by lysis. Much of that inoculum would never reach the 
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nucleus and I would define that as ‘bad material’. For this experiment to be successful the ratio of 
‘good’ to ‘bad’ material needs to high enough that MS based techniques or Western Blot can pick up 
the difference between wild-type and VP1-2ΔNLS capsids. 
There are probably two options where ‘good material’ could be isolated; either during  their way 
through the cytoplasm but prior to docking at the nuclear pore or once bound at the nuclear 
membrane. A major factor complicating the first option is that the time and place where capsids pick 
up nuclear transport factors and how many do so eludes the scientific community. Recent data  
suggested that this might happen late during entry, potentially immediately prior to nuclear docking, 
since defective VP1-2NLS capsids can move along microtubules to accumulate in a juxta-nuclear 
position near the MTOC (Abaitua et al. 2012). This means the time frame to obtain ‘good material’ 
would be rather short. This could be a significant problem since the uncoating and migration towards 
the MTOC for the majority of capsids would have to be synchronous. To achieve some level of 
synchronicity infection can be done on ice. When the temperature is raised virions fuse more or less 
synchronously. However, this cooling procedure shatters the microtubule network.and re-assembly 
will almost certainly not be synchronous in every cell. Secondly, once the cytoskeleton is functional 
again some capsids will take substantially longer than others to navigate the cytosol and many will not 
get there. Thus it would be very difficult to obtain sufficient ‘good material’. 
Although importin-β localises to the cytosol, a very recent report found importin-β to form part 
of the NPC permeability filter within the central channel (Lowe et al. 2015). If capsids were to recruit 
importin-β at the nuclear pore, the time window for capsid isolation would be longer than in the just 
described scenario, since capsids were found to remain bound to nuclear pore for up to 6 hpi 
(Batterson et al. 1983). This would allow isolation of more uniform material (i.e. all capsids at the 
nucleus) while removing most of the ‘bad capsids’ that were not bound at the nucleus. However, 
although importin-β was shown to be required for nuclear docking (Ojala et al. 2000), it is unknown 
whether would be required for this prolonged attachment. I believe that, if the attachment is that 
strong, it would pose a considerable challenge to isolate these capsids. 
(iii) Stripping virions and using them as ‘bait’  
What can be done to improve the ratio ‘good’ to ‘bad’ capsids? I would argue that during natural 
infection a susceptible cell does not give up without putting up a fight. Capsids will be diverted into 
dead-end pathways or get degraded. Thus to increase the ‘good’ material I have to artificially bypass 
these cellular traps. To achieve this, one could envisage using whole capsids extracted from virion 
preparations. These can subsequently be used as an affinity matrix to recruit cellular binding proteins. 
Several groups have used a stripping approach using mild extraction buffers which allowed interactions 
with cellular proteins (Radtke et al. 2010; Wolfstein et al. 2006; Ojala et al. 2000). The methods 
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involved multiple rounds of ultracentrifugation and resuspension steps and used sodium or potassium 
based buffers (depending on the assay). These were designed to mimic de-envelopment (detergent) 
and de-tegumentation (achieved through salt). The resulting capsids were subsequently shown to 
retain interaction with several proteins including microtubule motors. Because of the ease of obtaining 
sufficient ‘good’ capsids that retained interactions with proteins that are important during entry, I 
chose to use a similar approach. The challenge will be to balance the use of chemicals to achieve a 
level of de-tegumented capsids that would be proficient at interacting with the nuclear transport 
machinery. 
Herein, I present a simple one step protocol, termed SIEVH (Simultaneous Incubation and 
Extraction of Virus in Host) assay, to find capsid binding partners. For this approach to work the virion 
envelope has to be dissolved and most tegument should be removed. To achieve this two approaches 
were employed. (a) Purified virions were stripped using gentle extraction buffers (Radtke et al. 2010; 
Wolfstein et al. 2006) containing non-ionic detergents and different salt concentrations In this 
‘uncoating’ scenario I explored the effect of ionic strengthon the removal of tegument proteins. The 
aim was to reduce the protein layer without removing the inner tegumentproteins VP1-2, pUL37 and 
pUS3, which are thought to remain attached during the early entry processes. (b) De-tegumentation is 
not thought to be a passive process which is caused by loss of the envelope but is contributed to by 
cellular factors and the reducing milieu. For example, many of the tegument proteins are targets of 
cellular kinases, proteases or connected by disulphide bridges. Thus I also explored the effects on 
capsid constitutionof cellular proteins. For this, cells were extracted in commonly used IP buffer but 
without ionic detergent (e.g. using RIPA containing only TX-100 but not SDS or deoxycholate). 
 
5.2.2.2 Effect of salt concentration on capsid constitution 
As elaborated above I decided to use the virion stripping approach. For this, concentrated virion 
preparations will be subjected to different extraction buffers for a set amount of time on ice. This 
should solubilise the envelope and some tegument proteins but leave the capsid intact. In turn, I 
attempted to sediment these capsids using a 45 min high speed centrifugation step. Only capsid-bound 
material should co-sediment during this procedure whereas solubilised proteins remain in the 
supernatant. The presence of representative capsid, tegument and envelope proteins in the different 
fractions will be tested by Western blot and silver stain. 
Standard extraction in PBS containing physiological salt concentrations and oxidising conditions 
showed near complete solubilisation of envelope protein gB and some other glycoproteins (Figure 
28A/B, lane 1 and 2, buffer 1 and Figure 29, lane 1, blue arrowhead) after 15 min which was slightly 
improved with another 45 min of incubation (Figure 28B). As judged from the silver stain the extraction 
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caused the release of a lot of virion proteins (Figure 29, lane 1, red arrowheads). The major capsid 
protein VP5 (Figure 29, lanes 1 and 2) was present only in the pellet giving rise to a strongly stained 
band around 170 kDa. The minor capsid component pUL25 (Figure 28A/B, lane 1/2), which anchors 
VP1-2 to the capsid, was also detected almost exclusively in the pellet fraction at both time points. This 
indicates that capsid integrity was undisturbed generally and also meant VP1-2 remained firmly 
attached to the capsid (Figure 28A/B and Figure 29, lanes 1 and 2). Most of its binding partner pUL37 
was also found in the pellet at both time points (Figure 28A/B and Figure 29, lanes 1 and 2). Only a 
small percentage was found in the soluble fraction (Figure 28A/B, lane 1), which implies that at 
physiological salt concentrations both VP1-2 and slightly less so pUL37 remained firmly attached to 
capsids. The other VP1-2 binding protein VP16 appeared to be released to some extent as judged by 
the bands in lanes 1 and 2. However, the amount of VP16 per virion is much higher than that of pUL37 
and the ratio between pelleted and solubilised VP16 was much smaller than the ratio of pelleted and 
solubilised pUL37, which suggests weaker binding of VP16 to VP1-2. The tegument proteins ICP4 and 
VP22 appeared to withstand isotonic extraction since both were recovered almost fully in the pellet 
fraction (Figure 28A/B and Figure 29, lanes 1 and 2). Again, time had little to no effect on the interaction 
of ICP4, VP16 or VP22 with capsids in buffer 1. In fact, time appeared to be at most a minor factor for 
solubilisation of outer tegument and thus could be limited to 15 min. 
Higher concentrations of NaCl (Figure 28A/B and Figure 29; lanes 3/4; buffer 3) may remove 
unwanted tegument proteins but could also be deleterious to capsid integrity since it would weaken 
ionic interactions. At first glance all proteins, except for gB, which was almost completely released in 
buffer 1 already, were more affected by increasing ionic strength of the extraction buffer as judged by 
Western Blot (Figure 28A/B). This was slightly more difficult to judge using silver stained SDSPA-gels, 
although there was evidence that at least three major bands that were abundant in the pellet fraction 
in buffer 1 were reduced or almost absent from the pellet recovered from buffer 3 (Figure 29; lanes 
3/4, orange arrowheads). This effect was not increased using salt concentrations as high as 1M (Figure 
30A, see buffer 6). While VP5 content (Figure 29, lane 4) was not affected by high salt concentrations 
the minor capsid protein pUL25 and slightly more so parts of the inner tegument, represented by 
pUL37 and ICP4, appeared affected by salt, although most of the three proteins still remained in the 
pellet. The slight release of pUL25 points to some disturbance of the capsid but this should be very 
limited since capsids were found to remain intact in similar extraction conditions (Wolfstein et al. 2006; 
Radtke et al. 2010) and only very harsh extraction conditions using guanidium hydrochloride were able 
to cause the release of viral DNA from capsids (Newcomb & Brown 1994). VP1-2 was also found to be 
released at a very low level compared to buffer 1 (Figure 28, see S3). This was probably not surprising 
since it binds to capsids via pUL25. The ratio of pelleted to solubilised bands for VP1-2 was also very 
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similar to that found with pUL25. The effect on capsid and inner tegument proteins could not be 
detected by silver stain due to limited sensitivity of this technique. For the outer tegument protein 
VP16 the ratio of P3 to S3 was found to be increased compared to buffer 1 (Figure 28A/B and Figure 
29, lanes 3 and 4, red/orange arrowhead at 58 kDa) indicating that this protein was released a bit more 
and might thus be interacting more weakly. In comparison pUL37, the other VP1-2 binding protein, 
was largely retained in the pellet. VP22 was similarly affected by ionic strength and I would say it was 
the most sensitive component tested in this assay since almost no release was observed in buffer 1. 
This places both VP22 and VP16 into the outer tegument category. 
To assess whether some proteins might just stick to precipitating capsids I attempted a higher 
stringency purification using different salt concentrations (Figure 30A). For this the procedure was 
repeated almost identically just instead of simply pelleting capsids I layered them onto a 35% sucrose 
cushion to get better separation of the soluble and pellet fractions. Only proteins whose interaction 
was strong enough to withstand the force of precipitation through the heavy sucrose would be 
sedimented with capsids. The soluble fractions clearly show that 500 mM and 1 M NaCl differed very 
little in their effects on solubilisation. The only noteworthy point was that recovery dropped 
significantly using the cushion whereas qualitatively there were no differences compared to the 
conventional sedimentation. In fact, this would only mean I would have to significantly increase the 
virion input to practically obtain the same result. 
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Figure 28 Effects of time, salt concentration, reducing milieu and cellular proteins on tegument and capsid components. 
Purified virions were extracted for (A) 15 or (B) 60 min using a PBS buffered solution containing 0.5% Triton X-100, protease 
inhibitors and 137mM NaCl as standard (buffer 1). The other buffers were additionally fortified as follows: Buffer 3 contains 
500mM NaCl, buffer 4 contains 10mM DTT, buffer 5 contains approximately 1mg/ml of cellular protein. Lysates were 
subsequently centrifuged at 25,000 rpm for 45 minutes. Solubilisation and capsid integrity were tested by Western blotting 
with antibodies against representative proteins for the envelope (gB), outer tegument (VP22, VP16, ICP4), inner tegument 
(VP1-2, pUL37) and capsid (pUL25). S = soluble fraction; P = pellet after ultracentrifugation; number refers to buffer (e.g. 
P3 = capsid pellet of extraction with buffer 3). Approximately 10x more equivalent fractions were loaded for pellet 
compared to soluble. 
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5.2.2.3 Effect of reducing milieu on capsid consitution 
A previous report suggested that the reducing potential of the cellular milieu contributes to 
removal of certain tegument proteins from the capsid. To mimic this effect I supplemented buffer 1 
with 10 mM dithiothreitol (DTT), which effectively reduces disulphide bridges between proteins 
(Newcomb et al. 2012). This treatment (Figure 28A/B and Figure 29, lanes 5 and 6) had little effect on 
the composition of the pellet as judged by Western blot or silver stain. That is, the ratio of band 
intensities between the pelleted and solubilised fractions was comparable to that of buffer 1. In fact, 
it would have been very challenging to find any difference on a silver stained PA-gel. The only protein 
that could be modestly solubilised was VP22, which was only detected using Western Blot (Figure 28). 
This does not mean that other tegument proteins were not affected by DTT but it certainly suggests 
that ionic strength was better at removing outer tegument than reducing milieu alone. 
 
5.2.2.4 Effect of cellular proteins on capsid constitution 
Besides reducing power the cytoplasm contains cellular proteins which could through 
phosphorylation and dephosphorylation, limited proteolysis and/or competition for binding sites 
release some tegument from capsids. To account for this, I incubated virions in buffer 5 which 
contained all cellular proteins. Briefly, as in a simple IP, HEK293 cells were solubilised with an extraction 
buffer (here buffer 1). After 30 minutes of extraction, the cellular debris were removed and the 
supernatant recovered. This mixture of cellular proteins was designated buffer 5. When this cocktail 
was added to virions (Figure 28A/B and Figure 35, lanes 7/8), capsid integrity was undisturbed as 
judged by band intensity in the pellet fraction of the capsid components VP5 or pUL25. Recovery was 
comparable to buffer 1. Strikingly, VP1-2 and even more so pUL37 appear to be preferentially retained 
on the capsids as evidenced by Western Blot (Figure 28A/B). For pUL37 the band intensity in the soluble 
fraction (Figure 35A/B, lane 7) appeared much reduced. This might not have been visible for VP1-2 
since the levels released in buffer 1 were already not detectable (lane 1). These data suggest 
stabilisation of the interaction between capsids and VP1-2 and pUL37. While VP16 appeared 
unaffected by cellular proteins, the VP22-capsid interaction was less stable (lanes 7/8) compared to 
extraction in buffer 1 which points to a role of cellular factors in selective removal of some outer and 
retention of inner tegument proteins. For this buffer, silver stain cannot yield interpretable 
information on removal or retention of most virion components due to the amount of cellular proteins 
present in the soluble fraction. However, the fact that the banding pattern of the pellet in lane 8 (Figure 
29) did not change grossly indicated that capsids did not randomly co-precipitate cellular proteins. In 
fact only a few bands (green arrowheads, Figure 29) were selectively precipitated with capsids. These 
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bands probably represent cellular binding proteins. This suggests that, using this method, it would be 
possible to identify cellular binding proteins.  
 
 
Figure 29 Effects of different extraction conditions on the protein composition of capsids. 
Protein profiles were assessed with silver stained SDS-PA gels. Purified virions were extracted using the same buffers as 
described for Figure 28. Capsid components VP5, pUL25, pUL6, pUL17, VP19C and VP23, and selected tegument proteins 
(VP1-2, pUL37, ICP4) and glycoprotein gB are labelled. Blue (examples of solubilised glycoproteins) and red (examples of 
solubilised virion components) arrowheads demarcate protein bands that were released during the extraction procedure. 
Orange arrowheads (examples of solubilised outer tegument component) demarcate protein bands with altered band 
intensity compared to standard extraction (buffer 1). Green arrowheads demarcate additional bands, potentially of cellular 
origin, which were co-precipitated with capsids. Cell extract without virions (equivalent to buffer 5) and the resulting 
ultracentrifugation pellet (no virions) are also shown (last two lanes). 
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5.2.2.5 Effect of potassium on capsid composition 
The above assays were looking at the standard co-IP conditions usually used to extract proteins 
or to look at protein-protein interactions. However, they still did not truly recapitulate cellular 
conditions subsequent to membrane fusion. Besides reducing milieu and proteins the cellular milieu 
also comprises potassium rather than sodium (Lodish et al. 2008). In fact some microtubule interaction 
studies specifically use potassium based buffers at a slightly lower pH of 6.8-7 (Radtke et al. 2010). To 
exclude potential extraction artefacts caused by the choice of buffer, the extraction procedure was 
repeated using a PIPES based buffer containing physiological [KCl] (137 mM) and a pH just below 7 
(Figure 30B). A direct comparison of the pellets obtained by extraction-centrifugation in buffer 1 (PBS-
NaCl) and buffer 7 (PIPES-KCl) (compare lanes 3 and 8) showed that the protein profiles looked 
comparable, although it appeared as though the KCl buffer increased the ratio of capsid components 
to major capsid protein VP5 (strong band at approximately 170 kDa) since the staining intensity 
appeared to increase in lane 7 (Figure 30) while VP5 was slightly reduced (compared to lane 3). In 
contrast, the amount of VP1-2 was reduced probably reflecting the lower amount of capsid protein 
VP5 recovered. Moreover, VP1-2 was probably also released during extraction since it was present in 
the input in lane 6 (reasonably strong band 2 mm from the top of gel). Addition of cellular proteins 
(lanes 5 and 10) to buffers 1/7 gave rise to similarly complex profiles with very few significant 
differences. Of note was that VP5 and VP1-2 appeared somewhat more abundant, which probably 
reflected a slightly increased amount of input virions. Interestingly, one band of likely cellular origin at 
approximately 65 kDa is reproducibly found in pellets extracted in both conditions (green arrowheads). 
This band (at approximately 65 kDa) was of particular interest since it falls into the approximate size 
bracket for α importins. Only one obviously altered band was found using buffer 8 (same a buffer 7 but 
containing cellular proteins) compared to buffer 5 (Figure 30B, lane 10, red arrowhead) which 
separated between 170-200 kDa. This means that in different extraction conditions different cellular 
proteins could bind to capsids underscoring the importance of salt types in this kind of assay. To get 
the most out of this technique both conditions likely have to be pursued in parallel. 
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Figure 30 Effect of high stringency extraction and purification, and potassium on virion extraction. 
(A) Virions were extracted with buffers 1, 3 and 6 (1M NaCl) as in Figure 29. The extract was either sedimented directly or 
through a 35% sucrose cushion which only allows dense protein ensembles to sediment. (B) Virions were extracted as 
before in standard buffer 1, buffer 5, buffer 7 (PIPES-KCl) and buffer 8 (PIPES-KCl containing cellular proteins). Red 
arrowhead demarcates an additional band of capsid bound protein likely of cellular origin which was only identified in 
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buffer 8. The green arrowheads indicate the position of a reproducibly co-precipitated protein band of likely cellular origin. 
IN = input before extraction; S = soluble left after extraction and sedimentation; P = pellet  
5.3 Discussion 
Through work conducted for this chapter I was able to set up systems to identify interacting 
proteins of the VP1-2 N-terminus and of capsids using in vitro pulldown approaches. Using inducible 
cell lines I found several bands interacting with NT3 and/or NT3ΔNLS that were absent from the 
control. Although I did not identify any nuclear transport factors, that could be involved in capsid 
docking at the nucleus, an E3 ubiquitin ligase, DTX3L, could be confirmed as a VP1-2 interacting protein 
by MS and Western Blot. Interestingly, cells treated with the DNA damaging agent doxorubicin lacked 
53BP1 recruitment to sites of DNA damage when NT3 and to a slightly lesser extent when NT3ΔNLS, 
were present. This points to a completely novel function of VP1-2 modulating the DDR. 
With a different approach I used a modified, one-step capsid extraction procedure to identify 
capsid interacting proteins. Distinct bands likely of cellular origin can be seen using silver staining which 
can now be analysed using MS. The data also showed that ionic strength and cellular proteins 
contribute to loss of certain tegument components during the extraction procedure, while at the same 
time cellular proteins were able to stabilise VP1-2 and pUL37 on the capsid. 
 
5.3.1 Identification of VP1-2 interacting proteins using NT3 
5.3.1.1 Technical considerations for the IP 
While the pulldown of NT3 was a good technique to find interacting proteins of VP1-2 there 
were several issues using this system which could be improved using a few tweaks to the procedure. 
(i) IP of NT3 worked poorly with very little recovery overall 
(ii) Importins were not identified using this technique 
(iii) Silver stained gels of the IP revealed many, potentially non-specifically precipitated 
protein bands 
(i) One major problem with the IP approach was the obviously low recovery of bait protein from 
the cellular input (Figure 24A, lanes 8-10). I would argue that the antibody was just not good enough 
or was in some way sterically hindered by the position of the tag. The simplest way to solve this would 
be to switch antibodies to a commercially available rabbit polyclonal anti-V5 antibody or using a 
combination of the two. 
(ii) Since my initial aim was to identify nuclear transport receptors that bind the NLS I have 
reflected on the procedure. Was it even possible to identify nuclear transport factors with this pairwise 
approach? Can the assay be improved? 
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The assay was designed to reveal NLS interacting proteins through comparing one protein with 
a NLS to one that lacked this region using a Silac-MS approach. In retrospect, the two bait proteins 
cannot be used in a pairwise comparison since they localise to different compartments. A closer look 
at the localisation results show that NT3 was mostly nuclear (Figure 23B), possibly sequestered in 
complexes with nuclear proteins that were not compatible with importin binding. Also, importins are 
liberated from their cargo immediately after transport (i.e. only transient interaction). This implies that 
the proportion of NT3 actively shuttling into the nucleus at the time of lysis was probably minor and 
thus problematic to find. This was reflected by a large amount of differences seen in the band profile 
(Figure 24B, lanes 2-4) and MS results comparing NT3 and NT3ΔNLS. In fact, 99 and 32 proteins 
preferentially binding NT3 or NT3ΔNLS were identified, respectively. 
To solve this problem of localisation, NT3 and NT3ΔNLS could be expressed in bacteria followed 
by purification. Using these purified proteins as bait it would theoretically be possible to identify NLS 
binding proteins using heavy and light cell extracts. This system would compare both bait proteins like-
for-like eliminating the confounding factor of localisation. 
Another group reported that another HEAT repeat containing protein, transportin-3, was only 
found to interact with its cargo if zwitterionic detergents were used. Thus the second tweak to this 
assay would be to include a suitable positive control (e.g. NT3 containing the SV40 lTag NLS) to check 
if it would at all be possible to precipitate any importins using the buffer conditions. 
Thirdly, to increase the proportion of NT3 that is actively shuttling I propose to insert a NES at 
the N- or C-terminus. This will allow nuclearly sequestered NT3 to re-enter the cytoplasm and to re-
start the cycle of nuclear transport. 
Fourthly, the size of the bait could be reduced to below the nuclear diffusion limit. This would 
eliminate the need for a NES and additionally prevent other non-relevant parts of NT3 (e.g. USP) 
forming complexes that could preclude importin binding. If only the NLS region were fused to GST, for 
example, its small size would allow free travel between compartments. GST is generally expressed well 
and the pulldown very efficient using glutathione coated beads. This would also solve the recovery 
problems. 
Finally, to improve the chances of importin binding individual constructs encoding for tagged 
importins could be co-transfected. This could be done in combination with any of the previous 
suggested tweaks. Additionally, if the transfected importin-α sub-types could harbour deletions of 
their Importin-β binding domain this would enable them to bind cargo but render them unable to 
release it since this step requires importin-β. 
(iii) It would be much easier to identify binding proteins if there would not be as many 
contaminating and potentially non-specific interacting proteins co-precipitating with NT3 (Figure 24B). 
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This could be achieved by either introducing a second elutable or cleavable tag to the N- or C-terminus 
(e.g. His tag). Briefly, bait proteins could initially be purified using a cobalt resin followed by washes 
with increased concentrations of sodium chloride (up to 300 mM) to increase stringency and elution 
with imidazole or cleavage by a specific protease (depending on the cleavage site, e.g. precision 
protease). In a second round of purification a mixture of anti-V5 antibodies could be used to re-
precipitate NT3 as before. Alternatively, I could use a similar approach with the unmodified NT3 
construct since the cell lines already exist. For this, in a first round of purification, NT3 can be 
precipitated using anti-V5 antibody followed by elution with excess V5 peptide supplemented into the 
wash buffer. The eluate would then be re-precipitated using an anti-USP antibody. 
 
5.3.1.2 NT3 interacting proteins 
VP1-2 is a multifunctional protein comprising multiple functional domains. At least four 
functional domains can be found in its N-terminus alone which include a ubiquitin specific protease 
(Schlieker et al. 2005), a VP16 binding site (Mijatov et al. 2007), a NLS (Abaitua & O’Hare 2008) and 
another binding site for pUL37 (Mijatov et al. 2007). VP16 and pUL37 binding are critical for secondary 
envelopment (Desai et al. 2001; Fuchs, Granzow, et al. 2002) while the NLS enables capsid docking at 
the nucleus (Abaitua et al. 2012). The USP on the other hand is mostly dispensable for HSV-1 in cell 
culture (Bolstad et al. 2011) but was shown to fulfil accessory functions, including antagonising innate 
immunity (Wang et al. 2013), that probably contributes to successful lifelong infection of its host. As 
such inactivating mutations dramatically reduce the ability of PRV to establish latency (Böttcher et al. 
2008). VP1-2 is a late protein and an N-terminal cleavage product was observed in infected cells, which 
can bind to ubiquitin (Kattenhorn et al. 2005; Schlieker et al. 2005). Since ubiquitination plays roles in 
proteasomal degradation it is conceivable that the USP facilitates stabilisation of target proteins in the 
wake of host protein shutoff. Ubiquitin, which can be linked into chains in multiple ways, fulfils 
additional signalling functions, usually to recruit other proteins to a particular ubiquitinated protein 
(reviewed in Bhoj & Chen 2009; Haglund & Dikic 2012; Jackson & Durocher 2013). Thus the USP could 
bind target proteins in order to modify their function. 
In my pulldown 199 proteins were identified that bound either NT3 or NT3ΔNLS or both but 
were not precipitated from a control cell line not expressing bait protein. Several interesting proteins, 
which cover functions in cell cycle control, transcription, mRNA metabolism, RNA binding, translation 
and DNA repair, could be identified with this screen. 
While HSV-1 might bring over 70 of its own proteins into the cell it certainly makes use of cellular 
factors to facilitate its replication (summarised in Tables 9-11). At least 4 proteins from the list of 
identified proteins were found to be required for HSV-1 infection, three seem to affect replication 
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negatively, two are upregulated in at least one setting and at least one more binds directly or via 
previously confirmed interacting proteins.  
Although there is no evidence that VP1-2 (or here NT3) modulates mRNA metabolism or 
translation during HSV-1 infection it is well established that, as part of the viral programme, HSV-1 
shuts off host protein production whilst maintaining viral protein synthesis (Roizman et al. 2013). 
Binding to proteins with annotated functions in cell cycle and DNA replication control which may 
contribute to the HSV-1 imposed cell cycle modulation (Flemington 2001) during infection to allow 
optimal replication of viral genetic material. 
An intriguing finding of the nuclear transport assay using GFP-R2 was that it localised to nuclear 
dots which looked like nucleoli (Figure 9A, panel III). Coincidentally, 32 proteins were found to bind 
nucleolar proteins. Upon closer inspection using a nucleolar localisation algorithm, the sequence 
around R1, specifically R5, resembles a nucleolar localisation signal. Since R5 was not required for 
nuclear localisation of NT6 (Figure 16B/C) but was essential for infection (Figure 18B) it would be 
intriguing to speculate that its nucleolar localisation, if a true phenomenon, might be one of the 
reasons why replication of HSV-1.VP1-2.ΔR5 was abolished. To test this, the rescue assay could be 
repeated with mutant NT6 comprising a different nucleolar localisation signal instead of R5 or in a 
different position in the background of ΔR5.  
 
5.3.1.3 NT3 interacts with DTX3L 
To validate that the MS did not erroneously identify certain binding partners I chose to follow 
up on DTX3L, an E3 ligase, that also bound to NT3ΔNLS (Table 9, Figure 27A, although weaker than 
NT3) and was separately verified in an excised band just below the NT3 band (Figure 24C). DTX3L was 
particularly intriguing since it and its binding partner PARP9 were found to be upregulated during HSV-
1 infection (Miyazaki et al. 2011) and through interferon signalling (Schoggins et al. 2011; Juszczynski 
et al. 2006) and DTX3L has both nuclear and cytoplasmic functions stimulating the DDR (Yan et al. 2009) 
and modulating the ESCRT pathway (Holleman & Marchese 2014), respectively. Both these pathways 
are likely required during HSV-1 infection. 
Since the anti-DTX3L antibody sample I used was not very good and the level of DTX3L in HEK293 
very low (Figure 27C/F) it would be required to repeat this reciprocal pulldown with a better antibody, 
in other cells that express more DTX3L (e.g. Hela) or using a tagged DTX3L. It would also be beneficial 
to know where the interaction site lies. If it binds to a region after the USP it is more likely to be specific 
and, more interestingly, might be unique to α-HVs or even HSV-1. The interaction site can be mapped 
initially using sequentially shorter constructs of NT3. However, it has to be remembered here, that 
DTX3L might not bind directly to NT3. The MS data revealed that PARP9 was recovered at similar levels 
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in the NT3 sample but to almost two-fold higher levels in the NT3ΔNLS sample. Since DTX3L and PARP9 
interact (Yan et al. 2013) NT3 might precipitate it via PARP9. 
What could the binding of an E3 ligase mean for VP1-2 function? The most obvious reason for 
DTX3L to bind NT3 could be to ubiquitinate it. It is conceivable that in that way VP1-2 stability is 
affected since USP activity protects VP1-2 from degradation (Bolstad et al. 2011). Secondly, screens of 
the cellular ubiquitome (as retrieved from Uniprot and Genecards) identified at least 5 C-terminal 
ubiquitination sites in DTX3L, which can be auto-ubiquitinated to increase its own E3 ligase function  
(Takeyama et al. 2003). Thus, the USP might de-ubiquitinate DTX3L to reduce its activity. Thirdly and 
most intriguingly, the USP might affect targets of DTX3L by either preventing them to bind to the E3 
ligase or by removing any attached ubiquitins immediately thereby inactivating particular pathways. 
This would not be a new mechanism since other cellular USPs can often be found in complex with an 
E3 ligase and quite often they reciprocally modulate each other’s activity or fine tune activity of ligase 
targets (reviewed in Ventii & Wilkinson 2008). 
 
5.3.1.4 Proposed activity of VP1-2 in altering the cellular DDR 
In addition to the pulldown studies that identified DTX3L (and PARP9) I was able to show that in 
the presence of NT3 (and slightly less so with NT3ΔNLS) 53BP1 foci formation in response to DNA 
damage was abolished. DTX3L and PARP9 are recruited to sites of DNA damage in PARP1 dependent 
manner and, once there, enable recruitment of 53BP1 through ubiquitination of Histone 4 at lysine 91 
(Yan et al. 2009). As DNA damage signalling and the interferon response increase during HSV-1 
infection, DTX3L and PARP9 are also upregulated (Taylor & Knipe 2004; Shirata et al. 2005; Mohni et 
al. 2010; Wilkinson & Weller 2004; Unterholzner et al. 2010; Juszczynski et al. 2006; Miyazaki et al. 
2011) and thus potentially contribute anti-HSV-1 effector functions. The USP could modulate nuclear 
DTX3L/PARP9 function and consequently the nuclear environment in favour of the virus by altering 
DTX3L activity or by selectively de-ubiquitinating its target proteins. The following paragraphs will 
discuss the literature around DTX3L functions, the DDR in HSV-1 infected cells and implications arising 
from interaction of NT3 with DTX3L. 
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Figure 31 Simplified schematic of one of the pathways leading to 53BP1 activation and how HSV-1 could potentially 
modulate this part of the DDR. 
Adapted from Yan et al. (2013) with further information gathered from Grady et al. (2012); Lilley et al. (2011); Min et al. 
(2010); Jackson & Durocher (2013); Yan et al. (2009). (A) As soon as viral DNA synthesis increases, the amount of unusual 
DNA structures and DNA damage does, too, leading to PARP1 activation. (B) This leads to PARP9 dependent DTX3L 
recruitment, which ubiquitinates itself and histones (including H4K91 mono-ubiquitination). This induces structural 
changes in nucleosomes causing methylation at H3K79 and H4K20 to get exposed. (C) 53BP1 and BRCA1 are recruited by 
these histone marks. Immediate early HSV-1 protein ICP0 induces PARG degradation which deregulates PARP1 and 
consequently DTX3L activity. (D) The late protein VP1-2 (as the N-terminal product NT3) could remove ubiquitin from 
DTX3L or H4K91 (or others) which abolishes 53BP1 recruitment to nascent viral DNA. Reducing DTX3L auto-ubiquitination 
could reduce its activity with the same outcome. 
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There are multiple pathways that lead to 53BP1 recruitment to sites of DNA damage. The 
schematic in Figure 31 explains the relevant 53BP1 recruitment pathway (Yan et al. 2013) and how 
HSV-1 might subvert it. This involves the direct recognition of DNA damage or other unusual DNA 
structures (e.g. stable ssDNA and non-B form DNA) by PARP1/2, whose activity has also been 
implicated in the immune response (Galbis-Martínez et al. 2010) and apoptosis (Yu et al. 2002), 
followed by auto-ADP-ribosylation (reviewed in Bürkle & Virág 2013). This transient modification is 
quickly antagonised by PARG (poly-ADP-ribose glycohydrolase) activity which cleaves poly-ADP chains, 
either releasing chains of different lengths or monomers of ADP (Min et al. 2010). The PARP9-DTX3L 
complex accumulates at activated PARP1 foci transiently which leads to ubiquitination of histones 
including at H4K91 (Yan et al. 2009). As a direct result chromatin structure is opened revealing 
constitutive modifications including H3K79 (H3K79me) and H4K20 methylation (H4K20me). In turn 
53BP1 and BRCA1 recognise the exposed modifications and accumulate to guide the decision of 
specific DDR pathways. 53BP1 supposedly promotes NHEJ while BRCA1 favours homologous 
recombination (HR) (Bunting et al. 2010; Nakamura et al. 2011). 
As soon as HSV-1 DNA enters the nucleus it faces the cellular machinery trying to silence 
expression of viral proteins and to set off a cascade culminating in the induction of an innate immune 
response. The DNA damage repair is not only pivotal to preserving cellular integrity during stress it is 
also part of the first line of defence against invading DNA. Intriguingly, HSV-1 inhibits NHEJ and 
homologous recombination (HR) but enhances ssDNA break repair (Schumacher et al. 2012). During 
HSV-1 infection DNA damage repair was found to be a two-edged sword with some part being required 
or beneficial while another was acutely anti-viral (Lilley et al. 2011; Taylor & Knipe 2004; Wilkinson & 
Weller 2004). Some parts of the DDR machinery are absolutely required for DNA replication 
contributing molecular functions such as helicase activity, dsDNA break and ssDNA protection and 
circularisation of genomes (Muylaert & Elias 2007; Lilley et al. 2005; Taylor & Knipe 2004; Wilkinson & 
Weller 2003; Placek & Berger 2010). Unsurprisingly, HSV-1 globally activates some DDR pathways to 
initiate and sustain an infection (Lilley et al. 2011; Taylor & Knipe 2004; Wilkinson & Weller 2004; 
Schumacher et al. 2012; Placek & Berger 2010; Mboko et al. 2012; Smith et al. 2014) For example it 
was shown that knock-down of γH2AX, the upstream signal for assembly of many DDR proteins, 
drastically reduced (Lilley et al. 2011) while ablation of NHEJ by deletion of Ku70 (Taylor & Knipe 2004) 
increased viral titres. DDR could cause inhibitory recombination events between the linear viral 
genomes which could be recognised as damage sites or could in fact enable replication (Smith et al. 
2014; Muylaert & Elias 2007). Additionally, DNA damage and interferon responses are inherently linked 
(Mboko et al. 2012) which could allow an infected cell to induce an anti-viral state. 
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Interestingly, the DDR is facilitated by a network of post-translational modifications which 
includes many different ubiquitination events (Huen & Chen 2008; Thomson & Guerra-Rebollo 2010) 
which the VP1-2 USP could potentially modulate. 
 
Figure 32 Simplified schematic of protein levels and PARP1 activity during infection. 
ICP0 is delivered into cells and transcribed very early on which leads to a steep rise in levels which plateau as immediate 
early transcription stops. ICP0 causes degradation of PARG and RNF8/168 proteins, which are involved in regulation of 
ADP-ribosylation and alternative 53BP1 recruitment, respectively. Since cellular protein synthesis is antagonised 
effectively their levels will not recover in the course of infection. With the onset of viral DNA synthesis DNA damage 
signalling is induced leading to PARP1 activation. VP1-2 levels only rise to very high levels after onset of DNA synthesis 
although a small amount is delivered into the cell with incoming virions. That means VP1-2 could modulate part of the DDR 
late on to maintain peak viral DNA synthesis. Information gathered from Min et al. (2010); Grady et al. (2012); Jackson & 
Durocher (2013); Roizman et al. (2013). Axes and levels not to scale. 
 
ICP0 is highly expressed early on (Jones & Roizman 1979; Honess & Roizman 1974) (see Figure 
29) and . During late infection the amount of viral DNA, DNA damage signalling and unusual DNA 
structures (e.g. concatemeric non-nucleosomal DNA) increase (Muylaert & Elias 2007; Schumacher et 
al. 2012; Grady et al. 2012). This leads to recruitment of PARP1 to replication compartments (Taylor & 
Knipe 2004) where it could activate the DDR through its ADP-ribosylating activity. ICP0 could 
inadvertently deregulate PARP1 activity through degradation of the regulatory protein PARG (Figure 
31C) (Grady et al. 2012). 
In this scenario DTX3L could be recruited in a PARP1-dependent manner (potentially to 
replication compartments but this needs to be shown) and marks the DNA by ubiquitinating target 
proteins. With increasing amounts of viral DNA (>6hpi for example) and increasing PARP1/2 activity, 
this may make viral DNA more prone to DTX3L induced 53BP1 foci formation. 53BP1 in turn favours 
NHEJ which contributes to the anti-viral response to HSV-1 (Taylor & Knipe 2004). In this model the 
de-ubiquitinating activity contributed by the N-terminus of VP1-2, expressed after onset of DNA 
replication (Figure 32), could modulate DTX3L activity. This could occur via reversion of auto-
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ubiquitination by DTX3L or by de-ubiquitination of its targets. This theory is in agreement with the 
localisation of a NT3-like fragment, which, if transfected into cells prior to infection, showed strong 
signal corresponding to the NT3-like fragment in nuclear domains which are devoid of cellular DNA and 
could be replication compartments (Calistri et al. 2014). 
To test the hypothesis that VP1-2 might augment replication via modulation of DNA repair it first 
needs to be established which parts of the cellular DDR are affected and how VP1-2 might alter DTX3L 
function. To map the interaction site within VP1-2 co-precipitations and functional 
immunofluorescence (53BP1 foci formation) with smaller versions of N-terminal VP1-2 can be 
performed. To check if USP activity is required these studies should also be performed with USP-
inactive N-terminal VP1-2 mutants. Additionally, the functional immunofluorescence analysis should 
be expanded to include various other DDR (including γH2AX, BRCA1, ATM, ATR, Ku70, etc.) which might 
reveal very specific (i.e. only 53BP1 affected) or more global modulation of the DDR.  
The second approach would look at HSV-infected cells comparing wild-type, USP-inactive 
mutants and ICP0-null virus. It would be worth introducing the USP-inactivating mutation (Bolstad et 
al. 2011) into a ICP0-null background, since ICP0 function is very dominant in cell culture systems. Since 
USP function in HSV-1 was previously shown dispensible for growth in cell culture it might require 
deletion of ICP0. Knocking out ICP0 makes the virus more susceptible to the effects of genome silencing 
and anti-viral factors (ICP0 functions reviewed in (Hagglund & Roizman 2004; Smith et al. 2011)) and 
reveal the potentially more subtle USP function. As DTX3L levels vary in different cells (Yan et al. 2009) 
and are increased by an immune response (Juszczynski et al. 2006) it will be worth including conditions 
such as interferon exposure and using cells with higher expression of DTX3L. For this experiment, I 
propose that DDR protein function in HSV-1 infected cells should be monitored using 
immunofluorescence. This can then be compared between the different virus mutants and correlated 
to the amount of virus released or viral DNA produced. 
The third approach, which should complement the other two, would look at cells lacking or 
overexpressing DTX3L and/or 53BP1. In these cells viral fitness can be evaluated using simple yield 
experiments or growth curves. Theoretically, overexpression of DTX3L might reduce viral fitness and 
viral DNA synthesis while knock-down should do the exact opposite. 
 
5.3.2 Identification of cellular capsid binding proteins 
With the preliminary work presented in this part I have shown that capsids that can be used for 
interaction studies can be obtained by simultaneous de-envelopment and de-tegumentation. Their 
tegumentation state, as judged by Western Blot against representative tegument proteins and silver 
stain profile, was influenced by salt concentration and cellular proteins but not by time of extraction, 
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reducing agents more stringent purification. Additionally, using a one-step extraction-binding 
procedure, partially de-tegumented capsids, that bound proteins likely of cellular origin, can be 
obtained from small scale virion preparations. This technique might thus be useful to identify cellular 
capsid binding proteins. 
To optimise a protocol to obtain capsids that could be used to identify the nuclear transport 
receptors involved in capsid docking at the NPC one question should be addressed first; what do 
relevant capsids look like? Thus far the exact composition of capsids at the nuclear pore is unknown. 
But from immuno-EM and microtubule binding studies it can be inferred that these should ideally lose 
the outer tegument (including VP16 and VP22) but retain at least VP1-2 and possibly pUL37 as these 
proteins can be found on naturally de-tegumented capsids (Granzow et al. 2005; Radtke et al. 2010; 
Wolfstein et al. 2006). There could be several ways to identify factors that allow capsid nuclear docking 
and in my opinion I have chosen the approach that would yield the highest chance of obtaining the 
‘right’ type of capsid to tackle this problem (explained in section 4.3.2.1). 
Briefly, nuclear capsid preparations are a good source of highly pure capsids but this requires a 
high amount of input material and purification (Radtke et al. 2010; Wolfstein et al. 2006). There is 
ongoing controversy where VP1-2 is added to the capsids (Radtke et al. 2010; Henaff et al. 2013) which 
may relate to sample handling or the cellular system of choice. This makes nuclear capsids a risky 
choice. Even more risky would be the isolation of capsids during natural infection since the exact time 
of recruitment of nuclear transport factors remains unknown. Additional problems with synchronicity 
of infection and the fact that many capsids never reach their destination make this endeavour a 
substantial challenge. In contrast, extraction of capsids in vitro circumvents many of these problems. 
For once all virions would contain the essential proteins VP1-2 and pUL37 and overall yield of the ‘right’ 
capsids will be much improved. However, this technique comes with its own challenges including 
stringency of extraction and multiple sequential purification steps. 
My extraction experiments showed that virions can easily be de-enveloped as indicated by loss 
of gB from the pellet fraction (Figure 34). In fact, it could be argued that envelope removal was slightly 
better than found in another study (Wolfstein et al. 2006). Moreover, capsid integrity was arguably 
undisturbed even at highest salt concentrations tested since almost all of VP5 (Figure 36A) and pUL25 
(Figure 34) were present in the pellet and mostly absent from the supernatant. While time and a 
reducing agent had no effect on solubilisation of most tegument proteins, high concentrations of salt 
and less so cellular proteins were able to induce partial de-tegumentation which was detectable by 
Western Blot (VP22) for both conditions and by silver stain for salt concentration only. This was in 
agreement with previous reports on salt susceptibility of tegument proteins. From the silver stained 
PA-gels it could be concluded that recovery was much better using a simple spin rather than a sucrose 
Biochemical analysis of VP1-2 binding partners 
 
 
- 175 - 
 
cushion. Remarkably, the omission of stringent purification did not increase non-specific binding 
(retention) of viral proteins on capsids (Figure 36A). None of the extractions removed much of VP1-2 
indicating that theoretically all these capsids should be able to engage nuclear transport factors 
relevant to NPC docking. However, it had been suggested that capsids extracted at salt concentrations 
below 500mM cannot engage microtubules (Radtke et al. 2010; Wolfstein et al. 2006) indicating steric 
hindrance or occlusion of binding sites by outer tegument. This in turn could indicate that the capsids 
obtained by extraction in buffer 1, 4 and, most importantly, 5 might not be useful for binding studies. 
Although these previous studies found microtubule interactions with capsids extracted in high salt 
(500 mM) they were not able to identify nuclear transport factors. 
A notable modification to the protocol of previous reports analysing capsid binding proteins was 
the use of simultaneous de-envelopment, de-tegumentation and incubation with cellular proteins 
combined with the omission of stringent purification steps (gradients or cushions). I would argue that 
the capsids I pelleted using my one-step approach were very similar to those found in a previous study 
(Wolfstein et al. 2006) as judged by Western Blot. The capsids obtained using the SIEVH protocol 
contained modestly more VP22 but similar levels of other tegument proteins. Most strikingly, VP1-2 
and pUL37 retention was improved compared to standard extraction in the absence of proteins in 
agreement with the notion that cellular proteins stabilise certain capsid components (Henaff et al. 
2013). To make more definitive statement it would be interesting to expand the study of the above 
described capsids. This would involve testing for the presence of more tegument proteins using 
immunoblots. Interestingly, cellular proteins co-sedimented with capsids extracted in cellular lysate. 
There were several distinct bands that were absent from pellets extracted in buffer 1 (Figure 36B). 
Slightly different results were obtained using potassium rather than sodium which could indicate that 
more physiological conditions might be superior. 
Whether the capsids obtained with the SIEVH assay are relevant is unknown. But what I have 
learnt was that these capsids could reproducibly bind cellular proteins which now could be identified 
using MS. The results from these studies will guide further optimisation of this system. Several aspects 
of the extraction could still be modified to potentially improve tegument removal. 
Increasing the temperature would be an obvious choice since on ice some tegument structures 
might be retained (low temperature slows/inhibits many processes including proteolytic degradation 
and modifications, and it lowers free energy which might prevent de-tegumentation). VP1-2 binding 
partner pUL37, for example, was released only at 37°C but not on ice in a previous study (Newcomb & 
Brown 2010; Henaff et al. 2013; Cardone et al. 2012). Although pUL37 is an inner tegument component 
it is not absolutely required for capsids to dock at the nucleus (Roberts et al. 2009), suggesting that 
increasing the temperature might improve the SIEVH protocol. However, increasing the temperature 
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also increases degradation of proteins by cellular proteases. Thus the timing and concentrations of 
protease inhibitors might have to be adapted. 
Further studies should combine the tweaks of the extraction conditions with those mentioned 
for the NT3 pulldown approach (exogenous expression of importins including their mutants lacking the 
importin-β binding domain). The capsid approach is more suitable for Multiplex Silac-based MS analysis 
since wild-type and VP1-2ΔNLS capsids can be directly compared in their ability to bind cellular 
proteins. Briefly, mutant and wild-type capsids could be produced in cells labelled with two different 
isotopes (‘light’ and ‘heavy’). These capsids could be extracted in two different labelled cellular lysates 
(both labelled with different ‘intermediate’ amino acid isotopes). After the extraction and incubation 
both samples are mixed and purified as before. The pellets could subsequently be processed for MS 
analysis. This would yield a comparative binding profile which in theory should allow identification of 
NLS binding proteins. 
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6 Constructing a VP1-2 ΔNLS mutant expressing GFP-VP16 to 
study infected-cell fate 
6.1 Background 
Cells in a monolayer rarely act as isolated individuals but rather are interconnected via tight 
association between their cellular membranes which enable them to exchange factors and relay signals 
quickly thus allowing a monolayer to act in a concerted manner. Our group has previously shown that 
HaCaT cells (immortalised human keratinocytes) move as a group rather than single cells and 
uninfected cells are drawn into a developing plaque (Abaitua et al. 2013). To understand what is 
happening in the infected cells and in the adjacent non-infected cells it is vital to be able to follow them 
‘live’ over time. The NLS virus is the ideal tool to study the adjacent (non-infected) cells as in this case 
these would not get infected. To allow for live cell studies of what happens in different cell lines, I 
created a VP16-GFP fluorescent derivative of the K.VP1-2.NLS virus. VP16 was chosen because it has 
been shown to function in the presence of a large tag, such as GFP, and it will be incorporated into 
nascent virions (Boissière et al. 2004; Heine et al. 1974; Newcomb et al. 2012). As it is expressed in 
high amounts late on it one can follow productively infected cells over time. To obtain a recombinant 
virus viral DNA and plasmid DNA (GFP-VP16) were co-transfected to allow homologous recombination 
to occur. Recombinant virus is subsequently serially purified on complementing cells until only GFP-
positive plaques are formed. 
6.2 Results 
6.2.1 ΔNLS.GFP-VP16 replication is modestly affected by the 
presence of GFP 
To confirm that I have obtained the correct recombinant virus I initially checked whether the 
fusion protein was expressed. For this, RSC and RSCUL36 cells were infected with high MOI of both the 
parental virus (VP1-2.ΔNLS) and one of the purified recombinant virus clones. Parental virus expressed 
a protein of 56kDa (predicted size) that could be detected with specific monoclonal antiserum (Figure 
33A, lanes 8 and 11). This band was essentially absent from the recombinant virus (lanes 9 and 12). 
Expectedly, a band reacting with the same monoclonal antiserum was found to migrate at a position 
approximately 30kDa larger than VP16 indicating the presence of the GFP-VP16 fusion protein. To 
confirm this the same samples, separated on another SDS-PA gel, were blotted and the membrane 
probed with anti-GFP antibody (Figure 33A, lanes 1-6). The only observed band (lanes 3 and 6) had 
approximately the same molecular weight as that observed with anti-VP16 antibody (lanes 9 and 12). 
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Both mock infected cells and cells infected with parental virus lacked an anti-GFP reactive band (lanes 
1, 2, 4 and 6). In conclusion, these data suggest that the correct virus was obtained. 
Adding a substantially sized tag to a protein usually interferes with function at some level. 
Additionally, it could be possible that the combination of VP1-2.NLS and VP16-GFP could affect virual 
fitness more than expected. Therefore, I initially looked at the ability of the recombinant virus to 
spread cell-to-cell which can be monitored by measuring plaque size (Figure 33C). All plaques were 
measured on RSCUL36 or HS30 cells as NLS and its derivative ΔNLS.GFP-VP16 do not form plaques on 
non-complementing cells. NLS mutant virus shows plaque formation was rescued by the 
complementing RSCUL36 line as plaques were of similar size as for NLS revertant virus (NLS.R). On 
complementing Vero cells (HS30) NLS virus also forms plaques, however, their size was modestly 
reduced compared to wild type (ΔNLS.R). This could be caused by different levels of complementing 
wild-type VP1-2 protein (here supplied in trans from the cellular genome) which competes with the 
mutant NLS form (encoded for by the virus genome) for capsid occupancy. It may require a certain 
critical ratio of wild-type VP1-2 to VP1-2NLS which might be lower in HS30 compared to RSCUL36 
cells. Expectedly, NLS.GFP-VP16 plaques were less than half the size of ΔNLS.R and ΔNLS viruses on 
RSCUL36. On HS30 plaque size of the recombinant was still around half that of its parental virus but 
compared to wild type (ΔNLS.R) the effect was exacerbated with plaque size around 75% decreased. 
This indicated a fitness cost of GFP beyond the ΔNLS mutation (Figure 33C). 
To check whether the reduction in plaque size was due to the combination with the ΔNLS 
mutation I used two previously validated strain 17 recombinant viruses, comprising VP16 tagged at 
either the N- or the C-terminus, as controls (Figure 33D). This confirmed that adding a tag, such as GFP, 
to VP16 reduced plaque size up to two-fold in non-complementing cells. This defect was not specific 
to RSC cells which I used to create the recombinant virus, since a similar reduction of plaque size also 
occurred in Vero cells using both fluorescent VP16 fusion viruses (Figure 33D). Since these two wild-
type viruses contain VP16 tagged at opposing termini it suggests that the position of the tag did not 
matter either.  
Another measure of viral fitness compares virus yield during one round of replication (single 
step growth curve). For this virtually all cells in a dish were infected (MOI of 5) and released virus titres 
determined over the course of 24 h. Comparing ΔNLS.GFP-VP16 to its parental VP1-2ΔNLS virus 
showed a reduction in yield of around one log unit (Figure 33B). Despite the large reduction in virus 
titre, reasonable amounts of infectious virions could still be recovered, which compared favourably 
with failure to obtain infectious virus from non-complementing cells. In conclusion, the modest 
reduction in plaque size and viral yield appeared to be a normal phenomenon when VP16 function as 
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a transcription factor was impaired. For the purpose of creating viral stocks this modest impairment 
was of low significance since I was able to obtain viral stock with reasonably high titres. 
 
Figure 33 Characterisation of ΔNLS.GFP-VP16 recombinant virus. 
(A) Western blot showing the presence of GFP-VP16, in cells infected at high MOI with the recombinant virus. Cells were 
lysed in Laemmli buffer and fusion protein was detected using anti-VP16 (right) or anti-GFP (left) (B) Single step growth 
kinetics comparing ΔNLS.GFP-VP16 and ΔNLS viruses. RSCUL36 cells were infected with high MOI (5) and total virus 
harvested at the indicated time points. Yield was titrated on RSCUL36 cells. (C) Plaque size comparison of wild type (ΔNLS.R 
= revertant), ΔNLS and ΔNLS.GFP-VP16 in two complementing cell lines, RSCUL36 and HS30. Plaque were stained with 
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immunoperoxidase. Error bars represent standard deviation of 20-50 plaques. (D) Plaque size comparison to check how 
tagging VP16 N-terminally or C-terminally affects replication of another wild-type strain (17). Two non-complementing cell 
lines were infected at low MOI and plaques stained with immunoperoxidase. Error bars represent standard deviation from 
20-50 plaques. 
6.2.2 ΔNLS.GFP-VP16 virus does not spread in normal cells 
To study the defect of the ΔNLS virus and the behaviour of infected cells I could now use the 
GFP-VP16 recombinant virus (Figure 34B). To illustrate the defect of the ΔNLS virus I have fixed and 
visualised a plaque assay of the ΔNLS parental and revertant viruses. For this complementing cells were 
infected at high MOI (>5) with virus that had been produced in complementing cells. Thus they carry a 
mixture of wild type and mutant VP1-2 on their capsids. This allowed all cells to become infected and 
consequently replicate the virus. This is illustrated in Figure 34A (first well of ΔNLS) where little crystal 
violet stain was retained by the fixed cells (i.e. they are dead). Upon further dilution of this virus stock 
the ΔNLS defect became apparent and plaques were only visible for the revertant ΔNLS.R (Figure 34A). 
When RSC cells were infected with ΔNLS virus it consistently looked like virus might be able to 
form small cell clusters that stained stronger with crystal violet (Figure 34D, white arrows).Thus, in 
order to find out what happens to infected cells and to see whether virus can actually spread to 
neighbouring cells, four non-complementing cell lines (HaCaT, RSC, RPE-1 and Vero) were infected with 
the recombinant virus (intermediate MOI of 0.2). The complemented virus (made in RSCUL36 cells) 
was able to infect cells (Figure 34B, white arrows) but then infection failed to progress in most non-
complementing cells (see HaCaT, RPE-1 and Vero), whereas in the complementing cell line (Figure 34C) 
it could spread to form a plaque. Even after 72 h no progression was observed in HaCaT, RPE-1 and 
Vero cells even though this should have been sufficient time to form large plaques (compare to Figure 
34C, 72 hpi). In fact, over time infected cells ‘rounded up’ but appeared to remain loosely attached, 
somewhat on top of the monolayer, for up to five days. This confirmed that through serial passage in 
complementing cells the ΔNLS mutation was still present in the recombinant ΔNLS.GFP-VP16 virus 
(Figure 34B). A closer look at the RSC cells, though, revealed that some virus spread might have 
occurred since several cells showed a positive signal for GFP (Figure 34B, RSC 48 h, 72 h and 120 h). 
These clusters increase in size very slowly, however, and neither the morphology nor the signal 
intensity of GFP resemble that of a typical plaque (Figure 34C).  
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Figure 34 Analysis of spread and plaque formation of ΔNLS.VP16-GFP recombiant virus over time. 
(A) RSC monolayers were infected with increasing dilutions of either ΔNLS or ΔNLS.R virus (from  right to left decreased by 
1 log unit per well) and the wells fixed and stained at 3 dpi with 1% formaldehyde and crystal violet. (B) Monolayers of 
non-complementing cell lines were grown to almost 90-100% confluence in 24 well plates and subsequently infected with 
0.2 PFU/cell or 0.04 PFU/cell. Three fields with a reasonable amount of infection were followed for each cell line over five 
days and images of the same field were collected over 5 days. (C) A representative example of a ΔNLS.GFP-VP16 plaque on 
complementing RSCUL36 cells at 3 dpi. (D) Crystal violet stained RSC cells infected with ΔNLS virus showing small intensely 
stained cell clusters (white arrows). 
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6.2.3 Using NLS.GFP-VP16 as a tool to study the infected cell 
fate 
I have already shown that cells infected with the KΔNLS.VP16-GFP virus appear to remain part 
of the cellular monolayer up to 120 hpi but it was unclear whether these cells were viable and what 
brought about cluster formation. It is conceivable that the defect of the ΔNLS mutation might have 
attenuated the recombinant virus affecting to outcome of infection (e.g. no cell death). Following 
ΔNLS.GFP-VP16 virus could yield valuable information on how infection progresses in individual cells.  
Thus to follow up on the curious finding of cluster formation in RSC cells and to study in more 
detail the live dynamics of virus infection, RSC cells were infected with ΔNLS.VP16-GFP (ΔNLS.VP16-
GFP) virus at an MOI of 0.001. Three individual fields were imaged in phase and FITC channels every 
20 min from 24-78 hpi and the images were collated into short movies. Two types of infected cells 
could be observed. Type 1 cells (movie 1, see attached CD) were already rounded up by approximately 
24 hpi, as would be expected from infected cells. These cells appeared to be dead or dying and clusters 
did not originate from these cells. Type 2 cells, however, were not rounded but appeared somewhat 
healthier as judged by their general ability to retain attachment to the substratum. In fact, they 
appeared to ‘spread’ fluorescence to surrounding cells by an unknown mechanism (movie 2 and 3, 
both parts). As judged from the still images taken between 3-5 dpi (Figure 34B, RSC) the plaques 
appeared unconventional, with some uninfected (GFP-negative) cells in the centre of the cluster. The 
observed spread could have been casued by cell division, although, if you follow the time course frame-
by-frame it revealed that the infected cell did not undergo mitosis. In movie 2 (part 1) the infected cell 
appeared to contain large vacuoles and a part of this cell containing some of these vacuoles had 
become separated from the main body of the cell. Intriguingly, parts of the infected cells seemed to 
have fused with neighbouring cells or parts of cells were taken up by uninfected cells through processes 
possibly involving endocytosis or macropinocytosis (movie 2, part 2 and movie 3, parts 1 and 2). 
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6.3 Discussion 
The work in this chapter lead to the generation of a derivative of the VP1-2ΔNLS virus that 
expresses a fluorescently tagged tegument protein, GFP-VP16. This was achieved through 
recombination of exogenous DNA with the viral genome in infected cells. The recombinant virus 
expressed a protein approximately 30 kDa larger than the parental ΔNLS virus which could be detected 
with GFP and VP16 specific antisera. Adding a large tag to VP16 modestly decreased viral fitness of the 
recombinant and of two other wild type strains indicating the function of VP16 was modestly affected 
by the presence GFP. Cells infected with GFP-VP16 virus could be followed in cell culture for at least 
five days. Interestingly, the defective recombinant virus appeared to retain some limited infectivity in 
non-complementing RSC cells forming GFP positive clusters. Time-lapse fluorescence microscopy 
revealed an intriguing mechanism of ‘spread’ of viral components to neighbouring cells which could 
not be explained by infection. Using this recombinant virus it is now possible to investigate this 
phenomenon of cluster formation. 
 
6.3.1 Viral fitness was impaired by GFP-VP16 
I have shown through two independent measurements, single step growth kinetics and plaque 
formation, that the N-terminal fusion of GFP to VP16 affected viral fitness of the ΔNLS recombinant 
virus leading to a 65% and 74% reduction in plaque size on RSCUL36 and HS30 cells, respectively, and 
a ten-fold drop in virus production from RSCUL36 cells compared to parental virus (ΔNLS). This was 
surprising since the same fusion protein in wild type strain 17 had no effect on single step growth 
kinetics (Boissière et al. 2004). However, I could show that plaque size of two different strain 17 
recombinants, expressing a N- or C-terminally tagged VP16, was also around 35% reduced in both cell 
types (Figure 34D). Since the presence of the ΔNLS mutation reduced plaque size of the parental virus 
in HS30 cells by approximately 50% already this indicated that the observed reduction of fitness was 
likely due to additive effects of expressing mutant VP1-2 and of the GFP-VP16 fusion protein. 
VP16 is an α-HV specific, essential transcription factor that is required to initiate viral 
transcription early on. It is delivered as part of the inoculum and translocates into the nucleus by virtue 
of its interaction with its transcriptional co-activator HCF (host cell factor) (La Boissière et al. 1999; 
Weinheimer et al. 1992; Campbell et al. 1984; Post et al. 1981). Once in the nucleus this complex 
assembles onto DNA via Oct-1 binding and recruits the transcription machinery via its extreme 
C-terminus (Milbradt et al. 2011). Viral fitness could have been reduced due to disruption of these 
VP16 interactions. However, since this was a N-terminal GFP fusion and the Oct-1/HCF binding regions 
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were mapped to the C-terminus on the other side of the protein structure (Liu et al. 1999) this implies 
that this function was likely not affected. 
VP16 also contains regions that allow it to be packaged into virions, which lie closer to the N-
terminus (Ace et al. 1988). Thus, it is conceivable that the introduction of an N-terminal tag like GFP 
could have affected virion incorporation. However, this did not seem to be the case for the 
recombinant wild-type (strain 17) viruses also tested (Figure 34D) as part of this chapter (Boissière et 
al. 2004). Although the available data give no indication of why VP16 function might be affected, one 
has to take into account the formation of a considerable complex around the transcription initiation 
site (Milbradt et al. 2011). It is conceivable that GFP causes steric hindrance that might affect this 
process and thus transcription initiation causing the observed reduction in viral fitness. 
 
6.3.2 Cluster formation 
As illustrated in Figure 35B (and with arrows in Figure 35D) ΔNLS viruses lead to formation of 
clusters of GFP positive cells. This phenomenon was also previously detected with indirect 
immunofluorescence using an anti-gC antiserum in rabbit cells infected with a PRV mutant virus lacking 
VP1-2 (Fuchs et al. 2004). The authors concluded that this was not due to a division event but rather 
production of some infectious virus particles. It is noteworthy that I only observed clusters consistently 
in rabbit skin cells which suggests that this might be a rabbit cell specific phenomenon and potentially 
dependent on cellular processes either of the infected cell or of neighbouring uninfected cells. The 
movies I took were in agreement with the conclusions drawn by Fuchs et al. (2004) that cluster 
formation was not brought about by cellular division. However, it did not conclusively resolve whether 
these cells actually got infected and were producing virions. Although the question remains open 
without further experiments, four scenarios might explain this phenomenon. 
(i) Infected cells produced a low amount of infectious virions that spread through residual 
binding of nuclear transport factors by VP1-2ΔNLS or another capsid (or tegument) 
component, or via direct binding to the nuclear pore through capsid and/or tegument 
components 
(ii) Wild-type VP1-2 from incoming, complemented virions can be incorporated into nascent 
capsids to allow some infectivity 
(iii) ΔNLS capsids can find an alternative route into the nucleus 
(iv) Neighbouring cells take up infected-cell material actively 
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(i) Production of low amount of infectious virions? 
The authors of the study conducted by Fuchs et al. (2004) suggested that a small amount of 
infectious virions could be produced that infect neighbouring cells. This was a reasonable conclusion 
because VP1-2ΔNLS might retain some importin binding activity. A closer look at the raw data of the 
MS results of NT3ΔNLS (see Appendix 5, importin-8) revealed that importins may potentially still bind 
the ΔNLS isoform but affinity and binding strength would be severely reduced in the absence of an NLS 
(Cutress et al. 2008; Hodel et al. 2006). Thus, there could be the possibility that even capsids carrying 
exclusively mutant VP1-2.ΔNLS might be able to use nuclear transport factors to get to the nucleus at 
highly reduced frequency. 
Alternatively, there are several candidate proteins that might lend their functions to allow 
docking of ΔNLS capsids at the NPC at very low frequency (see Table 11). These proteins might be part 
of the capsid or the tegument. Anderson et al. (2014), for example, showed that nuclear C capsids, 
which in their setting did not comprise VP1-2, bound nuclear pores almost as well as capsids extracted 
at 0.5M KCl. This implies capsids might bind to nuclear transport factors or the NPC in the absence of 
tegument proteins. The only capsid proteins that contain a recognised NLS are VP19C and VP24. The 
former is buried between capsomeres and the latter within the mature capsids, likely rendering them 
unable to bind any transport factors. Although not comprising functional NLSs, VP5 and VP26 cover 
the whole capsid surface and thus might be able to recruit ‘adapters’ that in turn allow nuclear docking. 
However, VP5 is also likely buried and deletion of VP26 was tolerated well in cell culture (Desai et al. 
1998) making both unlikely candidates. The Portal pUL6 and vertex associated protein pUL25, despite 
lack of a confirmed NLS, are nuclear proteins and according to one report can bind nucleoporins hCG1 
and Nup214, respectively (Pasdeloup et al. 2009; Rode et al. 2011; Copeland et al. 2009). This 
interaction might occur even in the absence of the VP1-2 NLS or full length VP1-2 to enable NPC 
docking. 
Other likely proteins to recruit nuclear transport receptors belong to the tegument. Of all 
tegument proteins only three do not localise to the nucleus (products of UL11, UL46 and US2) and one 
only translocates to the nucleus during late on during the cell cycle (VP22). All others can access the 
nucleus (Table 11), although only seven are known to contain functional NLSs which could directly 
recruit nuclear transport factors (see Table 11 including references). The most likely candidates are 
ICP0, pUS3, pUL14, pUL16, pUL21, pUL37 and VP1-2 which form part of the inner tegument shell, 
although all with the exception of VP1-2 and pUL37 were found to be dispensable for infection in cell 
culture (Desai 2000; Desai et al. 2001). Although VP1-2 is thought to be the assembly platform for 
tegument proteins, there is some evidence that some inner tegument proteins bind to capsids in the 
absence VP1-2. For example, pUS3, ICP0, ICP4 and pUL14 were found on nuclear capsids amidst 
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controversy over when VP1-2 is recruited (Radtke et al. 2010). The capsid interaction of said proteins 
was strongest for pUS3, pUL14 and ICP0 while pUL16 and pUL21 could be removed from capsids more 
easily with higher salt concentrations. Intriguingly, pUL14 had previously been implicated in nuclear 
import of capsids (Yamauchi et al. 2008). The authors report that fewer UL14-null capsids bound to 
nuclei of U2OS cells. VP1-2 is a prerequisite to bind pUL37 (Klupp et al. 2002). Although pUL37 
appeared to be essential for HSV-1 replication (Desai et al. 2001) it was not required for the closely 
related PRV (Leege, Granzow, et al. 2009). Since pUL37 also does not contain a confirmed NLS it is an 
unlikely candidate for rescuing the ΔNLS phenotype. 
Since cell clusters were observed with PRV which lacks VP1-2 (Fuchs et al. 2004) and VP1-2 likely 
forms an assembly platform for outer tegument proteins (Bucks et al. 2007) this excludes a function of 
most outer tegument proteins during nuclear docking. Of the other tegument proteins the only 
realistic candidates are ICP4 and ICP34.5. ICP4 may already be recruited to capsids in the nucleus and 
the ICP4-capsid interaction appeared stronger than that of the outer tegument protein VP22 (see 5.2.2, 
buffer 3 extraction of capsids), as salt and reducing environments only allowed partial solubilisation of 
this protein (also in Radtke et al. 2010; Wolfstein et al. 2006). Being an essential transcription factor, 
it contains a functional NLS and to improve its own transport it might hijack the capsid as a taxi to the 
nucleus and thus might also allow capsid docking at the NPC. ICP34.5, a neurovirulence factor, also 
comprises a functional NLS but reports are scarce on when ICP34.5 is recruited to capsids. The capsid 
interaction tolerated high salt treatment reasonably well (Radtke et al. 2010) and could mean it is 
localised closer to the capsid. Whether it remains attached during transit has not been shown but it 
appears likely that tegument removal is not 100% complete on all capsids and thus it might allow capsid 
docking at the nucleus in the absence of VP1-2. 
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Table 11 Localisation and presence of NLSs in documented capsid and tegument proteins. 
Green script indicates proteins that were not required for retrograde transport (Antinone et al. 2006) and red boxes 
highlights proteins that show no experimentally confirmed nuclear translocation or are thought not to contain an NLS. A 
systematic review of the ability of most HSV-1 proteins to translocate EYFP to the nucleus as part of a fusion protein was 
undertaken by Xing et al. (2011). 
 ORF Protein name NLS Nuclear localisation observed? References 
Te
gu
m
en
t 
UL7  ? yes (Xing et al. 2011; Roller & Fetters 2015) 
UL11  no no; nuclear membrane (Xing et al. 2011) 
UL13  ? no/yes (Xing et al. 2011) 
UL14  yes yes 
(Xing et al. 2011; Ohta et al. 2011; 
Yamauchi et al. 2002) 
UL16  ? yes (Xing et al. 2011) 
UL21  ? yes but mostly cytoplasmic (Xing et al. 2011) 
UL23  ? yes (Xing et al. 2011) 
UL36 VP1-2 yes yes but mostly cytoplasmic 
(Xing et al. 2011; D. S. McNabb & 
Courtney 1992) 
UL37  ? yes but mostly exported (Xing et al. 2011; Watanabe et al. 2000) 
UL41 Vhs ? yes (shuttling) (Shu et al. 2013) 
UL46 VP11-12 ? no (Xing et al. 2011; Kopp et al. 2002) 
UL47 VP13-14 yes yes 
(Donnelly & Elliott 2001; Xing et al. 2011; 
Kato et al. 2011) 
UL48 VP16 yes yes 
(Yedowitz et al. 2005; Xing et al. 2011; 
Salsman et al. 2008; Morrison et al. 
1998) 
UL49 VP22 ? yes (during M phase) 
(Elliott & O’Hare 2000; Xing et al. 2011; 
Blouin & Blaho 2001) 
UL50  ? yes (Xing et al. 2011) 
UL51  ? yes (Roller & Fetters 2015; Xing et al. 2011) 
UL55  ? yes (Yamada et al. 1998; Xing et al. 2011) 
US2  ? no (Xing et al. 2011) 
US3  ? yes (Reynolds et al. 2002; Xing et al. 2011) 
RL1 ICP34.5 yes yes 
(Salsman et al. 2008; Cheng et al. 2002; 
Harland et al. 2003) 
RL2 ICP0 yes yes (Mullen et al. 1994) 
RS1 ICP4 yes yes (Mullen et al. 1994) 
Ca
ps
id
 
UL19 VP5, ICP5 no yes but mostly cytoplasmic (Rixon et al. 1996; Salsman et al. 2008) 
UL38 VP19C yes yes 
(Rixon et al. 1996; Salsman et al. 2008; Li 
et al. 2012; Adamson et al. 2006) 
UL18 VP23 no yes (Rixon et al. 1996; Salsman et al. 2008) 
UL26 VP24 yes yes (Salsman et al. 2008) 
UL35 VP26 no yes (via pUL14) 
(Yamauchi et al. 2001; Salsman et al. 
2008) 
UL6 Portal ? yes 
(Burch & Weller 2004; Nellissery et al. 
2007) 
UL25  ? yes (Cockrell et al. 2011) 
 
(ii) Complementation in trans by wild type input VP1-2? 
Our group has already shown that when non-complementing cells (e.g. RSC or Vero) were 
infected with a complemented ΔNLS virus they become infected and produce virions normally. The 
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resulting non-complemented virions in turn showed approximately 1000 fold lower infectivity (Abaitua 
et al. 2012). When cells are infected with complemented virus these carry some wild-type VP1-2 on 
their capsids. One could argue that some residual wild-type VP1-2, derived from the initial inoculum, 
might be integrated at a low frequency into nascent capsids and thus allow for very low infectivity and 
limited cluster formation. However, it would be unlikely for this to be the case. Firstly, the infection 
was undertaken at low enough MOI to limit complemented input capsid to a few capsids per infected 
cell. Secondly, VP1-2 is not the most stable protein in the absence of infection and shows breakdown 
and turnover (Bolstad et al. 2011) in cells that are not yet at the peak of replication (D. S. McNabb & 
Courtney 1992). Thirdly, since in complementing RSCUL36 cells ΔNLS viral titres were still around 5 fold 
reduced (80% less) compared to a wild-type virus (Abaitua et al. 2012) it argues that the two VP1-2 
isoforms compete for capsid binding and implies a negative, if not partially dominant-negative, effect 
of mutant VP1-2. The number of VP1-2 binding sites per capsid vertex is estimated to be 5, which 
corresponds to the number of UL25 copies (Newcomb et al. 2006; Coller et al. 2007). Thus up to 60 
copies of VP1-2 could bind to all 12 vertices. It might require more than one copy, or even the majority 
(or a maximum of 5 copies), of wild-type VP1-2 per vertex to allow for efficient nuclear transport factor 
binding. Assuming the presence of equal amounts of mutant and wild-type VP1-2 and that their 
likelihood of capsid binding is exactly the same, the chance of having at least one wild-type VP1-2 at 
any one vertex is 96.9% but drops to 68% if you want at least one wild-type copy at each vertex. This 
means 1 in 10 capsids would carry at least one wild-type VP1-2 per vertex. Thus it appears likely that 
more than one wild-type VP1-2 per vertex would be necessary to provide the necessary nuclear 
transport function. In the non-complementing scenario, when VP1-2 complemented ΔNLS virions 
infect non-complementing cells, a large amount of mutant VP1-2 (generated during infection) and a 
low amount of wild-type VP1-2 (from the input) compete for capsid binding. This would lower the 
chance to have a wild-type VP1-2 at the vertex. Taken together there is only a low likelihood that 
residual input VP1-2 would allow sufficient infectivity to cause the observed cluster formation. 
 
(iii) An alternative nuclear entry pathway? 
Interestingly, I found it difficult to obtain chimeric VP1-2 viruses (containing homologous R1s) in 
Vero cells but succeeded in RSC cells. Rabbit cells might harbour specific properties to allow VP1-2NLS 
mutants to propagate. Interestingly, it has previously been shown that in rabbit cells an otherwise 
highly debilitated PRV mutant, which lacks the capacity to form the essential nuclear egress complex, 
made up of pUL31 and pUL34, and consequently was unable to exit the nucleus, can utilise an 
alternative route to overcome its defect (Grimm et al. 2012). Passaging this virus gave rise to a 
revertant that locally dissolved the nuclear membrane (during infection) to reach the site of secondary 
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envelopment (Table 3, introduction). It might be possible for HSV-1 ΔNLS capsids or other delivered 
proteins (as part of the inoculum) to locally disrupt the integrity of the nuclear membrane. Through 
these perforations capsids or released DNA could directly enter uninfected nuclei. On the one hand, 
DNA release required the concerted actions of importin-β and the RanGTP cycle in addition to the 
ability to dock at the NPC, implying recruitment of nuclear transport machinery must be required for 
this process. On the other hand, Horan et al. (2013) has shown that HSV-1 capsids can be degraded by 
the proteasome which causes a release of HSV-1 DNA. In this hypothetical scenario cytoplasmic or 
nuclear proteasomes might act to release infectious viral DNA which can enter through nuclear pores 
or perforated NE. Alternatively, the virus could exploit NEBD during division. 
These scenarios are entirely hypothetical and would require further investigations relating to 
infectivity of non-complemented stocks in RSC cells and whether these could be serially passaged. If 
during serial passage a spontaneous revertant arose which retained the ΔNLS mutation then one could 
find out which alternative pathways may be utilised. Such a virus lends itself to ultrastructural 
investigation using EM which might indicate any of the above mentioned phenomena (e.g. capsid 
degradation, NEBD, nuclear capsids) Why rabbit cells appear to be more conducive to VP1-2 mutant 
viruses is unknown and could also warrant further investigation (e.g. different nucleoporins, nuclear 
transport factor types and specificities or different capsid de-tegumentation kinetics). 
 
(iv) Active uptake of infected-cell material by uninfected cells? 
HSV-1 infected cells are generally dead within one day when infected with wild type viruses. 
Using a mutant like ΔNLS.GFP-VP16 might slow down replication but cells still looked like they 
underwent terminal processes as seen in movies 1-3. When cells undergo apoptosis their remnants, 
exposing ‘uptake signals’ including phosphatidylserine (Fadok et al. 2001), generally get taken up by 
other cells which is not solely an immune cell function. Human keratinocytes, for example, were 
observed to internalise microspheres up to a diameter of 20m in vitro (Morhenn et al. 2002). Thus, I 
propose, that these filmed uptake or fusion events could either be a normal clearance and recycling 
process of cells in a monolayer which may look like spread of infection between neighbouring cells. 
One could speculate that this may be a way HSV-1 could spread from cell to cell. 
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6.3.3 Proposed experiments to solve the question of cluster 
formation 
To test if ΔNLS virus (or even ΔVP1-2) deposits DNA into neighbouring RSC cell nuclei several 
complementary techniques could be used. Firstly, it has to be established whether ΔVP1-2 virus can 
deposit capsids into neighbouring RSC cells by EM. Their localisation would be of particular interest. 
Are they near the nucleus and, if so, can any be seen docking at the NPC? Following this, it could be 
checked if any viral DNA can be found in uninfected nuclei of a cluster by fluorescence in situ 
hybridisation. This will give a definitive answer as to whether infection could be the cause of the 
observed cluster formation. 
To exclude phagocytosis or macropinocytosis, cells could be tested for the presence of relevant 
receptors (e.g. for phosphatidyserine). Also, specific inhibitors to signalling pathways could be 
employed to see if this process can be blocked. Staining for certain endosomal markers for analysis by 
immunofluorescence or EM could ascertain whether these pathways were involved. 
The arguably most interesting experiment would be to obtain a revertant virus through serial 
passage on rabbit cells. This might reveal previously unknown functions of HSV-1 proteins or even a 
new way of HSV-1 to spread from cell-to-cell 
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7 General discussion 
7.1 Summary 
For HVs to establish a life‐long infection their genome needs to reach the nucleus of a 
susceptible cell. The last step of entry involves binding of nuclear transport factors which are required 
to dock at the nuclear pore and subsequently uncoat the genome. I set out to elucidate the mechanism 
of nuclear docking of HV capsids. 
I met the original objectives of 
(i) defining a suitable system to screen for NLSs in VP1-2 homologues 
(ii) identifying the relevant NLS motifs in homologues of all HV sub‐families both by in 
silico analyses and through empirical testing in two different in vitro systems 
(iii)  showing NLS functionality of VP1-2 homologues in the context of HSV‐1 replication 
(iv) identifying functional determinants in the HSV‐1 NLS region required for nuclear 
localisation  
(v) characterising functional determinants of the HSV-1 NLS required for viral replication 
(vi) isolating and characterising recombinant viruses harbouring mutant and chimeric VP1-2 
NLS regions 
(vii) optimising a simple one‐step protocol to isolate viral capsids in complex with cellular 
interacting proteins which can subsequently be analysed by MS 
(viii) using mass spectrometric analysis to identify cellular interacting proteins of VP1-2 
(ix) confirming one VP1-2 interacting protein by IP and a functional DDR assay 
(x) creating a fluorescently tagged VP1-2.ΔNLS recombinant virus to study infected-cell 
behaviour 
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7.1.1 Nuclear localisation and viral replication 
The data in the preceding chapters has shown that VP1‐2 homologues of all herpesvirus sub‐
families contain a motif at an analogous position, which could be predicted using a variety of in silico 
sequence analysis tools. These putative NLSs function in nuclear transport assays in the context of a 
heterologous protein and in a long N-terminal fragment of VP1‐2 itself (see summary in Table 
12).From the structural organisation of R1 (or R8) it can be assumed that, with the exception of 
HHV-8.R8, all R1 equivalents identified in the α‐, β‐ and γ1 HV sub‐families comprise a bpNLS, which 
could functionally substitute, albeit only partially, for the equivalent HSV‐1 region. More importantly, 
for these bpNLS motifs (VZV, HCMV and EBV R1s) purification of recombinant viruses was possible. 
Although they all exhibited a generally modest reduction in viral fitness (reduction in plaque size, 
comet tails and yield of infectious virions) on several cell lines, their replication was significantly 
impaired in Vero cells compared to wild type virus. The defect of these viruses could be precipitated 
by a combination of delayed entry and replication kinetics and reduced production of infectious 
virions.  
Table 12 Summary of the functionality of the homologous NLS regions. Efficiency is indicated compared to wild type virus 
(+++ same as wild type, - demarcates negative result). 
Virus Region 
Nuclear localisation 
Type of 
NLS 
Function during HSV replication 
β-gal VP1-21-1875 
ΔNLS 
Rescue 
Virus 
prep 
Viral 
replication 
HSV-1 R4 +++ +++ mpNLS - (ΔR5) - - 
HSV-1 R1 +++ +++ 
mpNLS, 
bpNLS 
+++ Yes +++ 
VZV R4 - Not done 
 
Not done Not done Not done 
VZV R1 +++ ++ bpNLS ++ Yes + 
HCMV R1 +++ +++ bpNLS + Yes + 
EBV R1 +++ +++ bpNLS + Yes + 
HHV-8 R1 - -  - -  
HHV-8 R8 +++ +++ mpNLS - -  
HSV-1 
R1.Myo
NLS 
+++ +++ 
2x mpNLS, 
bpNLS 
+ Yes + 
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My initial hypothesis that NLS function would be the sole requirement for rescue of the ΔNLS 
phenotype and thus viral replication had to be modified; NLS function was absolutely required but not 
sufficient for rescue. There was correlation, however, with the organisation of R1 and ΔNLS rescue. All 
motifs that contained a bpNLS, that is, two basic patches separated by a variable spacer, were able to 
function in the context of HSV-1 replication. 
Table 13 Summary of the functional determinants of the HSV-1 NLS region. Efficiency is indicated compared to 
wild type virus. (+++ same as wild type, - demarcates negative result) 
Region Mutation 
Nuclear localiation 
Function during HSV 
replication 
β-gal VP1-2
1-1875
 NLS 
Rescue 
Virus prep 
R1  +++ +++ +++ Wild type 
R4  +++ + (R5) - (ΔR5) - 
R5  - - (ΔNLS) - (ΔNLS) - 
R4 K428R - Not done Not done - 
R1 K428R +++ + ++ Yes 
R1 K428A - - - - 
R1 ΔNLS - - - - 
R1 ΔR5 +++ + - - 
R1 mutR5 +++ + - - 
 
For the HSV‐1 motif (see Table 13) I established that the R1 region contains a mpNLS which is 
part of a larger bpNLS structure. Although both NLS types are sufficient to translocate a heterologous 
protein into the nucleus, integrity of R1 was required for infectivity. In the context of VP1-2 and during 
replication R4 (the first basic patch) contributes the majority of NLS function, given that ΔR5 but not 
ΔR4 constructs could confer nuclear localisation. These data corroborate data on the PRV NLS which 
led to the conclusion that the HSV‐1 NLS, and probably that of all other α-HVs, likely acts as a bpNLS 
during infection. 
 
7.1.2 Interaction studies 
To identify interaction partners of the VP1‐2 NLS I established cell lines inducibly expressing 
nuclear and cytoplasmic (ΔNLS) versions of the N‐terminal quarter of VP1‐2, which can be used to 
identify VP1‐2 interacting proteins. Initial analysis identified VP1-2 interacting partners although these 
were probably not directly dependent on the NLS for interaction but likely on the localisation of the 
VP1‐2 fragment. This work is relevant to infection since an N‐terminal fragment of VP1‐2, comprising 
General discussion 
 
 
- 195 - 
 
the USP and probably the NLS, may be released during infection (Kattenhorn et al. 2005), which might 
fulfil important functions. For the purpose of this thesis I identified and validated the interaction of the 
VP1-2 N-terminus with DTX3L, an important regulator of the DDR, by IP. Additionally, I showed that 
NT3 and less so NT3ΔNLS, likely by virtue of their interaction with DTX3L, abolished 53BP1 recruitment 
in response to doxorubicin. This could have implications during infection since several aspects of the DDR 
appear to be modulated at several stages of the HSV‐1 life cycle (discussed earlier).  
Additionally, I optimised a modified approach to identify VP1‐2 NLS interacting proteins of relevance 
during the entry process by using a one‐step capsid purification protocol. I showed that extraction of 
capsids from purified virions reproducibly and selectively removed selected glycoproteins and outer 
tegument proteins. This was enhanced with salt concentrations above 500mM but not by reducing 
agents. Compared to extraction in standard lysis buffer, extracting capsids in the presence of soluble 
cellular proteins stabilised important capsid tegument interactions (VP1-2, pUL37) while destabilising 
others (VP22). Intriguingly, few distinct bands probably of cellular origin, can be identified using silver 
stain. Thus, this work forms the basis of a simple one-step protocol to isolate de‐enveloped and 
partially de‐tegumented capsids complexed with potentially relevant cellular proteins by co-extracting 
purified virions and intact cells. 
Although I was not able to identify the nuclear transport factors involved in HSV‐1 entry, this 
work led to the preliminary identification of a potentially novel and unexpected function of the 
structural protein VP1-2 in modulating the DDR. The described NT3 based expression system can be 
used in future to pursue interesting questions concerning VP1‐2 (USP) functions during HSV-1 infection. 
 
7.2 Discussion 
7.2.1 Conclusions 
From the work undertaken for this thesis four reasonable conclusions can be drawn. 
(i) Taking into account the relative conservation of VP1-2 domain structure, the conservation of 
the basic patches and the localisation results it is very likely that all HVs contain an NLS within the linker 
between the USP and the central domain. 
(ii) Since the VP1-2 sequences from all homologues except for HHV-8 were able to rescue the 
ΔNLS defect, it appears that this motif likely functions to guide incoming HV nucleocapsids to the 
nuclear pore. 
(iii) NLS strength did not correlate with ΔNLS rescue and viral fitness of the recombinant viruses 
if foreign sequences were inserted into VP1-2. However, if the wild type NLS was weakened through 
mutation viral replication was reduced. 
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(iv) Since the R5 region was essential for viral replication but was not absolutely required for 
nuclear localisation it could indicate that additional functions might be attributed to this region. 
 
7.2.2 Model of nuclear docking 
In a simplified model of HV nuclear docking (exemplified by HSV-1) HV capsids are deposited 
into the cytosol and tegument dissociates except for VP1-2 and a few other proteins. These capsid 
structures engage the cytoskeleton and exploit cellular motor proteins such as dynein to move towards 
the MTOC in retrograde fashion. To get to the nucleus capsids might have to switch their preferred 
transport direction (anterograde) to move towards the nucleus. Since ΔNLS capsids accumulate at the 
MTOC there are two not mutually exclusive possibilities where capsids could engage the nuclear 
transport machinery. They could pick up importins during or immediately prior to transport from the 
MTOC to the nucleus which would mean ΔNLS capsids cannot move beyond the MTOC. Whether this 
is because they fail to switch transport direction or were unable to dock at the nucleus remains open. 
Alternatively, capsids could bind nuclear transport factors at the NPC. In that case, ΔNLS capsids would 
migrate from the MTOC to the NPC but, due to failure to engage the NPC, inadvertently accumulate 
near the MTOC. The data from my experiments imply that the inserted NLS sequences were sufficient 
to allow docking but cannot distinguish between these two scenarios. 
 
7.2.3 Wider impact of NLS study 
Although resistance to conventional anti‐virals including acyclovir is rare, in 
immunocompromised patients the risk of generating resistant virus is increased. Thus, it is important 
to develop new drugs targeting conserved cellular features of virus-host interactions, which may be 
exploited to lower the risk of emerging resistance. One possible target is the interaction of capsids 
with their cognate nuclear transport factor. The presented results and tools could have a wider impact 
on the HV community. Using the knowledge about conservation of the NLS in all HVs and its ability to 
rescue HSV-1 replication the chimeric VP1-2 derivatives could be used to elucidate the nuclear entry 
mechanism of potentially all HVs and guide the rational design of inhibitors of capsid nuclear docking. 
Using a combination of nuclear localisation of chimeric NT6 (or β-gal fusions), recombinant HSV-1 
capsid binding studies and HSV-1 uncoating assays, it is possible to directly measure the contributions 
of individual proteins to the docking process by siRNA-mediated knockdown, chemical inhibition or 
expression of dominant negative nuclear transport factors. Using the developed HSV-1 based system 
has a few notable advantages over studying the native virus.  
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(i) Very little cloning and prior knowledge about structure of the VP1-2 homologues in 
questions are required 
(ii) Nuclear import assays can easily be expanded with further NLSs and the constructs 
could form the basis for interaction studies 
(iii) HSV-1 replicates to reasonably high titre in many cell lines (e.g. RSC, BHK) even in the 
presence of a foreign NLS 
(iv) The one-step capsid isolation protocol can be performed on any high titre HSV-1 stock 
(v) HSV-1 DNA can be labelled with ‘clickable’ nucleoside analogues such as EdC 
(Dembowski & DeLuca 2015) 
(vi) Our group has developed a HSV-1 genome uncoating assay which can be performed in 
susceptible cell lines. For this assay HSV-1 genomes are labelled with ‘clickable’ 
nucleoside analogues. Labelled genomes can in turn be detected in newly infected 
nuclei. 
In future work using techniques established in this work and in combination with other tools, a 
specific workflow could be established. Initially, nuclear localisation of NT6 could be scored in the 
presence of specific inhibitors, siRNAs or dominant negative importin-αs. Secondly, the effect of 
inhibition of certain factors could subsequently be verified in a genome uncoating assay using the 
chimeric viruses. Finally, using the one-step capsid purification nuclear transport factor interactions 
could be confirmed. This could lead to the identification of nuclear transport factors used by each HV 
and be used for the rational design of drugs to inhibit HV infection.  
 
7.2.4 Some intriguing questions remain 
7.2.4.1 NLS function 
Nuclear localisation is a complicated process which appears to not only involve nuclear transport 
factors. There are several mechanisms for a cell to modulate the function of a protein which act at the 
level of protein expression or stability. Additionally, protein function can also be modulated at the level 
of localisation, more specifically by inhibiting or augmenting NLS activity through, for example, 
phosphorylation (Jain et al. 1993; Flanagan et al. 1991). Since NLS strength had no influence on ΔNLS 
rescue efficiency for the homologous NLSs, it would be intriguing to test if the functional differences 
could be precipitated by altered regulatability. 
The lack of ΔNLS rescue using the HHV-8 motif and the reduction in viral fitness seen with the 
motifs derived from the α-, β- and γ1-HVs also led to another hypothesis. The sub-group specific 
organisation and conservation indicate that this motif might be adapted to the viral life cycle, 
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specifically the cell types these viruses infect. This could be a reason why in Vero cells all the 
homologous NLSs were essentially non-functional. The Vero cell defect could prove a fortuitous 
finding, since it enables the investigation of the observed phenotype by qualitative (microscopy) and 
quantitative (protein expression time courses, qRT-PCR) means. Effectively, the contribution of cellular 
(nuclear transport) factors to the HV capsid entry process can be assessed when individual nuclear 
transport factors are exogenously overexpressed. 
On a grander scale the linker regions between USP and the body of VP1-2 are highly 
heterogenous even within sub-families with only the NLS region being reasonably well conserved. 
More specifically, only the basic residues of R4 were highly conserved throughout the sub-families 
(Figure 8). In contrast, R5 (second basic patch) or the spacer exhibits very little resemblance between 
HV sub-families except between very closely related species (i.e. HSV-1/2 or EBV/McHV-4). It appears 
as though a comparatively high selective pressure acted upon the first basic patch compared to the 
rest of the linker region (i.e. R5 or the residues surrounding R1) suggesting that they might bind 
similarly conserved cellular proteins in their respective hosts (e.g. major binding site of α-importins). 
In contrast, the surrounding area could fulfil more plastic accessory functions (e.g. presentation or 
regulation of NLS function in cell/host-specific manner, proteolytic site, etc.). This conclusion may not 
be that far fetched since the basic residues in R4 contribute most of the function of this region (see 
K428R and K428A defects). Future work to refine the system to co-precipitate VP1-2 interacting 
proteins could lead to elucidation of the role of the more variable parts of R1. 
 
7.2.4.2 The expanding roles of VP1-2 
In the third results chapter I attempted confirm interaction of VP1-2 with DTX3L. There were 
several more proteins identified by MS that were not followed up but their functions open up new 
opportunities to expand the list of roles for VP1-2 in the virus life cycle that could explain some of the 
previously unexplained defects observed with USP mutants of PRV or the temperature sensitive HSV-1 
mutant tsB7 (Böttcher et al. 2008; Abaitua et al. 2011; Abaitua et al. 2009). It may also not be surprising 
that NT3 gave rise to such an extensive list of interacting proteins since the region following the USP 
(including the NLS) likely assumes no rigid secondary structure. This plasticity could potentially enable 
VP1-2 to interact with many different proteins as was suggested for intrinsically disordered regions 
(Dunker et al. 2001 and references therein); these binding proteins could in turn be modulated by the 
USP.  
Since this study revealed a previously unappreciated (potential) function of VP1-2 the question 
remains how modulating DTX3L (and/or PARP9) activity could be beneficial to virus replication. This 
intriguing protein has previously been shown to affect endosomal sorting (Holleman & Marchese 2014) 
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and the DDR (Yan et al. 2009; Yan et al. 2013), processes which are extensively modulated by HSV-1 
(some aspects discussed in 5.3.1.4). Hypothetically, VP1-2 can act as a soluble, potentially truncated 
(Kattenhorn et al. 2005) or capsid-bound full length protein (see sections 1.2.2 and 1.2.3) during viral 
replication. But in which form does VP1-2 affect DTX3L? Two equally exciting possibilities arise. 
(i) The soluble full length or N-terminal VP1-2 product (i.e. the USP) could affect the DDR late on 
during infection to facilitate DNA replication. The physiological VP1-2 cleavage product described by 
Kattenhorn et al. (2005) differs from NT3 in that NT3 is approximately 400 residues longer and thus 
could contain regions for interaction with DTX3L downstream of the cleavage site. Additionally, it is 
unknown whether the physiological cleavage product of VP1-2 comprises the NLS and thus whether 
NT3, which mostly localises to the nucleus, is a relevant system. Follow up experiments (discussed 
earlier) are underway to establish the nature of the VP1-2-DTX3L interaction and if this augments viral 
replication through modulation of the DDR. 
(ii) VP1-2, in its full length capsid-bound form, facilitates secondary envelopment of HV capsids 
and is required for capsid movement (see section 1.2.3). The ESCRT pathway of endosomal sorting is 
extensively regulated by ubiquitination (Urbé 2005). The modulation of the function of the E3 ubiquitin 
ligase, DTX3L, by the VP1-2 USP in one pathway (DDR) could be reason to believe that the endosomal 
sorting functions of DTX3L (Holleman & Marchese 2014) are equally affected. These data could link 
functions of VP1-2 during different life cycle stages to the USP and form the basis of new studies to 
unravelling open questions (e.g. the mechanism of the defect in egress of the PRV lacking VP1-2 USP 
function found by Böttcher et al. 2008). 
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9 Appendix 1: List of primers 
prTH1 
CCCAAGCTTACCATGACTCCCAAGAGGAAAAAGGGATTGGGCAAAGATAGCCCCCACAAGAAGCCCACCTCCGGCCGCCGCCTCCCTAGAT
CTGGG 
R4.EBV 
prTH2 
CCCAGATCTAGGGAGGCGGCGGCCGGAGGTGGGCTTCTTGTGGGGGCTATCTTTGCCCAATCCCTTTTTCCTCTTGGGAGTCATGGTAAGC
TTGGG 
R4.EBV complementary 
prTH3 CCCAAGCTTACCATGGATTGTCGTCGTAGACGCCGTCCTTCATGGACTCCTCCTTCAAGCGAGGAAAATTTAAGATCTGGG R4.VZV 
prTH4 CCCAGATCTTAAATTTTCCTCGCTTGAAGGAGGAGTCCATGAAGGACGGCGTCTACGACGACAATCCATGGTAAGCTTGGG R4.VZV complementary 
prTH5 
CCCAAGCTTACCATGTCACCCAAAAAAACACCCGAGAAACGCCGCAAGGACCTCAGCGGTAGCAAACACGGAGGCAAAAAGAAACCCAGAT
CTGGG 
R4.CMV 
prTH6 
CCCAGATCTGGGTTTCTTTTTGCCTCCGTGTTTGCTACCGCTGAGGTCCTTGCGGCGTTTCTCGGGTGTTTTTTTGGGTGACATGGTAAGC
TTGGG 
R4.CMV complementary 
prTH7 
CCCAAGCTTACCATGACGCGCCCGCGCAGACCTCGCGTCGTCATTCCTCCTTACGATCCGACAGACCGCCCACGACCGCCTCACCAAGACC
GCCCGAGATCTGGG 
R4.HHV-8 
prTH8 
CCCAGATCTCGGGCGGTCTTGGTGAGGCGGTCGTGGGCGGTCTGTCGGATCGTAAGGAGGAATGACGACGCGAGGTCTGCGCGGGCGCGTC
ATGGTAAGCTTGGG 
R4.HHV-8 complementary 
prTH9 CTACATCACGTGCGCATG 
UL35 PCR primer (antisense strand of 
VP1-2 C-terminus) 
prTH10 GTGGGTGGTTGGTGCTG 
UL35 PCR primer (sense strand of C-
terminus of UL34) 
prTH11 CATTCGCCATTCAGGCTG 
β-gal sequencing primer N-terminus 
reverse 
prTH12 GGATTGGGCAAAGATAG β-gal.EBV PCR 
prTH13 CACCCGAGAAACGCCGC β-gal.CMV PCR 
prTH14 GTCGTCATTCCTCCTTAC β-gal.HHV-8 PCR 
prTH15 GATTGTCGTCGTAGACG β-gal.VZV PCR 
prTH16 GAAAGCCGATCCCAAAC V5 PCR primer 
prTH17 [Phos]AGCTTGCCACCATGGGAAAGCCGATCCCAAACCCTTTGCTGGGATTGGACTCCACCA V5 tag forward 
prTH18 [Phos]AGCTTGGTGGAGTCCAATCCCAGCAAAGGGTTTGGGATCGGCTTTCCCATGGTGGCA V5 tag reverse 
prTH19 GCCTATAAAAAAGGACGCACCG 
nested primer to amplify VP26 region; 
goes with primers prTH9 and TH10 
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prTH20 CCTATCCCACTCCCTTGAATAAACA 
nested primer to amplify VP26 region; 
goes with primers prTH9 and TH10 
prTH21 gggaagcttaccatgcttcgcaagcgccgccgacccacctggactccgccttccagcgtcgaagacctgagatctccc R4.HSV P427R 
prTH22 gggagatctcaggtcttcgacgctggaaggcggagtccaggtgggtcggcggcgcttgcgaagcatggtaagcttccc R4.HSV P427R complementary 
prTH23 gggaagcttaccatgcttcccaggcgccgccgacccacctggactccgccttccagcgtcgaagacctgagatctccc R4.HSV K428R 
prTH24 gggagatctcaggtcttcgacgctggaaggcggagtccaggtgggtcggcggcgcctgggaagcatggtaagcttccc R4.HSV K428R complementary 
prTH25 gggaagcttaccatgtgtcgtcgtagacgccgtccttcatggactcctccttcaagcgaggaaaatttaagatctccc R4.VZV (w/o leader aspartate) 
prTH26 gggagatcttaaattttcctcgcttgaaggaggagtccatgaaggacggcgtctacgacgacacatggtaagcttccc R4.VZV (no D) complementary 
prTH27 gggaagcttaccatgtgtcgtaagagacgccgtccttcatggactcctccttcaagcgaggaaaatttaagatctccc R4.VZV (no D); R2>K 
prTH28 gggagatcttaaattttcctcgcttgaaggaggagtccatgaaggacggcgtctcttacgacacatggtaagcttccc R4.VZV (no D); R2>K; complementary 
prTH29 gggaagcttaccatgtgtcctcgtagacgccgtccttcatggactcctccttcaagcgaggaaaatttaagatctccc R4.VZV (no D); R1>P 
prTH30 gggagatcttaaattttcctcgcttgaaggaggagtccatgaaggacggcgtctacgaggacacatggtaagcttccc R4.VZV (no D); R1>P; complementary 
prTH31 gggaagcttaccatgtgtcctaagagacgccgtccttcatggactcctccttcaagcgaggaaaatttaagatctccc R4.VZV (no D); R1>P; R2>K 
prTH32 gggagatcttaaattttcctcgcttgaaggaggagtccatgaaggacggcgtctcttaggacacatggtaagcttccc 
R4.VZV (no D); R1>P; R2>K; 
complementary 
prTH33 
CCCAAGCTTACCATGGGAAACAAAGGACGCGGCGGTAACAAAGGACGCGGCGGAAAGACGGGACGTGGCGGAAATGAAGGACGCGGTAGAT
CTGGG 
R5.HHV-8 
prTH34 
CCCAGATCTACCGCGTCCTTCATTTCCGCCACGTCCCGTCTTTCCGCCGCGTCCTTTGTTACCGCCGCGTCCTTTGTTTCCCATGGTAAGC
TTGGG 
R5.HHV-8 complementary 
prTH35 CCCAAGCTTACCATGCTAACTGCCACAAGAGGGCAGAAACGCAAATTTTCCTCGCTTAGATCTGGG R9.HHV-8 
prTH36 CCCAGATCTAAGCGAGGAAAATTTGCGTTTCTGCCCTCTTGTGGCAGTTAGCATGGTAAGCTTGGG R9.HHV-8 complementary 
prTH37 CCCGGATCCGATATAATTCCGCCTATAGCTGTC 
forward primer to clone VZV homolog of 
UL36 with BamHI site 
prTH38 CCCGGATCCGCTACTTTATATATATGTTCC 
reverse primer to clone VZV homolog of 
UL36 
prTH39 GGGGGATCCGCTCTGTCAAAGCACGG 
cloning RFP with N-terminal BamHI and 
C-terminal XbaI site 
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prTH40 GGGTCTAGATTATCCGGGCAATGCGG 
cloning RFP with N-terminal BamHI and 
C-terminal XbaI site 
prTH41 [Phos]AGCTTGCCACCATGTACCCATACGATGTTCCAGATTACGCTC 
HA tag with HindIII on both sides; 2nd 
HindIII lost upon integration 
prTH42 [Phos]AGCTGAGCGTAATCTGGAACATCGTATGGGTACATGGTGGCA 
HA tag with HindIII on both sides; 2nd 
HindIII lost upon integration 
prTH43 [Phos]AGCTTGCCACCATGGGAAAGCCGATCCCAAACCCTTTGCTGGGATTGGACTCCACCC 
V5 tag with HindIII on both sides; 2nd 
HindIII lost upon integration 
prTH44 [Phos]AGCTGGGTGGAGTCCAATCCCAGCAAAGGGTTTGGGATCGGCTTTCCCATGGTGGCA 
V5 tag with HindIII on both sides; 2nd 
HindIII lost upon integration 
prTH45 GAAAGCCGATCCCAAAC 
forward primer to confirm insertion of 
V5 tag 
prTH46 ccctctagaggtttagtgaaccgtcagatccgc 
forward primer to clone EGFP-C2 with 
N-terminal XbaI site 
prTH47 gcgccatagatccggtggagctcgagatctgagtccggcc 
reverse primer to clone EGFP-C2 with C-
terminal XcmI site 
prTH48 CCCAAGCTTGCCACCATGGTGAGCAAGGG 
alternative forward primer to 
complement prTH47 (+ 5' HindIII site) 
prTH49 GTACCCATACGATGTTCCAG 
forward primer to confirm insertion of 
HA tag 
prTH52 AGGTGGGTCGGCGGCGAGC 
antisense primer. anneals perfectly to 
K>A mutation (last three nucleotides are 
complementary to the mutated codon) 
prTH53 GGACGAAGCGTTCAGCGAAC 
sense primer to amplify region 1188bp-
2351bp of NT6 (BamHI-MluI) 
prTH54 GAGTTTTCGTCCAGCACGTGC 
anti-sense primer to amplify region 
1188bp-2351bp of NT6 (BamHI-MluI) 
prTH55 GGTCTTGGTGAGGCGGTCGT goes with prTH53 
prTH56 ACGACCGCCTCACCAAGACC goes with prTH54 
prTH57 cagaggcggccgaagaagatg BamHI-MluI sequencing 
prTH58 ggtgccgaggcgaggacag BamHI-MluI sequencing 
prTH59 cgtgtttgctaccgctgagg 
primer in NT6v3.CMV (antisense) to 
confirm insertion. goes with prTH53 
prTH60 cctcagcggtagcaaacacg 
primer in NT6v3.CMV (sense) to confirm 
insertion. goes with prTH54 
prTH63 ccggttggtaagaagaggagg 
sense primer within MyoPondin NLS 
insert; paired with prTH54 
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prTH64 ggaggcaacggcattgtcg 
sense primer in mutR5 to confirm virus; 
paired with prTH54 
prTH65 gccgacccacctggactc 
sense primer to confirm wild type NLS in 
virus; paired with prTH54 
prTH66 ctactcggccggcacctg 
sense primer to confirm deletion of NLS 
in virus; paired with prTH54 
prTH67 CCCGCTAGCGCCACCATGGGTAAACCAATTCCTAATCCTCTACTTGGCCTAGATAGTACGAGCGGCCGCTGG V5-tag flanked by NheI/NotI; sense oligo 
prTH68 CCAGCGGCCGCTCGTACTATCTAGGCCAAGTAGAGGATTAGGAATTGGTTTACCCATGGTGGCGCTAGCGGG 
V5-tag flanked by NheI/NotI; antisense 
oligo 
prTH73 ctgacttcgggggagaaaacga 
sense primer to go with pTH54; anneals 
to the wild type R5 to confirm second 
basic patch 
prTH74 ccaatgtgcctggatgcgttc 
made by Beckman Genomics; sense 
primer to C-terminal region of GST 
approx. 200bp away from MCS; 
prTH85 tcgagatgggcgtcgtcccggttggtaagaagaggaggaggagggccaggaagacccccgtcggggccgcggtccccg 
sense oligo; R1.HSV-1 region with 
Myopodin NLS instead of R4/R5 
prTH86 ctagcggggaccgcggccccgacgggggtcttcctggccctcctcctcctcttcttaccaaccgggacgacgcccatc 
antisense oligo; R1.HSV-1 region with 
Myopodin NLS instead of R4/R5 
prTH87 
tcgagatgggcgtcgtcccggttggtaaacgcccggcggcgaccaagaaagcgggccaggcgaagaagaagaaaacccccgtcggggccgc
ggtccccg 
sense oligo; R1.HSV-1 region with 
Nucleoplasmin NLS instead of R4/R5 
prTH88 
ctagcggggaccgcggccccgacgggggttttcttcttcttcgcctggcccgctttcttggtcgccgccgggcgtttaccaaccgggacga
cgcccatc 
antisense oligo; R1.HSV-1 region with 
Nucleoplasmin NLS instead of R4/R5 
prTH89 gtagcggatcccgagtttactccctatcagtg 
sense primer to 5'-end of pTRE-tight 
operator/promoter; incl. 5' BamHI site 
prTH90a/b gtacgctcgagctccaggcgatctgacggttc 
antisense primer to 3'-end of pTRE-tight 
operator/promoter; incl. 3' XhoI site 
prTH90c 
CGATGAATTCAATGATCAGATCTAGAGCAGATCTCCATCGATATAGATATCTCACGCGTTGAATGCGGCCGCTTGAATCTCGAGCTCCAGG
CGATCTGACGGTTC 
antisense primer to 3'-end of pTRE-tight 
operator/promoter; incl. Multi cloning 
site 
prTH93 GTGGCTAGCGCCACCATGGGAAAGCCGATCCCAAACC 
V5 tag at N-terminus of NT3; including 
Kozak 
prTH94 CCAGTGTGATGGATATCTGCAG NT3 antisense primer; with prTH93 
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prTH95a Gcgaagcttgccaccatgtcccctatactaggttattgg 
incl. 5' HindIII, followed by Kozak and 
GST 
prTH96a gaattcaagcttggatccaggggcccctggaacag for cloning from pCAG-GST-NT4 vector 
prTH97 TAAGACACGATGCGATAAAATCTGTTTGTAAAATTTATTAAGGGTACAAATTGCCCTAGC 
60-mer dsDNA oligo complementary to 
prTH98; used to induce a STING 
dependent response (probably IFI16 
initiated) 
prTH98 GCTAGGGCAATTTGTACCCTTAATAAATTTTACAAACAGATTTTATCGCATCGTGTCTTA 
60-mer dsDNA oligo complementary to 
prTH97; used to induce a STING 
dependent response (probably IFI16 
initiated) 
prTH99 ctggattcatcgactgtg 
sense primer to Neomycin C-terminal 
domain; used to confirm pQ-TetR-
Neo_v2 
prTH100 gctggtgatattgttgagtc 
antisense primer to confirm pQ-TetR-
Neo_v2 
prTH101 gtgcacaattggcggatcccccctccgccgac 
Forward primer to clone BamHI-MluI 
fragment from pTH19 into pCAG-GST, 
includes MfeI site (lost upon cloning) 
prTH102 GAGCTGAATTCGAGGCCCAGCCCGAGCTC 
 Reverse primer to clone BamHI-MluI 
fragment from pTH19 into pCAG-GST, 
includes EcoRI site 
prTH103a Gatcagcggccgcccgaattcatatgtctaga 
5' forward primer for amplification of 
TetON (rtTA) from Clontech vector; NotI 
included upstream of ORF; using this 
method the HA-tag of pQ-HA will be lost 
prTH103b Gatcaaccggttctagattagataaaagtaaag 
5' forward primer for amplification of 
TetON (rtTA) from Clontech vector; AgeI 
included upstream of ORF; lacks first 
methionine using this method the HA-
tag of pQ-HA will be kept giving rise to a 
HA-rtTA fusion 
prTH104 cttatcatgtctggatcctc 
3' reverse primer for amplification of 
rtTA; goes with prTH103a/b; use 
naturally occurring BamHI site for 
cloning 
prTH105 cacgctagcttgccgcctcttgagagattgaccctaagatctgac 
REV NES in frame into XhoI-NheI inserts 
via NheI-BglII. For transfer into EGFP-C3 
in frame. 
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prTH106 gtcagatcttagggtcaatctctcaagaggcggcaagctagcgtg 
REV NES complementary in frame into 
XhoI-NheI inserts via NheI-BglII. For 
transfer into EGFP-C3 in frame. 
prTH107 GGGTCAATCTCTCAAGAGG 
reverse primer to confirm insertion of 
the REV NES sequence into pTH29 or 
any other. pair with HA-primer 
prTH108 gatctacgcgtgaattcGccaccatggtgagcaag 
forward primer to pTH117/118; cloning 
of EGFP-NLS-NES or GFP-NLS into pQ-
Flag or pQ-CMV-MCS-IRES-Neo_v2 
prTH109 gctaagcggccgcgaattccagttatctagatccggtgg 
reverse primer to pTH117/118; cloning 
of EGFP-NLS-NES or GFP-NLS into pQ-
Flag or pQ-CMV-MCS-IRES-Neo_v2 
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Intensity 
PEP 
score 
MS/MS 
Count 
Unique peptides 
MW Ids Protein name Gene name 
NT3 NT3NLS NT3 NT3NLS 
1 24,5413 0 0 207 2 0 48 
Q5JP53 P07437 Q5ST81 
E9PBJ4 
Tubulin beta chain TUBB 
2 27,5482 0 
2E-
280 
158 6 1 50 
P68363 Q9BQE3 F5H5D3 
A8MUB1 P68366 F8VVB9  
Tubulin alpha-1B chain, Tubulin alpha-1C 
chain, Tubulin alpha-4A chain 
TUBA1B TUBA1C TUBA4A 
3 28,9973 26,9931 
9E-
261 
112 10 8 73 
O00571 B4DXX7 O15523 
B4E3C4 B4DLA0 C9J8G5 
ATP-dependent RNA helicase DDX3X, ATP-
dependent RNA helicase DDX3Y 
DDX3X DDX3Y 
4 25,8649 0 0 105 2 0 113 P09874 Q5VX84 Q5VX85 Poly [ADP-ribose] polymerase 1 PARP1 
5 27,2874 24,1357 
8E-
174 
75 9 4 80 
Q92841 H3BLZ8 C9JMU5 
G5E9L5 
Probable ATP-dependent RNA helicase 
DDX17 
DDX17 
6 26,6509 0 
3E-
168 
67 3 1 71 
P11940 E7ERJ7 E7EQV3 
H0YAR2 H0YBN4 Q9H361 
Polyadenylate-binding protein 1 PABPC1 
7 24,2034 0 2E-65 66 2 0 33 P05141 
ADP/ATP translocase 2, ADP/ATP 
translocase 2, N-terminally processed 
SLC25A5 
8 25,6427 0 
6E-
175 
52 4 1 81 P33993 C9J8M6 DNA replication licensing factor MCM7 MCM7 
9 30,9121 28,7984 
4E-
209 
46 13 12 92 Q96QK1 I3L4S0 I3L4P4 
Vacuolar protein sorting-associated 
protein 35 
VPS35 
10 26,5806 0 
6E-
174 
34 4 1 84 Q8TDB6 E3 ubiquitin-protein ligase DTX3L DTX3L 
11 27,5987 0 
8E-
103 
32 3 0 29 
P62258 K7EM20 B4DJF2 
I3L3T1 K7EIT4 I3L0W5 
14-3-3 protein epsilon YWHAE 
12 26,0217 0 4E-86 28 2 1 64 
P46060 F8W7I9 H0Y4Q3 
B0QYT5 B0QYT4 B0QYT6 
Ran GTPase-activating protein 1 RANGAP1 
13 26,2397 0 2E-09 4 2 0 28 
P31947 E5RGE1 Q4VY20 
E5RIR4 E9PD24 E7EVZ2 
14-3-3 protein sigma SFN 
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Selected proteins identified by MS in SDS-PA gel slices from NT3 and NT3ΔNLS sample lanes. 
Details about the experiment can be found in Figure 23. Bands demarcated with black arrowheads were excised, proteins isolated and tryptically digested. Peptides were analysed by MS and 
the 13 most interesting proteins that were at least four fold enriched in the NT3 slices compared to the NT3ΔNLS slices are listed. Relative amount of a protein is given on a log2 scale, that is a 
change of 1 unit equals a doubling in abundance. 
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Intensity 
PEP score 
MS/MS 
Count 
unique peptides 
MW Protein names Gene names 
functional 
annotation 
localisation 
NT3 NT3 ΔNLS paren tal NT3 NT3NLS control 
1 30,0184 27,6219 27,1171 5,68E-175 52 26 18 18 81 
DNA replication licensing factor 
MCM7 
MCM7 cell cycle Nuclear 
2 32,3941 29,2294 29,2263 3,18E-120 43 13 9 8 22 60S ribosomal protein L18 RPL18 translation Cytoplasmic 
3 31,6468 29,5047 29,2383 3,20E-45 42 13 9 8 13 60S ribosomal protein L26 RPL26 KRBA2 translation Cytoplasmic 
4 30,0753 27,4888 0 6,27E-174 34 18 15 0 84 
E3 ubiquitin-protein ligase 
DTX3L 
DTX3L 
ubiquitin and 
SUMO pathway 
Nuclear, 
cytoplasmic 
5 28,3236 26,2524 26,1291 3,37E-63 17 12 5 8 60 
RNA polymerase II-associated 
factor 1 homolog 
PAF1 transcription nuclear 
6 28,3477 24,2055 23,0033 6,29E-86 14 15 4 3 161 
Mediator of RNA polymerase II 
transcription subunit 14 
MED14 transcription Nuclear 
7 27,6883 25,3861 25,6694 6,79E-43 11 7 4 5 49 
Testis-specific Y-encoded-like 
protein 1 
TSPYL1 genome structure nuclear 
8 27,2093 0 0 1,14E-32 7 7 1 1 34 
tRNA-splicing endonuclease 
subunit Sen34 
TSEN34 
translation, tRNA 
metabolism 
nuclear 
9 27,0931 24,7393 24,7187 1,61E-31 7 5 4 3 89 
Leucine-rich repeat-containing 
protein 41 
LRRC41 
ubiquitin and 
SUMO pathway 
membrane 
10 25,6633 0 0 7,02E-25 6 5 1 0 34 
MKI67 FHA domain-interacting 
nucleolar phosphoprotein 
MKI67IP RNA metabolism nuclear 
11 25,974 0 0 6,63E-55 6 2 1 1 42 
Actin, alpha skeletal muscle 
Actin, alpha cardiac muscle 1 
Actin, gamma-enteric smooth 
muscle Actin, aortic smooth 
muscle 
ACTA1 ACTC1 
ACTG2 ACTA2 
cytoskeletal cytoplasm 
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12 25,1609 0 0 6,99E-43 5 3 2 0 58 
SWI/SNF-related matrix-
associated actin-dependent 
regulator of chromatin 
subfamily D member 1 
SMARCD1 genome structure nuclear 
13 25,7742 0 23,452 8,36E-16 5 5 1 3 98 
Uncharacterized protein 
CXorf57 
CXorf57 not annotated not annotated 
14 26,2469 0 0 3,02E-27 4 2 1 1 50 
Histone acetyltransferase type 
B catalytic subunit 
HAT1 genome structure 
nuclear, 
cytoplasmic 
15 25,4644 22,9001 22,9826 1,48E-19 4 3 2 2 79 
Testis-specific Y-encoded-like 
protein 2 
TSPYL2 transcription nuclear 
16 24,78 22,6472 22,0634 2,95E-14 4 3 3 2 110 
Mediator of RNA polymerase II 
transcription subunit 24 
MED24 transcription Nuclear 
17 25,5797 0 0 2,08E-13 4 4 2 2 20 Aurora kinase B AURKB 
protein kinase, cell 
cycle 
nuclear 
18 24,1387 0 0 2,96E-12 4 3 1 1 47 
Putative methyltransferase 
NSUN5 
NSUN5 RNA metabolism nuclear 
19 24,3653 0 0 2,09E-10 4 2 1 1 30 
Exosome complex component 
RRP43 
EXOSC8 RNA metabolism 
nuclear, 
cytoplasmic 
20 24,2364 0 0 8,23E-08 4 2 1 2 71 
Leucine-rich repeat and WD 
repeat-containing protein 1 
LRWD1 cell cycle 
nuclear, 
cytoplasmic 
21 23,7259 0 0 1,91E-07 4 2 1 1 21 Cytochrome b-245 light chain CYBA metabolism membrane 
22 24,03 0 0 2,74E-07 4 3 0 0 22 
Transcription initiation factor 
TFIID subunit 9 Transcription 
initiation factor TFIID subunit 
9B 
TAF9 TAF9B transcription nuclear 
23 24,3195 0 0 4,539E-07 4 3 1 0 77 Cirhin CIRH1A transcription nuclear 
24 24,1941 0 0 9,69E-07 4 2 1 1 44 
p21-activated protein kinase-
interacting protein 1 
PAK1IP1 cell cycle nuclear 
25 23,1428 0 0 3,202E-09 4 2 2 2 219 Endoribonuclease Dicer DICER1 
RNA metabolism, 
miRNA biogenesis 
cytoplasmic 
26 25,1453 0 0 6,05E-09 4 4 1 2 309 Protein PRRC2C PRRC2C mRNA metabolism Cytoplasmic 
27 24,8918 0 0 3,57E-05 3 2 0 0 15 Galectin-7 LGALS7 apoptosis 
nuclear, 
cytoplasmic, 
exosomes 
28 26,4832 24,3834 0 4,56E-14 3 3 2 1 25 Casein kinase II subunit beta CSNK2B 
protein kinase, 
multiple 
pathways, 
differentiation 
Nuclear, 
cytoplasmic 
29 24,9509 0 0 1,08E-13 3 2 1 1 19 Gem-associated protein 6 GEMIN6 mRNA metabolism 
nuclear, 
cytoplasmic 
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30 26,2117 0 0 1,60E-30 3 3 1 1 44 
Non-structural maintenance of 
chromosomes element 4 
homolog A 
NSMCE4A 
genome structure, 
DNA repair 
nuclear 
31 25,749 0 0 1,51E-18 3 5 2 2 97 
Mediator of RNA polymerase II 
transcription subunit 16 
MED16 transcription nuclear 
32 24,7728 0 0 7,43E-11 3 2 1 1 17 M-phase phosphoprotein 6 MPHOSPH6 RNA metabolism 
nuclear, 
cytoplasmic 
33 23,9499 0 0 2,107E-09 3 2 1 1 115 
RNA-binding protein 27 RNA-
binding protein 26 
RBM27 
RBM26 
mRNA metabolism 
nuclear, 
cytoplasmic 
34 25,7301 0 0 5,54E-13 3 3 1 1 101 
General transcription factor 3C 
polypeptide 2 
GTF3C2 transcription nuclear 
35 24,6446 0 0 2,92E-09 3 3 0 0 69 E3 ubiquitin-protein ligase RLIM RLIM 
ubiquitin and 
SUMO pathway 
nuclear, 
cytoplasmic 
36 24,1607 0 0 3,60E-12 3 3 1 1 66 
Origin recognition complex 
subunit 2 
ORC2 cell cycle nuclear 
37 25,459 0 0 4,61E-12 3 3 1 1 50 
DNA polymerase delta subunit 
2 
POLD2 cell cycle nuclear 
38 24,1682 0 0 5,21E-12 3 2 1 1 12 
39S ribosomal protein L53, 
mitochondrial 
MRPL53 translation mitochondrium 
39 24,4644 0 0 1,25E-11 3 3 2 3 106 WD repeat-containing protein 3 WDR3 RNA metabolism nuclear 
40 23,922 0 0 4,22E-09 3 3 1 3 89 
Leucine-rich repeat flightless-
interacting protein 1 
LRRFIP1 transcription 
nuclear, 
cytoplasmic 
41 23,8516 0 0 1,98E-08 3 3 1 1 52 
CUGBP Elav-like family member 
1 
CELF1 mRNA metabolism 
nuclear, 
cytoplasmic 
42 23,5272 0 0 1,87E-10 3 2 0 1 43 
Prostate tumor-overexpressed 
gene 1 protein 
PTOV1 transcription 
membrane, 
nuclear 
43 23,7276 0 0 5,125E-10 3 2 1 1 106 
Zinc finger CCCH domain-
containing protein 18 
ZC3H18 mRNA metabolism nuclear 
44 24,6918 0 0 2,12E-05 3 2 1 1 27 Protein lin-28 homolog B LIN28B RNA metabolism 
nuclear, 
cytoplasmic 
45 23,4686 0 0 1,57E-07 3 2 1 2 154 
Protein strawberry notch 
homolog 1 Protein strawberry 
notch homolog 2 
SBNO1 
SBNO2 
transcription nuclear 
46 24,6081 0 0 1,09E-06 3 3 1 1 48 
Ribosome biogenesis protein 
WDR12 
WDR12 RNA metabolism nuclear 
47 24,4627 0 0 2,90E-06 3 2 1 1 12   C11orf48 not annotated not annotated 
48 24,0945 0 0 1,86E-04 3 2 1 1 33 
Transcriptional activator 
protein Pur-beta 
Transcriptional activator 
protein Pur-alpha 
PURB PURA transcription nuclear 
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49 24,6364 0 0 2,76E-12 3 4 3 2 188 Golgin subfamily B member 1 GOLGB1   
Cytoplasmic, 
golgi 
50 25,2247 0 0 1,70E-10 3 3 2 1 24 
Mitotic spindle assembly 
checkpoint protein MAD2A 
MAD2L1 cell cycle cytoplasmic 
51 24,1257 0 0 5,28E-09 3 2 1 1 16 
p53 and DNA damage-
regulated protein 1 
PDRG1 DNA repair cytoplasmic 
52 25,6583 0 0 1,05E-08 3 2 1 1 93 
MAP7 domain-containing 
protein 1 
MAP7D1 cytoskeletal cytoplasm 
53 23,8272 0 0 8,406E-06 2 2 0 0 75 Symplekin SYMPK mRNA metabolism 
nuclear, 
membrane, 
cytoplasmic 
54 24,9167 0 0 1,07E-07 2 2 1 0 26 Transmembrane protein 109 TMEM109 apoptosis nuclear, ER 
55 25,0132 0 0 3,92E-13 2 2 0 0 27 
Cyclin-dependent kinase 2 
Cyclin-dependent kinase 3 
CDK2 CDK3 
protein kinase, cell 
cycle 
Nuclear, 
cytoplasmic 
56 23,5498 0 0 1,27E-07 2 2 0 0 22 Kinetochore protein Spc24 SPC24 cell cycle 
nuclear, 
cytoplasmic 
57 25,3824 0 0 1,46E-07 2 3 1 1 71 
SUMO-activating enzyme 
subunit 2 
UBA2 
ubiquitin and 
SUMO pathway 
nuclear, 
cytoplasmic 
58 23,6703 0 0 1,80E-05 2 2 0 0 48 
Helicase-like transcription 
factor 
HLTF 
transcription, 
ubiquitin and 
SUMO pathway 
nuclear, 
cytoplasmic 
59 25,4414 0 0 4,38E-19 2 2 0 1 14 
Histone H2A.V Histone H2A.Z 
Histone H2A Histone H2A type 
1-A 
H2AFV H2AFZ 
HIST1H2AA 
genome structure nuclear 
60 24,3738 0 0 2,69E-15 2 2 1 1 179 
Ras GTPase-activating-like 
protein IQGAP3 
IQGAP3 small GTPase membrane 
61 24,618 0 22,546 6,17E-14 2 2 1 2 16 
General transcription factor IIH 
subunit 3 
GTF2H3 transcription nuclear 
62 24,7109 0 0 6,33E-13 2 4 1 0 100 Pre-mRNA-splicing factor SYF1 XAB2 mRNA metabolism nuclear 
63 23,6613 0 0 6,34E-13 2 2 1 0 22 
U3 small nucleolar 
ribonucleoprotein protein IMP3 
IMP3 RNA metabolism nuclear 
64 24,2329 0 0 1,31E-12 2 2 0 1 14 
G patch domain-containing 
protein 4 
GPATCH4 mRNA metabolism nuclear 
65 24,2898 0 0 3,53E-12 2 3 2 2 146 
Ribosome biogenesis protein 
BMS1 homolog 
BMS1 translation nuclear 
66 26,633 0 0 5,10E-11 2 2 1 1 14 
Cyclin-dependent kinase 
inhibitor 2A, isoform 4 
CDKN2A cell cycle nuclear 
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67 24,9746 0 0 7,92E-10 2 3 1 1 258 
DNA polymerase DNA 
polymerase epsilon catalytic 
subunit A 
POLE cell cycle nuclear 
68 25,3114 0 0 5,11E-09 2 2 0 1 48 
N-acylneuraminate 
cytidylyltransferase 
CMAS 
nucleotide 
metabolism 
nuclear, 
membrane 
69 24,6684 0 0 8,03E-09 2 2 1 1 25 
Ribosome production factor 2 
homolog 
RPF2 
translation, mRNA 
metabolism 
nuclear 
70 24,907 0 0 3,13E-08 2 2 1 1 13 
DNA-directed RNA polymerase 
II subunit RPB11-b2 DNA-
directed RNA polymerase II 
subunit RPB11-b1 DNA-directed 
RNA polymerase II subunit 
RPB11-a 
POLR2J3 
POLR2J2 
POLR2J 
POLR2J1 
transcription nuclear 
71 22,8072 0 0 9,19E-04 2 2 1 0 40 Modulator of apoptosis 1 MOAP1 apoptosis 
cytoplasmic, 
mitochondrium 
72 22,2295 0 0 2,13E-07 2 2 0 0 89 Protein FAM91A1 FAM91A1 not annotated not annotated 
73 24,0277 0 0 1,389E-06 2 2 1 0 119 
Zinc finger and BTB domain-
containing protein 11 
ZBTB11 transcription nuclear 
74 24,0888 0 0 9,01E-06 2 2 1 0 85 
Heterogeneous nuclear 
ribonucleoprotein U-like 
protein 2 
hCG_2044799 
HNRNPUL2 
mRNA metabolism nuclear 
75 22,7283 0 0 9,118E-06 2 2 1 1 19 
Ribonuclease P/MRP protein 
subunit POP5 
POP5 RNA metabolism nuclear 
76 22,7954 0 0 3,82E-05 2 2 0 0 113 Genetic suppressor element 1 GSE1 not annotated not annotated 
77 23,2631 0 0 4,39E-05 2 2 1 1 24 RNA-binding protein 34 RBM34 RNA binding nuclear 
78 23,4769 0 0 3,10E-04 2 2 0 0 61 
Cell division cycle 7-related 
protein kinase 
CDC7 
protein kinase, cell 
cycle 
nuclear 
79 26,3113 0 0 4,26E-04 2 2 1 1 82 
Zinc finger protein 225 Zinc 
finger protein 221 Zinc finger 
protein 224 
ZNF225 
ZNF221 
ZNF224 
transcription nuclear 
80 26,1687 0 0 8,64E-04 2 2 0 1 104 Exocyst complex component 2 EXOC2 exocytosis 
membrane, 
golgi 
81 31,2931 0 0 2,06E-06 2 2 1 1 201 
E3 ubiquitin-protein ligase 
listerin 
LTN1 
ubiquitin and 
SUMO pathway 
cytoplasmic 
82 24,3401 0 0 9,87E-06 2 2 0 0 22 
Receptor expression-enhancing 
protein 4 
REEP4 cell cycle Cytoplasmic 
83 22,9113 0 0 1,49E-03 2 2 1 1 148 
Regulator of nonsense 
transcripts 2 
UPF2 RNA metabolism cytoplasmic 
84 23,7052 0 0 0,0015373 2 2 1 1 134 Sperm-associated antigen 5 SPAG5 cell cycle cytoplasmic 
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85 24,826 0 0 5,52E-11 1 3 2 2 65 
Selenocysteine-specific 
elongation factor 
EEFSEC translation 
nuclear, 
cytoplasmic 
86 24,0317 0 0 2,86E-10 1 2 1 1 63 Protein AATF AATF apoptosis 
nuclear, 
cytoplasmic 
87 23,5443 0 0 1,704E-06 1 2 1 0 11 
Cyclin-dependent kinase 
inhibitor 2A, isoforms 1/2/3 
Cyclin-dependent kinase 4 
inhibitor B 
CDKN2A 
CDKN2B 
cell cycle 
nuclear, 
cytoplasmic 
88 22,8387 0 0 4,29E-04 1 2 0 1 47 
Diphthamide biosynthesis 
protein 1 
DPH1 
amino acid 
metabolism and 
modification 
nuclear, 
cytoplasmic 
89 24,3684 0 0 5,42E-06 1 2 0 1 68 
Neuroepithelial cell-
transforming gene 1 protein 
NET1 
small GTPase, cell 
cycle 
cytoplasmic, 
membrane 
90 25,7769 0 0 1,31E-13 1 2 1 0 48 Histone-binding protein RBBP4 RBBP4 genome structure nuclear 
91 24,2344 0 0 8,64E-10 1 3 1 2 21 
Macrophage erythroblast 
attacher 
MAEA apoptosis membrane 
92 23,923 0 0 1,92E-08 1 2 1 1 81 
TFIIH basal transcription factor 
complex helicase XPD subunit 
ERCC2 transcription nuclear 
93 24,5032 0 0 1,68E-07 1 3 1 1 65 Zinc finger protein 512 ZNF512 transcription nuclear 
94 23,2994 0 0 3,649E-07 1 2 1 1 93 Zinc finger protein 598 ZNF598 mRNA metabolism nuclear 
95 24,4966 0 0 6,65E-07 1 2 1 0 29 
28S ribosomal protein S18b, 
mitochondrial 
MRPS18B translation mitochondrium 
96 24,9449 0 0 3,40E-06 1 2 0 1 35 Actin-related protein 2 ACTR2 cytoskeletal cytoplasmic 
97 23,4385 0 0 3,46E-05 1 2 1 1 616 Dystonin DST cytoskeletal Cytoplasmic 
98 24,2085 0 0 8,75E-05 1 2 1 1 45 
Dimethyladenosine transferase 
2, mitochondrial 
TFB2M transcription mitochondrium 
99 24,2223 0 0 1,33E-03 0 2 1 1 139 
Splicing factor, arginine/serine-
rich 19 
SCAF1 
transcription, 
splicing 
nuclear 
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Intensity 
PEP score 
MS/MS 
Count 
unique peptides 
MW Protein names 
Gene 
names 
functional 
annotation 
localisation 
NT3 NT3 ΔNLS 
paren 
tal 
NT3 NT3NLS control 
1 0 26,7455 24,2334 1,04E-50 7 0 8 2 70 
Very long-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
ACADVL metabolism 
cytoplasmic, 
nuclear, 
mitochondrium 
2 0 26,6598 0 9,31E-14 7 1 4 0 11 Protein S100-A7 S100A7 immunity 
cytoplasmic, ER, 
exosomes 
3 24,341 26,3518 24,2033 1,97E-16 5 2 4 2 21 Nucleolar protein 16 NOP16 
mRNA 
metabolism 
nuclear 
4 0 24,019 0 2,25E-09 4 1 2 2 34 Estradiol 17-beta-dehydrogenase 12 HSD17B12 metabolism ER 
5 0 24,6258 0 9,18E-17 3 2 2 1 24 Zinc finger protein ubi-d4 DPF2 
apoptosis, 
transcription 
cytoplasmic, 
nuclear 
6 0 25,3732 0 1,48E-15 3 2 2 1 11 
Mitochondrial import inner membrane 
translocase subunit Tim13 
TIMM13 chaperone mitochondrium 
7 0 23,8669 0 1,73E-10 3 2 2 2 72 HAUS augmin-like complex subunit 5 HAUS5 cell cycle cytoplasmic 
8 0 24,1955 0 3,26E-08 3 1 3 1 24 Protein THEM6 THEM6 not annotated secreted 
9 0 23,2888 0 3,06E-07 3 1 2 2 58 
Beta-hexosaminidase Beta-hexosaminidase 
subunit alpha 
HEXA metabolism lysosome 
10 0 24,1923 0 4,82E-07 3 0 2 1 48 
Mitochondrial tRNA-specific 2-thiouridylase 
1 
TRMU 
RNA 
metabolism 
mitochondrium 
11 0 24,275 0 2,69E-06 3 0 3 1 42 
Prostaglandin E synthase 2 Prostaglandin E 
synthase 2 truncated form 
PTGES2 
metabolism, 
immunity 
cytoplasmic, Golgi 
12 0 23,8981 0 2,76E-05 3 1 2 1 62 
Serine/threonine-protein phosphatase 4 
regulatory subunit 3A Serine/threonine-
protein phosphatase 4 regulatory subunit 
3B 
SMEK1 
SMEK2 
DNA repair 
cytoplasmic, 
nuclear 
13 0 23,6613 0 9,15E-17 2 1 2 1 10 Dynein light chain Tctex-type 1 DYNLT1 cytoskeletal cytoplasmic, Golgi 
14 0 25,7572 23,741 4,90E-13 2 1 2 2 42 Ribonuclease P protein subunit p40 RPP40 
RNA 
metabolism 
nuclear 
15 0 24,2274 0 1,76E-12 2 1 3 1 76 THO complex subunit 1 THOC1 transcription 
cytoplasmic, 
nuclear 
16 0 22,8592 0 5,72E-08 2 1 2 1 44 Metastasis-associated protein MTA3 MTA3 transcription nuclear 
17 0 25,879 0 1,35E-07 2 2 3 2 43 GTP-binding protein 10 GTPBP10 translation nuclear 
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18 0 24,0409 0 1,06E-06 2 1 2 1 19 Replication protein A 32 kDa subunit RPA2 cell cycle nuclear 
19 0 24,4321 0 2,64E-06 2 1 2 0 285 Spectrin alpha chain, non-erythrocytic 1 SPTAN1 cytoskeletal cytoplasmic 
20 0 25,4809 0 7,06E-06 2 2 2 1 46 
Guanine nucleotide-binding protein G(s) 
subunit alpha isoforms short 
GNAS 
GNAT1 
GNAI1  
signalling 
cytoplasmic, 
membrane 
21 0 24,2396 0 1,12E-05 2 1 3 2 120 Importin-8 IPO8 nuclear import cytoplasmic 
22 0 24,7104 0 2,19E-05 2 1 2 1 8 
Cytochrome c oxidase assembly protein 3 
homolog, mitochondrial 
COA3 translation mitochondrium 
23 0 23,1143 0 6,57E-05 2 1 2 1 46 Nuclear pore glycoprotein p62 NUP62 nuclear pore cytoplasm, nuclear 
24 0 24,9024 0 6,90E-05 2 2 2 1 15 39S ribosomal protein L41, mitochondrial MRPL41 translation mitochondrium 
25 0 22,5174 0 0,0002895 2 1 2 1 41 NADPH--cytochrome P450 reductase POR metabolism membrane, ER 
26 0 23,6455 0 0,0010227 2 1 2 1 134 Tight junction protein ZO-2 TJP2 cell adhesion 
nuclear, 
membrane 
27 0 23,0346 0 0,002062 2 1 2 1 112 
Zinc finger CCCH domain-containing protein 
7B 
ZC3H7B 
RNA 
metabolism 
nuclear 
28 0 23,0143 0 4,30E-09 1 3 3 1 94 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit STT3B 
STT3B ERAD ER 
29 0 23,5728 0 5,52E-06 1 1 2 1 119 Unconventional myosin-Ic MYO1C cytoskeletal 
cytoplasmic, 
nuclear 
30 0 23,0214 0 0,00020092 1 0 2 0 233 HEAT repeat-containing protein 1 HEATR1 
translation, 
RNA 
metabolism 
nuclear 
31 0 24,0015 0 0,00020596 1 1 2 1 110 WD repeat-containing protein 59 WDR59 metabolism   
32 0 23,6688 0 0,00079983 0 2 2 1 90 
Probable ATP-dependent RNA helicase 
DDX27 
DDX27 
RNA 
metabolism 
nuclear 
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Intensity 
PEP score 
MS/MS 
Count 
unique peptides 
MW Protein names Gene names functional annotation localisation 
NT3 
NT3 
ΔNLS 
paren 
tal 
NT3 NT3NLS control 
1 37,248 38,0163 34,6338 0 808 62 51 41 70 
Heat shock 70 kDa protein 
1A/1B 
HSPA1A chaperone 
cytoplasmic, 
nuclear 
2 34,896 35,9609 32,9485 0,00E+00 365 38 40 30 71 
Heat shock cognate 71 
kDa protein 
HSPA8 chaperone 
cytoplasmic, 
nuclear, 
membrane, 
exosomes 
3 30,711 31,8923 29,5806 0,00E+00 127 36 33 25 94 
Heat shock 70 kDa protein 
4 
HSPA4 chaperone 
cytoplasmic, 
mitochondrium 
4 32,719 30,7855 26,4064 0 106 38 28 10 119 
Large proline-rich protein 
BAG6 
BAG6 chaperone 
cytoplasmic, 
nuclear 
5 32,36 32,1061 30,1849 2,17E-302 60 10 9 6 31 
Complement component 1 
Q subcomponent-binding 
protein, mitochondrial 
C1QBP 
transcription, 
translation , RNA 
metabolism, mRNA 
metabolism, 
immunity 
cytoplasmic, 
nuclear, 
membrane, 
mitochondrium 
6 30,872 30,8642 28,4727 1,76E-251 33 12 9 7 24 
BAG family molecular 
chaperone regulator 2 
BAG2 chaperone not annotated 
7 27,29 28,8847 26,5464 5,10E-238 16 9 7 7 70 
Heat shock-related 70 kDa 
protein 2 
HSPA2 chaperone 
cytoplasmic, 
nuclear, 
membrane, 
mitochondrium, 
exosomes 
8 30,833 30,1861 23,2049 3,94E-209 46 21 17 3 92 
Vacuolar protein sorting-
associated protein 35 
VPS35 transport 
cytoplasmic, 
membrane, 
exosome 
9 30,157 30,5403 27,4961 9,47E-189 44 18 15 12 35 
E3 ubiquitin-protein ligase 
CHIP 
STUB1 
Ubiquitination/SUMO, 
DNA repair 
cytoplasmic, 
nuclear, 
membrane, ER 
10 30,198 28,3735 0 2,58E-169 43 23 17 1 96 
Poly [ADP-ribose] 
polymerase 9 
PARP9 DNA repair, immunity 
cytoplasmic, 
nuclear 
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ΔNLS 
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11 30,199 31,0953 27,9133 1,36E-161 82 29 28 19 63 
Stress-induced-
phosphoprotein 1 
STIP1 chaperone cytoplasmic 
12 30,8 29,0125 28,6645 2,25E-119 38 15 9 9 34 
rRNA 2-O-
methyltransferase 
fibrillarin 
FBL RNA metabolism 
nuclear, 
membrane, 
exosomes 
13 28,052 29,02 23,5777 1,26E-113 35 16 16 3 70 
Very long-chain acyl-CoA 
synthetase 
SLC27A2 metabolism ER 
14 25,684 26,503 24,4823 2,16E-99 7 3 4 2 50 
Elongation factor 1-alpha 
2 
EEF1A2 translation 
cytoplasmic, 
nuclear 
15 29,569 30,7969 26,2014 2,31E-62 29 13 7 6 41 
Hsc70-interacting protein 
Putative protein FAM10A5 
ST13 ST13P5 chaperone cytoplasmic 
16 26,647 26,6055 24,2582 3,471E-61 9 6 4 3 30 
Exosome complex 
component RRP40 
EXOSC3 RNA metabolism 
cytoplasmic, 
nuclear 
17 28,473 27,2566 25,8036 1,005E-55 15 8 7 5 39 ATPase ASNA1 ASNA1 transport 
cytoplasmic, 
nuclear, ER 
18 28,492 27,3756 0 2,707E-54 12 7 5 0 21 
Vacuolar protein sorting-
associated protein 29 
VPS29 transport 
cytoplasmic, 
membrane, 
Golgi 
19 26,516 25,902 24,0389 9,233E-51 9 8 4 6 169 
Condensin-2 complex 
subunit D3 
NCAPD3 cell cycle 
nuclear, 
membrane 
20 28,02 27,7688 0 3,31E-50 17 10 6 0 39 
Vacuolar protein sorting-
associated protein 26B 
VPS26B transport 
cytoplasmic, 
membrane, 
Golgi 
21 27,337 26,1278 0 5,379E-44 15 6 5 1 37 
Golgi to ER traffic protein 
4 homolog 
GET4 transport cytoplasmic, ER 
22 28,864 30,2853 26,4916 6,88E-43 15 4 6 5 25 
Transmembrane protein 
33 
TMEM33 not annotated 
membrane, 
exosomes 
23 26,724 27,3248 0 1,046E-41 16 8 7 1 51 
BAG family molecular 
chaperone regulator 5 
BAG5 
Ubiquitination/SUMO, 
chaperone 
cytoplasmic, 
nuclear, 
membrane, 
mitochondrium 
24 27,096 25,3863 24,2501 6,043E-40 13 7 4 2 28 Myeloid leukemia factor 2 MLF2 not annotated 
cytoplasmic, 
nuclear, 
membrane 
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NT3 
NT3 
ΔNLS 
paren 
tal 
NT3 NT3NLS control 
25 28,113 29,9879 27,5981 1,33E-38 25 9 8 6 45 LanC-like protein 1 LANCL1 signalling 
cytoplasmic, 
nuclear, 
membrane 
26 28,451 27,5324 24,5152 2,444E-36 17 8 7 3 18 Ubiquitin-like protein 4A UBL4A transport cytoplasmic 
27 25,308 24,4955 22,806 2,222E-34 4 2 3 3 95 
Lon protease homolog, 
mitochondrial 
LONP1 protease mitochondrium 
28 26,045 25,9514 0 7,331E-33 7 7 5 2 254 
Nucleolar pre-ribosomal-
associated protein 1 
URB1 mRNA metabolism nuclear 
29 25,938 26,1511 0 2,713E-27 3 2 2 2 17 
Transcription factor BTF3 
homolog 4 
BTF3L4 not annotated not annotated 
30 26,84 25,2449 24,5453 2,988E-26 6 3 4 4 22 
Uncharacterized protein 
C7orf50 
C7orf50 mRNA metabolism not annotated 
31 24,928 23,9051 0 3,978E-26 5 2 2 2 39 
Programmed cell death 
protein 2-like 
PDCD2L cell cycle cytoplasmic 
32 26,045 26,9526 0 3,4E-25 9 4 8 1 209 Protein RRP5 homolog PDCD11 
mRNA metabolism, 
RNA metabolism, 
translation 
cytoplasmic, 
nuclear 
33 24,964 24,0154 0 5,035E-21 6 4 2 1 50 AP-2 complex subunit mu AP2M1 transport membrane 
34 26,4 24,7335 0 6,688E-21 5 3 3 1 29 
Multiple myeloma tumor-
associated protein 2 
MMTAG2 mRNA metabolism nuclear 
35 24,652 24,8493 0 6,578E-20 4 3 2 1 43 Protein AAR2 homolog AAR2 not annotated not annotated 
36 25,503 24,2924 0 1,567E-17 3 2 3 3 39 
U5 small nuclear 
ribonucleoprotein 40 kDa 
protein 
SNRNP40 
DKFZp434D199 
mRNA metabolism nuclear 
37 25,021 23,4432 22,9097 3,28E-17 5 4 2 2 88 
BRCA1-associated ATM 
activator 1 
BRAT1 DNA repair 
nuclear, 
membrane 
38 24,068 23,5491 0 3,291E-17 3 2 2 1 44 
Telomeric repeat-binding 
factor 2-interacting 
protein 1 
TERF2IP transcription 
cytoplasmic, 
nuclear 
39 25,09 25,1571 0 1,679E-16 6 3 2 1 13 
28S ribosomal protein S25, 
mitochondrial 
MRPS25 translation mitochondrium 
40 25,229 24,7373 0 2,013E-15 5 2 2 1 15 Protein LLP homolog LLPH mRNA metabolism not annotated 
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41 25,237 24,6357 0 4,211E-15 2 2 2 1 53 
Serine 
hydroxymethyltransferase, 
cytosolic Serine 
hydroxymethyltransferase 
SHMT1 metabolism cytoplasmic 
42 25,15 24,6204 0 2,208E-14 6 2 3 3 45 
Prolactin regulatory 
element-binding protein 
PREB 
transcription, 
transport 
nuclear, ER 
43 25,232 23,8169 0 4,274E-14 3 3 2 0 65 
Nuclear valosin-containing 
protein-like 
NVL mRNA metabolism 
nuclear, 
membrane 
44 22,946 23,098 0 1,523E-12 3 2 2 0 86 
Melanoma-associated 
antigen D1 
MAGED1 transcription 
cytoplasmic, 
nuclear, 
membrane 
45 24,057 23,1927 0 1,351E-11 3 3 2 1 105 
Ubiquitin carboxyl-
terminal hydrolase 
Ubiquitin carboxyl-
terminal hydrolase 11 
USP11 Ubiquitination/SUMO cytoplasmic 
46 24,155 25,1036 0 1,346E-10 3 2 2 1 16 
DNA-directed RNA 
polymerase II subunit 
RPB4 
POLR2D 
mRNA metabolism, 
translation 
cytoplasmic, 
nuclear 
47 26,027 25,7514 0 5,087E-10 5 4 3 2 17 
AP-2 complex subunit 
sigma 
AP2S1 transport, immunity 
membrane, 
endosomes 
48 25,39 25,6718 0 2,289E-09 5 4 3 3 70 
Nuclear RNA export factor 
1 
NXF1 mRNA metabolism 
cytoplasmic, 
nuclear 
49 24,952 23,7913 0 3,883E-09 2 2 2 1 32 
Condensin-2 complex 
subunit H2 
NCAPH2 
cell cycle, genome 
structure 
nuclear, 
membrane 
50 24,547 23,0577 22,5368 1,417E-08 5 3 2 3 179 
Bromodomain adjacent to 
zinc finger domain protein 
1A 
BAZ1A 
cell cycle, genome 
structure 
nuclear 
51 25,146 23,7655 0 5,137E-08 3 2 2 1 19 
Exosome complex 
component CSL4 
EXOSC1 RNA metabolism 
cytoplasmic, 
nuclear 
52 24,72 24,462 0 6,998E-08 3 2 3 2 92 
Serine/threonine-protein 
phosphatase 6 regulatory 
subunit 3 
PPP6R3   
cytoplasmic, 
nuclear 
53 23,409 24,9448 0 8,263E-08 3 2 2 1 7 
N-alpha-acetyltransferase 
38, NatC auxiliary subunit 
NAA38 mRNA metabolism nuclear 
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54 24,586 24,2722 0 8,266E-08 4 3 2 3 43 Protein pelota homolog PELO cell cycle 
cytoplasmic, 
nuclear 
55 25,022 24,7909 0 2,644E-07 3 2 3 1 52 
Cleavage and 
polyadenylation specificity 
factor subunit 6 
CPSF6 mRNA metabolism nuclear 
56 25,869 24,9879 0 3,531E-07 3 2 3 1 93 
Nucleolar complex protein 
3 homolog 
NOC3L mRNA metabolism nuclear 
57 24,371 24,1229 0 5,102E-07 3 3 2 1 171 
Unhealthy ribosome 
biogenesis protein 2 
homolog 
URB2 not annotated nuclear 
58 23,769 23,5937 0 2,195E-06 2 2 2 1 15 
Ribonuclease P protein 
subunit p20 
POP7 RNA metabolism nuclear 
59 26,171 27,3642 0 2,988E-06 3 3 3 1 45 
DNA/RNA-binding protein 
KIN17 
KIN cell cycle, DNA repair 
cytoplasmic, 
nuclear 
60 24,747 24,5003 0 5,371E-06 3 3 3 2 41 Surfeit locus protein 6 SURF6 translation nuclear 
61 24,405 23,9568 0 1,099E-05 4 3 3 2 74 
Nucleolar and coiled-body 
phosphoprotein 1 
NOLC1 cell cycle 
cytoplasmic, 
nuclear 
62 25,165 25,167 0 3,458E-05 3 2 2 1 6 
Putative 60S ribosomal 
protein L39-like 5 60S 
ribosomal protein L39 
RPL39P5 RPL39 translation cytoplasmic 
63 22,262 20,4963 0 6,409E-05 2 2 2 1 125 
NE pore membrane 
protein POM 121C NE 
pore membrane protein 
POM 121 
POM121C 
POM121 
mRNA metabolism, 
transport 
nuclear, ER 
64 22,795 23,1311 0 9,144E-05 5 2 2 2 90 
U4/U6.U5 tri-snRNP-
associated protein 1 
SART1 mRNA metabolism 
cytoplasmic, 
nuclear, golgi 
65 25,587 25,0155 0 9,673E-05 5 2 2 1 54 
Monocarboxylate 
transporter 1 
SLC16A1 transport membrane 
66 24,351 23,9725 0 0,0006535 2 2 2 1 168 
Mediator of RNA 
polymerase II transcription 
subunit 1 
MED1 transcription 
nuclear, 
membrane 
67 23,974 23,9065 0 0,0006825 3 2 2 1 49 
Vacuolar protein sorting-
associated protein 4A 
Vacuolar protein sorting-
associated protein 4B 
Fidgetin-like protein 1 
VPS4A VPS4B 
FIGNL1 
cell cycle, transport 
membrane, 
endosomes 
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68 23,972 24,1649 0 0,0013653 2 2 2 2 62 Nardilysin NRD1 protease 
cytoplasmic, 
membrane 
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One CD has been attached to this copy of my thesis containing the cross-referenced movies in 
section 6.2.3. 
One copy of my publication ‘Functional analysis of nuclear localisation signals in VP1-2 
homologues from all herpesvirus subfamilies’ (Hennig et al. 2014) has also been attached to the bound 
copy of my thesis.
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